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ABSTRACT 
MOLECULAR MECHANISMS OF SENESCENCE RESPONSE 
TO TRANSFORMING GROWTH FACTOR-BETA IN LIVER 
CANCER  
 
Şerif Şentürk 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet ÖZTÜRK 
August 2010, 250 Pages 
 
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the 
world. HCC is associated with several etiological factors including infections with 
hepatitis B and C viruses, heavy alcohol consumption and chronic aflatoxin B1 
exposure. Due to its multi-step disease hallmark characterized with genetic 
heterogeneity, liver cancer has very limited therapeutic options. In light of many 
previous findings, cellular senescence acts as a barrier against immortalization and 
prohibits the proliferation of premalignant cells in various tumors including HCCs. 
However, implications of this anti-tumor mechanism in hepatic tissues are not well-
known.  
TGF-β is a multifunctional cytokine implicated in diverse cellular processes 
including senescence arrest as well as liver physiology and pathophysiology. 
Although TGF-β-induced senescence has been described in different cell types, this 
issue has never been addressed for hepatic cells. According to our recent data, TGF-
β1 expression pattern in various HCC malignancies closely correlated with reported 
frequencies of SABG activities in these corresponding disease stages. Therefore, we 
hypothesized that TGF-β signaling might play key role in hepatocellular senescence. 
Well-differentiated (WD) five cell lines characterized with epithelial-like 
morphology displayed TGF-β-induced growth inhibition associated with SABG 
activity, with lack of evidence of apoptosis induction. Even a brief exposure to TGF-
β was sufficient to trigger a massive senescence response. Senescence arrest in WD 
cell lines was linked to c-myc down-regulation and a reciprocal increase in p21Cip1 
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and p15Ink4b protein levels. In addition, TGF-β-induced senescence was correlated 
with Nox4 induction, intracellular accumulation of reactive oxygen species (ROS) 
and sustained 53BP1 foci formation as a mark of DNA-damage response. Moreover, 
intratumoral injection of TGF-β in human HCC tumors, generated subcutaneously in 
immunodeficient mice, induced expanded SABG that was associated with a strong 
anti-tumor response activity.  
On the other hand, poorly differentiated (PD) HCC cell lines with 
mesenchymal-like characteristics appeared to be resistant to TGF−β-induced 
senescence. However, PD cell lines had intact TGF-β signaling from cell membrane 
to nucleus. Resistance of PD cell lines was partially due to zeb2 overexpression, 
homozygous p15Ink4b deletion and lack of pRb expression. Besides, PD cells did not 
display Nox4 upregulation and also lacked ROS accumulation upon TGF-β 
stimulation.  
In addition, we demonstrated that sustained exposure to TGF-β established 
resistant Huh7 subclone. The resistance was partially attributed to deregulated Smad 
signaling, permanent epithelial-mesenchymal transition-like transformation. 
Surprisingly enough, removal of TGF-β from culture medium of continuously treated 
Huh7 subclone did not resolve the resistance phenotype in the rescued subclone. 
Epigenetic regulations mainly histone modifications are considered as candidate 
mechanisms responsible for irreversible TGF-β-resistance and maintenance of 
mesenchymal-like phenotype. Taken together, our results establish a close link 
between senescence arrest and anti-tumor activity of TGF-β signaling pathway in 
WD cell lines by delineating the mechanisms underlying TGF-β-induced growth 
arrest. Moreover, we propose partial explanation for the resistance to TGF-β-
mediated growth arrest in PD cell lines and thoroughly signify the potential 
mechanisms of acquired resistance to TGF-β in continuously treated cultures. Further 
studies to enlighten our knowledge about implications of TGF-β signaling in less 
differentiated HCCs are necessary. As a conclusion, we identify TGF-β signaling as 
a potent therapeutic option for well-differentiated early HCCs.       
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ÖZET 
KARACİĞER KANSERİNDE BAŞKALAŞTIRICI BÜYÜME 
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Şerif Şentürk 
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Ağustos 2010, 250 Sayfa 
 
 
 
 Hepatoselüler kanser dünyada beşinci sıklıkta görülen kanser türüdür ve 
hepatit b ve c virüsü enfeksiyonlarına, yüksek alkol tüketimine ve aflatoksin b1’e 
maruz kalmak gibi etiyolojik faktörlere bağlı olarak gelişir. Genetik heterojenlik 
özelliği ile karakterize edilen karaciğer kanseri çok basamaklı bir hastalık olması 
özelliği ile de tedavi edici opsiyonlar bakımından sınırlıdır. Daha önce elde edilen 
bilgiler ışığında, hücre yaşlanmasının ölümsüzleşme karşıtı bir mekanizma olduğu ve 
bu yönüyle de karaciğer kanserleri de dahil olmak üzere birçok kanser türünde habis 
oluşuma engel olan bir bariyer olduğu düşünülmektedir. Ancak tümör karşıtı bu 
mekanizmanın karaciğer kanserindeki rolü tam olarak bilinmemektedir.  
TGF-β çok yönlü bir sitokin olup, hücre yaşlanması ve karaciğer hastalıkları 
da dahil olmak üzere birçok hücresel işlemde rol aldığı belirtilmektedir. Daha 
önceleri, TGF-β’ya bağlı yaşlanma gözlemleri birçok hücre için belirtilmiş olduğu 
halde bu konu karaciğer hücreleri için çalışılmamıştır. Yeni elde ettiğimiz bulgulara 
göre, farklı karaciğer hastalık dokularında görülen TGF-β ifadesi, yine aynı 
dokularda tespit edilen hücre yaşlanması sıklığıyla benzerlik göstermektedir. Bundan 
yola çıkarak, TGF-β sitokininin karaciğer rahatsızlıklarında görülen yaşlanma ile 
ilintili olabileceğini düşündük. Epitel kökenli iyi diferansiye beş karaciğer kanseri 
hücre hattı TGF-β muamelesi ile birlikte yaşlanma belirtgeci için pozitif aktivite ile 
karakterize olan hücre bölünmesinde inhibisyon göstermiştir. TGF-β ile bir 
dakikadan daha az muamele bile çok belirgin bir yaşlanma yanıtı oluşturmak için 
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yeterli olmuştur. Iyi diferansiye hücrelerde görülen yaşlanma yanıtı c-myc düşüşü ve 
karşıt p15Ink4b ve p21Cip1 protein artışı ile ilintilidir. Öte yandan TGF-β tarafından 
tetiklenen yaşlanma yanıtı Nox4 artışı, hücre içi reaktif oksijen türleri birikimi ve 
kalıcı dna hasarı yanıtı olarak nükleer 53BP1 odaklarının oluşmasıyla ilişkilidir. 
Dahası, deri altı tümörlerinde, tumor içi TGF-β enjeksiyonu çok belirgin yaşlanma 
yanıtı geliştirmiş ve bu yanıt tümör engelleyici sonuçlar doğurmuştur.    
 Diğer taraftan, mezenkimal kökenli kötü diferansiye hücre hatları TGF-β’ya 
bağlı yaşlanma yanıtına direnç göstermektedirler. Bu hücre hatlarında TGF-β sinyal 
yolağında herhangi bir sorun olmadığını tespit ettik. Direnç mekanizmasının kısmen 
zeb2 protein miktarındaki artışa, p15Ink4b delesyonuna ve pRb eksikliğine bağlı 
olduğu gösterildi. Bununla birlikte bu hücrelerde Nox4 artışı ve reaktif oksijen 
türlerinde birikimi gözlemleyemedik. Öte yandan Huh7 hücrelerini devamlı TGF-β 
muamelesine maruz bıraktığımızda dirençli klonlar elde ettik. Direnç 
mekanizmasının kısmen Smad yolağındaki bozukluklara ve kalıcı epitel-mezenkimal 
dönüşüme bağlı olduğu tespit edilmiştir.  
İlginç olarak, devamlı muamele edilen dirençli klonları TGF-β’dan kurtarıp 
elde ettiğimiz ikincil klonda TGF-β yanıtının geri gelmediğini gözlemledik. Bu geri 
dönüşümsüz direnç mekanizmalarının temelinde olası epigenetik regülasyonların rol 
aldığıyla ilgili sonuçlar elde ettik. 
 Sonuç olarak, bu çalışmada elde edilen bulgular yaşlanma yanıtı oluşturan 
mekanizmalarla TGF-β’nın tümör karşıtı özelliği arasında yakın bir bağlantı 
kurmaktadır. Bundan başka, kötü diferansiye hücre hatlarındaki direnç için kısmi 
açıklama da getirmiş bulunuyoruz. Uzun dönem TGF-β muamelesi sonucunda 
oluşan direnç için de mekanizmalar üzerinde detaylı çalışmalar yürütmüş 
bulunuyoruz. Netice itibari ile, TGF-β sinyal yolağının iyi diferansiye karaciğer 
kanserlerinde tümör karşıtı tedavi edici özelliği konusunda önemli ipuçları 
sunuyoruz. 
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CHAPTER 1. INTRODUCTION 
1.1. Liver Homeostasis 
Animals are in constant battle efforts with many different sources of danger, 
in order to reach to enough food sources to prevent dehydration, overheating and/or 
freezing, and to run away from a certain predator, and so forth. Therefore, to survive 
and reproduce in this hostile environment, animals have adapted well-organized 
behaviors and evolutionized bodily features.  
For survival, animal kingdom has to maintain critical parameters within a 
certain range. For instance, a certain animal must regulate its body temperature, 
energy levels and amount of fluids. Maintenance of these critical parameters 
necessitates that the animal might come into direct or indirect contact with the 
corresponding satisfactory stimulus. In a simplified manner, each stimulus can be 
viewed as a native specified requirement. The physiological mechanisms which work 
for the regulation of these requirements are extremely complex and distinct. Such 
physiological mechanisms are entirely carried out in the body of the animals. Cells 
situated at different target organs of the entire body, work for their best to regulate 
body temperature, glucose levels, and bodily fluids at optimum survival levels.  
Maintenance of such a constant environment in the body is referred to as 
homeostasis. Homeostatic regulation is referred to the process of maintaining critical 
parameters regulated by certain cell types. All animals have a sustained body 
temperature that is 370C for humans which is absolutely constant in hot or cold 
environments. Animals also have to maintain a certain range of glucose levels. 
Humans have an exact level of glucose in the blood necessitated by the cells. In 
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addition, water levels in the body are controlled to maintain the necessary amount of 
the water in the body.  
Such maintenance of homeostasis under constant composition of the fluids, 
glucose and body temperature is under the control of different body systems. Each 
system is composed of different organs and each organ has its own contribution in 
maintaining the body homeostasis.  
Liver is one of the most important organs safeguarding the maintenance of 
homeostasis. Liver is the largest internal organ weighing 1.5 kg in the human body 
and is present in vertebrates and some other animals. It fills the upper right costal 
margin of the human abdomen just beneath the rib cage. The main liver functions 
involve metabolism, excretion, secretion, interconversion, synthesis, storage and 
body defense (Fan et al., 2009; Francini et al., 2009; Jourdan et al., 2009).  
Hepatocytes are the functional cells of the liver and consist of almost over 
90% of the total liver mass. Ito cells, also known as hepatic stellate cells, are unique 
to this organ. Kupffer cells are macrophages specified to function in the liver. Bile 
duct cells occupy approximately 5% of the total cell population in the liver (Fan et 
al., 2009).  
Liver receives all exiting circulation from the small and the large intestine, as 
well as spleen and pancreas, through the portal vein. In addition, the strategic 
location of liver allows it to function as a biochemical defense mechanism against 
toxic chemicals entering the body through food ingredients. Nutrients which enter 
the liver are generally converted into secreted proteins namely, albumin, coagulation 
and plasma carrier proteins, lipids which are sent as lipoproteins to other tissues, and 
carbohydrates that are stored in the liver as glycogen. Liver is the major regulator of 
plasma glucose levels therefore, is essential for optimal function of the whole body.  
The functions performed by liver towards the rest of the body have been 
devoted by evolutionary events which attributed to liver with an incredible capacity 
to regenerate. Liver is an interesting organ with high regenerative capacity (Chu and 
Sadler, 2009; Mishra et al., 2009; Sawitza et al., 2009). This process allows liver to 
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recover lost mass without disturbing functionality of the entire body. The capacity of 
liver regeneration following loss of liver mass is quite similar in all vertebrate 
organisms, from humans to fish. Regeneration is also stimulated when livers from 
small animals (e.g., dogs) are transplanted to large recipients of the same species.  
Liver homeostasis is lost in many different conditions among which are 
various sources of pathological conditions as briefly described in the following 
sentences; 
 
• Wilson's disease is a hereditary disorder in which the liver to detain copper 
(Schilsky, 2009).  
• Haemochromatosis is a hereditary disorder which leads to the accumulation 
of iron in the liver and thereby causes hepatocyte damage (Janssen and 
Swinkels, 2009).  
• Hepatitis is characterized with by inflammation of the liver by various viral 
infections but also by several poisons, autoimmunity or genetic conditions 
(Iadonato and Katze, 2009).  
• Cirrhosis replaces dead liver cells through the formation of fibrous scar 
tissue. Such pathological conditions are typically caused by viral hepatitis, 
alcohol consumption or contact with carcinogenic chemicals (Cavazza et al., 
2009; Hirschfield and Siminovitch, 2009). 
• Primary sclerosing cholangitis is characterized by inflammation of the bile 
duct which makes this disease likely to be autoimmune (Tischendorf and 
Schirin-Sokhan, 2009).  
• Primary biliary cirrhosis is associated with autoimmunity of bile ducts 
(Lindor et al., 2009).  
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1.2. Hepatocellular Carcinoma 
Liver cancer is comprised of various primary hepatic neoplasms including 
hepatocellular carcinoma (HCC), intrahepatic bile duct carcinoma 
(cholangiocarcinoma), hepatoblastoma, haemangiosarcoma (Di Bisceglie, 2009; 
Dufour and Johnson; Kirk et al., 2006). Among these, HCC is the most common type 
of liver neoplasms, representing 83% of all cases (Hernandez-Alcoceba et al., 2007; 
Hoffmann et al., 2007). It is also the 3rd most lethal cancer with lack of biomarkers 
and potentially curative treatment options, affects many of the world’s populations 
(Farazi and DePinho, 2006) with more than 600,000 annual deaths (Bruix and 
Llovet, 2009; Minguez et al., 2009) and continues to increase in incidence rate in 
several regions of the world and is associated with poor overall survival. 
Hepatocellular carcinoma is usually diagnosed at late stages of the disease 
characterized with heterogeneous phenotypic and genetic malformations of patients 
with poor prognosis. Therefore, hepatocellular carcinoma has been classified as a 
heterogeneous disease.  
 
1.3 Pathogenesis of Hepatocellular Carcinoma 
Hepatocellular carcinoma has different epidemiologic features including 
dynamic and well-documented variations among geographic regions and between 
men and women (El-Serag and Rudolph, 2007). Various host and environmental 
factors interact at molecular level to cause hepatocyte damage that is accompanied 
with hepatocyte proliferation. Continuous rounds of hepatocyte regeneration 
develops into pathological liver diseases from normal liver through fibrosis to 
chronic hepatitis/cirrhosis and dysplastic nodules to HCC (Azam and Koulaouzidis, 
2008; Bartosch et al., 2009; Schlaeger et al., 2008). The progression of HCC, 
however, is not well-defined as other cancer types (Figure 1.1).  
Liver fibrosis is a condition in which the liver gradually deteriorates and 
malfunctions due to chronic hepatocyte injury, stellate cell activation and collagen 
deposition. Scar tissue surrounded by collagen deposition replaces healthy liver 
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tissue, partially blocking the flow of blood throughout the liver and manifesting 
hepatocyte loss associated with apoptotic cell death (Cavazza et al., 2009).  
 
Figure 1.1: Molecular pathogenesis of hepatocellular carcinoma. Hepatocyte injury 
is provoked by several factors incuding HBV and HCV infections, heavy alcohol consumption and 
aflatoxin B1 contamination. Necrosis, apoptosis and replicative senescence are major cellular 
mechanisms followed by hepatocyte damage (Farazi and DePinho, 2006). 
 
Liver cirrhosis is one of the most important pathological conditions that lead 
to hepatocarcinogenesis. Cirrhosis is strongly characterized by increased 
chromosomal aberrations, gene mutations, allelic losses, epigenetic alterations and 
deregulations in various signaling pathways. Some of these alterations are 
accompanied by a stepwise increase in different pathological disease stages during 
hepatocarcinogenesis. Abnormal liver nodules observed in cirrhotic livers often 
develop into precancerous hyperplastic nodules with moderate genomic instability. 
The distinction between precancerous and cancerous lesions remains elusive, and the 
developmental process with clear evidence of molecular pathogenesis from 
preneoplastic lesions to manifest HCC is still not well-known.  
Nonetheless, what is known so far is that pre-neoplastic nodules that are in an 
intermediate stage between non-neoplastic regenerating nodules and HCC evolve 
into dysplastic nodules with high regeneration capacity. HCC usually develops on 
the background of dysplastic nodules with genomic instability, telomerase 
 6
reactivation and loss of p53 function characterized by hotspot mutations and micro-
deletions (Gouas et al., 2010). Moreover, HCC can be classified into three distinct 
histological groups which are generally defined as well-differentiated (WD), 
moderately differentiated (MD), poorly differentiated (PD) or undifferentiated types 
of HCC (Nam et al., 2005). 
 
1.3.1. Viral Hepatocarcinogenesis  
Hepatocarcinogenesis in humans has various aetiologies. Heavy alcohol 
consumption and chronic infections with HBV and HCV, as well as naturally 
occurring aflatoxins and hereditary disorders have been the most common causes of 
chronic liver diseases (Fung et al., 2009; Kuniholm et al., 2008; Marcellin, 2009). 
Cirrhosis usually precedes the multistep tumor development, in which viral 
carcinogenesis can be identified (Raoul, 2008).  
HCC evolves during a process that usually takes more than 30 years after 
infections with HBV and HCV. Such chronic infections provoke active immune 
response activation followed by inflammation and fibrosis, which progresses to 
cirrhosis and ultimately unfold into HCC (Thorgeirsson and Grisham, 2002). The 
incidence rate of hepatocellular carcinoma is usually correlated with the incidence 
rate of chronic hepatitis B virus infection. For chronic hepatitis B carriers who were 
characterized by high serum HBsAg, the HCC risk has been estimated to be up to 40-
50% (Marcellin, 2009).  
Although both viruses cause hepatotropic infections; there are significant 
differences in their oncogenic mechanisms. HBV belongs to the Hepadnavirus family 
and has an estimated number of 350 million human infections in the world 
(Zuckerman, 1999). Viruses in this family have very small (approximately 3200 kb) 
and partially double-stranded relaxed DNA molecule with two uneven strands 
consisting of a full length of negative strand and a shorter positive strand. Viruses in 
this family replicate through an RNA intermediate, which they translate back into 
DNA using reverse transcriptase. Most common clinical course of infection, on the 
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other hand, is vertical transmission meaning that from mother to neonate which is 
followed by childhood infection (Rehermann and Nascimbeni, 2005). HBV genomic 
integration has been demonstrated in many cases that is not solely restricted to 
transformed hepatocytes but normal hepatocytes in non-tumor tissues also carry 
HBV genome after chronic infections (Tsai and Chung, 2010). Integration of HBV 
genome into human genomic DNA has various effects such as; genomic instability 
associated with chromosomal abnormalities as deletions and translocations, 
amplification of cellular DNA and alterations in the expression patterns of various 
oncogenes, tumor suppressor genes and miRNAs (Feitelson and Lee, 2007)(Figure 
1.2).  
 
 
Figure 1.2: Molecular mechanisms of liver cancer development (Farazi and DePinho, 
2006).  
 
 
A large proportion of HCC cases with HBV genome integration have HBV X 
(HBx) protein expression which affects various cellular processes and functions of 
molecular signaling pathways (Figure 1.3). HBx physically binds to and inactivates 
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the wild-type p53 tumor suppressor protein as well as proteasome subunits and UV-
damaged DNA binding proteins (Zhang et al., 2006b).  
 
Furthermore, HBx protein has been implicated in activation of NF-kB and 
TGF-β signaling. Together with that, sevaral growth regulatory genes including c-
myc and EGF were associated with HBV infection and HBx protein (Brechot et al., 
2000).  
 
 
Figure 1.3: Cellular signaling pathways impicated in HBV X related hepatocarcinogenesis (Tsai 
and Chung, 2010). 
 
HCV, on the other hand, is classified in Flaviviridae family with more than 
170 million infections reported by World Health Organization. Notably, patients with 
the background of persistent HCV infection usually develop liver cirrhosis in 
approximately 30 years. In addition, HCV is an enveloped, single stranded, positive 
sense RNA virus which consists of a 10-kb genome that contains a large open 
reading frame encoding several structural proteins as core protein, envelope protein 1 
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and 2, p7 and non-structural proteins NS2, -3, -4A, -4B, -5A, -5B (Lindenbach et al., 
2005). In contrast to HBV, HCV does not enter the nucleus of host cells. Instead, 
RNA genome of HCV functions in the cytoplasm of the infected cell. HCV core 
protein interacts with many intracellular proteins including p53, p73 and pRb and 
thus affects diverse range of functions in the cell (Majumder et al., 2001; Ray et al., 
1997).  
 
1.3.2. Alcohol-induced Hepatocarcinogenesis 
Chronic heavy alcohol consumption is closely associated with 
hepatocarcinogenesis. Numerous studies established a causal link between high 
incidence rate of HCC and alcohol abuse (Hassan et al., 2002; Horie et al., 2003; 
Kew, 1986). However, the exact contribution of alcohol abuse to liver cancer 
compared to HBV and HCV infections is still not well-defined largely due to the 
contribution of other risk factors that can affect the systemic and intrahepatic effects 
of alcohol. Persistent exposure of the liver to alcohol elicits hepatocyte hyper 
regeneration due to activation of several survival factors, interference with hepatic 
metabolisms and direct DNA damage mostly associated with increased production of 
intracellular reactive oxygen species (Gao et al., 2004; Wu and Cederbaum, 2003; 
Wu et al., 2006). Furthermore, alcohol-induced hepatocellular injury can lead to 
fibrosis and finally cirrhosis, the latter being per se associated with an increasing risk 
of HCC development. 
 
1.3.3. Aflatoxin-induced Hepatocarcinogenesis  
Aflatoxin B1 is one of the most potent naturally occurring hepatocarcinogens, 
and a metabolic byproduct, mycotoxin of fungi, Aspergillus Flavus and Aspergillus 
Parasiticus. Aflatoxin B1 can contaminate the food supply such as rice, nuts, spices, 
corns at any time during production, processing, transport and storage (Picco et al., 
1999). Data on aflatoxin exposure by contamination of food correlates well with 
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incidence rates in Africa and to some extent in China. Chronic exposure of the liver 
to aflatoxins is associated with a specific AGG to AGT transversion mutation at 
codon 249 of the p53 gene specifically in human HCC, providing mechanistic 
support to a causal link between exposure and liver disease (Bressac et al., 1991; 
Puisieux et al., 1991). 
 
1.3.4. Other Aetiological Factors Associated With HCC 
In addition to most common factors associated with HCC, other factors have 
been proposed to play role in liver cancer development with a lower frequency. 
Several common conditions or diseases were associated with high risk of developing 
HCC. Those include inherited genetic diseases antitrypsin deficiency, glycogen 
storage disease, heamochromatosis and hereditary tyrosinemia type. Several other 
diseases were also implicated in increased risk of hepatocarcinoma development. 
Hereditary heamochromatosis is a common genetic disorder that is associated with 
increased iron absorption by hepatocytes which then hasten hepatocellular damage 
(Pietrangelo, 2009). Alpha1-antitrypsin deficiency (AATD) is an autosomal co-
dominantly inherited disease which affects about 1 in 2000 to 5000 people. AATD 
affects the liver predominantly through appearance of increased antitrypsin polymers 
in hepatocytes provoking hepatocyte death and cirrhosis (Kaplan and Cosentino; 
Parfrey et al., 2003).  
HCC has also been described in patients with obesity and diabetes with no 
previous history of liver disease associated with other risk factors (Chuang et al., 
2009; Polesel et al., 2009). This predisposition has been well-correlated with insulin 
resistance and elevated free fatty acid production in the liver (Maclaren et al., 2007; 
Ooi et al., 2005). Lipid accumulation in the liver can subsequently provoke 
hepatocyte damage mostly characterized by apoptosis, senescence and cytokine 
production, and reactive oxygen species generation due to high rates of oxidation of 
fatty acids and ultimately the development of fibrosis (Farrell and Larter, 2006). 
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1.4. Genetics of Hepatocellular Carcinoma 
Human cancers arise as a result of genetic changes that impact on cell 
proliferation through diverse mechanisms. Cancers, in addition, are usually 
associated with the presence and accumulation of genetic alterations which mainly 
target various chromosomal locations. Tumor development usually takes long 
periods which indicates that different genetic variations may be necessary to evolve 
the malignant transformation (Fearon and Vogelstein, 1990). It is believed that 
hepatocarcinogenesis shares this common molecular pathogenesis as other solid 
tumors. HCC has been extensively studied in terms of genetic abnormalities.  
Hepatocarcinogenesis involves complex combinations of molecular events, 
such as genetic aberrations, epigenetic changes and altered gene expression profiles. 
Hepatocellular cancers display many chromosomal changes such as polyploidy, loss 
of heterozygosity (LOH), allelic imbalance (AI), amplifications as well as 
translocations. Likewise in other solid tumors, a large number of genetic variations 
such as activating mutations of proto-oncogenes as well as inactivating mutations of 
many tumor suppressor genes have been reported to accumulate during the course of 
hepatocarcinogenesis.  
After the development of Comperative Genomic Hybridization (CGH), 
Restriction Fragment Length Polymorphism (RFLP) and Micro Satellite Analysis 
(MSA) techniques along with new publicly available genomic data obtained with the 
efforts of the Human Genome Project, important molecular pathways involved in 
hepatocellular carcinoma, and several chromosomal and genetic aberrations have 
been identified to be altered during the carcinogenic process. 
 
1.4.1. Genetic Aberrations in Hepatocellular Carcinoma 
Chromosomal aberrations are alterations in chromosome structure and 
morphology and have been reported frequently in HCC (Kishnani et al., 2009; 
Midorikawa et al., 2009). Common chromosomal copy number losses associated 
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with HCC are 1p, 2q, 4q, 6q, 8p, 9p, 10q, 13q, 16p, 16q and 17p (Chochi et al., 
2009). These chromosomal regions contain key players in hepatocarcinogenesis such 
as TP53, RB1 (retinoblastoma 1), AXIN1 (axis inhibition protein 1), CDKN2A 
(cyclin-dependent kinase inhibitor 2A). Originally identified as an oncogene TP53, 
the most frequently altered gene in human cancers, is located at 17p, a common site 
for deletion (Hanahan and Weinberg, 2000; Hollstein et al., 1991).  
The frequency of p53 mutations, mostly associated with Aflatoxin B1 
ingestion in HCC, has been reported to be around 30% worldwide (Bressac et al., 
1991). Strong correlation between p53 mutations and large tumor size as well as poor 
differentiation state has been reported (Qin et al., 1997). The retinoblastoma protein 
is the universal inhibitor of the cell cycle progression and a gatekeeper at G1 phase 
(Nevins, 2001). The Rb gene is localized to 13q, which is a common LOH site for 
different cancer types including HCCs. In addition, inactivating RB1 mutations were 
observed with more than 15% reported frequency (Ozturk, 1999).  
Cyclin-dependent kinase inhibitors have been reported to be inactivated in 
many cancers including HCC. Two closely located cdk-inhibitor genes at 
chromosome 9p, CDKN2A and CDKN2B, display genomic alterations such 
homozygous deletions. Expression patterns of these genes are also modulated 
through de novo methylation.  Recently, β-catenin gene has been identified as one of 
the most frequently mutated genes in both hepatocellular carcinomas and 
hepatoblastomas. Both missense mutations and in-frame deletions affect the function 
of this gene product thereby deregulating Wnt signaling (Yam et al., 2010). Common 
amplifications, on the other hand, have been reported to be mainly located on 1q, 7q, 
8q and 17q (Midorikawa et al., 2009). These regions are likely to harbor genes that 
are implicated in tumor progression. In many cases, amplification of myc and cyclin 
genes have been reported (Ozturk, 1999).   
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1.5. Liver Cirrhosis and senescence 
 Liver cirrhosis is a well-defined pathological condition characterized by 
abnormal liver nodule generation and widespread fibrous scarring induced by many 
intrinsic and extrinsic factors such as viral hepatitis, heavy alcohol consumption, 
prolonged biliary obstruction, genetically transmitted disorders, and others. 
Independent of its etiology, cirrhosis is considered a major clinical and 
histopathological risk factor for hepatocarcinogenesis. Regenerative nodules are 
characteristic complications of liver cirrhosis. Such lesions lack bile ducts and 
exhibit poorly organized hepatocytes surrounded by fibrotic tissue.  
 Chronic liver diseases are associated with progressive telomere shortening 
during excessive proliferation of hepatocytes. Hepatocyte telomeres undergo 
shortening during progression of chronic liver diseases which is accompanied by 
decline of hepatocyte proliferation. Hepatocyte telomere shortening and senescence 
are general markers of human liver cirrhosis, and correlate with progression of 
fibrosis in cirrhosis samples (Wiemann et al., 2002).  
Telomere shortening in cirrhosis has been demonstrated to be hepatocyte 
specific, although stellate cells have been reported to undergo senescence arrest in 
vivo as well (Krizhanovsky et al., 2008). 
 
1.5.1. Cellular senescence 
Most of the primary cells have a limited number of population doublings as 
proposed by Hayflick and Moorhead that when normal human fibroblast cells are 
explanted from embryonic tissues into culture they have limited capacity to 
proliferate (Hayflick and Moorhead, 1961). Such cells, after around 50 to 70 
population doublings are irreversibly arrested in G1 phase of the cell cycle and 
become unresponsive to proliferative mitogenic stimuli (Harley et al., 1990).  
Cellular senescence is a condition in which cells, despite being alive, are 
unable to proliferate further. Cellular senescence is a stable proliferative arrest in 
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response to diverse intrinsic and extrinsic factors such as dysfunctional telomeres, 
DNA damage, oncogenic signaling such activated Ras or Raf, and lack of growth 
stimulating signals and disrupted chromatin and therefore it is different from 
quiescence or terminal differentiation (Serrano et al., 1997)(Figure 1.4).  
Upon entering senescence, cells undergo dramatic changes. Such cells 
acquire large volume, flattened cytoplasm morphology accompanied by changes in 
nuclear structure, gene expression, protein processing and metabolism and 
senescence associated β-galactosidase activity (Campisi, 2000; Dimri et al., 1995; 
Narita et al., 2003).  
 
 
Figure 1.4: Various signals that provoke cellular senescence (Ben-Porath and Weinberg, 2005). 
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1.5.2. Replicative senescence 
Human chromosome telomere ends are special structures composed of 
stretches of repetitive tandem hexameric units-TTAGGG in vertebrates and 
associated telomeric proteins that cap the ends of linear chromosomes. The length of 
human telomeres range from a few kilobases to 10–15 kbs. Telomere specific 
proteins protect chromosome from degradation or chromosomal end-to-end fusion 
during DNA-repair process (Reaper et al., 2004).  
 
In the absence of maintenance mechanism, progressive erosion of telomeres 
at each replicative round limits the continuous replication. During every S-phase, due 
to the end-replication problem of DNA polymerase, telomeres shorten during each 
DNA replication cycle by 50-100 base pairs (bp).  
In summary, when the length of one or more telomeres gets below a certain 
threshold, usually characterized with the single-strand overhang erosion, the exposed 
telomeric DNA ends are recognized as double-strand breaks (DSBs) by the DNA 
damage response (DDR) mechanism to release a senescence inducing signal to the 
cell (Figure 1.5).  
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Figure 1.5: Senescence as a general stress response program. DNA damage response 
and activation of p53 through ATM/ATR and CHK1/CHK2 play central roles in all indicated 
pathways (Ozturk et al., 2009). 
 
DNA-damage is dangerous because it compromises the structural integrity of 
chromosomes. DNA-damage response checkpoint is a safety mechanism that 
prohibits proliferation of damaged cells under such conditions and thereby provokes 
replicative senescence (also referred to as telomere-initiated or telomere-dependent 
senescence) which is the inevitable consequence of this end-replication problem.  
Specialized complexes on single-stranded DNA and DSBs recruit and 
activate apical local kinases such as ATM and ATR. Activation of these specialized 
kinases at the DNA-damage site in senescent cells is usually mediated through 
autophosphorylation of ATM that is usually associated with nuclear foci formation 
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by phosphorylated H2AX. Nuclear foci accumulation is also characterized with DNA 
repair damage checkpoint factors such as MREII, MDC1, RAD9 and NBS1 as well 
as the activation of CHK1 and CHK2 kinases. Ultimately, DNA-damage checkpoint 
machinery often responds with activation of signaling pathways that eventually 
converge on key decision making factors such as p53 and the cell-division cycle 25 
(CDC25) phosphatases (d'Adda di Fagagna, 2008). Finally, the CDC25 phosphatases 
along with p53 interface DNA-damage response with the core of the cell-cycle 
progression machinery (Figure 1.6).   
 
 
Figure 1.6: Activation of DNA-damage response (DDR) machinery. Increased local 
ATM and ATR activity above a threshold engages DDR factors that may function far from the 
damaged site (d'Adda di Fagagna, 2008).     
 
The signaling pathways leading to permanent growth arrest in relation to 
shortened telomeres has been well-characterized. In this regard, a role for reactive 
oxygen species (ROS) in telomere shortening and uncapping has also been defined 
(Cattan et al., 2008; von Zglinicki, 2002).  
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In summary, senescence is not simply the end result of telomere shortening as 
the rate of shortening varies between cells during in vitro culture and there is not 
such a strict threshold of shortened telomere length at which the mechanism would 
be provoked (Lundberg et al., 2000). 
 
1.5.3. Oncogene-induced senescence (OIS) 
Telomere attrition is clearly not the only stimulus for senescence since mouse 
cells possess very long telomeres but still undergo senescence arrest in vivo (Kim et 
al., 2009b; Kortlever et al., 2006; Murga et al., 2009). Although, various physiologic 
stress conditions could hasten the onset of senescence. Induction of senescence is 
also the frequent outcome of oncogene activation in normal cells. Like oncogene-
induced apoptosis, OIS has been implicated as a powerful tumor suppressive 
mechanism that impedes the proliferation of cells with high expression of an 
aggressive oncogene.  
OIS can be triggered by activated onco-proteins like E2F1, MYC and RasV12 
(Courtois-Cox et al., 2006; Grandori et al., 2003; Lazzerini Denchi et al., 2005). Ras 
overexpression triggers a hyper replicative phase in which cells proliferate faster than 
control cells. However, this transient hyperproliferation state is quickly restrained by 
aberrant activation of DDR checkpoint pathways along with engagement of negative 
cell-cycle regulators that eventually establish cellular senescence (Di Micco et al., 
2006; Mallette et al., 2007). Therefore, OIS is primarily a DNA-damage response as 
demonstrated by recent findings that senescent cells in response to oncogene 
expression depict increased appearance of DNA damage sites together with the 
accumulation of heterochromatin foci that lead to silencing of proliferative genes 
(Figure 1.5).   
Expression of other onco-proteins downstream of Ras, like BRAFE600, has 
also been shown to trigger cell cycle arrest (Michaloglou et al., 2005). Conversely, 
the loss of PTEN, which is an inhibitor of the same pathway, also leads to senescence 
(Alimonti et al., 2010). Oncogene-induced senescence appears to be engaged by a 
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variety of intrinsic and extrinsic signals. Nevertheless, OIS is not clearly associated 
with telomere shortening, although established independently of any telomere 
attrition or dysfunction (Hornsby, 2007). Independent of the mechanism, cells that 
have undergone OIS and replicative senescence share common features such as flat 
morphology, SABG activity and induction of cell cycle inhibitory proteins such as 
p53 and p16Ink4a (Ferbeyre et al., 2002; Serrano et al., 1997).  
Additionally, similar to replicative senescence, oncogene-induced senescence 
has a causal link to reactive oxygen species (ROS) accumulation and can be 
abrogated by culturing cells in the presence of antioxidants (Lee et al., 1999). 
 
1.5.4. Reactive oxygen species (ROS)-induced senescence  
Respiratory chain processes in the mitochondria are the major sources of 
intracellular oxygen radicals. Reactive oxygen species are also produced by 
intracellular NOX enzymes. Experimental induction of ROS accumulation in cells 
through H2O2 treatment or glutathione depletion provokes senescence-like growth 
arrest in various cell types (Blanchetot and Boonstra, 2008). Besides, several studies 
have linked intracellular accumulation of ROS to telomere shortening. On the other 
hand, depending on the level of stress such free radicals may also lead to telomere-
independent senescence response (Lu and Finkel, 2008). Thus, ROS-dependent 
senescence shall be raised as a process to limit the ROS-induced mutation by 
removing damaged cells. Therefore, any disturbance in the physiologic intracellular 
levels of ROS would be expected to provoke senescence induction (Colavitti and 
Finkel, 2005).  
Nevertheless, the mechanisms of ROS-initiated senescence are still not well-
known. However, the issues discussed above thus suggest that cellular senescence, 
whether induced by telomere attrition, DNA replication stress provoked by oncogene 
activation, or ROS accumulation, share a common underlying reason, which is the 
DNA-damage response. In view of this, reactive oxygen species are the major agents 
responsible for endogenous oxidative DNA damage in the cells and DNA-damage 
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response is the critical mediator in triggering senescence. The signaling pathways 
activated by these responses eventually converge on p53 (Figure 1.5).  
 
1.5.5. DNA-damage-independent senescence 
DNA-damage mediated activation of p53 induces the upregulation of the 
cyclin-dependent kinase (CDK) inhibitor p21Cip1, a factor known to have a direct 
inhibitory link to cell-cycle progression. However, absence of p21Cip1 in mouse 
embryonic fibroblasts does not overcome senescence induction. This would suggest a 
prominent role for other senescence relaying signals as well. Other mechanisms of 
senescence mainly focus on the 35 kilobases INK4/Arf locus encoded tumor 
suppressors, namely ARF, p16Ink4a and p15Ink4b. These cyclin-dependent kinase 
inhibitors (CDKIs) represent the most important regulatory factors in senescence and 
immortality. Activation of these CDKIs promotes growth arrest and/or senescence, 
and inhibits entry into S-phase of the cell cycle depending on the cellular context.  
Independent of p53 activation, driven by DNA-damage checkpoint 
machinery, these tumor suppressors oppose aberrant mitogenic stimuli and engage 
senescence inducing signals to retinoblastoma (pRb) pathway (Takahashi et al., 
2006). Activity of pRb, a crucial gatekeeper of cell cycle progression, is controlled 
by various post-translational modifications such as phosphorylation, acetylations and 
ubiquitination (Chen et al., 2003; Markham et al., 2006). Several lines of evidence 
suggested the phosphorylation event to be the key step in imposing the G1 arrest 
(Sherr and McCormick, 2002). In particular CDK2, CDK4 and CDK6, a series of 
cyclin-dependent kinases, have been implicated to play prominent role in pRb 
phosphorylation (Malumbres and Barbacid, 2007). By phosphorylating the 
retinoblastoma (pRb) family members, CDKs enable the transcription of cell-cycle 
regulatory genes that are under the control of transcription factors belonging to E2F 
family proteins. Cyclin-dependent kinase activities, on the other hand, are tightly 
controlled by INK4 proteins. Through direct association with CDK4 and CDK6, 
these INK4 proteins block the assembly of catalytically active cyclin-CDK 
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complexes. The association of the INK4 proteins to CDK4 and CDK6 induces an 
allosteric change that inhibits the binding of these kinases to D-type cyclins, 
abrogating CDK4/6-mediated phosphorylation of retinoblastoma (Rb) family 
members (Kim and Sharpless, 2006). Thus, the net result of elevated expression of 
INK4 proteins; maintains Rb-family proteins in hypophoshorylated state which 
promotes inhibitory binding to E2F and therefore causes a G1-phase cell-cycle arrest 
(Gil and Peters, 2006).  
Given the importance of factors expressed from INK4 locus in tumor 
suppression and aging, several intensive studies have been conducted on regulation 
of this particular locus. Thus, work in this field enhanced the understanding of the 
regulation of INK4 locus. Consequently, several factors were identified in the last 
decade with evidenced implications on the control of expression of these tumor 
suppressors (Figure 1.7).       
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Figure 1.7: Regulation of the INK4/Arf locus. Activators and repressors of the locus are 
indicated above and below each gene, respectively (modified from (Gil and Peters, 2006)).    
 
1.5.6. Cancer Cell Senescence 
 Senescence is now considered as an anti-tumor program to limit proliferation 
of transformed cells in vivo. Since senescent cells can no longer proliferate, cancer 
cell senescence acts as a barrier against tumor progression. Although senescent cells 
are absent in malignant tumors, there are examples of cellular senescence in pre-
malignant tumors suggesting senescence as a limiting factor for malignant 
transformation. Senescence tumor cells were initially identified in pre-malignant 
lung adenomas, pancreatic neoplasias and melanocytic nevi (Collado et al., 2005). 
Unfortunately, such senescent cells were not detected in corresponding malignant 
adenocarcinoma tumors.  
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Several lines of evidence demonstrated senescence in diverse liver diseases, 
with most striking outcomes implicated in liver cirrhosis samples which are closely 
associated with hepatocyte specific telomere shortening. Some HCC samples were 
also demonstrated to harbor cell populations with SABG activity. All these 
observations implicated senescence as a tumor suppressive mechanism. Supporting 
evidence came from the studies performed with genetically well-defined mouse 
models. Murine HCC tumors generated through mutant Ras overexpression in p53-
deficient hepatoblasts were efficiently cleared by reactivation of p53 expression (Xue 
et al., 2007).  
Surprisingly enough, restoration of the tumor suppressive function of p53 in a 
similar study triggered a senescence response for tumor regression only in tumor 
cells leaving normal cells unaffected (Ventura et al., 2007). In this experimental 
setting tumor regression was closely associated with infiltration of neutrophils, 
macrophages and natural killer cells suggesting a functional role for immune system 
in tumor cell clearance.  
Other studies with particular interest in titrated activation of Nras oncogene 
or ablation of tumor suppressor Pten also contributed to the field by describing 
experimental evidence for oncogene-induced senescence in vivo (Alimonti et al., 
2010; Braig et al., 2005). Of note, all these senescence programs described so far 
converge on p53 and p21Cip1 activation as well as a contribution from p27Kip1. Since 
these factors monitor the presence of oncogenic signaling; abrogation of single one 
of them contributes well to malignant transformation.  
However, senescence observed in pre-malignant tumors is not solely 
modulated by INK4 locus proteins, p21Cip1 or p53. β-catenin overexpression as well 
as BRAF activation in the absence of p53 or p16Ink4a resulted in senescent cells in 
melanomas (Dhomen et al., 2009; Xu et al., 2008). All these data support the 
hypothesis that other cell cycle regulators might also be engaged in senescence 
initiation and maintenance in pre-malignant tumors and their loss of function is one 
of the mechanisms to escape from redundant senescence program and progress to a 
more malignant phenotype.   
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Taken together, induction of senescence program in pre-malignant tumors as 
well as in some malignant stage cancers may be considered as an anti-tumor therapy 
as an alternative development to current strategies. Currently available targeted 
therapies are mainly designed to kill malignant cells, although they are often 
prohibited by pro-survival factors present in cancer cells. Therefore, attacking tumor 
cells by senescence-inducing strategies alone or in combination with currently 
available therapies might prove effective in an alternative intervention perspective in 
various malignant lesions including some forms of HCC.                 
 
1.6. Transforming growth factor-beta signaling 
 Transforming growth factor-beta (TGF-β) signaling controls a diverse set of 
functions mainly those related to cell proliferation, development, differentiation, 
adult homeostasis and disease. TGF-β superfamily cytokines are virtually secreted by 
all type of cells and have overlapping receptor usage (Massague, 1998).  
 
1.6.1. TGF-β ligands and receptors 
 Cytokines belonging to this superfamily are initially secreted as precursor 
proteins which undergo proteolytic cleavage and reach maturation. The functional 
form of TGF-β ligand is a 12-15 kDa homo-dimer stabilized by hydrophobic 
disulfide-rich core characteristic of a tight structure known as “cysteine knot” (Sun 
and Davies, 1995). The cleavage of covalent bonds between the pro-peptide and the 
mature ligand is facilitated via a furin-like convertase (Derynck et al., 1985; 
Miyazono et al., 1988).  
The two dimeric polypeptides formed by cleavage remain intact through non-
covalent interactions, and they are secreted as a latent complex.  Latency-associated 
protein (LAP), the propeptide portion of this complex keeps the mature propeptide 
biologically inactive by preventing accessibility to membrane receptors (Lee and 
McPherron, 2001). In some cases, LAP may remain as the noncovalently bound 
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predominant extracellular partner in the secretory pathway of the TGF-β ligand.  
Alternatively, LAP complex may bind to large secretory glycoproteins known as 
latent TGF-β binding proteins (LTBPs). LTBPs are known to aid the secretion or 
activation of LAP-ligand complexes. The release of biologically active TGF-β 
ligands from latent complexes is mediated through proteolytic processing of 
LAP (Massague and Chen, 2000).  
Pleiotropic cytokine, TGF-β, initiates signal transduction through direct 
contact with a membrane-anchored proteoglycan, known as type III receptor or 
betaglycan (Wrana et al., 1992). This process then facilitates the formation of a bi-
dimeric receptor complex. Binding of TGF-β to receptor type I (TGFβRI, also 
known as ALK5) brings together receptor type II family forming a complex of two 
serine/threonine kinase receptors which initiate intracellular signaling (Shi and 
Massague, 2003).  
TGF-β superfamily receptors consist of 12 members, namely seven type I 
receptors and five type II receptors, all belonging to TGF-β signaling pathway 
(Figure 1.8)(Manning et al., 2002).  
 
 
Figure 1.8: TGF-β superfamily ligands and receptors in vertebrates (adapted from 
(Shi and Massague, 2003)).   
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1.6.2. Mechanisms of receptor and Smad activation 
 Ligand binding to the extracellular domains of both types of the 
transmembrane receptors promotes direct contact and induces conformational change 
at the intracellular kinase interface of receptors thereby forming a heterotetrameric 
complex. This close proximity promotes phosphorylation of type I receptor at 
multiple serine and threonine residues at the cytoplasmic GS region by constitutively 
active type II receptor (Attisano and Wrana, 2002).  
Subsequent activation of receptor type I is mediated through 
autophosphorylation. Activated TGFβ-RI then specifically recognizes intracellular 
receptor-regulated Smad proteins (R-Smads) with the aid of adaptor protein SARA 
(Smad anchor for receptor activation) (Wu et al., 2000), and subsequently transmits 
the signal through direct phosphorylation at serine residues located at the extreme 
carboxy terminus (Attisano and Wrana, 2000).  
Once activated by phosphorylation, Smad2 and/or Smad3 form a 
heterodimeric or heterotrimeric complex with a common signaling partner Smad4, 
also known as cooperating-Smad (Co-Smad), and translocate into the nucleus and in 
concert with adaptor transcription factors regulate the transcription of a large set of 
target genes (Figure 1.9)(Chen et al., 2002; Derynck et al., 1998; Derynck and 
Zhang, 2003; Gomis et al., 2006).  
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Figure 1.9: Simple diagram of TGF-β signaling from cell membrane to nucleus 
(Derynck and Zhang, 2003). 
 
The R-Smads are composed of two conserved domains separated from each 
other by a proline-rich less-conserved linker region (Shi et al., 1998). MH1 domain 
located at the far N-terminus has DNA-interaction domain, whereas subcellular 
localization and transcription regulatory activity is mediated by MH2 domain 
situated at the C-terminus (Figure 1.10) (Hill, 2009; Wu et al., 2000).  
 
Figure 1.10: Conserved domain structures in receptor-regulated Smads in 
vertebrates. S: serine, V: valine, M: methionine, P: mark of phosphorylation (Hill, 2009).   
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1.6.3. Dynamic Smad nucleocytoplasmic shuttling for proper signal 
transduction 
 Receptor mediated activation of R-Smads mediates their subsequent 
translocation into the nucleus. At steady-state, R-Smads are predominantly in the 
cytoplasm in their inactive forms, whereas Smad4 is distributed through the 
cytoplasm and the nucleus. Unlike R-Smads, inhibitory-Smads (I-Smads, Smad6 and 
Smad7) which block TGF-β signaling by recruiting ubiquitin ligases-Smurfs to the 
receptors and ensuring their internalization and degradation (Kavsak et al., 2000), are 
nuclear and upon initiation of TGF-β signal propagation tend to move to the 
cytoplasm (Hanyu et al., 2001; Itoh et al., 1998).  
Upon activation, R-Smads and Smad4 translocate into the nucleus. Shuttling 
between the nucleus and cytoplasm is controlled by reciprocal functions of importin, 
a transporter that binds to nuclear localization sequences (NLS) and carries the cargo 
into the nucleus, and CRM1, an importin-like adaptor protein which binds to nuclear 
export sequences on Smads mediates their export from the nucleus (Xiao et al., 2003; 
Xiao et al., 2000).  
 
1.6.4. Target gene activation by Smads 
 Recruitment of activated R-Smads to DNA is the key step in modulation of 
gene expression in response to TGF-β stimulation. The presence of additional amino 
acids encoded from exon 3 (Ex3) on MH1 domain in the most common splice form 
of Smad2 interferes with its DNA-interaction feature which renders Smad2 different 
from Smad3 and Smad4. Direct contact with DNA located on regulatory regions of 
target genes is ensured by 5 bp sequence CAGAC, referred as Smad-binding 
element, although CAGA has been reported to suffice for optimal binding (Kim et 
al., 1997).  
Smad-binding element can be found on average once every ~1 kb on human 
genome (Massague and Wotton, 2000). This also corresponds to one CAGA 
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sequence on every candidate gene with the similar average size. However, all these 
sequences do not bind Smad factors and association of Smads with DNA is quite 
unstable to solely provide an effective binding in vivo and explain target gene 
selection by TGF-β (ten Dijke et al., 2000). Selectivity and high affinity for target 
gene activation is achieved through direct association of R-Smads and Co-Smads 
with more that one SBE together with additional DNA contacts mediated by DNA-
binding partners and transcriptional co-activators and co-repressors (Zawel et al., 
1998).  
Smad interactions with other transcription factors can be mediated by MH1 
and/or MH2 domains. In addition, selective gene responses either transcriptional 
activation or repression could be direct which involves contact of Smads with DNA, 
or “self enabled” in which product of a direct target subsequently associates with 
Smads to control another set of gene regulations (Kang et al., 2003).  A list of Smad 
co-activators and co-repressors is depicted below which explains Smad signaling 
through protein and DNA interactions (Table 1.1). 
 
 
 
 30
   
Table 1.1: Smad co-activators and co-repressors (ten Dijke et al., 2000) 
 
1.6.5. Regulation of cell cycle progression and apoptosis by Smad proteins 
TGF-β pathway has been demonstrated to regulate many intracellular 
processes along with proliferation and apoptosis in many cell types. Cell cycle 
inhibition manifested by TGF-β is predominantly a G1-phase arrest (Ewen et al., 
1995; Geng and Weinberg, 1993; Herrera et al., 1996; Zhang et al., 1999), although 
G2-arrest has also been reported (Hashimoto et al., 2003). TGF-β-mediated anti-
proliferative responses are controlled by multiple mechanisms and depend on the 
cellular context. Several studies have implicated TGF-β in growth arrest of various 
through upregulation of p15Ink4b and p21Cip1 (Polyak et al., 1994; Senturk et al., 
2010), which then inhibit cyclin-dependent kinase (CDK)-mediated phosphorylation 
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of retinoblastoma protein (pRb) (Florenes et al., 1996; Rich et al., 1999; Robson et 
al., 1999). TGF-β-induced upregulation of p21Cip1 is in most cases p53-independent 
(Datto et al., 1995). TGF-β can also induce cell cycle arrest in p15Ink4b-deficient cells 
by upregulation of p27Kip1 expression as well as inhibition of the expression of CDK 
tyrosine phosphatase cdc25A (Iavarone and Massague, 1997). 
 TGF-β inhibits the expression of c-Myc proto-oncogene through direct 
interaction of Smad3 and Smad4 to regulatory regions located in the Myc promoter 
(Chen et al., 2001). Although E2F4/5, p107 and p130 were demonstrated to be direct 
targets of TGF-β (Belbrahem et al., 1996), they were also implicated as Smad 
cofactors in c-myc down regulation mechanism (Chen et al., 2002). TGF-β-induced 
c-myc downregulation has also been shown to regulate TGF-β-mediated activation 
of p15Ink4b (Seoane et al., 2001).  
TGF-β family factors can also induce apoptotic cell death in many cell types 
which is typically accompanied by growth arrest. Several lines of evidence 
implicated JNK and p38 pathways in TGF-β-induced apoptosis which is mediated by 
the adaptor protein Daxx (Edlund et al., 2003; Perlman et al., 2001). Programmed 
cell death induced by TGF-β is usually accompanied by reactive oxygen species 
accumulation (Langer et al., 1996), decreased expression of Id2 (Cao et al., 2009) 
and transcriptional modulation of BIK and BCL-XL proteins (Spender et al., 2009). 
 
1.6.6. Role of TGF-β signaling in epithelial-mesenchymal transition 
 TGF-β signaling pathway is also a potent inducer of epithelial mesenchymal 
transition. EMT is a complex machinery which involves break-down of polarized 
epithelial morphology and transformation into spindle shaped cells together with 
reduced adhesion at cellular junctions. These phenotypic alterations are mainly 
accompanied by loss of apical-basolateral cell polarity, actin reorganization and 
down regulation and internalization of E-cadherin and ZO-1 and increased cell 
motility (Levayer and Lecuit, 2008). TGF-β-induced EMT has been demonstrated in 
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many different cell types including keratinocytes, mammary epithelial cells and 
hepatocytes (Cui et al., 1996; Davies et al., 2005; Miettinen et al., 1994; Sheahan et 
al., 2008). Several lines of evidence implicated the combinatorial action of 
transcriptional factors during TGF-β-induced mesenchymal transdifferentiation. 
These factors function in a tissue- and developmental stage-specific manner 
associated with their expression patterns (Peinado et al., 2007). These factors belong 
to Snail family, ZEB family and helix-loop-helix transcription factors including 
Twist transcription factors (Xu et al., 2009). Snail and Zeb family transcription 
factors bind to regulatory E-box elements found on various target genes (Figure 
1.11).  
 
Figure 1.11: Expression of epithelial mesenchymal markers by TGF-β-regulated 
transcription factors. (Xu et al., 2009). 
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Through direct association with DNA together with recruitment of a complex 
consisting of HDAC, TGF-β-induced Snail family transcription factors regulate the 
expression of various target genes including E-cadherin (Dhasarathy et al., 2007; 
Zavadil and Bottinger, 2005). Similarly, Zeb family factors recognize E-box 
elements on regulatory regions of targets genes and repress transcription of E-
cadherin by recruiting transcriptional co-repressor C-terminal binding protein (CtBP) 
(Vandewalle et al., 2005). Smad-interacting protein-1 (SIP1), member of Zeb family 
transcription factors, is a downstream target of TGF-β signaling pathway (Kojima et 
al., 2008). Interestingly sip1, hereafter termed as zeb2, interacts predominantly with 
activated Smad3 and inhibits expression of epithelial marker genes (Postigo et al., 
2003). The HLH factors Twist1 and Twist2 and high mobility group A2 (HMGA2) 
proteins are other downstream effectors of TGF-β during EMT (Mani et al., 2007; 
Thuault et al., 2006).        
 
1.6.7. TGF-β signaling pathway in cancer 
 TGF-β signaling perturbations are frequently observed during carcinogenesis. 
Genetically unstable cancer cells have the capacity to escape the suppressive 
functions of TGF-β pathway through accumulation of inactivating mutations in 
major components. Mutations and allelic loss of heterozygosity (LOH) are frequently 
detected in receptor type II (TGFBR2) in various types of cancers (Levy and Hill, 
2006). Truncating mutations on both alleles of TGFBR2 frequently occur in colon, 
gastric, head and neck carcinomas. Such mutations are typically associated with 
replication errors in tumors with microsatellite instability. On the other hand, 
infrequent mutations such as frameshift and missense mutations have been reported 
for receptor type I (TGFBRI) coding region in ovarian and esophageal cancers 
(Kaklamani et al., 2004). In addition, deregulated expression of both types of 
receptors through epigenetic alterations have been identified in prostate and bladder 
cancers (Kim et al., 2000).        
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 In sharp contrast to R-Smads, Smad4 inactivating mutations are more 
frequent in cancers (Levy and Hill, 2006). Smad4 has been demonstrated to be 
inactivated in most of the pancreatic and gastric carcinomas, juvenile polyposis, and 
biliary tract carcinomas (Hahn et al., 1998; Howe et al., 1998; Powell et al., 1997). 
Smad2 and Smad3 mutations were very rare in colorectal, esophageal and 
hepatocellular carcinomas (Kawate et al., 1999; Osawa et al., 2000; Yakicier et al., 
1999). Nevertheless, TGF-β pathway disruption in hepatocarcinomas is frequently 
associated with perturbed expression of adaptor protein embryonic liver fodrin (ELF) 
(Baek et al., 2008; Mishra et al., 2004). 
 Several lines of evidence presented above implicated TGF-β pathway as a 
potent tumor-inhibitory mechanism. Frequent inactivations observed with receptors 
and Co-Smad supports this notion. Loss of TGF-β-mediated cytostatic response in 
various tumors is achieved through perturbation of p15Ink4b and p16Ink4a expression 
by epigenetic silencing of INK4 locus as well as homozygous deletions (Herman et 
al., 1996; Krimpenfort et al., 2007; Krimpenfort et al., 2001). Loss of TGF-
β responsiveness could also be related to oncogene activation.  
Cancer cells that loose tumor-suppressive arm of TGF-β pathway usually 
acquire ability to interpret TGF-β signals as tumorigenic to enhance tumor growth, 
invasion and distal metastasis (Gupta and Massague, 2006). Recently, much attention 
has been paid on linker region phosphorylation of R-Smads as a candidate 
mechanism to switch tumor-suppressive function of TGF-β pathway into tumor-
promoter role. For instance oncogenic Ras can suppress inhibitory functions of TGF-
β pathway through linker phosphorylation of Smads (Sekimoto et al., 2007). GSK3β 
is one of the factors identified to directly phosphorylate several residues situated in 
the linker region and perturb TGF-β signal (Lu et al., 2008; Wang et al., 2009). In 
addition, HCV core protein expression in the liver inhibits TGF-β cytostatic 
responses (Battaglia et al., 2009). Direct crosstalk between hyperactive PI3K and 
TGF-β pathways is also implicated in suppression of TGF-β cytostatic responses 
(Conery et al., 2004; Danielpour and Song, 2006; Song et al., 2006).   
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 Tumor-promoting activities of TGF-β pathway is typically linked to epithelial 
mesenchymal transition by which contributes to tumor invasion and dissemination 
(Giampieri et al., 2009; Moutsopoulos et al., 2008). In addition to that, cancer cells 
resistant to cytostatic responses benefit from immunosuppressive functions of TGF-β 
to evade immunity (Gorelik and Flavell, 2001).             
 
1.7. Reactive oxygen species (ROS) and NADPH oxidase system 
 Oxygen-derived small molecules produced by cells are, in general, termed as 
reactive oxygen species (ROS). Intracellular ROS generation is usually initiated by 
formation of superoxide which is then converted to hydrogen peroxide by superoxide 
dismutases. ROS molecules interact with a diverse set of intracellular 
macromolecules and may therefore irreversibly destroy their functions.  
 The physiological ROS generation is usually considered as generation of 
byproducts of several other biological functions. Intracellular ROS generation occurs 
in several intracellular organelles by endogenous sources including mitochondria, 
peroxisomes, cytochrome p-450, cell membrane and other cellular entities (Balaban 
et al., 2005; Gonzalez, 2005; Pritchard et al., 2001). ROS can also be produced by 
exogenous sources including environmental agents, pharmaceuticals (Klaunig and 
Kamendulis, 2004). Such reactive oxygen species may then influence many 
biological processes by inducing DNA and protein-damage, damage to protein-
coding and non-coding RNA, and chromosomal instability together with loss of 
tumor-suppressor genes and finally oxidative damage on other biological systems 
that may provoke carcinogenesis (Ishikawa et al., 2008; Kumar et al., 2008; Tanaka 
et al., 1999). 
 Oxidative DNA-damage has been proposed as a major source of DNA 
mutations with a diverse array of DNA adducts (Dizdaroglu, 1992; Lu et al., 2001). 
Much effort has been made on studies with most abundant oxidative DNA lesion 8-
hydorxydeoxy guanosine (8-OHdG) showing elevated levels in various human 
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cancers, including hepatocarcinomas (Diakowska et al., 2007; Miyake et al., 2004) 
and in vivo hepatocarcinogenesis models (Muguruma et al., 2007).  
 
1.7.1. NADPH (reduced nicotineamide adenine dinucleotide phosphate) oxidase 
system  
The NOX family members are transmembrane proteins that control the 
transfer of electrons in various biological membranes found in virtually all cell types. 
In this system, the electron acceptor is oxygen and superoxide (O2.-) is the end 
product of this reaction. Therefore, the ultimate biological function of NOX family 
NADPH oxidases is the generation of ROS. Several Nox homologs have been 
identified in the last few decades. In accordance with conservation, all members have 
been demonstrated to have preserved structural and functional features together with 
known regulatory factors (Table 1.2). Phox, gp91phox, is the first super-oxide 
generating NADPH oxidase identified in macrophages and neutrophils (Han et al., 
2001).    
 
Table 1.2: Human Nox/Duox enzymes and tissues with highest level of 
expression. (adapted from (Lambeth, 2004)). 
 
 The Nox family members were grouped into three in accordance with their 
common domain gp91phox and additional domains necessary for complete 
functionality (Lambeth et al., 2000). The first group includes Nox1, Nox3 and Nox4 
enzymes which are almost identical in structure and size to gp91phox. Nox5 presents 
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high identity to gp91phox with an additional calmodulin-like domain which consists 
of four binding sites for calcium which makes this unique among previous enzymes 
to be regulated by other factors (Banfi et al., 2001). Along with preserved similarity 
to Nox5, Duox1 and Duox2 enzymes constitute the third group with an additional 
peroxidase-homology domain (Edens et al., 2001; Ritsick et al., 2004). Function of 
these two enzymes is also modulated by calcium.  
 Regulation of Nox family members is also modulated by other identified 
factors, namely membrane-associated p22phox and the cytosolic subunits p47phox, 
p67phox and p40phox and small GTPase RAC (Vignais, 2002). 
  
1.8. Objectives and rationale 
 Hepatocellular carcinoma (HCC) is among the most frequent cancers in the 
human population. Despite its high incidence rate in the world, there is only little 
understanding of the molecular mechanisms leading to the onset of 
hepatocarcinogenesis. Owing to genetic heterogeneity of HCCs, development of 
therapeutic options are very limited (Farazi and DePinho, 2006). Therefore, it is of 
ultimate importance to delineate the mechanisms leading to transformation of 
hepatocytes and develop new strategies to implement novel tumor-suppressive 
therapeutics.  
Somatic cells have a limited proliferative potential in culture. Following a 
number of divisions they cease proliferation due to end-replication problem of 
telomeric regions and terminally enter a cellular state referred to as replicative 
senescence. Nevertheless, replicative immortality is a hallmark of cancers (Hanahan 
and Weinberg, 2000). Recently, senescent cells have been identified in various 
premalignant tumors and multiple liver disease stages; therefore senescence has been 
implicated as an anticarcinogenic program against malignant transformation and 
immortalization. In hepatocellular carcinoma, senescence inducing factors p16Ink4a 
and p53 are usually inactivated through epigenetic and genetic mechanisms (Ozturk, 
1999). Nonetheless, a few recent reports have provided strong evidence that the 
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senescence machinery could be utilized as an anti-tumor barrier in HCCs (Ozturk et 
al., 2006; Wu et al., 2007; Xue et al., 2007).    
 Transforming growth factor-beta (TGF-β) has been implicated in senescence 
induction in various cell types as well as liver diseases (Nagasue et al., 1996; 
Reimann et al., 2010; Sacco et al., 2000; Sugano et al., 2003; Vijayachandra et al., 
2009). We demonstrated close correlation between TGF-β expression patterns and 
senescence frequencies of various liver disease stages. Therefore, we hypothesized 
that TGF-β could be used as a senescence-inducing agent in hepatocellular 
carcinomas.  
In the framework of this study, we aimed to study implications of TGF-β 
signaling in a set of HCC cell lines. Screening of HCC cell lines for TGF-β 
responsiveness demonstrated senescence-induction in only epithelial-like well-
differentiated (WD) cell lines, while those with high mesenchymal marker 
expression referred to as poorly-differentiated (PD) were typically resistant to TGF-
β-induced senescence. In this regard, we divided the study into two and aimed to 
characterize the senescence induction in WD cell lines and address the potential 
implications of senescence in vivo. In addition, we further aimed to study the 
mechanisms underlying resistance to TGF-β-induced growth arrest in mesenchymal-
like cell lines.  
 Having elucidated the rapid onset of permanent senescence arrest after very 
brief stimulation with TGF-β, we also aimed to investigate the implications of 
sustained exposure of Huh7 cells to TGF-β treatment.       
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CHAPTER 2. MATERIALS AND METHODS 
2.1. MATERIALS 
2.1.1. General reagents 
 Most of the chemicals used in the laboratory including bradford reagent, 
haematoxylin, ethanol and methanol were from Sigma-Aldrich (St. Louis, USA) and 
Merck (Darmstadt, Germany). Additionally, ECL+ Western blot detection kit was 
from Amersham GE Healthcare Life Sciences (Buckinghamshire, UK). Fluorescent 
mounting medium was from Dako (Denmark). Ponceau S and DMSO were from 
Applichem Biochemica (Darmstadt, Germany). X-Gal was from Fermentas GmbH 
(Germany). Total RNA isolation kit: Nucleospin RNA II was from Macherey-Nagel 
(Duren, Germany). Standard agarose was from Sigma Biosciences (St. Louis, USA). 
Purified recombinant human TGF-β1 was from R&D Systems (Minneapolis, USA). 
Maxi-prep kit (for large scale plasmid isolation) and Gel-extraction kit (for recovery 
and extraction of DNA from agarose gel) were from Qiagen (Chatsworth, CA, USA). 
Agar, tryptone and yeast extract were obtained from Gibco, BRL Life Technology 
Inc. (Gaithersburgs, MD, USA). Doxocycline was purchased from Appligene 
(France). 
 
2.1.2. Bacterial Strains 
 The bacterial strain used in this study was E.Coli DH5a. 
 
2.1.3. cDNA synthesis and polymerase chain reaction (PCR) reagents 
 Fermentas RevertAid First Strand cDNA synthesis kit was from Fermentas 
(Leon-Rot, Germany). Polymerase Chain Reaction (PCR) reagents were also 
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purchased from Fermentas. Master Mix for qPCR reactions, DyNAmo HS SYBR 
Green qPCR Kit F-410L, was purchased from Finnzymes (Finland). 
 
2.1.4. Nucleic acids 
 DNA molecular weight markers and ultrapure deoxyribonucleotides were 
purchased from MBI Fermentas. pEGFP-N2 (Clontech) and pcDNA-3.1C 
(Invitrogen) were obtained commercially. pSBE4-luc and p3TP-lux constructs were 
kindly provided by Edward B. Leof (Mayo Clinic Cancer Center, MN, USA). The 
Nox4 and control siRNAs were synthesized by Metabion (Martinsried, Germany). 
 
2.1.5. Oligonucleotides 
Oligonucleotides used in this study were synthesized by İONTEK (Istanbul, 
Turkey). The complete list of oligonuclotides is given in Table 2.1. 
Primer ID Sequence (5’ → 3’)                                           Product Size (bp)
c-Myc-F CCTACCCTCTCAACGACAGC 248 
c-Myc-R CTCTGACCTTTTGCCAGGAG 
PAI-1-F CACCCTCAGCATGTTCATTG 188 
PAI-1-R CCAGGTTCTCTAGGGGCTTC 
Nox4-RT-F TCCTCGGTGGAAACTTTTGT 136 
Nox4-RT-R TGTCCCATATGAGTTGTTCTGG 
Nox4-Ex1-F GCCAACGAAGGGGTTAAACA 733 
Nox4-Ex2-R CTGGCCCTTGGTTATACAGC 
Nox4-Ex9-F CGGCTGCATCAGTCTTAACC 163 
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Nox4-Ex9-R AGCTTGGAATCTGGGCTCTT 
Smad2-F CGAAATGCCACGGTAGAAAT 130 
Smad2-R GATTACAATTGGGGCTCTGC 
Smad3-F CAGAGTGCCTCAGTGACAGC 134 
Smad3-R AGCGAACTCCTGGTTGTTGA 
Smad4-F TTTGGGTCAGGTGCCTTAGT 142 
Smad4-R TGACACTGACGCAAATCAAAG 
p27Kip1-F GGCCTCAGAAGACGTCAAAC 147 
p27Kip1-R ACAGGATGTCCATTCCATGA 
p15Ink4b-RT-F ATGCGCGAGGAGAACAAG 138 
p15Ink4b-RT-R GAAACGGTTGACTCCGTTG 
p15Ink4b-Ex1-F CGGGGACTAGTGGAGAAGGT 174(cDNA)-297(gDNA) 
p15Ink4b-Ex2-R GGTGAGAGTGGCAGGGTCT 
p16Ink4a-F GGGTCCCAGTCTGCAGTTA 131 
p16Ink4a-R GGAGGGTCACCAAGAACCT 
GFP-F ACTACCTGAGCACCCAGTCC 
GFP-R CTTGTACAGCTCGTCCATGC 
GAPDH-F GGCTGAGAACGGGAAGCTTGTCAT 169 (cDNA) 
GAPDH-R CAGCCTTCTCCATGGTGGTGAAGA 272 (gDNA) 
Alk4-RT-F CGTGAAGAACGGTCTTGGTT 153 
Alk4-RT-R GGACCCGTGCTCATGATAGT 
p15-Clon-Iso1&2-F GATGCCAAGCTTATGCGCGAGGAGAACAAGG 441 
p15-Clon-Iso1-R TTGTCAGAATTCTCAGTCCCCCGTGGCTGTG 
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p15-Clon-Iso2-R ATGCCAGAATTCCTAGGTTCCAGCCCCGATC 261
p21-Clon-F GATGCCAAGCTTATGTCAGAACCGGCTGGGG 519
p21-Clon-R AGTCGCGGATCCTTAGGGCTTCCTCTTGGAG 
p15-Seq-Ex1-F CGTTAAGTTTACGGCCAACG 307
p15-Seq-Ex1-R ACATCGGCGATCTAGGTTCC 
p15-Seq-Ex2-F GGGTGAAAACTTTGCAATTAGG 461
p15-Seq-Ex2-R TGGCAGCCTTCATCGAATTA 
Cdh1-F AGCGTGTGTGACTGTGAAGG 240
Cdh1-R CTCTTCTCCGCCTCCTTCTT 
Zeb2-F TCCTGTCTGTCTCGCAAAAA 193
Zeb2-R GCCTTGAGTGCTCGATAAGG 
Vimentin-F CGTCACCTTCGTGAATACCA 169
Vimentin-R CCAGAGGGAGTGAATCCAGA 
Alk5-F TGAATCCTTCAAACGTGCTG 207
Alk5-R TCACAGCTCTGCCATCTGTT 
TGF-betaRI-F TTGTGGCACGGTGAGAGTGT 865
TGF-betaRI-R TGCTCCTGGGCTATTGAATCA 
TGF-betaRII-F GTTAACCGGCAGCAGAAGCT 401
TGF-betaRII-R ATCAGCCAGTATTGTTTCCC 
 
Table 2.1: Primer list 
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2.1.6. Electrophoresis, luciferase assay, spectrophotometer and ELISA readings 
Horizontal electrophoresis equipment was from Thermo Scientific 
(Wilmington, USA). Power supplies Power-PAC200 and Power-PAC300 were from 
Bio-Rad Laboratories (CA, USA). Protein concentrations were measured by 
Bradford Assay with the aid of spectrophotometer Beckman Du640, from Beckman 
Instruments Inc. (CA, USA). Nucleic acid measurements were performed with 
NanoDrop from Thermo Scientific. Luciferase reporter assay reagents were from 
Promega. The Reporter Microplate Luminometer Reader was from Turner Bio-
Systems (Sunnyvale, USA). ELISA reader was from Beckman Instruments. 
 
2.1.7. Tissue culture materials and reagents 
 Dulbecco’s modified Eagle’s medium (DMEM) and Roswell Park Memorial 
Institute (RPMI) 1640 medium were purchased from GIBCO (Invitrogen, Carlsbad, 
CA, USA). Opti-MEM medium, penicillin/streptomycin solution, trypsin-EDTA, 
fetal calf serum (FCS) and Geneticin-sulphate (G418, neomycin) were also from 
GIBCO. Tissue culture flasks, petri dishes, plates, cryovials were obtained from 
Corning Life Sciences Incorporated (USA). Serological pipettes were from Costar 
Corporation (Cambridge, UK). Transfection reagents, namely Oligofectamine, 
Lipofectamine 2000, and Lipofectamine RNAiMax were purchased from Invitrogen.  
  
2.1.8. Antibodies 
 Primary and secondary antibodies used throughout the study were 
commercially obtained from various sources. Working dilutions of primary 
antibodies are depicted in Table 2.2.  
 
 44
Primary/Secondary          
Antibody 
Company and 
catalog number 
Western Blot (tested 
dilution) 
Immunostaining 
working dilution 
p15Ink4b Santa Cruz, sc612 1:400 (RT)   1:1000 
(O/N) 
1:1000 (IP) 
p21Cip1 Calbiochem, OP64 1:100 (RT)     1:250 
(O/N) 
1:100 (IF, IP) 
p27Kip1 BD Biosciences, 
554069 
1:250  1:100 (IF) 
p53 BD Biosciences, 
554293 
1:500 (RT) - 
p-p53 Cell Signaling, 9284 1:500 (O/N) - 
c-myc Calbiochem, OP10 1:1000 (O/N) 1:150 (IP) 
α-tubulin Calbiochem, CP06 1:10000 (RT) 1:25000 
(O/N) 
- 
Calnexin  Sigma, C4731 1:10000 (RT) - 
p16Ink4a Calbiochem, NA29 1:250 (RT) - 
pRb BD Biosciences, 
554136 
1:500 (O/N) - 
Vimentin Dako, M7020 1:5000 (O/N) 1:500 (IF, IP) 
ZO-1 Transduction, 610966 1:2500 (O/N) 1:500 (IF) 
p-Smad2 Cell Signaling, 3101 1:1000 (O/N) 1:200 (IF) 
p-Smad3 Cell Signaling, 9514 1:1000 (O/N) 1:150 (IF, IP) 
Smad2/3 BD Biosciences   
610843 
1:1000 (O/N) 1:250 (IF) 
Smad3 Santa Cruz, sc8332 1:1000 (O/N) 1:200 (IF) 
Smad4 Santa Cruz, sc7966 1:1000 (O/N) 1:250 (IF) 
GSK3β Transduction, 
G22320 
1:2500 (O/N) - 
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Actin Santa Cruz, sc1616 1:2000 (O/N) - 
PARP Santa Cruz, sc8007 1:1000 (O/N) - 
Cleaved Caspase-3    
(Asp 175) 
Cell Signaling, 9664 1:500 (O/N) 1:150 (IP) 
Phospho-pRb Cell Signaling, 9308 1:1000 (O/N) - 
e-cadherin Santa Cruz, sc7208 1:2000 (O/N) - 
CK19 Santa Cruz, sc6278 - 1:250 (IF) 
PAI-1 Santa Cruz, sc5297 1:500 (O/N) - 
p107, p130 Santa Cruz, sc318 
sc317 
1:200 (O/N) - 
β-catenin Santa Cruz, sc7963 1:2000 (O/N) 1:350 (IF) 
Nox4 Santa Cruz, sc30141 1:2500 (O/N)          
1:750 (RT) 
1:250  (IF) 
H3K9me1 (rabbit 
antiserum) 
Abcam, Ab9045 - 1:350 (IF) 
H3K9me3 (rabbit 
antiserum) 
Upstate, 07-523 - 1:350 (IF) 
H3K27me1 (rabbit 
polyclonal) 
Upstate, 07-448 - 1:350 (IF) 
H3K27me3 (rabbit 
polyclonal) 
Upstate, 07-449 - 1:350 (IF) 
H3K36me3 (rabbit 
polyclonal) 
Abcam, ab9050 - 1:350 (IF) 
BrdU DAKO, M0744 - 1:500 (IF, IP) 
Anti-mouse-HRP Sigma, A0168 1:5000 - 
Anti-rabbit-HRP Sigma, 6154 1:5000 - 
Anti-mouse/rabbit-Alexa 
Fluor 488 
Invitrogen, A11034 - 1:750 (IF) 
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Anti-mouse/rabbit-Alexa 
Fluor 568 
Invitrogen, A11031 - 1:600 (IF) 
WHSC1 Abcam, 75359 1:5000 (O/N) 1:1000 (IF) 
 
Table 2.2: Antibody dilutions and working conditions 
 
2.1.9. Restriction endonucleases  
 All restriction enzymes used in this study were purchased from Fermentas. 
T4 DNA ligase was from Promega.  
 
2.1.10. Immunoperoxidase staining reagent 
 In immuno-peroxidase staining experiments; DAKO EnVision+ System was 
used, DAKO (Glostrup, Denmark). 
 
2.2. SOLUTIONS AND MEDIA 
 
2.2.1. Electrophoresis buffers 
50X Tris-acetic acid-EDTA (TAE)  2 M Tris-acetate, 50 mM EDTA 
pH 8.5 Diluted to 1X for working 
solution. 
 
Ethidium bromide  10 mg/mL in water (stock 
solution),       30 ng/mL (working 
solution) 
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6X Gel loading dye solution  10 mM Tris-HCl (pH 7.6), 
0.03% bromophenol blue, 0.03% 
xylene cyanol, 60% glycerol, 
60mM  EDTA (0.5M pH8.0) 
 
2.2.2. Reagents used in bacteria experiments 
Luria-Bertani medium (LB)     10 g bacto-tryptone, 5 g  
       bacto yeast extract, 10 g NaCl. 
       For agar plates, add 15 g/L  
       bacto agar. 
 
Ampicillin   100 mg/mL solution in double
 distilled water, sterilized by  
 filtration and stored at -20°C  
 (stock solution). 100 μg/mL  
 (working solution) 
 
Kanamycin       300 mg/mL solution in double-
       distilled water sterilized by  
       filtration and stored at -20°C  
       (stock solution). Working  
       solution was 30 μg/mL. 
 
 
 
 48
SOB medium       20 g tryptone (2%), 5 g  
       yeast extract (0.5%), 0.584 gr 
       NaCl (10 mM), 0.1864 g KCl 
       (2.5 mM) autoclaved to sterilize. 
       Then, 2.46 g MgSO4 and 2.03 g 
       MgCl2 (10 mM) are added. 
 
SOC medium SOB + 20 mM glucose from 
filter sterilized 1M glucose stock 
solution in ddH2O. 
 
Transformation Buffer (TB)     10 mM K.PIPES, 55 mM MnCl2, 
       15 mM CaCl2, 250 mM KCl.  
       Filter sterilize and store at 4oC. 
 
2.2.3. Cell culture solutions 
DMEM/RPMI working medium    10% FBS/FCS, 1% penicillin/
       streptomycin, 1% non-essential 
       amino acid. Store at 4oC. 
 
10X Phosphate-buffered saline (PBS)  80 g NaCl, 2 g KCl, 14.4 g 
Na2HPO4, 2.4 g KH2PO4, pH 7.4. 
Store at 4oC.  
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2.2.3.1. Antibiotics and reconstitution of TGF-β1 
Geneticin-G418 (Sulfate)     500 mg/mL solution in double-
       distilled water. Sterilized by  
       filtration and stored at -20°C  
       (stock solution).  
 
Puromycin  2 mg/mL in double-distilled 
water (stock solution). Sterilized 
by filtration (0.2 μm pores) and 
stored at -20°C.  
 
 
Doxocycline 1 mg/mL stock solution in 70% 
ethanol, sterilized by filtration 
(0.2 μm pores) and stored at -
20°C.  
 
2.2.3.2. Reconstitution of TGF-β1 
 Reconstitute at a concentration of no more than 10 μg/mL in filter sterilized 4 
mM HCl containing 1 mg/mL bovine serum albumin to ensure complete recovery 
from glass surfaces. Reconstitute TGF-β1 antibody (monoclonal mouse IgG1) at 0.5 
mg/mL in sterile PBS. 
 
2.2.4. Western blotting reagents 
NuPAGE pre-cast 4-12% gradient or 10% Bis-Tris mini gels were purchased 
from Invitrogen. MES and MOPS running buffers and 20X transfer buffer were also 
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obtained commercially from Invitrogen. 4X sample loading buffer, 10X denaturing 
agent and antioxidant used in immunoblotting were also from Invitrogen.  
 
NP-40 lysis buffer 150 mM NaCl, 50 mM TrisHCl 
(pH 8.0), 1% NP-40, 1x protease 
inhibitor (from 25X conctail) in 
double-distilled water. 
 
Modified RIPA lysis buffer 10 mM Tris-HCl (pH 7.6), 5 
mM EDTA, 50 mM NaCl, 30 
mM sodium pyrophosphate, 50 
mM sodium fluoride, 100 μM 
sodium orthovanadate, 1% 
TritonX-100 and 1X protease 
inhibitor complex in double-
distilled water. 
 
10X Tris buffered saline (TBS) 12.2 g Trisma base, 87.8 g NaCl 
in 1 liter ddH2O, pH 7.8. 
 
TBS-tween (TBS-T) 0.2% Tween-20 was dissolved in 
1x TBS. 
 
Ponceau S 0.1% (w/v) Ponceau, 5 % (v/v) 
acetic acid in double-distilled 
water. 
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Blocking solution 5% (w/v) non-fat dry 
milk/bovine serum albumin in 
0.2% TBS-T. 
 
2.2.5. Immunohistochemistry solutions 
Blocking solution 10% FBS, 0.1% Triton-X in 1x 
PBS. 
 
DAPI (4’, 6-diamino-2-phenylindole) 0.1-1 μg/mL working solution in 
double-distilled water. 
 
2.2.6. Senescence associated β-galactosidase (SABG) assay solution 
SABG buffer 40 mM citric acid/sodium 
phosphate buffer (pH 6.0), 5 
mM potassium ferrocyanide, 5 
mM potassium ferricyanide, 150 
mM NaCl, 2 mM MgCl2, 1 
mg/mL X-gal (from 40 mg/mL 
stock solution) in ddH2O. Adjust 
pH to 6.0, and filter the solution 
before use. 
2.2.7. BrdU stock preparation 
BrdU stock solution Stock: 10 mg/mL BrdU in 
ddH2O. (Working solution is 30 
μM, 9.2 μl in 10 mL culture 
medium). 
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2.2.8. Cell cycle analysis solutions    
Propidium Iodide staining solution  50 μg/mL propidium iodide, 0.1 
mg/mL RNase A and 0.05% 
TritonX-100 in 1X PBS. 
 
2.3. METHODS 
 
2.3.1. General laboratory methods 
 
2.3.1.1. Agarose gel electrophoresis of DNA 
DNA fragments were separated by horizontal electrophoresis using standard 
running buffers and loading solutions. DNA fragments less than 1 kb were generally 
separated on 2.0% agarose gel, whereas those larger than 1 kb were typically run on 
0.8 or 1.0% agarose gels. Agarose gels were completely dissolved in 1X TAE buffer 
in microwave. Ethidium bromide was added to a final concentration of 30 μg/mL. 
The DNA samples were mixed either with 6X bromo-phenol blue or 6X xylene 
cyanol loading buffer and loaded onto gels. The gel was usually run at 100-120 V at 
room temperature until the fragments were spatially separated. Nucleic acids were 
visualized under ultraviolet light and size was estimated in comparison to standard 
DNA size markers (100 bp ladder and 1 kb ladder). 
 
2.3.1.2. Restriction enzyme digestion of DNA 
 These reactions were routinely performed in 20 or 50 μl reaction volume 
depending on the quantity of the DNA material to be digested. Generally the reaction 
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was carried out for 2-3 hr or sometimes for large quantities like 5-10 μg of plasmid 
DNA for O/N, supplemented with 5-15 units of restriction enzymes at 370C. 
Appropriate reaction buffers were utilized for digestion reactions according to 
manufacturer’s recommendations. In case of double digestion with two different 
restriction enzymes, web page (http://www.fermentas.com/doubledigest/index.html) 
was visited in order to determine the recommended buffer for the reaction. 
 
2.3.1.3. Databases and software tools 
 All the necessary information regarding the gene of interest was deduced 
from NCBI and Ensembl Genome Browser. Primers were designed according to the 
instructions given in the online web tool Primer3 (http://frodo.wi.mit.edu/primer3/). 
Promoter prediction tools and corresponding web pages were given throughout the 
following pages. 
 
2.3.2. Cell culture methods 
All cell lines used in this study were grown in media supplemented with 10% 
fetal calf serum (FCS), 1% non-essential amino acids, 100 mg/mL 
penicillin/streptomycin at 370C and 5% CO2. Huh7, HepG2, Hep3B, Hep3B-TR, 
Hep40, PLC/PRF-5, Mahlavu, Focus,SkHep1 and A431 cell lines were cultured in 
DMEM, whereas the rest of the cell lines including SNU182, SNU387, SNU398, 
SNU423, SNU449, SNU475 were cultivated in RPMI growing media.   
 
2.3.2.1. Cryopreservation of stock cells 
Cells were recovered by 5 mL of DMEM/RPMI after trypsin treatment. They 
were the centrifuged at 1500 rpm for 3-5 minutes. After washing with 5 mL 1X PBS, 
cells were again spinned down at 1500 rpm for 3-5 minutes. The pellet was then 
resuspended in 1 mL of ice cold Freezing medium containing complete growth 
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medium supplemented with 10% FCS and 8% DMSO after which the cell suspension 
was transferred to freezing vials. Cells were left at -200C for 1 hour and transferred 
to -800C for long term storage. In case of availability cells were transferred to 
nitrogen tank after O/N storage at -800C.  
 
2.3.2.2. Thawing of frozen cells 
One vial of the frozen cell line was taken from the nitrogen tank or -800C 
fridge and put into ice immediately. The vial was then placed into water bath at 370C 
until the ice became a cell suspension. The cells were resuspended gently using a 
pipette and transferred to 15 mL falcon tube with 5 mL of medium. Cells were then 
centrifuged at 1500 rpm for 3-4 minutes to get rid of the DMSO which was discarded 
following centrifugation by removing the supernatant. The pellet was then 
resuspended in complete culture medium with 20% FCS to be plated into suitable 
culture disk and/or flask. Cells were left O/N in culture and the following morning 
culture medium was refreshed. 
 
2.3.2.3. Transfection of cell lines 
2.3.2.3.1. Transfection of cell lines using Lipofectamine2000 
In general, transfections were carried out in 6-well plates with a 3:1 
Lipo2000:DNA ratio. One day before transfection, subconfluent cells (4 x 105 cells) 
were plated into 6-well plates in 2.5 mL of growth medium without antibiotics so 
that the cells would be 90-95% confluent at the time of transfection.  For each 
transfection sample, plasmid DNA (4 μg) was diluted in 250 μL of Opti-MEM 
Reduced Serum Medium and mixed gently. Meanwhile, 12 μL mixed 
Lipofectamine2000 was diluted in 250 μl Opti-MEM medium and incubated for 5-10 
minutes at room temperature. After incubation period, the diluted plasmid DNA was 
combined with diluted Lipofectamine2000 (total volume = 500 μl). Afterwards, the 
complex was mixed very gently and incubated for another 20-25 minutes at room 
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temperature. During this incubation period, cells were rinsed twice with 1X PBS and 
supplemented with 2 ml Opti-MEM growth medium. Finally, after incubation was 
over, the complex was added to each well and the plates were incubated at 370C in 
the CO2 incubator. Six to eight hr later, the transfection medium was replaced with 
normal growth medium without antibiotics until the assay to be performed. 
 
2.3.2.3.2. Transfection of cell lines using FuGene-6 
Transfections with Fugene-6 Transfection Reagent were performed in 6-well 
plates with optimized Fugene-6:DNA ratios (3:1) and desired cell density. In brief; 
one day prior to transfection, cells were trypsinized, counted manually and seeded at 
a density of 2 x 105/per well to achieve the desired density of confluency at the day 
of transfection. During transfection procedure, 3 μL Fugene-6 Transfection Reagent 
was diluted with 97 μL serum-free medium (without antibiotics). The tube was 
vortexed or flicked for one second and incubated at room temperature for 5 minutes. 
Meanwhile, 1 μg of plasmid DNA was added directly into the medium without 
allowing contact with the tube wall. Then, the transfection reagent:DNA mixture was 
allowed to incubate at room temperature for 20-30 minutes which was followed by 
addition of the complex to the cells in a drop-wise fashion. Finally, 6-well plates 
were cultivated in the incubator for 12-48 hr until the time of assay.    
 
2.3.2.3.3. Transfection of cell lines using Lipofectamine RNAiMax 
Scrambled (unsilencing) and human Nox4 RNAi duplexes were obtained 
commercially from Metabion (Martinsried, Germany). The sense oligo sequences 
were as follows: 5’-GUAAGACACGACUUAUCGC-3’ (unsilencing), and 5’-
GCCUCUACAUAUGCAAUAA-3’ (Nox4 specific). For transient siRNA 
transfection, Huh7 cells, at 30-50 % of confluency in 6-well plate were transfected 
using Lipofectamine RNAiMAX in Opti-MEM Medium as recommended by the 
manufacturer, with a final siRNA duplex concentration of 10 nM. Cells were left in 
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culture for 24h, then trypsinized and seeded in 24-well and/or 6-well plates. Effects 
of TGF-β (5 ng/mL) were analyzed after 72 h of treatment. 
 
2.3.3. Luciferase reporter assay 
pSBE4-luc and/or p3TP-lux reporter constructs were co-transfected with 
pRL-TK (Promega) that contains the herpes simplex virus thymidine kinase 
promoter to provide Renilla luciferase expression as an internal control. Transfection 
experiments were performed in triplicates in 24-well plates using Lipofectamine2000 
in accordance with manufacturer’s instructions. Transfection was done with 200 ng 
of reporter vector plus 3 ng of pRL-TK. Six-hour post-transfection, cells were 
supplemented with 5 ng/mL TGF-β1-containing growth medium and incubated for 
an additional 24 hr in culture before reporter assay. The luciferase reporter assay was 
performed using Dual-Glo Luciferase assay kit (Promega) as instructed by the 
manufacturer. The luminescence intensity of Firefly luciferase was normalized to 
Renilla luciferase. 
 
2.3.4. Bromodeoxyuridine (BrdU) labelling 
To identify cells with permanent cell cycle arrest associated with senescence, 
subconfluent cells treated with different doses of TGF-β in triplicate were incubated 
with 30 μM bromodeoxyuridine (BrdU) for 24 hr in freshly added TGF-β-containing 
culture medium, then fixed with ice-cold 70% ethanol for 10 min at -20°C. After 
DNA denaturation in 2N HCl for 20 minutes, cells were incubated with monoclonal 
anti-BrdU antibody (1 hr) and followed by incubation with 1:1000 dilution anti-
mouse Alexa Fluor 488 (1 hr) and DAPI counterstaining (60 sec). 
2.3.5. RNA extraction and cDNA synthesis 
Total RNAs from cultured cells were isolated using the NucleoSpin RNA II 
Kit (Macherey-Nagel) according to the manufacturer’s protocol. First-strand cDNA 
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synthesis was carried out using 2 µg of DNase I-treated total RNA as a template 
utilizing the RevertAid First Strand cDNA synthesis kit (Fermentas). cDNAs were 
stored at -20°C. Corresponding cDNAs were subjected to semi-quantitative reverse 
transcriptase PCR (RT-PCR) and quantitative PCR (qRT-PCR) amplification using 
specific primers. 
 
2.3.6. Semi-quantitative and quantitative real-time RT-PCR assays 
PCR assays were performed using appropriate primers. Thermal cycler 
conditions were an initial denaturation step at 95°C for 5 min; a loop cycle of 95°C 
for 30 sec, at 600C for 30 sec, at 700C for 30sec; and a final extension at 72°C for 5 
minutes. All primers used for PCR amplifications in this study work at 600C.  
Quantitative expression analyses were performed using SYBR Green I 
(Invitrogen) and DyNAmo HS SYBR Green qPCR Kit F-410 (Finnzymes) on 
iCycler iQ real-time RT-PCR machine (Bio-Rad) and Mx 3005P (Stratagene). The 
PCR reaction was performed according to the manufacturer’s instructions.  
Reactions were set up in a total volume of 20 μl with 1-2 μl cDNA for each 
sample. Reactions were initiated with 10 minutes initial denaturation at 95ºC, then 
amplification was run for 45 cycles (30 seconds at 95ºC, 30 seconds at 600C, 30 
seconds at 72ºC) Expression levels were calculated using the following formula:  
R = (Etarget)ΔCttarget(control-sample) /(Eref) ΔCtref(control-sample). In the above formula Etarget and 
Eref represent the primer efficiencies for target and reference genes, respectively. 
PCR amplification efficiencies for the genes range between 1.9 and 2.0. All 
experiments were performed in triplicates. GAPDH and β-actin were used as internal 
controls in qRT-PCR experiments. 
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2.3.7. Western blotting 
Cells treated with different doses of TGF-β for 72 hr were lysed with a 
slightly modified Radio-Immunoprecipitation Assay (RIPA) Buffer (10 mM Tris-
HCl, pH 7.6, 5 mM EDTA, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM 
sodium fluoride, 100 μM sodium orthovanadate, 1% TritonX-100 and 1X protease 
inhibitor complex (Roche, Indianapolis, USA). Cconcentrations of protein lysates 
were measured by the conventional Bradford assay utilizing spectrophotometer at 
595 nm. Sample protein concentrations were normalized in accordance with bovine 
serum albumin (BSA) protein of a known concentration.  
25 μg of total protein was subjected to gel electrophoresis using NuPAGE 
system with MES and/or MOPS buffers. Proteins were wet-transferred onto HyBond 
ECL nitrocellulose or PVDF membranes, depending on the protein of interest. The 
membranes were blocked for 1 hr at room temperature with either 5% non fat dry 
milk or BSA in TBS-T, depending on the specific antibodies used. Membranes were 
incubated with the primary antibodies either at room temperature for 1 hr, or 
overnight at +4ºC. Following primary antibody incubations and extensive washing 
with TBS-T, secondary antibodies conjugated with horse-radish peroxidase (HRP) 
were incubated 1 hour at room temperature. After an additional wash of half an hour, 
chemiluminescent reaction was detected using ECL+ western blot detection kit 
(Amersham, UK), according to the manufacturer’s protocols. X-ray films were 
exposed to the emitted chemiluminescence, duration depends on the specific 
antibody. 
 
2.3.8. Enzyme-linked immunosorbent assay 
Coating of Immulon 2HB plates (Thermo, USA) was done with monoclonal 
antibodies against human cytokines IL-6 and IL-8. Coating incubations were 
essentially run at +4°C overnight with 1-5 µg/mL antibody concentrations in 1x PBS. 
For coating, 50 µL of the antibody dilutions were distributed in wells. Following 
O/N coating, anti-cytokine solution was discarded and wells were blocked with 200 
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µL blocking buffer O/N at +4°C. Washing step was performed 5 times for 5 min 
each. Following washing, plates were rinsed twice with distilled water and dried by 
tapping. Next, collected supernatants were incubated in 96-well plates at a final 
volume of 50 μL/well for each cytokine. Corresponding recombinant cytokines were 
serially distributed. Corresponding recombinant cytokine standards were serially 
diluted by two-fold starting from 1000 ng/mL concentration in 1x PBS for 11 times. 
Plates were incubated at +4°C overnight. Following cytokine and supernatant 
incubations, plates were rinsed and dried as previous washing steps. Meanwhile, 
biotin-conjugated anti-cytokine antibodies were freshly prepared in T-cell buffer 
with a 1:1000 dilution, added in the wells with a final volume of 50 µL/well and 
incubated for another 2 hr at RT. After a series of washing steps, 50 μL of 
streptavidin-conjugated alkaline-phosphatase solution (SA-AKP, Pierce, USA) 
diluted in T-cell buffer was administered to the wells. After 1 hr of incubation at RT, 
washing and drying steps were repeated. Finally, 1 tablet fresh PNPP substrate 
(Pierce, USA) was dissolved in 4 mL ddH2O + 1 mL buffer and distributed onto the 
wells as 50 µL aliquots. Development of yellow color was followed continuously 
and multiple OD readings (at 405 nm) were recorded by ELISA reader (Molecular 
Devices). The OD measurements were analyzed at SoftMax Pro v5 software. The 
OD readings were terminated when 4-parameter standard curve was reached. 
Amount of released cytokines were calculated with respect to control recombinant 
standards. 
 
2.3.9. Plasmid construction and transient antibiotic selection 
Human p15Ink4b and p21Cip1 were reverse transcribed from total RNA of 
Hep40 and HepG2 cells, respectively, using the unique Phusion DNA polymerase 
(Finnzymes). Both p15Ink4b isoform sequences were reverse transcribed with primers 
(5’-ATGCCAAGCTTATGCGCGAGGAGAACAAGG-3’ and  
5’-TTGTCAGAATTCTCAGTCCCCCGTGGCTGTG-3’) and cloned into pcDNA-
3.1-C/Neomycin (Invitrogen) using the HindIII and EcoRI restriction enzymes and 
 60
sequence verified. p21Cip1 cDNA was amplified using primers (5’-
GATGCCAAGCTTATGTCAGAACCGGCTGGGG-3’ and 5’-
AGTCGCGGATCCTTAGGGCTTCCTCTTGGAG-3’), cloned into 
pcDNA3.1(+)/Hygromycin (Invitrogen) harboring  HindIII and BamHI restriction 
enzymes and sequence verified. For transfection, empty vectors and p15Ink4b and 
p21Cip1 gene expressing plasmids were transfected into Huh7 cells using 
Lipofectamine2000 as stated previously. Huh7 cells transfected with p15Ink4b and 
p21Cip1 expression plasmids, along with corresponding empty vectors, were selected 
with 700 μg/mL Geneticin-G418 (Gibco, USA) and/or 200 μg/mL Hygromycin-B 
(Roche, Indianapolis, USA), respectively, for eight days in culture. 
 
2.3.10. Immunoperoxidase and immunofluorescence staining 
Both methods were performed essentially similar. Except that secondary 
antibody incubations and visualizations were different. For immunoperoxidase 
staining, cells were fixed with 4% formaldehyde and permeabilized with phosphate-
buffered saline (PBS) supplemented with 0.5% saponin (Sigma) and 0.3% TritonX-
100 (Sigma). After blocking for 1 hour in blocking solution (10% fetal calf serum 
and 0.1% TritonX-100 in PBS), cells were incubated with primary antibodies for 1 
hour in PBS containing 2% fetal calf serum and 0.1% TritonX-100 solution. After 
washing with PBS, cells were incubated for 30 min with Cytomation Envision+Dual 
link system-HRP (Dako), and eventually the staining was performed with DAB 
detection solution (Dako). Cover slips were then rinsed with distilled water and 
counterstained with haematoxylin (Sigma) for 3-4 min, mounted on glass 
microscopic slides using 90% (v/v) glycerol and examined under light microscope.  
For immunofluorescence staining, fixed and permeabilized cells were 
incubated 1 hr with anti-mouse or anti-rabbit Alexa Fluor 488 and Alexa Fluor 568 
secondary antibodies. Following secondary antibody incubations, cells were 
counterstained using 1:10000 4', 6-diamidino-2-phenylindole, DAPI for 1 min. 
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Coverslips were mounted onto glass slides with ProLong Gold antifade reagent 
(Invitrogen).  
 
2.3.11. Fluorescent-activated flow cytometry analysis of cell cycle distribution 
Cells were treated with TGF-β for indicated time points and harvested 
respectively. Post incubation with TGF-β, cells were rinsed with PBS and collected 
by trypsinization. Cells were pelleted and resuspended in 1 mL 1XPBS and added up 
to 3.5 mL and fixed for 15 min with 70% ice-cold ethanol on ice. Fixed cells were 
collected by centrifugation and resuspended in PI-solution (50 μg/mL propidium 
iodide, 0.1 mg/mL RNase A and 0.05% TritonX-100), and incubated 40 min at 37°C. 
Following centrifugation at 1500 rpm for 3 min, fluorescently stained cells were 
transferred to polystyrene tubes with 600 μL PBS and analyzed using FACSCalibur 
Flow Cytometer (BD Biosciences). Cell cycle arrest was assessed through analysis of 
the proportion of cells in the G1, S, and G2/M fraction of the cell cycle using Cell 
Quest 3.2.  
 
2.3.12. Measurement of intracellular ROS production 
Endogenous amounts of ROS were qualified with 2’, 7’-dichlorofluorescein 
diacetate (DCFH-DA, Fluka). Cellular fluorescence staining and intensity was 
visualized with fluorescence microscope after 30 min of incubation with 10 μM 
DCFH-DA. 100-150 nM MitoTracker Red was used as a counterstain (Molecular 
Probes).  
 
2.3.13. Senescence-associated β-galactosidase (SA-β-Gal) assay 
Cells were rinsed twice with 1XPBS and fixed with 4% formaldehyde 
(diluted in 1XPBS from 37% stock solution) for 10 min at room temperature. After 
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two additional washes with PBS, cells were allowed to stain in SABG buffer. Blue 
staining was visible under the light microscope after incubation for 12-16 hr at 37°C 
in CO2-free incubator.  
 
2.3.14. In vivo tumor assays 
Huh7, Hep3B and Hep3B-TR cells (5 million) were suspended in 250 μL 
PBS, and injected subcutaneously on the back shoulders of Balb/c nude mice and 
animals were examined for palpable tumors on a weekly basis. Intratumoral injection 
of ~50 μL of 10 ng/mL TGF-β1 solution was initiated when Huh7 tumors reached 
easily palpable sizes. Control Huh7 tumors were treated similarly with vehicle.  
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CHAPTER 3. RESULTS 
3.1. Differential expression of TGF-β1 in normal liver, cirrhosis, and 
hepatocellular carcinoma 
Recently, TGF-β1 has been implicated in liver disease processes. Based on 
earlier findings on increased hepatic levels of TGF-β in cirrhosis and HCC, we first 
analyzed TGF-β1 expression in normal liver, cirrhosis and HCC, using the publicly 
available dataset generated by Wurmbach et al. (Wurmbach et al., 2007). This 
microarray dataset was established during a study in which the main concept was to 
define the molecular mechanisms of hepatocarcinogenesis and designate novel 
therapeutic candidates for liver cancer. In this microarray analyses, the gene 
expression profiles of 75 tissue samples were conducted. These samples represent the 
gradual hepatocarcinogenesis process. Sample pathological grades start from 
preneoplastic lesions such as cirrhosis and dysplasia and eventually evolve into 
neoplastic lesions including 4 different stages characterized with metastatic tumors 
from patients with HCV infection, namely very early HCC, early HCC, advanced 
HCC and very advanced HCC.  
In order to analyze the differential expression pattern of TGF-β1 among 
various disease stages of liver, we queried TGFB1 gene in Wurmbach et. al. 
microarray data. Of two probe-sets reported to represent TGF-β1 (203084_at, 
203085_s_at), 203085_s_at demonstrated statistically significant values between 
different paired disease stages, hence was used for further analyses. TGF-β1 
expression displayed a bell-shaped distribution with a sharp increase in cirrhosis 
(cirrhosis versus normal liver, P < 0.001), followed by a progressive decrease in 
early HCC (early HCC versus cirrhosis, P < 0.02) and advanced HCCs (Figure 3.1).  
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Figure 3.1: Expression analysis of TGF-β1 in liver diseases. Regrouped samples were 
categorized into four; representing each liver tissue stage as normal liver (n=10), cirrhosis (n=13), 
early HCC (n=17) and advanced HCC (n=15). Distribution of normalized and log(2) transformed 
TGF-β1 probe-set signal intensity for each relavant-sample was drawn to scale. Mean values obtained 
for different samples were indicated with a red full-circle. Two-sided interval bars were drawn with a 
95% confidence interval for the mean. TGF-β1 expression was substantially increased in cirrhosis 
samples as compared to normal liver samples (P < 0.001). Thereafter, the expression of TGF-β1 
displayed a significant decrease between cirrhosis and early HCC samples (P < 0.02). Expression 
change of TGF-β1 was not significant between early and advanced HCC samples (P = 0.485) (Senturk 
et al., 2010). 
 
Curiously, this expression pattern displayed almost a perfect correlation with 
reported frequencies of SA-β-Gal activities in normal liver, cirrhosis and HCC with 
lowest and highest rates in normal liver and cirrhosis, respectively (Ikeda et al., 
2009a; Ikeda et al., 2009b; Kim et al., 2009a; Paradis et al., 2001; Wiemann et al., 
2002). 
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3.2. TGF-β signaling pathway in well-differentiated (WD) HCC cell lines 
3.2.1. Expression of critical TGF-β signaling components 
 Based on this co-occurrence of TGF-β expression pattern and senescence in 
liver diseases, we hypothesized that this cytokine would be causally implicated in 
hepatocellular senescence. In order to test this hypothesis, we initialized our studies 
on a panel of “well-differentiated” HCC cell lines, including Huh7, Hep40, HepG2, 
PLC and Hep3B.  Well-differentiated HCC cell lines display e-cadherin expression 
and epithelial-like morphology and share many features with normal hepatocytes 
(Yuzugullu et al., 2009). They also share the same TGF-β early response gene 
expression patterns with normal hepatocytes (Coulouarn et al., 2008). All five cell 
lines, based on studies with semi-quantitative RT-PCR, expressed TGF-β1 ligand, 
and all critical components of TGF-β signaling pathway including its receptors 
(TGFBR1 and TGFBR2) and SMADs (Figure 3.2).  
 
 
 
Figure 3.2: Expression of TGF-β signaling pathway components in well-
differentiated HCC cell lines. Expression levels of these particular genes ware studied by RT-
PCR analysis of cDNAs extracted from different cell lines. Hep3B-TR lacked TGFBR2 expression. 
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 Hep3B-TR (TR: TGF-β resistant) cell line which displayed a loss of TGFBR2 
expression and was used for control experiments. This cell line was originally 
derived from Hep3B cell line through sustained exposure to increasing doses of 
TGF-β1 and has been reported to harbor a homozygous deletion as we also 
confirmed through PCR-based amplification of this particular locus with genomic 
oligo-pairs (Figure 3.3) (Hasegawa et al., 1995; Inagaki et al., 1993).  
 
Figure 3.3: PCR analysis of TGFBR2 in genomic DNAs displayed no amplification in Hep3B-TR 
cells indicating homozygous deletion. 
  
  
3.2.2. Intact TGF-β signaling in well-differentiated HCC cell lines 
 There are several ways to analyze intactness of a growth factor stimulated 
signal transduction pathway. Expression patterns of growth factor regulated target 
genes, as well as promoter activities using luciferase reporter-based systems shall be 
explored in this regard. Here, we used a firefly luciferase-based assay to assess the 
intactness of the signaling pathway as well as responsiveness of WD cell lines to 
TGF-β treatment. All five HCC cell lines displayed intact TGF-β signaling activity, 
as tested by pSBE4-Luc reporter activity. pSBE4-Luc plasmid is an artificial 
mammalian TGF-beta-inducible Smad2/3-responsive construct which contains four 
tandem copies of human SMAD3 and SMAD4 binding elements (5 bp sequence 
CAGAC, however 4 bp CAGA suffices for activation) upstream of a minimal 
promoter adjoining a luciferase reporter (Zawel et al., 1998). Such SBEs are often 
present in TGF-β-responsive regions of target genes. Inserts containing 8 bp 
palindromic SBE sequences were generated by ligation of concatamerized 
oligonucleotides to pGL3-basic. The complementary oligonucleotides used for 
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reporter construction were 5’-TAAGTCTAGACGGCAGTCTAGACGTAC-3’ and 
5’-GTCTAGACTGCCGTCTAGACTTAGTAC-3’.    
 Following 6 hr post Lipofectamine-based transfection of all cell lines with 
pSBE4-Luc in 24-well plates, together with pRL-TK (a vector developed for internal 
control, encodes Renilla luciferase under the control of herpex simplex virus 
thymidine kinase promoter), the transfection medium containing OPTI-MEM was 
replaced with standard growth medium supplied with TGF-β1. After performing 
Dual-Glo luciferase assay measurements using luminometer firefly luciferase signal 
intensities were normalized with similarly obtained renilla luciferase signals. 
Therefore, 24 hr 5 ng/mL (200 pM) TGF-β1 treatment of cells yielded 9 to 19-fold 
induction of pSBE4-Luc reporter activity in all cell lines with the exception of non-
responsive Hep3B-TR cells (Figure 3.4).  
 
 
 
Figure 3.4: Well-differentiated HCC cell lines are competent for TGF-β-
signaling activity. Cells were co-transfected with pSBE4-Luc and control pRL-TK plasmids, and 
treated with or without TGF-β1 (5 ng/mL) for 24 hr. The luciferase activity was measured and 
expressed as fold activity of pSBE4-Luc/pRL-TK (mean ± SD; n=3). 
 
3.2.3. TGF-β stimulated transcriptional responsiveness in well-differentiated 
HCC cell lines 
 Similarly, we also did another luciferase reporter-based study using p3TP-lux, 
a reporter that is empirically designed to obtain maximal TGF-β responsiveness. 
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Along intactness of the pathway, it simply measures transcriptional responsiveness of 
cells to TGF-β and Activin growth factors as well. p3TP-lux contains a portion of the 
TGF-β−response element of plasminogen activator inhibitor-1 (PAI-1) gene 
promoter along with three repeats of the collagenase I AP-1 site in front of a 
luciferase reporter (Wrana et al., 1992). Accordingly, upon TGF-β1 stimulation, the 
signal intensity obtained from p3TP-lux response is anticipated to be quite different 
form pSBE4-luc reporter. As expected, p3TP-lux reporter analyses displayed 
different results when compared to pSBE4-luc (Figure 3.5). Unlike very high and 
similar endogenous pSBE4-luc reporter activity among untreated controls, p3TP-Lux 
reporter activity has very low and incomparably distinct values which make it 
difficult to draw in an “in-scale” figure. Thereby, for simplicity the results for p3TP-
Lux are depicted as “fold change” instead of “fold activity”.    
 
 
 
 
Figure 3.5: Well-differentiated HCC cell lines demonstrate differential 
transcriptional responses to TGF-β treatment. Cells were co-transfected with p3TP-Lux 
and control pRL-TK plasmids, and treated with or without TGF-β1 (5 ng/mL) for 24 hr. The 
luciferase activity was measured and expressed as fold change of p3TP-Lux/pRL-TK (mean ± SD; 
n=3). 
 
 
 Following reporter assays, we also analyzed TGF-β1-regulated expression of 
plasminogen activator inhibitor-1 (PAI-1), a well characterized TGF-β target gene 
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(Sandler et al., 1994) in selected three cell lines. TGF-β1 treatment induced PAI-1 
protein expression in Huh7 and Hep3B cells, but not in Hep3B-TR cell line (Figure 
3.6-A) and this was associated with induced expression of PAI-1 transcripts (Figure 
3.6-B and 3.6-C).  
 
 
Figure 3.6: Upregulation of TGF-β target gene PAI-1 in different cell lines upon 
TGF-β1 exposure. (A) The expression of PAI-1 was tested by western blotting. Huh7 and Hep3B 
cell lines displayed a substantial increase in PAI-1 protein levels with increasing TGF-β1 
concentrations after 72 hr of treatment. As expected, TGFBR2-deleted Hep3B-TR cell line was non-
responsive. Calnexin was used as a control to normalize expression levels in western blots. (B, C) RT-
PCR (B) and qRT-PCR (C) analyses indicated that TGF-β1 induced the transcription of PAI-1 in 
Huh7 cells. GAPDH (B) and β-actin (C) were used as internal controls for RT-PCR and qRT-PCR 
experiments, respectively.  
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Thus, Huh7, PLC, Hep40, Hep3B and HepG2 cell lines not only produced 
TGF-β1, but also displayed intact TGF-β signaling activity as well as transcriptional 
responses both at the mRNA and protein levels. 
 
3.3. TGF-β1 induced senescence in well-differentiated HCC cell lines 
TGF-β signaling pathway has been linked to different cellular processes 
including senescence. The interplay between TGF-β and senescence observed in 
liver tissues has never been addressed in HCC cell lines. To test our hypothesis, we 
treated all these WD cell lines with different doses of TGF-β1 (1-5 ng/mL) in 
standard serum-containing cell culture medium (on cover-slips) and kept them in 
culture up to 12 days with medium change (without TGF-β1) every three days.  
After initiation of treatment, we examined all cell lines in culture on a daily 
based follow-up. All cell lines displayed morphological changes after 12-16 hr (our 
observations, unpublished data) which became robust after 48 hr. In order to test 
senescence induction upon TGF-β1 exposure, we subjected the cells to SA-β-Gal 
assay at different time points (Figure 3.7).  
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All cell lines tested, except Hep3B-TR, displayed growth inhibition 
associated with flattened cell morphology and > 50%-positive SA-β-Gal activity, as 
early as three days after TGF-β1 treatment (Figure 3.8).  
Figure 3.7: Growth inhibition associated with potent senescence-like 
response. Cells were plated at low density and treated with 1 or 5 ng/mL TGF-β1 for 72 hr, and 
tested for SA-β-Gal activity (blue) at days 3 and 7. 0: no treatment. Counterstain: Fast Red. 
TGFBR2-deleted Hep3B-TR cells were used as negative control. 
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Figure 3.8: Percent of senescent cells after TGF-β1-treatment. (Counts for White 
bars: No TGF-β1 treatment after 3 days; Grey bars in order: 1 ng/mL and 5 ng/mL after 3 days of 
treatment; Black bars: 5 ng/mL TGF-β1 treatment after 7 days). 
 
Senescence phenotype was still detectable seven days after TGF-β1 exposure 
(Figure 3.7) and remained stable for at least 12 days (data not shown).  
 
3.4. TGF-β-induced senescence was correlated with loss of BrdU incorporation 
To confirm the specificity of senescence response, we also tested the ability 
of selected cell lines to incorporate BrdU (bromodeoxyuridine) into cellular DNA 
after TGF-β1 exposure. BrdU is a synthetic thymine analog which is incorporated 
into DNA in replicating cells during S-phase progression. Antibodies specific for 
BrdU can be used to detect positive cells by immunocytochemical staining 
procedures. Of note, detection of BrdU in such methods requires denaturation of 
DNA, usually by exposing cells to acidic buffers. In this experimental setting, 
analysis of 24 hr BrdU incorporation into cellular DNA in Huh7 and PLC cell lines 
displayed time- and dose-dependent gradual decrease as demonstrated in Figure 3.9.  
 
0%
25%
50%
75%
100%
Huh7 PLC HepG2 Hep40 Hep3B Hep3B-TR
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Figure 3.9: Time- and dose-dependent changes in percent BrdU incorporation 
in Huh7 (upper graph) and PLC (lower graph). Y-axis: BrdU + cells. (White bars: 
No TGF-β1 treatment; Grey bars: 1 ng/mL; Black bars: 5 ng/mL). 
 
 Parental Huh7 cells usually have >95% positive cells after 24 hr of BrdU 
incorporation. Following 1 ng/mL or 5 ng/mL TGF-β1 treatment, the number of 
BrdU positive cells decreased by 15-25% after 24 hr, whereas this decrease became 
robust after 48 hr and reached to a maximal inhibition at 72 hr (Figure 3.9) where 
more than 80-85% of cells lost their ability to incorporate BrdU into cellular DNA 
suggesting a strong prohibition of proliferation (Figure 3.10).  
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Figure 3.10: Dose-dependent decrease in BrdU incorporation in Huh7 cells. After 
24 hr of incorporation, cells positively labeled for BrdU were stained with immunofluorescence 
technique using anti-BrdU (mouse) primary antibody which was followed by anti-mouse alexa-488 
secondary antibody incubation. DAPI was used for nuclear counter-staining. (See Figure 3.9 for 
statistical results). At least 5 areas were counted on each triplicate assay. 
 
PLC cells, on the other hand, have a total of approximately 90% BrdU 
positive cells in untreated conditions. After exposure to different doses of TGF-beta, 
proliferation of PLC cells also decreased gradually (Figure 3.11). Only 20-25% of 
cells were able to incorporate BrdU into cellular DNA after 72 hr of treatment.  
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Figure 3.11: Dose-dependent decrease in BrdU incorporation in PLC cells. After 
24 hr of incorporation, cells positively labeled for BrdU were stained with immunofluorescence 
technique using anti-BrdU (mouse) primary antibody which was followed by anti-mouse alexa-488 
secondary antibody incubation. DAPI was used for nuclear counter-staining. (See Figure 3.9 for 
statistical results). At least 5 areas were counted on each triplicate assay. 
 
These observations suggested a dose-dependent late occurring proliferation 
arrest by TGF-β1. 
    
3.5. Cell cycle arrest provoked by TGF-β1  
 Decreased proliferation as tested by BrdU incorporation is typically 
associated with inhibition of cell cycle progression. Propidium iodide is a DNA 
intercalating agent and a fluorescence molecule that is frequently used to stain DNA 
in various techniques (Senturk et al., 2010). Therefore, we utilized propidium iodide 
labeling in TGF-β-treated cells in order to evaluate cell viability and cell cycle 
progression using flow cytometry. As reported in BrdU incorporation experiments 
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cells treated with TGF-β1 for 72 hr similarly displayed a dose-dependent decrease in 
S-phase cells and a concomitant increase in G1-phase cells (Figure 3.12).  
    
Figure 3.12: Cell cycle distribution in Huh7 and PLC cells after 72 hr TGF-β1-
treatment. (Grey bars: G1-phase; Green bars: S-phase; Yellow: G2-phase). 
 
Well-differentiated HCC cell lines under normal culture conditions usually 
have a 60% G1, 20% S, and 20% G2-M cell-cycle distribution with slight variations 
depending on the experimentation. Nevertheless, TGF-β1 treatment in Huh7 cells 
induced a G1-phase accumulation in a dose-dependent manner (72% with 1 ng/mL 
and 90% with 5 ng/mL), accompanied by a reciprocal decrease in S-phase cells (11% 
with 1 ng/mL and 5% with 5 ng/mL). PLC cells also displayed a quite similar pattern 
of cell-cycle distribution in TGF-β1 treated and non-treated conditions. The increase 
in G1-phase was moderately lower when compared to Huh7 cells. However, this 
response was in support of BrdU incorporation results (Figure 3.9, lower panel).   
Similar to time-dependent experiments for BrdU incorporation assay, we also 
performed a cell-cycle distribution analysis in a time-dependent manner; this time 
treatment was done with single 5 ng/mL dose TGF-β1. As the report given in the 
 77
Figure 3.13, Huh7 cells displayed a gradual increase in G1-phase cells from 63% to 
over 80% after 48 hr together with a maximum after 72 hr and slight increases after 
96 and 120 hr. Please note that, treatments were initiated accordingly as to perform 
measurements at the same time to minimize experimental variations in flow 
cytometry readings. The table shows percentage of cell-cycle distributions in 
indicated time points. To the right, gated cell populations obtained from the readings 
in FL2-channel are depicted.  
 
Figure 3.13: Cell cycle distribution in Huh7 cells after time-dependent TGF-β1-
treatment. Control cells were obtained from untreated samples at 120 hr.  
 
 In this outcome, please note that the higher peak on the far left, displays 2N 
cells which are G1, far right 4N cells which are G2-M and in between are the S-
phase cells which are usually 2N-4N. For simplicity, gating was done accordingly to 
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exclude >4N cells from the results, which did not display variations between treated 
and non-treated samples. 
  
3.6. TGF-β is an autocrine senescence-inducing cytokine in HCC cells 
Autocrine signaling is a form of signaling in which chemokines or cytokines 
released from a cell act on the same cell through autocrine receptors to create a loop 
of signaling events. Expression of TGF-β1 in all tested cell lines implicated that it 
could act as an autocrine cytokine. Therefore, to test this hypothesis and confirm the 
TGF-β-mediated specificity of senescence response, Huh7 cells were plated at low-
density (day zero), exposed to either TGF-β1 (5 ng/mL) or anti-TGF-β1 antibody (5 
μg/mL) on day one in regular medium, incubated with repeated treatments on days 
four and seven, and total and SA-β-Gal-positive cells in isolated colonies were 
counted on day 10, as described previously (Ozturk et al., 2006). TGF-β1 caused 7-
fold decrease in colony size (P < 0.005) (Figure 3.14) and 5-fold increase in SA-β-
Gal activity (P < 0.0001) (Figure 3.15).  
 
Figure 3.14: Colony formation in Huh7 cells after TGF-β1 and anti-TGF-β1 
antibody treatment. Huh7 cells were seeded at low density in 6-well plates. Cells were either left 
untreated or treated with 5 ng/mL TGF-β1 or 5 µg/mL neutralizing anti-TGF-β1 antibody for 10 days 
by refreshing the medium with three days intervals. Cell numbers per colony were determined on day 
10 by manual counting of at least 10 colonies per treatment. TGF-β1 treatment significantly reduced 
colony size (P < 0.005) when used at three day intervals (TGF-β1), but not when used only once three 
days before the analysis (TGF-β1*). Conversely, cells treated with neutralizing anti-TGF-β1 antibody 
displayed significantly increased colony size (P < 0.04).  
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 When cells were treated with TGF-β1 just once three days prior to cell 
counting, colony size did not change significantly, but again there was 3-fold 
increase in SA-β-Gal activity (P < 0.0001). Conversely, cells treated with 
neutralizing anti-TGF-β1 antibody displayed 2-fold increased colony size (P < 0.04), 
and SA-β-Gal activity was decreased by 50% (P < 0.02).  
 
Figure 3.15: Modulation of spontaneous senescence in Huh7 cells by TGF-β1 
and anti-TGF-β1 antibody treatment. Huh7 cells were seeded at low density in 6-well 
plates. Cells were either left untreated or treated with 5 ng/mL TGF-β1 or 5 µg/mL neutralizing anti-
TGF-β1 antibodies for 10 days by refreshing the medium with three days intervals. Cell numbers per 
percent SA-β-Gal positive cells were determined on day 10 by manual counting of at least 10 colonies 
per treatment. TGF-β1 caused significant increase in SA-β-Gal activity, when tested after one (TGF-
β1*) or three-cycles (TGF-β1) of three-day treatment (P < 0.0001). Conversely, cells treated with 
neutralizing anti-TGF-β1 antibody displayed 50% decrease in SA-β-Gal activity (P < 0.02). 
 
Collectively, these findings indicated that ectopic TGF-β1 is able to induce a 
senescence-like growth arrest response in well-differentiated HCC cell lines. 
Furthermore, Huh7 cell line produced TGF-β1 that acted as a weak autocrine 
senescence-inducing signal that was inhibited by neutralizing antibody treatment and 
amplified by ectopic TGF-β1.  
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3.7. Brief exposure to TGF-β1 for a robust senescence response  
To test the shortest time of exposure to TGF-β1 for a full senescence 
response, three cell lines were treated with TGF-β1 between < 1 minute (~20 
seconds) and 72 hr, and subjected to SA-β-Gal staining after 3 days incubation in 
culture. To our surprise, < 1 minute (~20 seconds) exposure was sufficient for a 
robust senescence response (Figure 3.16). Of note, quite similar results were 
obtained when cells were continuously cultured until Day 8 (data not shown). Thus, 
the senescence-initiating effect of TGF-β1 was immediate, even though the 
senescence phenotype (>50% SA-β-Gal positive and flattened cells) was manifested 
three days later. 
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To investigate the robust senescence response mechanism underlying the high 
impact of brief exposure to TGF-β1, we performed a series of analysis with Huh7 
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cells. First, we analyzed the amplitude of shuttling of TGF-β1 signal from cell 
membrane to nucleus by activated Smad proteins using phospho-specific Smad3 
antibody in immunofluorescence experiments. Surprisingly, a very short exposure to 
TGF-β (~20 seconds) was able to induce a time-dependent translocation and 
sustained retainment for p-Smad3 in the nucleus (Figure 3.17).  
 
 
Figure 3.17: Localization of p-smad3 even after a very short stimulation by 
TGF-β1. Huh7 cells were treated with 5 ng/mL TGF-β1 for less than 1 min and tested for p-smad3 
localization by immunofluorescence at indicated time points. 30 min continuous treatment served as 
positive control. DAPI was used for counterstaining.  
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Second, we tested activation of pSBE4-luc luciferase reporter after brief 
exposure to TGF-β1, and demonstrated that even a very short treatment was able to 
produce a similar response as compared to 5 min and 24 hr treatment (Figure 3.18). 
 
Figure 3.18: Brief exposure to TGF-β1 for a sustained reporter activation. Cells 
were co-transfected with pSBE4-Luc and control pRL-TK plasmids, and treated with or without TGF-
β1 (1 ng/mL and 5 ng/mL) for ~20 sec, 5 min and 24 hr. The luciferase activity was measured and 
expressed as fold change of pSBE4-Luc/pRL-TK compared to non-treated controls (mean ± SD; n=3). 
 
3.7.1. Implications of autocrine positive-feedback loops in senescence secretome 
  Recent findings identified many cytokine factors implicated in oncogene-
induced and replicative senescence (Acosta et al., 2008; Kuilman et al., 2008). 
However, the most striking outcome of such studies was the identification of 
positive-feedback loops modulated by senescence-driving factors as well as autocrine 
contribution of cytokines released from senescent cells.  
On the other hand, we and others have demonstrated the growth inhibitory 
functions of autocrine loops of several cytokines including TGF-β (Gressner, 1995; 
Hov et al., 2004; Matsuzaki et al., 2000). TGF-β signaling pathway has also been 
implicated in control of a subset of cellular processes associated with cellular 
secretome (Bierie et al., 2009; Xu et al., 2010).  
 84
Therefore, we hypothesized a potential involvement of a positive-feedback 
loop in senescent Huh7 cells after a very brief exposure to TGF-β. In this respect, we 
tested the expression of TGF-β1 at the mRNA level in Huh7 cells which were 
stimulated to undergo senescence arrest after 3 days, only with a short pulse of TGF-
β1 exposure. Surprisingly enough, this very brief exposure to ectopic TGF-β caused 
a robust increase in its own endogenous transcript levels in a dose-dependent manner 
(Figure 3.19).  
DNA-damaging agents were also implicated in premature senescence 
induction as well as cytokine secretory phenotype (Novakova et al., 2010). The onset 
of senescence induced by DNA-damaging agents is quite different from TGF-β-
induced senescence. There are major differences in morphological changes  and cell 
cycle distributions (our own observations) as well as senescence-messaging 
secretome (Kuilman and Peeper, 2009). Therefore, we also tested the TGF-β1 
expression in doxorubicin- and cisplatin-induced senescence. Of note, DNA-
damaging compounds did not induce senescence in brief exposure conditions, hence 
the treatment with these chemicals was performed for 72 hr. 
 
 
Figure 3.19: Brief exposure to TGF-β induces its own endogenous expression. 
Huh7 cells were treated with 1 ng/mL and 5 ng/mL TGF-β1 for ~20 seconds and analyzed for TGF-β1 
expression after 3 days in culture by qRT-PCR. Results were indicated as fold change (treated/non-
treated). Experiments were performed in triplicate. Doxorubicin and Cisplatin were used as 
senescence inducers by DNA-damage (72 hr).   
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Taken together, TGF-β1 induced its own expression even when treated for a 
very short time. DNA-damage causing compounds also increased TGF-β1 
expression but to a lesser extent (~ 3 to 5 fold).  
In addition, we also performed experiments with other cytokines which were 
recently identified as mediators of senescence in different cellular models, namely 
IL-6 and IL-8 (Orjalo et al., 2009). As tested by real-time PCR, we demonstrated 
increased levels of expression for IL-6 (Figure 3.20) and IL-8 (Figure 3.21).  
 
Figure 3.20: Brief exposure to TGF-β1 induces IL-6 expression. Huh7 cells were 
treated with 1 ng/mL and 5 ng/mL TGF-β for ~20 seconds and analyzed for IL-6 expression after 3 
days in culture by qRT-PCR. Results were indicated as fold increase (treated/non-treated). 
Experiments were performed in triplicate. Doxorubicin and Cisplatin were used as senescence 
inducers by DNA-damage (72 hr).   
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Figure 3.21: Brief exposure to TGF-β1 induces IL-8 expression. Huh7 cells were 
treated with 1 ng/mL and 5 ng/mL TGF-β for ~20 seconds and analyzed for IL-8 expression after 3 
days in culture by qRT-PCR. Results were indicated as fold increase (treated/non-treated). 
Experiments were performed in triplicate. Doxorubicin and Cisplatin were used as senescence 
inducers by DNA-damage (72 hr).   
 
Moreover, elevations in levels of IL-6 expression were moderately low 
compared to IL-8; therefore we were not able to detect any increase in the amount of 
released form of IL-6 when tested with ELISA (data not shown). Nevertheless, we 
detected that parental Huh7 cells secrete significant amount of IL-8 with 
substantially increased levels in TGF-β1 (p < 0.01) and doxorubicin (p = 0.05) 
treated samples as assessed by ELISA (Figure 3.22).  
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Figure 3.22: Brief exposure to TGF-β induces IL-8 secretion. Huh7 cells were treated 
with 5 ng/mL TGF-β for ~20 seconds and conditioned media was analyzed for IL-8 secretion after 3 
days in culture. Experiments were performed in triplicate.  
 
Taken together, robust senescence induction even after a very short TGF-β1 
exposure might be modulated through amplification of an autocrine positive 
feedback loop. qRT-PCR and ELISA assays performed to analyze IL-6 and IL-8 
involvement in TGF-β-induced growth arrest also implicated a potential role for IL-8 
secretion in maintenance of senescence response. However, these results shall 
require further investigation to understand the details underlying the unnecessity for 
sustained exposure to TGF-β1 during permanent senescence arrest.  
  
3.8. Lack of evidence for TGF-β1-induced apoptosis 
Earlier studies indicated that TGF-β induces apoptosis in hepatocytes and 
HCC cell lines under serum-free conditions (Fan et al., 1996; Fan et al., 2002; 
Lamboley et al., 2000). However, it remains elusive whether the apoptotic response 
is also induced under serum-containing standard cell culture conditions. Under our 
culture conditions with 10% fetal calf serum-containing medium, all tested cell lines 
failed to undergo apoptotic cell death as tested by using NAPO (Negative in 
Apoptosis) antibody (Sayan et al., 2001) and active caspase-3 antibody assays. Cells 
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maintained NAPO expression when tested at 24 hr (Figure 3.23), and at day 7 
(Hep3B; Figure 3.24).  
 
Figure 3.24: There was no change in NAPO expression under TGF-β1 
treatment. Hep3B cells were treated with TGF-β1 (5 ng/mL) for 72 hr and subjected to NAPO 
immunoperoxidase staining (Sayan et al., 2001) on day seven. Arrow: Negative nucleus for NAPO. 
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Furthermore, activated caspase-3 immunoreactivity did not increase 
following TGF-β1 treatment (Figure 3.25 and 3.26).  
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Figure 3.25: There was no change in NAPO expression after TGF-β1 treatment. 
Active caspase-3 immunoreactivity was assessed by immunoperoxidase staining. Cells were exposed 
to 5 ng/mL TGF-β1 for indicated time periods and stained with an anti-activated caspase-3 (Asp175) 
antibody. There was no discernible increase in the number of caspase-3-positive cells under TGF-β 
treatment. Arrow indicates a cell that displayed positive caspase-3 staining. 
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Figure 3.26: Lack of Caspase-3 activation during TGF-β1 treatment. Hep40 cells 
were treated with different doses of TGF-β1 for 72 hr and assayed by western blotting. Etoposide-
treated (25 µM) Jurkat cell line extracts were used as positive control (+) for cleaved caspase-3 
immunoblotting. The α-tubulin was used as an internal control. 
 
Concusively, under our experimental conditions, we did not detect any 
significant apoptotic response in well-differentiated HCC cell lines. Of particular 
interest, Hep3B which has been used as a model for TGF-β1-induced apoptosis under 
serum-free conditions by others did not display such a response under serum-
containing conditions (Carmona-Cuenca et al., 2008). 
 
3.9. Molecular Mechanisms of TGF-β-induced Senescence 
3.9.1. TGF-β-induced senescence is associated with sustained induction of 
p21Cip1 and p15Ink4b 
 Cellular senescence is usually associated with cell cycle arrest induced by 
p53, p21Cip1, p16Ink4a and/or p15Ink4b, leading to the accumulation of 
underphosphorylated pRb protein (Campisi and d'Adda di Fagagna, 2007; Gil and 
Peters, 2006). In all cell lines tested, 72 hr of TGF-β1 treatment caused an 
upregulation of p15Ink4b and p21Cip1, in association with c-myc downregulation 
(Figure 3.27).  
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Figure 3.27: Protein expression patterns after TGF-β1 treatment. TGF-β1 treatment 
(72 hr) of HCC cell lines led to the induction of senescence markers p15Ink4b and p21Cip1 that was 
associated with c-myc downregulation. p16Ink4a blots were overexposed to visualize weak expression. 
α-tubulin served as equal loading control. 
 
In addition, p15Ink4b and p21Cip1 accumulation in protein levels was associated 
with transcriptional upregulation (Figure 3.28).  
 
Figure 3.28: mRNA expression patterns after TGF-β1 treatment. TGF-β1 treatment 
(3 days) of HCC cell lines induced transcriptional upregulation of senescence markers p15Ink4b and 
p21Cip1 as tested by semi-quantitative RT-PCR. GAPDH was used as equal loading control. 
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3.9.2. Sustained changes in c-Myc and p21Cip1 transcript levels 
TGF-β-induced senescence observed in well-differentiated cell lines was 
associated with activation of cyclin-dependent kinase inhibitors as well as 
downregulation in c-myc protein and transcript levels. On the other hand, TGF-β-
induced senescence was a sustained event. Three days of incubation was adequate to 
promote a permanent senescence arrest even after 12 days of incubation in culture. In 
this respect, we studied the expression levels of two genes implicated in senescence 
arrest after 12 days of incubation. As demonstrated in Figure 3.29, p21Cip1 mRNA 
levels were maintained even after the removal of TGF-β1 from the culture medium. 
 
Figure 3.29: Sustained changes in c-myc and p21Cip1 transcript levels. TGF-β 
treatment (3 days) of HCC cell lines induced transcriptional regulation of p21Cip1 and c-myc as tested 
by semi-quantitative RT-PCR. Expression changes in these particular genes were maintained even 
after 8 days following removal of TGF-β1 from growth medium. GAPDH; equal loading control. 
 
This observation was also supported with the decrease in relative levels of c-
myc expression when compared to control samples. Taken together, we can conclude 
that TGF-β1 provokes a sustained cytostatic response, as well as maintained 
expression levels for genes responsible for TGF-β1-induced senescence.   
 
3.9.3. Loss of pRb phosphorylation in TGF-β-induced senescence  
Additionally, TGF-β-treatment led to a decrease in pRb phosphorylation 
status, together with a decrease in p107 and reciprocal increase in p130 protein levels 
(Figure 3.30).  
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Figure 3.30: RB family proteins in TGF-β1-induced senescence. TGF-β1 treatment 
(72 hr) of HCC cell lines decreased phosphorylated pRb (ppRb) levels, together with a reciprocal 
increase in underphosphorylated pRb (upRb) levels. Also, p107 levels were decreased and p130 
increased. α-tubulin served as equal loading control. 
 
These changes in the retinoblastoma family proteins correlate well with exit 
from the cell cycle (Classon and Dyson, 2001).  
 
3.9.4. TGF-β-induced senescence is p16Ink4a and p53-independent  
All cell lines used in this study, except HepG2, harbor p53 mutations, 
therefore express mutant p53 proteins (Erdal et al., 2005). This data suggested a p53-
independent upregulation of p21Cip1 protein and mRNA levels.  
Moreover, we did not observe any change in the phosphorylation status of 
p53 protein (Figure 3.31), a modification that marks activation of p53, in p53 wild 
type HepG2 cells. HepG2 cells were treated with TGF-β1 to test p53 protein 
expression, as well as activation of p53 function through p53 (Ser15) 
phosphorylation. We used a previously tested DNA-damaging chemical 
(Doxorubicin) known to increase p53 expression and phosphorylation under 
genotoxic stress conditions (Liu et al., 2008; Vassilev et al., 2004). We treated 
HepG2 cells with 10 ng/mL doxorubicin for 72 hr and analyzed p53 expression as 
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well as phosphorylation status with western immunoblotting. Doxorubicin treatment 
substantially increased p53 expression as well as modulated p53 (Ser15) 
phosphorylation. This effect demonstrated a causal link in p21Cip1 induction. As 
opposed to doxorubicin-induced changes in p53, TGF-β-treatment did not alter p53 
protein levels or phosphorylation status (Figure 3.31, left).  
 
Figure 3.31: The induction of p21Cip1 by TGF-β was independent of p53. HepG2 
cells with wild-type TP53 gene (left) responded to TGF-β1 treatment by p21Cip1 accumulation, without 
an increase in p53ser15 phosphorylation (pp53) or in total p53 levels (p53). Doxorubicine (10 ng/mL)-
treated cells were used as a positive control (+) for p53 phosphorylation and accumulation. Calnexin 
was used as loading control. TP53-deleted Hep3B cells (right) also responded to TGF-β1 treatment by 
p21Cip1 accumulation, despite the lack of p53 protein. The α-tubulin was used as loading control for 
Hep3B cells. Cell lysates were tested by western blotting at day three, following TGF-β1 or 
doxorubicin treatment. 
 
 For control studies we used Hep3B cell line which has mutant p53 gene due 
to a large deletion (7-kbp), thereby lack p53 transcript and protein expression 
(Bressac et al., 1990). Like HepG2 cells, TGF-β-treatment substantially increased 
p21Cip1 protein expression in Hep3B cells independent of p53 status (Figure 3.31, 
right).  
 Moreover, TGF-β treatment did not change p16Ink4a levels. Indeed, the 
CDKN2A gene is frequently silenced in HCC (Roncalli et al., 2002). Accordingly, 
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p16Ink4a protein levels were extremely low in all tested cell lines, except Hep3B and 
Hep3B-TR cells (Figure 3.32).     
 
Figure 3.32: HCC cell lines expressed little or no p16Ink4a protein, except pRb-
deficient Hep3B and Hep3B-TR cell lines.  
 
 On the other hand, our observations for senescence arrest in Hep3B cells 
suggested that pRb expression was also dispensable for TGF-β1-induced senescence 
in HCC cells. Taken together, these findings suggested that TGF-β was able to 
induce senescence arrest in HCC cells independent of p53, p16Ink4a and pRb status.  
 
3.9.5. TGF-β-induced senescence can be reproduced by p21Cip1 or p15Ink4b 
overexpression 
 Cellular senescence is defined as an irreversible arrest of mitotic cells at G1-
phase, but some genetically deficient tumor cells can also senesce at G2 or S phases 
(Campisi and d'Adda di Fagagna, 2007) (our unpublished observations).   
Control and TGF-β1-treated (5 ng/mL) Huh7 cells were analyzed by flow 
cytometry. Cells exposed to TGF-β1 were examined three days later at the time of 
senescence. TGF-β1 treatment caused an increase of G1 phase cells from 59% to 
81% with a concomitant decrease of S phase cells from 23% to 8% in Huh7 cells 
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(Figure 3.33-A). Next we tested respective contributions of p21Cip1 and p15Ink4b to 
senescence arrest in Huh-7 cells by transient transfection with corresponding 
expression vectors. Transfected cells were selected with antibiotic treatment for eight 
days and subjected to following analyses. p21Cip1-overexpressing cells displayed an 
increase in G1 phase from 61% to 78%, together with a decrease of S phase from 
26% to 12% (Figure 3.33-B). Overexpression of p15Ink4b, on the other hand, 
increased G1 cells from 59% to 66% and decreased S phase cells from 22% to 15% 
(Figure 3.33-C). 
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Figure 3.33: The G1-arrest induced by TGF-β treatment can be recapitulated 
by ectopic expression of p21Cip1 and p15Ink4b. (A) Untreated and TGF-β1-treated Huh7 
cells were subjected to cell cycle analysis after three days of culture. G1 phase cells were increased 
from 59% to 81% together with a decrease in S phase cells from 18% to 8%. (B, C) Huh7 cells were 
transiently transfected with p21Cip1 and p15Ink4b expression vectors, and subjected to cell cycle analysis 
after eight days of culture under antibiotic selection. p21Cip1-transfected cells displayed an increase in 
G1 phase cells from 61% to 78% accompanied with a decrease of S phase cells from 26% to 12% (B). 
Similarly, p15Ink4b-transfected cells showed an increase of G1 phase cells from 59% to 66% together 
with a decrease of S-phase cells from 22% to 15% (C). Compared to p15Ink4b, p21Cip1 expression 
provoked a more pronounced G1-arrest. 
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p21Cip1-transfected cells demonstrated highly increased p21Cip1 protein 
expression (Figure 3.34-A). p15Ink4b-transfected cells displayed moderately increased 
expression of the short form of p15Ink4b, partly because of endogenous expression of 
p15Ink4b (Figure 3.34-B).  
 
 
Figure 3.34: Overexpression of p21Cip1 (A) and p15Ink4b (B) in transiently 
transfected Huh7 cells. Cells were transfected with expression plasmids encoding p21Cip1 (A) or 
p15Ink4b (B), selected for eight days in the presence of antibiotics, and cell extracts were analyzed by 
western immunoblotting. The α-tubulin was used as loading control. Only short form of p15Ink4b 
displayed increased expression (arrow in B), as we used a plasmid encoding this form. 
 
To support previous findings, we also performed senescence and BrdU 
incorporation assays. As expected, p21Cip1-induced changes were associated with 
increased SA-β-Gal activity (Figure 3.35, upper panel) and flattened cell morphology 
(Figure 3.35, lower panel), and decreased BrdU incorporation into cellular DNA (P < 
0.001; Figure 3.36).  
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Figure 3.35: Changes in p21Cip1 overexpressing cells. Transiently transfected p21Cip1 
overexpressing Huh7 cells displayed increased SA-β-Gal activity (upper panel), as well as flattened 
cell morphology (lower panel) at day eigth. Nuclear Fast Red was used for counterstaining in SA-β-
Gal staining experiments.  
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Figure 3.36: BrdU incorporation in p21Cip1 overexpressing cells. Transiently 
transfected p21Cip1 overexpressing Huh7 cells displayed decreased anti-BrdU immunofluorescence at 
day eight (p < 0.001). DAPI was used for counterstaining.  
 
Transient overexpression of p15Ink4b induced similar changes when 
compared to p21Cip1. p15Ink4b-transfected cells displayed moderately increased 
expression of the short form of p15Ink4b, partly because of endogenous expression of 
p15Ink4b (Figure 3.34-B). Overexpression of p15Ink4b increased G1 cells from 59% to 
66% and decreased S phase cells from 22% to 15% (Figure 3.33-C). These changes 
also were associated with increased SA-β-Gal activity (Figure 3.37), and decreased 
BrdU incorporation into cellular DNA (P < 0.001; Figure 3.38).  
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Figure 3.37: Changes in p15Ink4b overexpressing cells. Transiently transfected p15Ink4b 
overexpressing Huh7 cells displayed increased SA-β-Gal activity (upper panel) as well as flattened 
cell morphology (lower panel) at day eigth. Nuclear Fast Red was used for counterstaining in SA-β-
Gal staining experiments. 
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Figure 3.38: BrdU incorporation in p15Ink4b overexpressing cells. Transiently 
transfected p15Ink4b overexpressing Huh7 cells displayed decreased anti-BrdU immunofluorescence at 
day eight (p < 0.001). DAPI was used for counterstaining.  
 
Senescence-related effects of p21Cip1 were more dramatic than those induced 
by p15Ink4b. Collectively, these findings demonstrated that TGF-β-induced 
senescence in HCC cells was associated with G1-phase arrest and significant 
reduction in the ability to reinitiate DNA synthesis. These effects appeared to be 
mediated mostly by p21Cip1 with a significant contribution from p15Ink4b in Huh7 cell 
line.  
 
3.9.6. TGF-β-induced senescence is linked to Nox4 induction and intracellular 
accumulation of reactive oxygen species 
 Several lines of evidence have implicated ROS in limiting longevity and 
organism life. However, exact implications of biochemical ROS mechanisms in 
physiologic basis of aging are not known. On the other hand, there are studies 
indicating that ROS accumulation contributes to senescence induced by Ras 
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oncoprotein in fibroblasts (Lee et al., 1999) as well as INF-gamma induced 
senescence in human umbilical vascular endothelial cells (HUVEC) (Kim et al., 
2009b).  
 
The generation of reactive oxygen species can be monitored by the aid of 
luminescence analyses or fluorescence methods. The intracellular generation of ROS 
can be investigated using DCFH-DA which is a well-established compound to detect 
intracellular reactive oxygen species, particularly hydroxyl radical, nitric oxide, 
peroxyl radical, singlet oxygen and superoxide anion. Non-fluorescent probe DCFH-
DA is hydrolyzed inside the cell by nonspecific esterases to form DCFH. This 
compound is then oxidized by intracellular ROS to generate the highly fluorescent 
product DCF. In order to optimize intracellular ROS staining by DCFH-DA, we 
cultured Huh7 and Snu387 cells in serum-free growth conditions (data not shown), as 
oxidative stress inducing conditions (Osborne et al., 1998). Following these initial 
experiments, we decided on the concentration of DCFH-DA and the duration of the 
staining. Similar to DCFH-DA, we also utilized another compound MitoTracker Red 
CMXRos, a reduced and nonfluorescent version of MitoTracker Red. CMXRos 
diffuses across the plasma membrane, accumulates in active mitochondria and 
fluoresces upon oxidation; an event which is dependent on the membrane potential.  
 
Treatment of hepatocytes with TGF-β provokes ROS accumulation (Sanchez 
et al., 1996) most probably by activating a NADPH-oxidase (Nox)-like system 
(Herrera et al., 2004) via Nox4 induction (Carmona-Cuenca et al., 2006). In addition, 
Nox family members have recently been identified as candidates to promote ROS 
accumulation in human endothelial cells (Schilder et al., 2009). Therefore, we 
investigated the potential role of reactive oxygen species in TGF-β-induced 
senescence with a particular interest in the contribution of Nox4 induction.  
 
We first demonstrated that TGF-β regulated Nox4 expression in a dose-
dependent manner both at the mRNA and protein level (Figure 3.39).  
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Figure 3.39: TGF-β-regulated Nox4 expression in Huh7 and PLC cells. Both cell 
lines were treated with indicated doses of TGF-β1 for 72 hr and tested for Nox4 expression at RNA 
and protein level. A-tubulin and GAPDH served as internal controls in western blotting and RT-PCR 
experiments, respectively. 
  
 
We then tested ROS accumulation in selected well-differentiated cell lines 
upon TGF-β1-treatment in a similar experimental set-up used in senescence 
experiments. We observed high levels of intracellular ROS signals in TGF-β-treated 
cells, but not in non-treated cells (Figure 3.40).  
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Figure 3.40: TGF-β1 induced ROS accumulation in WD cell lines. WD cell lines 
were treated with different doses of TGF-β1 for 72 hr. DCFH-DA (green) staining indicates ROS 
accumulation inside the cell. Mitochondrial dye MitoTracker (red) was used as mitochondrial ROS 
probe. Pictures were taken at 20X. 
 
From these results, we excluded the possible involvement of TGF-β in 
mitochondrial ROS production in WD cell lines, as we were not able to detect a 
significant change in the mitochondrial signal after staining with MitoTracker 
CMXRos with IF technique.  
 
On the other hand, if ROS played a critical role in TGF-β1 induced 
senescence response, we should be able to interfere with this response by preventing 
ROS accumulation in TGF-β1-treated cells. We, therefore, used N-acetyl-L-cysteine 
(NAC) as a physiological ROS scavenger (Droge, 2002) to test this hypothesis. The 
co-treatment of 5 ng/mL TGF-β1-treated cells together with 10 mM NAC completely 
suppressed the accumulation of ROS in Huh7 and PLC cell lines (Figure 3.41), as 
well as the accumulation of SA-β-Gal-positive cells (Figure 3.42).  
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Figure 3.41: TGF-β1 induced ROS accumulation in WD cell lines after NAC 
treatment. WD cell lines were treated with 5 ng/mL TGF-β1 alone or together with 10 mM NAC 
for 72 hr. DCFH-DA (green) staining indicates ROS accumulation inside the cell. Mitochondrial dye 
MitoTracker (red) was used as mitochondrial ROS probe. Pictures were taken at 20X. 
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Figure 3.42: Rescue of senescence after NAC treatment. Co-treatment of TGF-β1 (5 
ng/mL)-treated cells with ROS scavenger NAC (10 mM) for 72 hr rescued senescence arrest as tested 
by SA-β-Gal assay. Pictures were taken at 20X. 
 
Co-treatment with NAC treatment also strongly inhibited TGF-β1-induced 
expression of p15Ink4b and p21Cip1, and restored pRb phosphorylation, without 
affecting Nox4 levels in PLC cells (Figure 3.43). Similar results were obtained with 
Huh7 (data not shown).  
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Figure 3.43: Implication of ROS in TGF-β-induced gene expression regulation. 
Co-treatment of TGF-β1 (5 ng/mL)-treated PLC cells with ROS scavenger NAC (10 mM) for 72 hr 
reversed TGF-β1 mediated expression effects. ppRb (ser807/811). α-tubulin was used for equal 
loading. 
 
  
Nevertheless, the prevention of ROS accumulation and the inhibition of 
p15Ink4b and p21Cip1 induction by NAC were sufficient to rescue TGF-β1-induced 
growth arrest as tested by BrdU incorporation (Figure 3.44, left) and cell cycle 
analysis in Huh7 and PLC cell lines (Figure 3.44, right).  
 110
 
 
Figure 3.44: Implication of ROS in TGF-β-induced growth arrest. Co-treatment of 
TGF-β1 (1 ng/mL and 5 ng/mL)-treated Huh7 and PLC cells with ROS scavenger NAC (10 mM) for 
72 hr reversed TGF-β1 mediated growth arrest effects.  
 
 
Taken together, all these effects exerted by NAC demonstrate a causal link 
between reactive oxygen species accumulation and the stimulation of TGF-β-induced 
growth arrest and the onset of senescence. Moreover, the inhibitory mechanism of 
NAC activity does not involve any interference with TGF-β signal transduction as 
we demonstrated by immunofluorescence experiment with activated Smad3 (Figure 
3.45). In this setting, we showed that treatment of PLC cells with 5 ng/mL TGF-β1 
for 30 min provoked nuclear localization of phospho-Smad3 and moreover this effect 
was not interrupted by 10 mM NAC co-treatment. We observed similar results when 
treatments were performed for 2 hr (data not shown).   
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Figure 3.45: TGF-β1 induced nuclear p-Smad3 accumulation in PLC cell line. 
PLC cells were treated with 5 ng/mL TGF-β1 alone or together with 10 mM NAC for 30 min. Cells 
were stained with primary abs against p-Smad3 which was followed by Alexa 568 secondary 
antibody. DAPI served as nuclear counterstaining. Pictures were taken at 40X (scale bar: 50 μM). 
 
3.9.7. NOX4 gene silencing interferes with TGF-β-induced p21Cip1 accumulation 
and growth arrest  
The correlation between Nox4 induction, ROS accumulation and senescence 
arrest, suggested that the Nox protein might serve as a key intermediate in TGF-β-
induced senescence. In order to test whether Nox4 was indeed involved in TGF-β-
induced senescence, we performed NOX4 gene silencing by siRNA. Huh7 cells were 
first transfected with NOX4 specific siRNA and a scrambled siRNA, as control. 
Cells were trypsinized and divided into two fractions following 24 hr post-
transfection. This was followed by treatment with either 5 ng/mL TGF-β1 or vehicle 
only for 72 hr. At this time-point, we tested the expression of NOX4 RNA and 
protein levels by qPCR and western blot, respectively.  
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We demonstrated that TGF-β-induced accumulation was inhibited by ~75% 
by NOX4-specific siRNA, but not scrambled siRNA (Figure 3.46).  
 
Figure 3.46: Inhibition of TGF-β-induced accumulation of Nox4 transcripts by 
siRNA transfection. Huh7 cells were transfected with 10 nM Nox4-specific siRNA and 
corresponding scrambled siRNA. Cells were treated with 5 ng/mL TGF-β for 72 hr and subjected to 
qRT-PCR analysis. Experiments were performed in triplicate. GAPDH was used as normalization 
control. 
 
Under these conditions, we also detected a substantial inhibition in TGF-β-
induced NOX4 protein accumulation after NOX4-specific siRNA transfection 
(Figure 3.47).  
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Figure 3.47: NOX4 gene silencing rescued TGF-β-induced Nox4, p21Cip1 and 
p15Ink4b protein accumulation and the inhibition of pRb phosphorylation. Huh7 
cells were transfected with 10 nM Nox4-specific siRNA and corresponding scrambled siRNA. Cells 
were treated with 5 ng/mL TGF-β1 for 72 hr and subjected to western blotting analysis. α-tubulin was 
used as control loading. 
 
Moreover, the inhibition of Nox4 protein expression resulted in strong 
inhibition of p21Cip1 accumulation, but p15Ink4b levels were affected mildly. More 
interestingly, the loss of phosphorylated pRb (ppRb) in TGF-β-treated cells was 
restored in association with Nox4 inhibition.  
The effects of siRNA-mediated Nox4 inhibition on cell proliferation were 
intriguing. The incorporation of BrdU into cellular DNA was inhibited by more than 
85% in TGF-β-treated cells in the absence of Nox4 siRNA. NOX4 gene silencing 
restored this effect, almost completely (Figure 3.48).  
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Figure 3.48: Nox4 gene silencing rescued TGF-β-induced growth arrest. Huh7 
cells were transfected with 10 nM Nox4-specific siRNA and corresponding scrambled siRNA. Cells 
were treated with 5 ng/mL TGF-β for 72 hr and subjected to BrdU immunostaining. Cells were 
labelled with BrdU for 24 hr prior to day 3, and percent BrdU-positive cells were counted manually. 
 
In conclusion, growth arrest induced by TGF-β in Huh7 cells was restored 
upon inhibition of Nox4 induction. 
 
3.9.8. Implications of DNA-damage response in TGF-β-induced senescence 
arrest  
3.9.8.1. 53BP1 foci formation  
Intracellular as well as mitochondrial reactive oxygen species have been 
implicated in DNA-damage response (Courtois-Cox et al., 2008). Moreover, both 
telomere-dependent and telomere-independent senescence is now recognized as a 
DNA damage response (DDR), and such response can be quantitatively examined by 
analyzing DNA foci formation with DDR proteins such as 53BP1 (d'Adda di 
Fagagna, 2008).  In development of such a hypothesis, we exposed Huh7 cell line to 
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1 and 5 ng/mL TGF-β1 for a short period (~ 20 seconds), and examined for nuclear 
53BP1 foci formation by an immunofluorescence assay (Figure 3.49).  
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Mean values for 53BP1 foci (> 4 foci/nucleus) were calculated by manual counting 
(Figure 3.50).  
 
 
 
 
 
 
 
 
Figure 3.50: DNA damage response in TGF-β-treated cells. Histograms indicate the 
percentage of cells with at least 5 clearly detectable foci (mean ± SD). More than 100 cells were 
screened per point in independent experiments. Compared to control cells, 1 ng/mL and 5 ng/mL 
TGF-β1 treatment significantly increased the percentage of 53BP1-positive cells (P < 0.001 for both 
doses and all time points tested). 
 
53BP1 foci were 6%, 5% and 7% in untreated cells at 24, 48 and 72 hr, 
respectively. With 1 ng/mL TGF-β1, 21%, 21% and 27% of cells displayed increased 
53BP1 foci formation at 24, 48 and 72 hr, respectively ~4-fold increase; P < 0.001. 
Similarly, with 5 ng/mL TGF-β1, 17%, 21% and 29% of cells displayed increased 
foci formation at 24, 48, and 72 hr, respectively ~4-fold increase; P < 0.001. 
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3.9.8.2. Ataxia telangiectasia mutated (ATM) activation 
ATM activation is a central event in DNA-damage response in double strand-
breaks. However, activation of ATM was also reported in various other studies 
which implicated a potential role for TGF-β signaling (Wiegman et al., 2007; Zhang 
et al., 2006a). Therefore, we tested TGF-β-stimulated ATM activation in Huh7 cells 
after exposure to commonly used doses 1 ng/mL and 5 ng/mL for less than 1 min. In 
an effort to assess time-dependent stimulation of ATM, we performed 
immunofluorescence staining at different time points (Figure 3.51). 
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Figure 3.51-A: ATM activation after brief exposure to TGF-β1. Huh7 cells were 
treated with 1 ng/mL and 5 ng/mL TGF-β for less than 1 min. Immunofluorescence analysis was 
performed after 30 min and 4 hr, respectively. DAPI was used to stain the nuclei.  
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Figure 3.51-B: ATM activation after brief exposure to TGF-β1. Huh7 cells were 
treated with 1 ng/mL and 5 ng/mL TGF-β for less than 1 min. Immunofluorescence analysis was 
performed after 12 hr and 24 hr, respectively. DAPI was used to stain the nuclei.   
 
 In control cells, p-ATM showed intracellular diffuse staining. Whereas, the 
treatment with TGF-β caused dense nuclear staining with detectable increase at the 
first time-point tested. The staining was also dose-dependent. Nuclear staining 
reached a peak level at 4 hr and maintained high until 24 hr. At 48 hr and 72 hr, 
nuclear staining density decreased with immense cytoplasmic staining. 
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Figure 3.51-C: ATM activation after brief exposure to TGF-β1. Huh7 cells were 
treated with 1 ng/mL and 5 ng/mL TGF-β for less than 1 min. Immunofluorescence analysis was 
performed after 48 hr and 72 hr, respectively. DAPI was used to stain the nuclei.   
 
Taken together, these results demonstrated a potential involvement of TGF-β 
signaling pathway in ATM activation and nuclear translocation of p-ATM. These 
findings also suggested a potential role for TGF-β in the onset of DNA-damage 
response.  
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3.10. TGF-beta-induced senescence and anti-tumor activity in vivo 
 Collectively, our in vitro studies provided strong evidence for a major 
senescence-inducing role for TGF-β in well-differentiated HCC cells. Additionally, 
we tested in vivo relevance of these findings by a series of animal experiments. In an 
effort to test this issue, we established human HCC tumors in immunodeficient mice.  
First, we tested whether TGF-β1 induces senescence in Huh7 tumors. TGF-
β1 (~ 50 μL of a 10 ng/mL solution) was injected into subcutaneous Huh7 tumors. 
Control experiments were performed using solution vehicle only, under parallel 
conditions.  Tumors were removed one week later (Figure 3.52) and subjected to SA-
β-Gal staining.  
 
Figure 3.52: Nude mice and extracted Huh7 tumors  
 
Intratumoral injection of TGF-β1 (~ 0.5 ng) induced local but expanded SA-
β-Gal activity in three of four tumors tested; whereas three tumors treated with 
vehicle only were completely negative (Figure 3.53).  
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Figure 3.53: TGF-β1-induced SA-β-Gal activity in Huh7 tumors. Huh7 cells were 
injected subcutaneously to nude mice to obtain tumors that were then injected with TGF-β1 (~50 ul of 
10 ng/mL solution) or a vehicle control by intratumoral injection, and animals were sacrificed seven 
days later to collect tumor tissues. Cryostat sections were prepared from freshly frozen tumors and 
subjected to SA-β-Gal staining (blue). Counterstain: Nuclear Fast Red. 
 
Next, we tested whether TGF-β treatment exerts any anti-tumor activity 
against Huh7 tumors raised in immunodeficient mice. Early subcutaneous tumors 
were subjected to either TGF-β1 (2 ng per peritumoral injection, ~ 50 ul of 10 ng/mL 
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solution) or vehicle treatment with four days of intervals. TGF-β1 treatment lasted 24 
days and tumor sizes were measured prior to each injection. As shown in Figure 
3.54, vehicle-treated tumors displayed exponential growth to reach 4 cm3 volume on 
average within 24 days. In contrast, TGF-β-treated tumors were growth arrested 
throughout the experiment and remained less than 1 cm3 on average at the same time 
period. 
 
Figure 3.54: Inhibition of tumor growth by TGF-β. Huh7 tumors were treated with 2 ng 
TGF-β or vehicle control only at 4-day intervals and tumor sizes were measured accordingly. TGF-β 
treated tumors were growth arrested, resulting in > 75% inhibition of tumor growth. * P < 0.05, ** P < 
0.01. 
 
This inhibition of preexisting tumor growth by TGF-β treatment was 
statistically significant after 12 days of treatment or after three doses (P < 0.05) 
Tumor inhibition remained significant at least 24 days or after six doses  (P < 0.01 to 
< 0.05). However, TGF-β treatment did not completely eliminate the tumor mass, 
even though two tumors totally regressed and disappeared. As an additional test for 
anti-tumor activity of TGF-β signaling, we compared the tumorigenicity of 
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TFGBR2-deleted Hep3B-TR cells (Inagaki et al., 1993) with parental Hep3B cells. 
Hep3B and Hep3B-TR cells were injected subcutaneously (5x106 cells/animal). 
Three animals injected with Hep3B-TR cells developed palpable tumors within two 
weeks of injection and died within 4-6 weeks. Three other animals injected with 
Hep3B cells also developed tumors, but with a latency of 6-7 weeks (Figure 3.55).  
 
 
Figure 3.55: Hep3B-TR cells that display homozygous TGFBR2 deletion displayed accelerated 
tumorigenicity, as compared to parental Hep3B cells. Cells (5x106) were injected subcutaneously to 
nude mice and tumor sizes were measured on a weekly basis. X indicates animal death. Pictures were 
taken from representative animals with tumors at day 35. 
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As increased tumorigenicity of Hep3B-TR cells has been reported by others 
during these studies (Zimonjic et al., 2009), we discontinued our animal experiments 
for ethical reasons and concluded that the genetic disruption of TGF-β signaling in 
HCC cells may lead to increased tumorigenicity. 
 
3.11. Resistance mechanisms to TGF-β-induced growth arrest in poorly 
differentiated cell lines 
 As previously stated, we classified human HCC cell lines into "well-
differentiated" (WD) and "poorly differentiated" (PD) subtypes based on the 
expression of hepatocyte lineage, epithelial and mesenchymal markers (Yuzugullu et 
al., 2009).  
 
3.11.1. TGF-β receptor expression in poorly differentiated (PD) cell lines 
 After we performed studies with well-differentiated cell lines to understand 
the relevance of senescence induction and mechanisms, we then moved on to 
evaluate poorly differentiated cell lines. In this context, we investigated nine PD cell 
lines to investigate their ability to undergo senescence arrest following TGF-β 
treatment.  
Prior to these studies, we explored the status of TGF-β1 ligand and TGF-β 
receptor and intracellular signaling components expression in these cell lines by RT-
PCR analysis of the relevant transcripts (Figure 3.56). Our studies demonstrated that 
almost all HCC cell lines tested expressed TGF-β1 ligand and receptors and 
intracellular signaling components. Of note, Snu398 cells had markedly decreased 
TGFβRII expression, as reported previously (Kitisin et al., 2007). SMAD genes 
located downstream to TGF-β receptors display mutations only rarely in primary 
HCC, but not in HCC cell lines (Yakicier et al., 1999). Thus, it appears that the main 
components of TGF-β signaling are intact and present in most HCC cell lines.  
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Figure 3.56: Expression of TGF-β1 ligand, receptors and intracellular signaling 
components. 
 
3.11.2. Lack of TGF-β1-induced senescence in poorly differentiated HCC cell 
lines 
 TGF-β-induced senescence has been extensively studied for well-
differentiated cell lines. WD cell lines responded to TGF-β1 by massive senescence 
induction of SABG staining within three days following treatment. However, this 
effect appeared to be limited to WD cell lines, as PD cell lines were completely 
resistant to senescence induction.  
PD cells were seeded at low density and subjected to TGF-β treatment effective 24 
hr of post-seeding. After three days of incubation, cells were stained for senescence 
associated β-galactosidase activity (Figure 3.57). 
 127
Fi
gu
re
 3
.5
7:
 L
ac
k 
of
 s
en
es
ce
nc
e-
lik
e 
re
sp
on
se
 in
 P
D
 c
el
l l
in
es
. C
el
ls
 w
er
e 
pl
at
ed
 a
t l
ow
 d
en
si
ty
 a
nd
 tr
ea
te
d 
w
ith
 T
G
F-
β1
 (5
 n
g/
m
L)
 fo
r 7
2 
hr
. S
A
-β-
G
al
 a
ct
iv
ity
 (b
lu
e)
 w
as
 te
st
ed
 a
t 7
2 
hr
. C
on
tro
l: 
no
 T
G
F-
β1
 tr
ea
tm
en
t. 
C
ou
nt
er
st
ai
n:
 
Fa
st
 R
ed
.  
 128
We tested nine PD cell lines, only six of them were depicted in the figure, and 
all of them were negative for SABG staining after three days and even after five days 
following removal of TGF-β1 (data not shown).  
 
3.11.3. TGF-β treatment does not alter BrdU incorporation in PD cell lines 
 Following SABG experiments, we assessed proliferation assays with Snu387 
and Snu449 cell lines. These cells were treated with TGF-β1 for three days and 
incubated for 24 hr with BrdU prior to staining (Figure 3.58).  
 
Figure 3.58: Cells were treated with 1 ng/mL and 5 ng/mL TGF-β1 for three days and subjected to 
immunofluorescence assay with anti-BrdU antibody. Positive cells in at least 5 areas for each 
triplicate were manually counted with reference to DAPI positive nuclei.  
 
Proliferation capacity of these two cell lines were not influenced by TGF-β 
treatment suggesting a marked resistance against TGF-β-induced cytostatic 
responses. 
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3.12. Target gene expression profiles in poorly differentiated hepatocellular 
carcinoma cell lines  
TGF-β-treated well-differentiated cells were growth arrested by upregulation 
of senescence markers such as p21Cip1 and p15Ink4b, with a reciprocal decrease of c-
myc and phosphorylated-Rb. In order to assess the mechanisms underlying resistance 
to TGF-β-induced growth arrest in poorly differentiated cells, we initially studied 
gene expression profiles controlled by TGF-β. Tested cell lines were treated with 1 
and 5 ng/mL TGF-β for three days and expression changes were studied with 
western blotting and RT-PCR assays. By western blotting technique, we detected no 
change in the expression levels of p21Cip1 and p15Ink4b upon TGF-β treatment. In all 
cell lines tested except Snu387, we reported no change in the status pRb 
phosphorylation (Figure 3.59). 
 
   
Figure 3.59: Gene expression profiles by western blot in TGF-β-treated of PD 
cell lines. Cells were treated with different doses of TGF-β1 and assayed for gene expression by 
western blotting. All incubations were essentially performed at room temperature. α-tubulin served as 
internal control.  
 
Besides, we were not able to observe any change in PAI-1, a well-known 
TGF-β target gene, and as well as in p21Cip1 transcript levels in Snu387, Snu449 and 
Mahlavu cells (Figure 3.60). 
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Figure 3.60: Gene expression profiles by RT-PCR in TGF-β-treated PD cell 
lines. Cells were treated with different doses of TGF-β1 and assayed for gene expression by 
semiquantitative RT-PCR. GAPDH served as internal control. 
 
 In order to confirm lack of expression in western blot, we also studied the 
expression of p15Ink4b at transcript level in all HCC cell lines. Three cell lines did not 
display any amplification (Figure 3.61-A). Then we performed genomic PCR 
experiments with cell lines that lack p15Ink4b expression at transcript level using 
specific primers amplifying INK4 locus. As shown in Figure 3.61-B, Snu387, 
Snu449 and SkHep1 cell lines have deletion at INK4 locus. 
 
Figure 3.61-A: RT-PCR analysis for selected genes in all HCC cell lines.  
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Figure 3.61-B: genomic-PCR analysis for selected regions on CDKN2B gene in 
all HCC cell lines.  
 
 
INK4 locus also harbors ARF and CDKN2A and those cell lines with 
deletion do not express p14Arf and p16Ink4a protein either (Figure 3.62). 
 
 
Figure 3.62: Western blot analysis for selected gene products in PD HCC cell 
lines. A-tubulin served as internal control.  
 
Homozygous deletion for this locus in HCC tumors has been reported in 
other studies as well (Liew et al., 1999; Tannapfel et al., 2001). 
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3.13. TGF-β signaling is functional in poorly differentiated hepatocellular 
carcinoma cell lines  
Several reasons may underlie the resistance to TGF-β-induced senescence as 
well as lack of activation of senescence marker genes. TGF-β signaling components 
were determined to be expressed at transcript level. In the context of identification of 
candidate resistance mechanisms, we tested functional TGF-β signal transduction 
from cell membrane to nucleus. TGF-β-mediated Smad activation in cytostatic 
responses is modulated through post-translational phosphorylation on serine residues 
located on the C-terminus. Therefore, we first tested the functionality of TGF-β 
receptors. In this respect, all poorly differentiated cell lines were treated with 5 
ng/mL TGF-β1 for 30 min. Cell lysates were subjected to western blotting against 
activated Smad. Here, we used Smad2 to perform functional assays. All cell lines, 
except Snu398, had substantially increased phosphorylated-Smad2 (Figure 3.63). 
 
Figure 3.63: TGF-β leads to early phosphorylation of Smad2 in PD cell lines. 
Cells were treated with 5 ng/mL TGF-β1 for 30 min under normal culture conditions and cell lysates 
were subjected to western blotting with specific p-Smad2 antibody. Calnexin was used as equal 
loading control. 
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Next we studied effective signal transduction from cell membrane to nucleus 
using phospho-Smad3 specific antibody in immunoperoxidase assays. Similar to 
previous experiment, cells were seeded on 12-well plate coverslips at moderate 
density, and treated for 30 min with 5 ng/mL TGF-β1 24 hr post-seeding (Figure 
3.64 and 3.65).  
 
 
Figure 3.64: p-Smad3 localization in PD cell lines. All cell lines were treated with 5 
ng/mL TGF-β1 for 30 min and stained with p-Smad3 specific antibody. Huh7 was used as positive 
control. Haemotxylin was used as nuclear counterstain.  
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We used Huh7 cells as positive control with active and intact TGF-β signal 
transduction. Hep3B-TR cell line was utilized as negative control for the specificity 
of the primary antibody, since we expected no or very faint nuclear staining. 
 
 
Figure 3.65: p-Smad3 localization in PD cell lines. All cell lines were treated with 5 
ng/mL TGF-β1 for 30 min and stained with p-Smad3 specific antibody. Hep3B-TR was used as 
negative control. Haemotxylin was used as nuclear counterstain.  
 
After fixation, cells were stained with p-Smad3 primary antibody and nuclei 
positive for p-Smad3 staining were determined by manual counting (Figure 3.66).  
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Figure 3.66: Positive nuclear staining in PD cell lines. 
  
All cell lines tested displayed distinctively increased nuclear staining upon 
TGF-β treatment. Besides, almost all cell lines displayed endogenous nuclear p-
Smad3 staining under normal culture conditions suggesting functional autocrine 
TGF-β signaling in PD cell lines similar to WD cells. Snu398 cells, on the other 
hand, were negative for p-Smad3 staining under TGF-β-treated and non-treated 
conditions, probably owing to diminished expression of TGFβRII (Kitisin et al., 
2007).  
 
3.14. TGF-β responsiveness of PD HCC cell lines 
 In order to analyze differential response of HCC cell lines to TGF-β 
treatment, we employed luciferase assay system similar to those performed with WD 
cell lines. To monitor responsiveness of PD HCC cell lines, we used two well-known 
TGF-β-responsive luciferase reporter constructs namely pSBE4-luc and p3TP-lux. 
Transfection efficiency was monitored with pEGFP vector.  
All cell lines had ~60-90% transfection efficiency. As evidenced in Figure 
3.67, all cell lines except Snu398 differentially responded to TGF-β with elevated 
pSBE4-luc reporter activity. All cell lines displayed 2 to 6 fold increase in luciferase 
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activity after treatment with TGF-β. Snu398 cells were completely unresponsive to 
treatment. 
 
 
Figure 3.67: Intactness of TGF-β signaling in PD cell lines by pSBE4-luc 
activation. All cell lines were co-transfected with pSBE4-luc and pRL-TK renilla luciferase 
vectors. Six hours post-transfection, cells were supplemented with 5 ng/mL TGF-β1 for 24 hr and 
assayed for luciferase activity. Luciferase activity of reporter constructs was normalized to renilla 
luciferase. All experiments were performed in triplicate. All non-treated controls were normalized to a 
value of “1 (One)”.  
 
On the other hand, p3TP-lux transfection also demonstrated that all tested PD 
cell lines, except Snu182 and Snu398, responded to TGF-β with varying amplitudes 
(Figure 3.68).  
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Figure 3.68: Responsiveness of PD cell lines by p3TP-lux activation. All cell lines 
were co-transfected with p3TP-lux and pRL-TK renilla luciferase vectors. Six hours post-transfection, 
cells were supplemented with 5 ng/mL TGF-β1 for 24 hr and assayed for luciferase activity. 
Luciferase activity of reporter constructs was normalized to renilla luciferase. All experiments were 
performed in triplicate. All negative controls were normalized to a value of “1 (One)”. 
 
These data clearly demonstrated that, most of the cell lines differentially 
responded to TGF-β treatment. However, the response of PD cell lines obtained with 
both vectors was comparably less than WD cell lines. 
 
3.15. Lack of reactive oxygen species accumulation in PD cell lines 
 TGF-β-induced senescence in well-differentiated cell lines was closely 
associated with reactive oxygen species accumulation and Nox4 upregulation. As 
evidenced from previous experiments, we did not detect any senescence signal in PD 
cells upon TGF-β1 exposure. When compared to WD cell lines, we wanted to study 
a potential involvement of ROS accumulation and Nox4 upregulation in these cells. 
When cells were cultured with 5 ng/mL TGF-β1 for three days under normal culture 
conditions, no increase was detectable in production of intracellular ROS, except 
some endogenously positive cells (Figure 3.69).  
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Figure 3.69: TGF-β1 failed to induce ROS accumulation in PD cell lines. PD cell 
lines were treated with 1 ng/mL and 5 ng/mL TGF-β1 for 72 hr. DCFH (green) staining indicates ROS 
accumulation inside the cell. Mitochondrial dye MitoTracker (red) was used as counterstain. Pictures: 
20X with objective lens. Huh7 cell were used positive control for staining but not depicted here. 
 
Nox4 accumulation has been linked to senescence arrest provoked by TGF-β 
in WD cell lines. Therefore, we similarly analyzed Nox4 mRNA expression after 72 
hr TGF-β treatment. Unlike well-differentiated cell lines, we failed to observe neither 
endogenous expression in Nox4 transcripts nor upregulation in the presence of TGF-
β (Figure 3.70).  
Figure 3.70: Nox4 is not expressed in PD cell lines. TGF-β did not induce Nox4 
expression as well. GAPDH was used as internal control. Huh7 mRNA was used as positive control 
for Nox4 expression, not included here. 
 
0 1 5 0 1 5 0 1 5TGF-beta
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 There are several reasons underlying the lack of expression of a specific gene 
under normal conditions including genetic and/or epigenetic impairment. Similar to 
INK4 locus deletion observed in PD cell lines, we wanted to assess the possibility of 
a deletion present in this locus. When we performed genomic PCR, we observed no 
deletion at two genomic regions of the NOX4 gene (Figure 3.71).   
 
Figure 3.71: Genomic PCR to amplify different regions on NOX4 gene. 
 
In addition, we also performed a bioinformatics search to check out putative 
Nox4 promoter methylations. Using different tools, we identified putative Nox4 
promoter over a 5.3 kb region (Figure 3.72).  
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Figure 3.72: CpG island prediction on putative NOX4 gene promoter. 
 
This region harbors a putative CpG island covering upstream of the 
transcription start site and ~200 bp downstream of the transcription start site through 
5’-UTR. Obviously these encouraging results need further exploration to determine 
the mechanisms that regulate endogenous Nox4 expression in PD cell lines. 
 
3.16. Smad-interacting protein-1 (Sip-1, Zeb2) in hepatocellular carcinoma 
Having elucidated the intactness and differential responsiveness of PD HCC 
cell lines to TGF-β, we further hypothesized that diminished senescence response of 
PD cell lines to this cytokine might be mediated through another mechanism 
independent of intracellular signal transduction. We concentrated on mesenchymal-
like phenotype hallmark of these cell lines. 
 141
Epithelial and mesenchymal markers expression analysis of HCC cell lines 
revealed differential expression of Zeb2 (sip1, smad-interacting protein 1) mRNA 
together with others (Yuzugullu et al., 2009). Zeb2 was highly expressed in PD cell 
lines whereas WD cell lines have diminished expression at the transcript level 
(Figure 3.73).  
 
Figure 3.73: Expression of zeb2 and zeb1 in HCC cell lines by RT-PCR. GAPDH 
served as internal control, negative control lane: without template. 
 
Zeb2 is a transcriptional repressor of e-cad (Vandewalle et al., 2005), cyclin-
D1 (Mejlvang et al., 2007) and human telomerase reverse transcriptase (hTERT) 
(Ozturk et al., 2006). Recently, zeb2 has been suggested as a downstream target of 
TGF-β signaling pathway, as well as a modulator of signal transmission and a 
repressor for certain TGF-β pathway target genes (Postigo, 2003; Postigo et al., 
2003). Recently, zeb2 has been proposed to play a prominent role in the interplay 
between EMT modulation and the onset of senescence (Ohashi et al., 2010). 
Nevertheless, its role in HCC is elusive. Whereas Zeb1, another two-handed zinc 
finger protein known to interact with Smads and activate transcription (Postigo, 
2003), did not exhibit a differential expression towards PD cell lines (Figure 3.73). 
We then investigated the expression and intracellular localization of zeb2 in 
HCC cell lines by immunostaining with a home made zeb2 antibody, namely 6E5. 
All WD cell lines had faint cytoplasmic staining and lacked nuclear zeb2 expression 
(Figure 3.74). 
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Figure 3.74: Expression and localization of zeb2 protein in WD HCC cell lines 
by immunoperoxidase staining. Zeb2 expression (brown staining). Haematoxylin was used as 
nuclear counterstain (blue). 
 
On the other hand, all PD cell lines presented intense nuclear staining with 
very faint cytoplasmic zeb2 expression (Figure 3.75).  
 143
  
Figure 3.75: Expression and localization of zeb2 protein in PD HCC cell lines by 
immunoperoxidase staining. Zeb2 expression (brown staining). Haematoxylin was used as 
nuclear counterstain (blue). 
 
 Snu398 and SkHep1 exhibit the highest expression whereas Snu387 and 
Snu449 had comparably low levels of expression.  
ZEB family proteins, zeb1 and zeb2, harbor two-handed zinc fingers with a 
high aminoacid sequence homology and have opposing functions on TGF-β 
signaling. Zeb1 synergizes with Smads and acts as an activator of TGF-β signaling to 
regulate a number of functions by promoting p300-Smad complex formation. On the 
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other hand, zeb2 has been demonstrated to act as a repressor of TGF-β signaling by 
recruiting CtBP corepressor along with Smads at certain target genes (Postigo, 2003). 
Therefore we hypothesized that high nuclear zeb2 expression in PD cell lines may 
block cytostatic functions of TGF-β signaling pathway by deregulating the activation 
of target genes such as p21Cip1 and p15Ink4b. To test our hypothesis, we used a Tet 
ON/OFF system controlling stable zeb2 expression generated in A431 cell line, a 
human epithelial skin carcinoma cell line with intact TGF-β signaling.  
Therefore, we asked the effects of zeb2 reexpression in A431 carcinoma cell. 
We initially co-transfected A431 cells with luciferase reporter p3TP-lux and pRL-TK 
and analyzed activation of the reporter by TGF-β1 in the presence of wild-type zeb2 
expression controlled by doxocyline. As demonstrated in Figure 3.76, reexpression 
of zeb2 inhibited TGF-β-induced activation of p3TP-lux reporter by more that 50%. 
This inhibition was also detectable in the absence of TGF-β. 
 
Figure 3.76: Inhibition of p3TP-lux activation by zeb2 protein in A431 cell line. 
p3TP-lux was co-transfected with pRL-TK. Six hour post-transfection, transfection medium was 
replaced by growth medium supplemented with 5 ng/mL TGF-β1 and 2 μg/mL doxocycline. 
Luciferase assay was performed in triplicate 24 hr post-addition of TGF-β1 and Dox.  
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 Next, we tested target gene activation by TGF-β. Similar to luciferase assay, 
we treated A431 cell line with TGF-β in the presence and absence of doxocycline for 
48 hr (Figure 3.77). Re-expression of wild-type zeb2 inhibited TGF-β-mediated 
p21Cip1 upregulation. All these effects were diminished in CtBP-interacting 
(transcriptional repressor) domain mutant zeb2 (mt CID). Similar results were 
obtained when treatments were performed for 24 hr. 
 
Figure 3.77: Inhibition of p21Cip1 upregulation in A431 cell line by wild-type 
zeb2 protein, but not by mutant zeb2. Cells were treated with/without 5 ng/mL TGF-β1 
and/or 2 μg/mL doxocycline. 48 hr later, cell lysates were subjected to western blotting with specific 
antibodies. Myc-tagged zeb2 expression was detected with a myc-epitope specific antibody. α-tubulin 
was used to quantify equal loading. 
 
Similar to western blotting assays, we performed immunoperoxidase staining 
analyses to determine the effects of zeb2 re-expression on p21Cip1 nuclear 
accumulation using p21Cip1-specific monoclonal antibody along with myc-epitope-
specific primary antibody. As pictured in Figure 3.78, re-expression of zeb2 by 
doxocycline inhibited nuclear p21Cip1 accumulation in A431 cells.  
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Figure 3.78: Inhibition of p21Cip1 nuclear upregulation in A431 cell line by wild-
type zeb2 protein. Cells were treated with/without 5 ng/mL TGF-β and/or 2 ug/mL doxocycline. 
48 hr later, cell were subjected to immunoperoxidase staining with specific antibodies. Myc-tagged 
zeb2 expression was detected with a myc-epitope specific antibody. Percent nuclear staining (bottom 
panel) was calculated by manual counting of at least 4 areas in each of the triplicate experiments. 
 
 Similar to those results obtained with mt CID zeb2 in western blotting 
experiments, we observed no significant change in nuclear p21Cip1 expression (Figure 
3.79). Please note that, zeb2 re-expression was not at same detectable level in all 
nuclei after 48 hr of doxocycline addition. Similar results were obtained in another 
study (Sayan et al., 2009).   
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Figure 3.79: Lack of inhibition of p21Cip1 nuclear upregulation by mutant zeb2 
protein in A431 cell line. Cells were treated with/without 5 ng/mL TGF-β and/or 2 μg/mL 
doxocycline. 48 hr later, cell were subjected to immunoperoxidase staining with specific antibodies. 
Myc-tagged zeb2 expression was detected with a myc-epitope specific antibody. Percent nuclear 
staining (bottom panel) was calculated by manual counting of at least 4 areas in each of the triplicate 
experiments. 
 
Following these experiments we performed similar assays with PLC cell line, 
an epithelial-like HCC cell line. Ectopic Zeb2 overexpression presented a similar 
response in PLC cells under TGF-β treatment conditions (Figure 3.80). 
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Figure 3.80: TGF-β-mediated p15Ink4b and p21Cip1 upregulation was 
inhibited by ectopic zeb2 expression in PLC cells. Cells were cotransfected with 
pUHD10.3/wt-zeb2 and reverse tetracycline-dependent transactivator (rtTA) expressing pUHD172-1 
plasmids. Cells were supplied with 5 ng/mL TGF-β1 and 2 μg/mL doxocycline for 24 hr prior to 
immunoblotting. α-tubulin was used as equal loading.  
 
All PD cell lines expressed high levels of Zeb2 protein as evidenced by RT-
PCR and immunoperoxidase staining procedures. Hence, we hypothesized that 
downregulation of zeb2 using siRNA technology could enhance TGF-β-mediated 
target gene activation. Therefore, we silenced zeb2 expression in Mahlavu and 
Snu449 cells using 10 nM zeb2 siRNA. Initially, we detected more that 75% 
decrease in zeb2 expression with a reciprocal ~7 fold increase in the expression of 
p21Cip1 in Mahlavu, by qRT-PCR (Figure 3.81).  
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Figure 3.81: p21Cip1 expression following knockdown of zeb2 in Mahlavu cells. 
Cells were transfected with 10 nM zeb2 siRNA and a corresponding scrambled siRNA sequence using 
RNAiMax Lipofectamine. Six hrs post-transfection, cells were supplied with 5 ng/mL TGF-β1 for 48 
hr prior to real-time pcr. All zeb2 values were normalized with GAPDH calues accordingly. Red bars 
indicate TGF-β addition. Y-axis: Fold difference, Upper graph: p21Cip1 expression, lower graph: 
zeb2 expression 
 
In addition to that, we also studied same effects of zeb2 knockdown in 
Snu449 cells. Unlike Mahlavu cells, upregulation of p21Cip1 in zeb siRNA 
transfected samples after TGF-β addition was moderately low but still detectable 
(Figure 3.82). 
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Figure 3.82: p21Cip1 expression following knockdown of zeb2 in Snu449 cells. 
Cells were transfected with 10 nM zeb2 siRNA and a corresponding scrambled siRNA sequence using 
RNAiMax Lipofectamine. Six hrs post-transfection, cells were supplied with 5 ng/mL TGF-β for 48 
hr prior to real-time pcr. All zeb2 values were normalized with GAPDH calues accordingly. Red bars 
indicate TGF-β addition. Y-axis: Fold difference, Upper graph: p21Cip1 expression, lower graph: 
zeb2 expression 
 
 These initial experiments with major interest in knocking down zeb2 
expression have clearly demonstrated a prominent role for zeb2 in conferring partial 
TGF-β resistance in poorly differentiated cell lines. 
 
3.17. Prolonged exposure to TGF-β generates resistant clones in Huh7 cell line 
 TGF-β-induced growth arrest in well-differentiated cell lines was studied in 
three days intervals. Initial experiments for SABG activity were studied after three 
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days of exposure to TGF-β. Later experiments were performed with cells which were 
stimulated with TGF-β for 72 hr and left untreated until day 12. As previously stated, 
we determined SABG positive cells in three days culture as well as 12 days culture. 
Up to this point, we demonstrated sustained senescence response in well-
differentiated cell lines. We next wanted to test the effects of TGF-β in long-term 
cultures. Thus, we initiated 5 ng/mL TGF-β1 treatment with parental Huh7 cells in a 
low-density clonogenicity based manner in 10 cm dishes. TGF-β1 was administered 
into cell culture medium on every three-four days period.  
 In this low density setting, non-treated control Huh7 cells were split every 
three days. Whereas, TGF-β1 treated cells were split whenever they reached 
confluency. Depending on the number of cells the experiment was initiated and the 
flattened morphology they obtain in sustained culture, they were split in 5-6 days 
intervals until all cells completely cease proliferation which is typically 2 passages. 
Together with live non-proliferating cells attached at the bottom of the dish, we 
observed a high population of unviable floating cells. Following prolonged 
senescence and proliferative decline due to various stress stimuli, the floating cells 
probably at the state of crisis (Macera-Bloch et al., 2002; Stein, 1985), were 
completely eliminated from cell culture after approximately 25 days. Surprisingly 
enough, approximately following 40 days from the initiation of first TGF-β addition, 
we observed few colonies with slow growing potential. We obtained a clone 
approximately after 50 days. Initial cell freezing was performed after ~60 days in 
culture when we reached a high number of proliferating cells. In the meantime, we 
continuously introduced TGF-β into the cell culture medium. The subclone 
established from Huh7 by prolonged TGF-β treatment was morphologically distinct 
from parental Huh7. Cells had fibroblast like outgrowing extensions with flattened 
cytoplasmic structure. Such clones were most likely delineated as mesenchymal-like 
cells.   
Recently, epithelial mesenchymal transition has been defined as an 
alternative mechanism to alleviate the pressure of senescence inducing stress signals 
(Ansieau et al., 2008; Weinberg, 2008).  Thus, we decided to perform a series of 
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analyses with the established subclone to delineate the structure-function interplays 
between resistance to TGF-β and escape from senescence arrest.  
 
3.17.1. Loss of TGF-β responsiveness in the established clone, Huh7-5 
As an initial experiment, we performed analysis with a primary goal to 
evaluate the current responsiveness of this ~60 days TGF-β treated subclone. As 
previously performed, we used luciferase reporters to investigate the response of 
Huh7 subclone to our cytokine. Parental Huh7 cells had ~10 fold increase in pSBE4-
luc activity after 24 hr TGF-β treatment, whereas the response of Huh7-5 (5 
designates the new clone with continuous treatment of 5 ng/mL TGF-β) was 
completely diminished (Figure 3.83). We also did a similar experiment with p3TP-
lux and reporter a quite similar outcome (Figure 3.76).     
 
 
Figure 3.83: Diminished response to TGF-β treatment with pSBE4-luc in Huh7-
5 clone after ~60 days. Cells were co-transfected with pSBE4-Luc and control pRL-TK 
plasmids, and treated with or without TGF-β1 (1 ng/mL and 5 ng/mL) for 24 hr. The luciferase 
activity was measured and expressed as fold change of Reporter/pRL-TK (mean ± SD; n=3). Y-axis: 
Fold Change 
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Figure 3.84: Diminished response to TGF-β treatment with p3TP-lux in Huh7-5 
clone after ~60 days. Cells were co-transfected with p3TP-lux and control pRL-TK plasmids, 
and treated with or without TGF-β1 (1 ng/mL and 5 ng/mL) for 24 hr. The luciferase activity was 
measured and expressed as fold change of Reporter/pRL-TK (mean ± SD; n=3). Y-axis: Fold Change 
 
These results clearly indicated a virtually complete loss of response to TGF-β 
treatment in the established subclone Huh7-5. 
 
3.17.2. Escape from TGF-β-induced loss of BrdU incorporation in the 
established subclone Huh7-5 
Senescence arrest provoked by TGF-β treatment in Huh7 cells is always 
characterized with loss of BrdU incorporation reaching a peak after three days of 
stimulation. Similar to that, we therefore decided to study the effects of TGF-β on 
BrdU incorporation in Huh7-5 clone. Parental Huh7 and subclone Huh7-5 were 
treated with increasing doses of TGF-β and supplied with BrdU 24 hr prior to 
detection and subjected to immunofluorescence assay after a total of 72 hr. Parental 
Huh7 had over 80% decrease in BrdU incorporating cells in both doses applied, 
whereas Huh7-5 subclone had complete resistance to TGF-β cytostatic responses 
with no inhibition in BrdU incorporation into cellular DNA (Figure 3.85).  
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Figure 3.85: Resistance to inhibition of BrdU incorporation in ~60 days TGF-β 
treated Huh7-5 cells. After 24 hr of incorporation, cells positively labeled for BrdU were stained 
with immunofluorescence technique using anti-BrdU (mouse) antibody. DAPI was used for nuclear 
counter-staining in IF experiments. At least 5 areas were manually counted in triplicate assays. 
 
3.17.3. The resistant subclone did not respond to TGF-β 
Cytostatic responses controlled by p21Cip1 and p15Ink4b seemed to be 
unaffected by TGF-β in Huh7-5 subclone (Figure 3.86). As previously described, we 
detected complete loss in phosphorylated Rb in parental Huh7 cells, while in Huh7-5 
subclone we almost detected no change. In addition, Nox4 expression was not 
induced by TGF-β in resistant clone. 
 
Figure 3.86: TGF-β treatment (72 hr) of parental Huh7 and Huh7-5 subclone 
cells. α-tubulin served as equal loading control. 
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3.17.4. Lack of responsiveness in rescued subclones 
 During the period of above experiments, we continued TGF-β treatment. At 
the day of ~70 of sustained treatment, we decided to generate another subclone of 
Huh7-5 which was rescued from TGF-β treatment. When reached at Day 100, we 
again performed a series of experiments in order to compare TGF-β responsiveness 
in parental Huh7, TGF-β-treated Huh7-5 subclone (continuously for 100 days) and 
rescued subclone Huh7-5-0 with no TGF-β treatment in the following 30 days. 
Therefore, the Huh7-5-0 subclone was designated as 70 days ON and 30 days OFF. 
We initially tested TGF-β response in the established subclones using luciferase 
based reporter systems. Parental Huh7, permanently TGF-β-treated subclone Huh7-5 
and rescued clone Huh7-5-0 were accordingly transfected with pSBE4-luc to 
investigate intactness of TGF-β signaling and with p3TP-lux to analyze TGF-β 
responsiveness. As depicted in Figure 3.87 and 3.88, two established subclones had 
diminished response to TGF-β treatment. Parental Huh7 cells served as control and 
had intact signaling.  
 
Figure 3.87: Diminished response to TGF-β treatment with pSBE4-luc in Huh7 
clones after ~100 days. Cells were co-transfected with pSBE4-Luc and control pRL-TK 
plasmids, and treated with or without TGF-β1 (5 ng/mL) for 24 hr. The luciferase activity was 
measured and expressed as fold change of Reporter/pRL-TK (mean ± SD; n=3). 
  
Parental Huh7 had over 20 fold increase in pSBE4-luc reporter activity under 
TGF-β treatment conditions. However, resistant subclone Huh7-5 and rescued Huh7-
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5-0 subclone were not responsive to TGF-β treatment and showed only ~2-3 fold 
increase which was negligible under these conditions.  
 
Figure 3.88: Diminished response to TGF-β treatment with p3TP-lux in Huh7 
clones after ~100 days. Cells were co-transfected with p3TP-Lux and control pRL-TK plasmids, 
and treated with or without TGF-β1 (5 ng/mL) for 24 hr. The luciferase activity was measured and 
expressed as fold change of Reporter/pRL-TK (mean ± SD; n=3).  
 
 Parental Huh7 responded to 24 hr TGF-β treatment by a ~8 fold increase in 
p3TP-lux reporter activity. On the other hand, resistant subclone Huh7-5 displayed 
diminished reporter activity both in the presence and absence of TGF-β. In contrast 
to that, the rescued clone Huh7-5-0 had ~1.5 fold increased endogenous reporter 
activity with ~2 fold increased reporter response under TGF-β treatment conditions 
when compared to non-treated parental Huh7.  
Next, we explored TGF-β-induced inhibition of BrdU incorporation. We 
found out that both resistant and rescued clones did not respond to TGF-β with a 
decrease in BrdU incorporation after 72 hr of treatment (Figure 3.89).        
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Figure 3.89: Resistance to inhibition of BrdU incorporation in ~100 days TGF-
β-treated Huh7-5 and rescued Huh7-5-0 cells following 72 hr treatment. After 24 
hr of incorporation, cells positively labeled for BrdU were stained by immunofluorescence (IF) 
technique using anti-BrdU (mouse) antibody. DAPI was used for nuclear counter-staining in IF 
experiments. At least 5 areas were manually counted in triplicate assays. 
 
 The subclones seemed to be completely resistant to TGF-β-induced cytostatic 
responses. In addition, we performed cell cycle analysis in there clones. Similar to 
BrdU incorporation results, we determined no change in cell cycle pattern in resistant 
and rescued clones (Figure 3.90). Parental Huh7 had around 60% G1 cells and 20% 
S-phase cells. After treatment with increasing doses of TGF-β1, G1-phase cells 
reached to ~75% and ~90% distribution in parental Huh7 with 1 ng/mL and 5 ng/mL 
TGF-β1, respectively.   
 
Figure 3.90: Cell cycle distribution in Huh7, resistant Huh7-5 and rescued 
Huh7-5-0 cells after 72 hr TGF-β1-treatment.  
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3.17.5. Intactness of TGF-β signaling pathway in resistant Huh7-5 and rescued 
Huh7-5-0 subclones 
There might be several reasons behind the resistance to TGF-β cytostatic 
response along with loss of responsiveness to TGF-β tested by luciferase reporters. 
In order to delineate possible mechanisms conferring resistance to TGF-β, we 
initially performed a series of analyses in TGF-β pathway integrity to assess the 
possibility of a disruption in signal transduction. Parental Huh7, resistant Huh7-5 
subclone and rescued Huh7-5-0 subclone cells were treated with TGF-β for 60 min 
under normal culture conditions. We then tested Smad2 activation by TGF-
β receptors using phospho-specific Smad2 antibody (Figure 3.91). 
 
Figure 3.91: Slightly decreased activation of Smad2 in resistant clone. Cells were 
treated with 5 ng/mL TGF-β for 60 min under normal culture conditions.   
 
 Treatment of cells with 5 ng/mL TGF-β for 60 min resulted in substantial 
activation of Smad2 as demonstrated by increase in the phosphorylated form of 
Smad2. Resistant subclone Huh7-5 had a slightly decreased but still detectable 
phosphorylation in Smad2 suggesting a possible desensitization to TGF-β after 
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prolonged exposure. On the other hand, we tested possible early activation of Nox4 
and p15Ink4b in all Huh7 clones but detected no change in 1 hr treatment indicating 
that these genes may not be early-response targets in HCC cells.   
Since we determined active receptor status with very low impairment in 
resistant Huh7-5 clone but intact signaling in parental Huh7 and rescued Huh7-5-0, 
we moved on to analyze the status of signal transduction from cell membrane to 
nucleus. We initially tested p-Smad3 localization after 60 min of TGF-β treatment. 
As depicted in Figure 3.92, p-smad3 was localized to nucleus upon TGF-β exposure 
with a bit of deregulation in resistant and rescued subclones. So that signal intensity 
in resistant and rescued clones was comparably less. 
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Figure 3.92: Decreased nuclear accumulation of activated p-Smad3 in 
resistant and rescued clones. Cells were treated with 5 ng/mL TGF-β for 60 min under 
normal culture conditions. Pictures taken at 40X objective lens. 
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On the other hand, we also studied nuclear localization of Smad4 and 
Smad2/3 by immunofluorescence experiments. Two primary antibodies against 
Smad2/3 were predominantly recognizing either Smad2 or Smad3. Due to high 
aminoacid sequence homology between Smad2 and Smad3, the antibodies generated 
against each of these proteins usually recognize the other partner as well, but with 
less affinity.  
TGF-β treatment, in parental Huh7, induced nuclear transduction of Smad3 in 
60 min. Nuclear smad3 was also detectable in resistant Huh7-5 and rescued Huh7-5-
0 subclones with additional positive cytoplasmic smad3 staining. However, the 
nuclear intensity was less when compared to parental Huh7 (Figure 3.93).  
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 Similar to Smad3, we also performed signal transduction experiments to 
detect smad2 and smad4 localization. This time we carried out the experiments in a 
time-based fashion in which we tried to detect cellular localization of Smad2 and 
Smad4 after 10 min, 30 min and 60 min of TGF-β stimulation. Intracellular 
localization of Smad2 presented a similar pattern to Smad3 in parental Huh7 and 
subclones at 60 min (Figure 3.94). Besides, time-dependent Smad2 distribution upon 
TGF-β stimulation clearly established a delayed Smad2 translocation into the 
nucleus.  
 
Figure 3.94: Decreased nuclear accumulation and time-dependent delay in 
Smad2 translocation in resistant Huh7-5 and Huh7-5-0 rescued clones. Cells were 
treated with 5 ng/mL TGF-β for indicated time frames under normal culture conditions. Pictures taken 
at 40X objective lens. 
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Additionally, nuclear smad4 translocation was prohibited in resistant Huh7-5 
and rescued Huh7-5-0 subclone cells (Figure 3.95). 
 
 
Figure 3.95: Diminished nuclear accumulation of Smad4 in resistant Huh7-5 
and rescued Huh7-5-0 clones. Cells were treated with 5 ng/mL TGF-β for indicated time 
frames under normal culture conditions. Pictures taken at 40X objective lens. 
 
 Qualitative analysis with resistant Huh7-5 and rescued Huh7-5-0 subclones 
demonstrated impairment in transduction of intracellular TGF-β signal transmitting 
molecules, Smads. In order to have a notion of the degree of this disruption in 
quantitative terms, we performed western blotting experiments with parental Huh7 
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and resistant Huh7-5. Both cell clones were treated with 5 ng/mL TGF-β for 60 min 
and cell lysates were prepared accordingly to have nuclear and cytoplasmic fractions.  
Similar to immunofluorescence experiments, we also reported impairment in 
Smad3 translocation, along with decreased p-Smad3 localization in the nuclei of 
resistant Huh7-5 subclone (Figure 3.96). 
 
 
 
Figure 3.96: Impairment in Smad3 transduction into nucleus. Cells were treated with 
5 ng/mL TGF-β for 60 min under normal culture conditions. Cytoplasmic and nuclear fractions were 
obtained accordingly. PARP and actin were used to test the efficiency of nuclear and cytoplasmic 
fractionation, respectively.    
 
 Nuclear accumulation of Smad3 and p-Smad3 in resistant Huh7-5 
clone was substantially inhibited. Whereas, upon TGF-β stimulation, Smad2 was 
predominantly localized into the nucleus in both parental Huh7 and resistant Huh7-5 
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subclones. In this experimental set-up, PARP served as nuclear fraction control, 
while actin and p15Ink4b served as cytoplasmic fraction controls. Please note that, 
p15Ink4b translocates into the nucleus following 72 hr of incubation (data not shown) 
where it acts as a senescence inducer, as previously stated. Besides, we used GSK3β 
as a control for equal loading. Smad2/3 detection was essentially performed with two 
different antibodies. Both antibodies have different epitopes and preferentially 
recognize one on another.  
Impairment in TGF-β signaling and cytostatic response could be in the form 
of decreased receptor expression and lack of increase in molecules that control TGF-
β-induced growth arrest. We therefore conducted western blotting and real-time PCR 
analyses to define the expression patterns of genes of our interest, particularly EMT 
promoting Smad complexes (Fuxe et al., 2010). We initially studied the expression 
of TGF-β receptors and Smads in parental Huh7, resistant Huh7-5 and rescued 
Huh7-5-0 subclones in the presence of the ligand.  
Surprisingly enough, we detected increased expression of both receptors in 
parental Huh7 in the presence of TGF-β. TGFβRII expression was substantially 
increased with increasing doses. However the level of increase in resistant Huh7-5 
and rescued Huh7-5-0 was lower (Figure 3.97).  
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Figure 3.97: Expression of TGF-β1 and its receptors. Cells were treated with 1 ng/mL 
and 5 ng/mL TGF-β for 72 hr under normal culture conditions. Real-time PCR analysis was 
performed with corresponding primer pairs. Expression values were normalized with respect to 
GAPDH. Y-axis: Fold Difference 
 
On the other hand, we detected ~10 fold increase in TGFb-RI in parental 
Huh7 when treated with 5 ng/mL TGF-β, whereas resistant and rescued subclones 
had diminished expression for this particular receptor both in the absence and 
presence of TGF-β. Besides, expression levels of TGF-β1 were highly elevated in 
parental Huh7, and endogenous levels were comparably higher in resistant and 
rescued subclones (Figure 3.97).  
We further studied the expression of intracellular signal transmitting 
molecules. Smad2 and Smad4 transcript levels were not affected by TGF-β treatment 
in parental Huh7, resistant Huh7-5 and rescued Huh7-5-0. Whereas, Smad3 
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expression was elevated in parental Huh7 with TGF-β treatment and stayed almost 
unaffected in resistant and rescued subclones (Figure 3.98). 
 
  
Figure 3.98: Expression of Smads. Cells were treated with 1 ng/mL and 5 ng/mL TGF-β for 
72 hr under normal culture conditions. Real-time PCR analysis was performed with corresponding 
primer pairs. Expression values were normalized with respect to GAPDH. Y-axis: Fold Difference  
  
Cytostatic responses controlled by TGF-β in Huh7 cells were mediated 
through upregulation of p21Cip1 and p15Ink4b with a reciprocal decrease in c-myc 
levels. Besides, nox4 was implicated in TGF-β-induced growth arrest in this study. 
With this information in mind, we studied the expression of above transcripts and 
demonstrated substantial increases in p15Ink4b, p21Cip1 and Nox4 mRNA expression 
with a reciprocal decrease in c-myc transcript levels in parental Huh7 (Figure 3.99). 
All these effects were reversed in resistant Huh7-5 and rescued Huh7-5-0 subclones, 
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suggesting a potential mechanism to explain resistance to TGF-β-induced cytostatic 
response.  
 
 
Figure 3.99: Expression of p15Ink4b and p21Cip1, Nox4 and c-myc genes in 
resistant and rescued subclones. Cells were treated with 1 ng/mL and 5 ng/mL TGF-β for 72 
hr under normal culture conditions. Real-time PCR analysis was performed with corresponding primer 
pairs. Expression values were normalized with respect to GAPDH. Y-axis: Fold Difference 
 
PAI-1 transcript levels were also unaffected by TGF-β treatment in the 
established subclones supporting the previous loss of response findings (Figure 
3.100). 
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Figure 3.100: Expression of PAI-1 in resistant and rescued subclones. Cells were 
treated with 1 ng/mL and 5 ng/mL TGF-β for 72 hr under normal culture conditions. Real-time PCR 
analysis was performed with corresponding primer pairs. Expression values were normalized with 
respect to GAPDH. Inner box: modified scaling for 2 and 3. Y-axis: Fold Difference 
 
 Following the work with specific genes at transcript level, we moved on to 
quantify gene expression at protein level. Phosphorylated–Rb expression was 
monitored as a positive control in TGF-β-induced growth arrest. As can be seen in 
Figure 3.101, TGF-β stimulation for 72 hr decreased phospho-Rb levels. Together 
with that, we also studied p15Ink4b and p21Cip1 expression at protein level in parental 
Huh7, resistant Huh7-5 and rescued Huh7-5-0 subclones and reported substantially 
increased amounts of protein levels in both cyclin-dependent kinase inhibitors in 
parental Huh7. Rescued Huh7-5-0 subclone had minor increments in p15Ink4b protein 
levels but not in p21Cip1 expression. This increased expression in p15Ink4b however 
was not remarkable, hence did not influence ppRb rates. Resistant Huh7-5, on the 
other hand, was completely unresponsive to TGF-β treatment. Quantitative real-time 
PCR results were thereby supported by these findings. In addition, PAI-1 and Nox4 
protein expression levels were increased in parental Huh7, but not in other subclones 
(Figure 3.101).       
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Figure 3.101: Protein expression of target genes in parental Huh7, resistant and 
rescued subclones. Cells were treated with 1 ng/mL and 5 ng/mL TGF-β for 72 hr under normal 
culture conditions. Western blotting analysis was performed with corresponding primary antibodies. 
A-tubuline was monitored as equal loading.  
 
 In addition to those targets surveyed above, we also investigated the 
expression of Smad signaling partners in these cells. Interestingly enough, we 
observed a dramatic decrease in Smad4 expression in parental Huh7 with increasing 
doses of TGF-β (Figure 3.102). Quite similar to qRT-PCR results, we detected a 
substantial increase in Smad3 expression in parental Huh7 cells in the presence of 
TGF-β. 
 
Figure 3.102: Expression of Smads in parental Huh7, resistant and rescued 
subclones. Cells were treated with 1 ng/mL and 5 ng/mL TGF-β for 72 hr under normal culture 
conditions. Western blotting analysis was performed with corresponding primary antibodies. A-
tubulin was monitored as equal loading. Smad3: lower band in Smad2/3 result. LE: long exposure, 
VSE: very short exposure. 
 172
 We further wanted to test the specificity of the decrease in Smad4 expression 
in parental Huh7 following TGF-β treatment. Therefore we performed a time-scale 
treatment of parental Huh7 with 5 ng/mL TGF-β. Cell lysates obtained from these 
treatments were subjected to immunoblotting. Smad4 expression was gradually 
decreased starting after 72 hr and reaching a maximum at day 5. Smad3 was detected 
to increase in a time-dependent manner as well, with highest levels at 48 hr and 72 hr 
(Figure 3.103).  
 
Figure 3.103: Time-dependent expression pattern of Smads and cytostatic 
response genes in parental Huh7. Cells were treated with 5 ng/mL TGF-β for indicated 
times. Western blotting analysis was performed with corresponding primary antibodies. A-tubulin was 
used as equal loading. Control samples were obtained from 120 hr cultured cells in the absence of 
TGF-β. 
 
 Interestingly enough, time-dependent increments in Smad3 levels in parental 
Huh7 cells overlapped well with decrease in ppRb levels and increases in p15Ink4b 
and p21Cip1 protein levels. Therefore, above results directed our attention much on 
Smad3. In regard to results which demonstrated lack of induction of Smad3 under 
TGF-β-treatment conditions in resistant and rescued clones, we hypothesized a 
potential involvement of TGF-β-induced Smad3 in provoking cytostatic response. 
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  Therefore we decided to transiently overexpress wild-type Smad3 in resistant 
Huh7-5 and rescued Huh7-5-0 subclones. These experiments were performed with 
subclones that reached 125 days in culture. Prior to these studies, we again checked 
the intactness and responsiveness of resistant and rescued clones to TGF-β using 
pSBE4-luc luciferase reporter assay. Similar to previous results with short-term 
cultured subclones, we depicted that the subclones at this time-point were still 
unresponsiveness to TGF-β treatment (Figure 3.104).   
 
Figure 3.104: Diminished response to TGF-β treatment in Huh7 clones after 
~125 days. Cells were co-transfected with pSBE4-Luc and control pRL-TK plasmids, and treated 
with or without TGF-β1 (5 ng/mL) for 24 hr. The luciferase activity was measured and expressed as 
fold change of Reporter/pRL-TK (mean ± SD; n=3). 
 
 In an effort to assess the contribution of Smad3 to signal transduction and 
cytostatic responses, we transiently overexpressed wild-type Smad3 in parental 
Huh7, resistant Huh7-5 and rescued Huh7-5-0 subclones. Cells were co-transfected 
with pcDNA3.1-Smad3 vector along with p3TP-lux and pRL-TK reporters, and 
corresponding empty vector pcDNA3.1 for control experiments. Transfected cells 
were treated with 5 ng/mL TGF-β for 24 hr, and treatment was initiated following 6 
hr post-transfection. Results clearly indicated that ectopic expression of Smad3 
increased endogenous luciferase reporter signals and enhanced reporter activation in 
parental Huh7 in the presence of TGF-β. Besides, the effects of TGF-β were 
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completely reversed in terms of luciferase reporter activation in established 
subclones as well (Figure 3.105).  
 
Figure 3.105: Restoring the response of Huh7 subclones to TGF-β treatment 
following ectopic Smad3 expression. Cells were co-transfected with pcDNA3.1-Smad3-WT 
and/or pcDNA3.1/p3TP-Lux and control pRL-TK plasmids, and treated with or without TGF-β1 (5 
ng/mL) for 24 hr. The luciferase activity was measured and expressed as fold change of 
Reporter/pRL-TK (mean ± SD; n=3). 
 
 Following these encouraging results, we further studied the TGF-β-mediated 
cytostatic response in the established subclones, in the presence of ectopic Smad3 
expression. Initially, we tested proliferation capacity of transfected cells using BrdU 
incorporation assays. We transiently overexpressed Smad3 in parental Huh7 and 
resistant subclone Huh7-5. Transfected cells were selected with G418 antibiotic for 
three days and then seeded in 12-well plates on cover-slips.  
One day following seeding, cells were treated with 5 ng/mL TGF-β for 72 hr. 
Following 24 hr BrdU incorporation, cells were fixed accordingly and stained with 
anti-BrdU primary antibody. Positive cells were calculated by manual counting with 
respect to nuclear DAPI staining. Results are shown in Figure 3.106. Ectopic Smad3 
expression led to a significant decrease, even in the absence of TGF-β, in BrdU 
incorporation in parental Huh7 (***, p < 0.01) and resistant Huh7-5 (*, p < 0.005) 
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when compared to corresponding empty vector transfected samples. BrdU 
incorporation in resistant Huh7-5 cells under TGF-β treatment condition decreased 
by ~50 percent (**, p < 0.0001).  
 
Figure 3.106: BrdU incorporation in parental Huh7 and resistant Huh7-5 
subclone after TGF-β treatment following ectopic Smad3 expression. Cells were 
transfected with pcDNA3.1-Smad3-WT and/or pcDNA3.1 plasmids, selected under antibiotic pressure 
for three days and then treated with TGF-β1 for 72 hr. Percent BrdU was calculated by manual 
counting of at least 5 areas from each triplicate experiment. (P value less than, *: 0.005, **: 0.0001, 
***: 0.01). Grey bars: 0 ng/mL TGF-β1, black bars: 5 ng/mL TGF-β1. 
 
 Using a portion of the same transfected cells, we studied cell-cycle analysis 
and obtained similar results (Figure 3.107). 
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Figure 3.107: Cell cycle analysis in parental Huh7 and resistant Huh7-5 
subclone after TGF-β treatment following ectopic Smad3 expression. TGF-β1: 5 
ng/mL 
 
 
 
3.17.6. Prolonged TGF-β treatment generates mesenchymal-like Huh7 cells 
 Epithelial mesenchymal transition is one of the escape mechanisms from 
TGF-β-induced cytostatic responses (Gal et al., 2008). Recently, EMT has also been 
implicated in generation of stem-cell like cells with enriched tumorigenicity capacity 
(Mani et al., 2008). Besides, in liver, CD133+ cancer stem cells were stated to be 
resistant to TGF-β-induced cytostatic responses (Ding et al., 2009).  
Thus, we tested potential EMT transformation in resistant Huh7-5 and 
rescued Huh7-5-0 along with expression analysis of stem cell markers. We 
performed qRT-PCR, western blotting and immunofluorescence experiments to 
determine EMT-like transformation. Initial experiments with qRT-PCR designated 
increased expression in mesenchymal marker vimentin together with decreased 
levels in epithelial marker e-cadherin (Figure 3.108).  
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Figure 3.108: Expression of epithelial and mesenchymal markers in resistant 
and rescued subclones. Cells were treated with 1 ng/mL and 5 ng/mL TGF-β for 72 hr. Real-
time PCR analysis was performed with corresponding primer pairs. Expression values were 
normalized with respect to GAPDH. Y-axis: Fold Difference 
  
 Endogenous e-cadherin expression was markedly increased in rescued Huh7-
5-0 subclone. Moreover, e-cadherin expression is regulated by TGF-β signaling 
pathway. Zeb2 transcription factor is one of the key players in TGF-β-induced 
epithelial-mesenchymal transition with particular role in downregulation of e-
cadherin expression. Through direct interaction with e-cadherin promoter together 
with activated Smad molecules, zeb2 downregulates transcription of e-cadherin 
(Comijn et al., 2001). Besides, recent findings implicated zeb2 in vimentin regulation 
(Bindels et al., 2006). Therefore, we studied zeb2 expression in established 
subclones, together with parental Huh7. We demonstrated that zeb2 is also a target of 
TGF-β signaling pathway in parental Huh7 (Figure 3.109).  
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Figure 3.109: Expression of zeb2 in resistant and rescued subclones. Cells were 
treated with 1 ng/mL and 5 ng/mL TGF-β for 72 hr. Real-time PCR analysis was performed with 
corresponding primer pairs. Expression values were normalized with respect to GAPDH. Y-axis: Fold 
Difference 
 
 We detected substantially high activation of zeb2 expression at transcript 
level. Likewise, endogenous expression of zeb2 in resistant Huh7-5 and rescued 
Huh7-5-0 was detected to be ~4 to 6 fold higher than parental Huh7, respectively. 
Besides these endogenous transcript levels were increased up to ~9 and 17 fold with 
5 ng/mL TGF-β treatment in resistant and rescued subclones, respectively. Taken 
together, these results indicated that zeb2 might have a potential implication in TGF-
β-induced EMT-like transformation in HCC cells. Additionally, endogenous 
vimentin transcript levels were comparably higher in resistant and rescued subclones 
than parental Huh7. These findings also indicated a possible mesenchymal-like 
transformation of parental Huh7 during the establishment of the resistant subclone. 
We also studied the expression of e-cadherin and vimentin at protein level, together 
with another epithelial marker ZO-1. These results were also in support of qRT-PCR 
findings (Figure 3.110).   
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Figure 3.110: Expression of e-cadherin, ZO-1 and vimentin in parental Huh7, 
resistant and rescued subclones. Cells were treated with 1 ng/mL and 5 ng/mL TGF-β for 72 
hr under normal culture conditions. Western blotting analysis was performed with corresponding 
primary antibodies. A-tubulin was monitored as equal loading.  
 
 Endogenous protein levels of vimentin in resistant Huh7-5 and rescued Huh7-
5-0 were quite high when compared to parental Huh7. Removal of TGF-β from 
growth medium during the establishment of rescued Huh7-5-0 did not lead to an 
escape of resistant Huh7-5 from mesenchymal-like state. Epithelial-mesenchymal 
transition is usually characterized with cytoskeletal changes depending on diverse 
stimulating agents (Boyer et al., 1989). We studied localization and staining 
intensities of selected EMT genes in parental Huh7 and the established clones. 
Endogenous vimentin expression in parental Huh7 was heterogeneous with a range 
from completely negative cells to highly positive cells. Whereas, TGF-β treatment 
induced vimentin expression in parental Huh7 cells similar to qRT-PCR and 
immunoblotting results (Figure 3.111). Together with that, all of the cells in resistant 
Huh7-5 and rescued Huh7-5-0 subclones were homogenously positive for vimentin 
expression with a few exceptional cells that have less but still detectable expression. 
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Figure 3.111: Staining pattern of vimentin in parental, resistant and rescued 
subclones of Huh7. Pictures were obtained at 20X with same exposure time (350 ms). 
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We next studied the staining pattern of ZO-1 and β-cat at the adherens and 
tight junctions in TGF-β-treated parental Huh7 and the established subclones. ZO-1 
staining pattern changed to a much wider membranous distribution after TGF-β 
treatment in parental Huh7, indicating the dissolution of tight junctions during EMT 
(Figure 3.112 and 3.113). Similar distribution was detected with resistant and 
rescued subclones both in the presence and absence of TGF-β as an indication of a 
sustained mesenchymal like phenotype. 
 
 
 
Figure 3.112: Staining pattern of ZO-1 in parental, resistant and rescued 
subclones of Huh7 in the absence of TGF-β. Pictures were obtained at 20X with same 
exposure time (350 ms). 
 
 182
 
Figure 3.113: Staining pattern of ZO-1 in parental, resistant and rescued 
subclones of Huh7 in the presence of TGF-β. Pictures were obtained at 40X with same 
exposure time (350 ms). 
 
The disruption of multiple reciprocal interactions between e-cadherin and b-
catenin at adherens junctions promotes EMT transformation (Lecuit and Lenne, 
2007). We were not able to detect cell surface staining with the e-cadherin antibody 
in different fixation methods, therefore decided to study e-cadherin associated β-
catenin staining patterns. Cell surface staining of β-catenin demonstrated an even 
distribution in un-treated controls. However, distribution of β-catenin in parental 
Huh7 under TGF-β-treatment conditions was diffused on cell surface and more 
pronounced in the cytoplasm. Nonetheless, similar staining patterns were visible in 
resistant Huh7-5 and rescued Huh7-5-0 subclones (Figure 3.114). These findings 
also support alterations in cell surface mechanics in the established subclones.   
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Figure 3.114: Staining pattern of β-catenin in parental, resistant and rescued 
subclones of Huh7. Pictures were obtained at 40X with same exposure time (650 ms). 
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Moreover, mesenchymal-like HCC cell lines have higher motility and 
invasion capacity when compared to epithelial like cells (Yuzugullu et al., 2009). In 
consideration of such an observation in our lab, we decided to look at motility ratios 
of the established subclones in the presence of TGF-β, in comparison to parental 
Huh7. We performed a simple wound healing assay. Cells were seeded in 12-well 
plates 24 hr prior to wounding, as such to have a 100% monolayer confluence at the 
time of scratching. Essentially, cells were cultured with growth medium containing 
2% FBS after scratching. Results for untreated and treated wells are depicted in 
Figure 3.115 and Figure 3.116, respectively.  
 
Figure 3.115: Differential motility of parental Huh7, resistant Huh7-5 and 
rescued Huh7-5-0 subclones in the absence of TGF-β. Cells were cultured in 12-well 
culture plates, and a single linear wound was made with a pipette tip in confluent monolayer cells. 
Phase contrast pictures at ×20 magnification. Dashed lanes indicate initial edges after scratching. 
Experiments were performed in duplicate with two wounds in each well.  
  
The established subclones had enhanced migratory and invasive properties 
even in the absence of TGF-β. Interestingly enough, none of the samples had 
significant changes in invasion capacity in the presence of TGF-β. 
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Figure 3.116: Differential motility of parental Huh7, resistant Huh7-5 and 
rescued Huh7-5-0 subclones in the presence of TGF-β. Cells were cultured in 12-well 
culture plates, and a single linear wound was made with a pipette tip in confluent monolayer cells. 
Phase contrast pictures at ×20 magnification. Dashed lanes indicate initial edges after scratching. 
Experiments were performed in duplicate with two wounds in each well. 
 
Quantitative results obtained through measurement of wound closure 
demonstrated significant differences between the motility of parental Huh7 and the 
established subclones (Figure 3.117). 
 
Figure 3.117: Wound closure capacity of parental Huh7, resistant Huh7-5 and 
rescued Huh7-5-0 subclones. The distances between wound edges were measured at fixed 
points in each dish according to standardized template. At least three measurements were used in 
calculation of each wound. Phase contrast pictures at ×20 magnification.  
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 Collectively, these results supported the findings of establishment of a 
mesenchymal-like phenotype and transformation after prolonged TGF-β exposure. 
Nonetheless, removal of TGF-β from resistant Huh7-5 did not provoke to a reversion 
of this established state in rescued Huh7-5-0 subclone.  
 
3.17.7. Lack of increased putative “cancer stem cell” marker expression in 
resistant Huh7-5 and rescued Huh7-5-0 subclones 
A direct link between epithelial-mesenchymal transition and cancer stem cells 
has been established very recently. Such cell populations were reported to be more 
refractory to various sources of cellular stresses including DNA-damaging drugs, as 
well as cytokines including TGF-β (Ding et al., 2009; Trumpp and Wiestler, 2008). 
Therefore, we decided to study the potential enrichment of this very small putative 
“cancer stem cell” population, other known as tumor-initiating cells, in Huh7 cells 
after TGF-β treatment. If this was the case, senescence cells would have been 
eliminated from the culture and the remaining resistant population might have been 
enriched with stem cell marker expressing cells.  
To test this hypothesis, together with EMT analysis experiments, we screened 
the expression of known putative cancer stem cell (CSC) markers, namely CD133, 
CD90 and CD44, in parental Huh7, resistant Huh7-5 and rescued Huh7-5-0 
subclone. These markers have been identified to be differentially expressed in a 
minor subpopulation found in Huh7 cells (Ma et al., 2007).  
Quantitative real-time PCR experiments demonstrated that we could exclude 
this possibility. Interestingly enough, we showed that TGF-β induced the expression 
of CD133 in parental Huh7 with increasing doses of TGF-β (Figure 3.118). Whereas, 
endogenous expression of CD133, CD90 and CD44 did not change in resistant 
Huh7-5 and rescued Huh7-5-0 subclones. Even TGF-β treatment did not alter 
expression patterns of these selected target genes.  
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Moreover, recent report has been published suggesting CD133 as a target 
gene of TGF-β signaling pathway (You et al., 2010), which also supported our 
findings. 
 
 
Figure 3.118: Expression of putative CSC markers in parental Huh7, resistant 
Huh7-5 and rescued Huh7-5-0 cells. All expression values were normalized with GAPDH 
calues accordingly. 
 
 Furthermore, a few others including CK19 and EpCAM/ESA were identified 
as bipotential hepatic progenitor cell markers in hepatocellular carcinomas (Andersen 
et al., 2010; Cornella and Villanueva, 2010; Yamashita et al., 2009). With the above 
information, we therefore studied the expression of CK19 and ESA. 
Immunohistochemical experiments demonstrated heterogenous staining for both 
antigens in parental Huh7 without being effected by TGF-β treatment. Likewise, the 
staining patterns in resistant Huh7-5 and rescued subclone Huh7-5-0 were quite 
similar to parental Huh7 (Figure 3.119 and 3.120).  
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Figure 3.119: Staining pattern of CK19 in parental, resistant and rescued 
subclones of Huh7. Pictures were obtained at 40X with same exposure time (600 ms). 
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Figure 3.120: Staining pattern of ESA/EpCAM in parental, resistant and 
rescued subclones of Huh7. Pictures were obtained at 40X with same exposure time (600 ms). 
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Taken together, these results indicated that there was no increase/enrichment 
in stem cell/progenitor population in TGF-β treated parental Huh7 and as well as in 
resistant and rescued subclones. 
 
3.17.8. Implications of epigenetic mechanisms in maintenance of irreversible 
resistance to TGF-β in the established rescued subclone Huh7-5-0 
Remarkably, EMT is an example of cellular plasticity and programming and 
maintenance of this highly complex process is usually controlled through epigenetic 
mechanisms including DNA methylations and covalent histone modifications 
(Vincent and Van Seuningen, 2009). We focused our attention on epigenetic 
mechanisms mainly histone variations in parental Huh7 and the established 
subclones after TGF-β treatment to have a better understanding of the molecular 
mechanisms underlying the intriguing interplays during EMT transformation. Among 
others, H3K9 and H3K14 acetylations and trimethylation type of H3K4 and H3K36 
modifications are generally detected at transcriptionally active gene regions (Barski 
et al., 2007). Increased levels of such modifications were detected at the INK4 locus 
and p21Cip1 transcription start sites in senescent cells (Egger et al., 2007).  
On the other hand, methylation type of modifications detected on H3K9, 
H3K27 usually mark gene repression (Bannister et al., 2001; Boyer et al., 2006). 
Loss of these repressive modifications is also observed during the onset of 
senescence in mouse-embryonic fibroblasts through activation of Arf, p16Ink4a and 
p15Ink4b (Agherbi et al., 2009). Based on previous findings, we initially studied these 
particular covalent histone modifications by immunofluorescence technique. 
Screening of histone variations displayed major differences in a set of modifications. 
Lysine 9 monomethyl H3 displayed mildly decreased intensity in TGF-β-treated 
parental Huh7, with no detectable changes in the established subclones (Figure 
3.121).    
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Figure 3.121: Staining pattern of H3K9me1 in parental, resistant and rescued 
subclones of Huh7. Pictures were obtained at 40X with same exposure time (150 ms). 
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Nevertheless, Lysine 9 tri-methyl H3 displayed no major differences in TGF-
β-treated parental Huh7 and the established subclones (Figure 3.122). 
 
 
Figure 3.122: Staining pattern of H3K9me3 in parental, resistant and rescued 
subclones of Huh7. Pictures were obtained at 40X with same exposure time (150 ms). 
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Moreover, Lysine 27 mono-methyl H3 displayed no major differences in 
TGF-β-treated parental Huh7 cells, but substantially increased in the established 
subclones (Figure 3.123). 
 
 
Figure 3.123: Staining pattern of H3K27me1 in parental, resistant and rescued 
subclones of Huh7. Pictures were obtained at 40X with same exposure time (150 ms). 
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Additionally, we did not observe any notable differences in H3K27me3 in 
TGF-β-treated parental Huh7 cells and the established subclones (Figure 3.124). 
 
 
Figure 3.124: Staining pattern of H3K27me3 in parental, resistant and rescued 
subclones of Huh7. Pictures were obtained at 40X with same exposure time (150 ms). 
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 We detected the most prominent finding with lysine 36 mono-methyl H3 
staining. Interestingly enough, H3K36me1 displayed almost a complete loss of 
expression in TGF-β-treated parental Huh7 cell. However, these modifications were 
not altered in resistant Huh7-5 and rescued Huh7-5-0 subclones (Figure 3.125).  
 
 
Figure 3.125: Staining pattern of H3K36me1 in parental, resistant and rescued 
subclones of Huh7. Pictures were obtained at 40X with same exposure time (150 ms). 
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In summary, deregulated balance in histone modifications may implicate key 
role in programming of mesenchymal phenotype through epithelial plasticity and 
maintenance of such a process could be largely relying on epigenetic regulation.  
Expression of histone modifying enzymes is usually deregulated in various 
human cancers (Kassambara et al., 2009). Moreover, histone modifications that 
presented alterations in our study are basically modulated by WHSC1 and EZH2 for 
H3K36 and H3K27 methylations, respectively (Martinez-Garcia and Licht, 2010; 
Nimura et al., 2009). Based on this information, we studied these selected genes in 
publicly available microarray database, ONCOMINE, to compare the expression data 
in tumor type with its non-tumor counterpart. Using ONCOMINE, we directed the 
search in Wurmbach et. al. (Wurmbach et al., 2007) data to display the individual 
expression values of particular genes in various liver disease stages. According to our 
query in ONCOMINE, we obtained the following results for WHSC1 (MMSET, 
NSD2) (Figure 3.126) and EZH2 (Figure 3.127).   
 
Figure 3.126: Expression analysis of WHSC1 in liver diseases. Distribution of 
normalized and log(2) transformed WHSC1 signal intensity for each relavant-sample was drawn to 
scale. Similar results were obtained with other probe-sets as well. 
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WHSC1 expression was substantially increased with hepatocarcinoma 
progression as compared to normal liver samples. Similar results were obtained with 
the query based on Grade comparison (data not shown). Additionally, EZH2 
displayed a similar pattern of gene expression data. 
 
Figure 3.127: Expression analysis of EZH2 in liver diseases. Distribution of 
normalized and log(2) transformed EZH2 signal intensity for each relavant-sample was drawn to 
scale. Single probe-set is available for EZH2. 
 
 These findings implicated a potential role for WHSC1 and EZH2 in the 
progression of hepatocarcinogenesis. Of particular importance to mention; aggressive 
HCCs are less-differentiated with higher invasive and migratory capacity. Similarly, 
poorly-differentiated HCC cell lines with mesenchymal marker expression displayed 
higher migratory capacity (Yuzugullu et al., 2009). Conclusively, the resistant Huh7-
5 and the rescued Huh7-5-0 subclones resemble in an aspect to poorly-differentiated 
HCC cell lines.  Together with our staining results in parental Huh7, resistant Huh7-5 
and rescued Huh7-5-0 subclones, we deduced that these two genes may be further 
studied to delineate the mechanisms of differential histone modifications upon TGF-
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β treatment and maintenance of mesenchymal-phenotype. Therefore, we studied the 
expression of WHSC1 in parental Huh7 and the established Huh7 subclones. 
Surprisingly, the gene expression pattern displayed close correlation with 
H3K36me3 staining. TGF-β treatment substantially decreased the expression of 
MMSET in parental Huh7, whereas the established subclones had increased 
expression which was not effected by TGF-β exposure (Figure 3.128). 
 
Figure 3.128: Protein expression WHSC1 (MMSet II) in parental Huh7 and the 
established subclones. Treatment was done for 72 hr. a-tubulin served as equal loading control. 
 
Based on this surprising result we wanted to establish a link between 
MMSET expression and TGF-β signaling. We studied the expression of MMSET 
isoforms, I and II, in a time-dependent fashion under TGF-β-treatment conditions. In 
support of previous findings, we demonstrated diminished expression of MMSET 
isoforms under TGF-β treatment conditions (Figure 3.129). 
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Figure 3.129: Protein expression MMSet isoforms in parental Huh7 and the 
established subclones. Treatment was done for 72 hr. A-tubulin served as equal loading control. 
 
 Taken together, these results established a close link between TGF-β 
signaling pathway and histone modifications that might be causally associated with 
TGF-β-mediated gene expression regulation of particular histone modifying 
enzymes. Obviously, we will have to extend our studies to further delineate the 
connection mechanisms between the maintenance of mesenchymal transformation 
and resistance to TGF-β-induced cytostatic response with particular focus on 
deregulated Smad signaling and involvement of histone modifications.  
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CHAPTER 4. DISCUSSION AND CONCLUSION 
 The role of TGF-β signaling in normal hepatocytes and HCC cells remains 
poorly understood. Here, we provide experimental evidence for a senescence-
inducing role of TGF-β in hepatocyte-like well-differentiated HCC cells. Role of 
TGF-β in hepatocytes and HCC cells have been previously linked to its EMT-
inducing, cell cycle inhibitory and apoptotic effects (Fan et al., 1996; Kojima et al., 
2008; Lamboley et al., 2000). Our findings indicate that senescence induction is a 
major component of hepatocellular response to TGF-β exposure. We believe that 
such an effect has not been noticed before because of the fact that the senescence 
response to TGF-β observed throughout this study is a late-occurring but permanent 
event that becomes evident only after 3 days of incubation but still detectable after 
12 days in culture. As shown for cell cycle analysis with Huh7 cell line at different 
time points following TGF-β stimulation, senescence-associated permanent G1-
arrest became prominently high after 48 hr of stimulation and reached the peak at 72 
hr. Analyses performed at 96 and 120 hr did not display much increase in the 
percentage of G1-arrested cell population suggesting that the establishment of 
growth arrest was ensured after 3 days. Taken together,  the response of well-
differentiated HCC cell lines to TGF-β was manifested by major characteristics of 
cellular senescence such as flattened morphology, SA-β-gal activity, G1-phase cell 
cycle arrest with permanent withdrawal from the cell cycle.  
 Surprisingly enough, we demonstrated that just a very short exposure (less 
than one minute) was sufficient to trigger a strong senescence response in Huh7, 
PLC and Hep40 cells. Further analyses presented that such a short TGF-β stimulation 
of Huh7 cells was also able to induce a sustained nuclear accumulation of Smad 
molecules. Besides, incubation with TGF-β for 5 min induced luciferase reporter 
activation similar to continuous treatment.  
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 Nevertheless, TGF-β receptors are continuously degraded and 
resynthesized through several mechanisms including endosomes and caveolin 
positive vesicles-mediated internalization (Di Guglielmo et al., 2003). Therefore it is 
highly possible that TGF-β-mediated senescence is a late-occurring response 
generated by short exposures. On the other hand, brief TGF-β exposure induced its 
own expression which was also reported by other studies (Lin et al., 1995; Van 
Obberghen-Schilling et al., 1988). Thus TGF-β amplifies the autocrine cytokine loop 
along with pronounced transcriptional activation and release of other senescence 
related cytokines IL-6 and IL-8. Such dynamic alterations may underlie the sustained 
senescence response. As a matter of fact, inhibition of autocrine signaling using 
specific anti-TGF-β1 antibody demonstrated the role of self-produced TGF-β 
cytokine molecule in spontaneous senescence typically observed in Huh7 cell line 
(Ozturk et al., 2006).  
 In contrast to previously published reports with hepatocytes and HCC cell 
lines performed with TGF-β (Herzer et al., 2005; Lin and Chou, 1992; Oberhammer 
et al., 1991), we did not detect any apoptotic cell death in our studies with NAPO and 
activated caspase-3 immunostainings. This could be related to different experimental 
conditions. Indeed, previously published TGF-β-induced apoptosis responses by 
hepatocytes and HCC cell lines were obtained under serum-free or low serum 
conditions. Instead, we used standard culture media (with 10% FCS), but not serum-
free conditions in our experiments to test mimicry of relevant TGF-β signaling in 
vivo.  It is a well-known fact that serum deprivation sensitizes different types of cells 
to apoptosis, including HCC cells (Irmak et al., 2003). In addition, although we used 
well-differentiated cell lines in our experiments the response of these cell lines to 
TGF-β may be different from that of normal hepatocytes. It would be interesting to 
know whether TGF-β also induces senescence in normal hepatocytes when tested 
under serum-containing growth conditions. 
 The TGF-β and senescence connection that we established here was 
strongly linked to upregulation of p21Cip1 and p15Ink4b. Previous studies have 
demonstrated these two genes as downstream targets of TGF-β signaling pathway 
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(Datto et al., 1995; Rich et al., 1999). Upregulation of p21Cip1 was p53 independent 
as all these cell lines except HepG2 are devoid of p53 activity. Moreover, possible 
p53 activation by TGF-β in HepG2 cells was negative as tested by p53 (ser15) 
specific primary antibody. This finding suggested that the TGF-β-mediated p21Cip1 
upregulation and the senescence-response was p53-independent. Plus, p16Ink4a 
protein expression was not modulated by TGF-β treatment indicating that the 
senescence response was also p16Ink4a-independent. Moreover, retinoblastoma 
protein also appeared to be dispensable for TGF-β-induced senescence, since Hep3B 
cell line used here is reported to be pRb-deficient (Puisieux et al., 1993). 
Nevertheless, the p107 ‘pocket protein’ has been shown to be required for initiation 
of accelerated cellular senescence in the absence of pRb (Lehmann et al., 2008) 
which may explain the senescence in Hep3B cells.  
 In addition to above findings, forced ectopic expression of p21Cip1, in the 
absence of TGF-β-treatment resulted in a senescence-like response with flattened 
morphology, increased SA-β-gal activity, G1-arrest, and inhibition of BrdU 
incorporation into cellular DNA in Huh7 cells. The overexpression of p15Ink4b also 
generated a similar response, but to a lesser degree, probably owing to high 
endogenous expression of p15Ink4b.  
 Another important component of TGF-β-induced senescence in well-
differentiated HCC cell lines was accumulation of ROS. As tested by DCFH 
staining, TGF-β provoked production of intracellular ROS. Mitochondrial ROS 
generation has been previously implicated in TGF-β-induced senescence arrest in 
Mv1Lu cells (Yoon et al., 2005). Together with DCFH, we also stained cells with 
mitochondrial respiration specific dye, namely MitoTracker Red. Unlike DCFH 
staining pattern, we detected similar endogenous staining with MitoTracker 
indicating that TGF-β induced ROS production in HCC cells was independent of 
mitochondrial membrane potential. NADPH oxidase system has been causally linked 
to TGF-β-induced ROS accumulation in normal and transformed hepatocytes with 
particular focus on the role of Nox4 protein (Carmona-Cuenca et al., 2006; Hu et al., 
2005; Sturrock et al., 2006). Similar to previous findings TGF-β induced Nox4 
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expression in our study as well. In addition, inhibition of ROS accumulation using a 
scavenger, N-acetyl-cysteine, inhibited TGF-β-induced growth arrest as well as 
upregulation of p15Ink4b and p21Cip1. Similar results were obtained with Nox4 
silencing. Thus both ROS accumulation and Nox4 upregulation were critical steps in 
TGF-β-mediated senescence in HCC cells (Figure 4.1). A very recent study also 
provided similar results about the role of Nox4 in ROS accumulation in Huh7 cells 
with particular interest in the connection of HCV infections and ROS accumulation 
triggered TGF-β signaling (de Mochel et al., 2010).  
 
Figure 4.1: A model summarizing major components of TGF-β-induced 
senescence in HCC cells. (see (Senturk et al., 2010)) 
 
 Intracellular accumulation of ROS was associated with sustained telomere-
independent DNA-damage in chronic liver diseases (Matsumoto et al., 2003), as well 
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as the onset of cellular senescence (Passos and Von Zglinicki, 2006; Rai et al., 2009). 
Screening of ATM and 53BP1 foci status demonstrated that TGF-β−induced 
senescence was also associated with DNA-damage response. However, we were not 
able to observe supporting results with COMET assay and activation status of 
H2AX. COMET assay recognizes both double- and single-strand breaks (Olive and 
Banath, 2006). Activation of H2AX requires double-strand breaks; however it is 
dispensable for the onset of DNA-damage response (Celeste et al., 2003). Taken 
together, TGF-β may play a prominent role in ROS-induced DNA-damage response 
in HCC cells which has never been addressed. Thus, these initial studies require 
further repeats to be able to establish a link between TGF-β signaling pathway and 
ROS-induced DNA-damage in hepatocarcinomas.      
 Two tumor-suppressor mechanisms, one mediated by p53, the other by 
p16Ink4a are lost frequently in HCC cells. Inactivating p53 mutations were found in a 
third of HCCs worldwide, but in a great majority of aflatoxin-related HCCs in Africa 
and China (Ozturk, 1991; Ozturk, 1999). Likewise, more than 50% of HCCs, 
independent of their geographical origins, display epigenetic or genetic inactivation 
of INK4 locus gene encoding p15Ink4b, ARF and p16Ink4a (Ozturk et al., 2009; 
Tannapfel et al., 2001). Since our findings indicate that TGF-β is able to induce 
senescence in p53 mutant HCC cells independent of p16Ink4a induction, candidate 
therapeutic interventions to induce TGF-β-mediated senescence are likely to be 
successful in HCC tumors with p53- and/or p16Ink4a-deficiency. In support of these in 
vitro findings, we performed in vivo studies with subcutaneous Huh7 tumors raised 
in nude mice. Single intratumoral injection of TGF-β induced local but robust SA-β-
Gal activity as tested with resected Huh7 tumors after 7 days. Together with that, 
peritumoral local injection of TGF-β with four days of intervals in long term follow-
up Huh7 tumors provoked a substantial anti-tumor activity together with successful 
regression in two of six TGF-β-treated tumors.  
 Senescence-associated secretome including inflammatory cytokines 
released from senescent cells in mouse model HCC tumors induces immune system 
activation (Krizhanovsky et al., 2008; Xue et al., 2007). Complete clearance of these 
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two tumors may be in part due to in vivo activation of natural killers and 
macrophages through known and unknown mechanisms including inflammatory 
cytokine release as evidenced by in vitro studies discussed throughout this study. 
Nonetheless, HCC cancers constitute a large population estimated to be in the order 
of several hundred thousands, worldwide. The therapeutic use of TGF-β could be 
considered at least for early HCCs.  
 Unlike, well-differentiated cell lines which responded to TGF-β with robust 
senescence arrest, poorly-differentiated cell lines displayed complete resistance to 
TGF-β-mediated cytostatic responses. In an effort to delineate the mechanisms of 
resistance we performed a series of analyses. Such resistance could be implemented 
by inactivating mutations together with deregulated expression of TGF-β signaling 
receptors as well as Smad molecules in various cancers (Bae et al., 2009; Kim et al., 
2000; Levy and Hill, 2006). The studies of others and our lab demonstrated that 
inactivating mutations of TGF-β receptors and Smads are infrequent in HCCs (Jong 
et al., 2002; Yakicier et al., 1999). In this study, we also demonstrated that all cell 
lines differentially express TGF-β receptor type II and I, except Hep3B-TR (TGF-
β resistant) and Snu398, which are devoid of TGF-β receptor type II expression. Our 
observations were also in support of others which showed TGF-β receptor type II 
deletion in Hep3B-TR (Hasegawa et al., 1995) and deregulated TGF-β receptor type 
II expression in Snu398 and Snu475 cell lines (Kitisin et al., 2007). Together with 
these abnormalities, recent publications highlighted the importance of beta-spectrin 
ELF, a Smad3/4 adaptor during hepatocarcinogenesis (Baek et al., 2008). Together 
with decreased TGF-β receptor type II, loss of ELF expression in several Snu398 and 
Snu475 cell lines has been linked to acquired resistance to TGF-β mediated growth 
arrest (Kitisin et al., 2007).  
 Nevertheless, our studies with luciferase reporter analysis in PD cell lines 
implicated intact TGF-β signaling although comparably less in amplitude than WD 
cell lines. Unlike previous studies, we showed that all PD cell lines except Snu398 
have functional TGF-β receptors as tested by Smad2 activation by phosphorylation. 
Deregulated translocation of core intracellular signaling cascade has been proposed 
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as another resistance mechanism in various cancer models with intact TGF-β 
receptors (Di Guglielmo et al., 2003; Mishra et al., 2004; ten Dijke et al., 2000). In 
order to test this, we analyzed all PD cell lines for effective Smad3 translocation 
from cell membrane into nucleus by immunostaining. As evidenced, all cell lines 
except Snu398 had detectable nuclear Smad3 upon TGF-β stimulation.  
 Furthermore, PD cell lines lack endogenous Nox4 expression which was 
not induced by TGF-β either. Together with that we did not detect any sign of ROS 
accumulation in tested PD cell lines. These results suggested that unknown 
mechanisms responsible for deregulation in ROS production and Nox4 expression 
may be partially responsible for resistance to TGF-β-induced senescence arrest. 
Moreover, we also demonstrated that three cell lines, namely Snu387, Snu449 and 
SkHep1 are p15Ink4b-deficient due to a deletion in INK4 locus. Besides Focus cell 
line lack pRb expression (Puisieux et al., 1993). Since we closely implicated those 
genes in growth arrest in WD cell lines, such malformations may also be responsible 
for TGF-β-resistance in PD cell lines.  
 Lately, zeb2 overexpression has been associated with TGF-β pathway 
functions in epithelial-mesenchymal transition and suppression of target gene 
activation (Kojima et al., 2008; Ohashi et al., 2010; Postigo, 2003). Therefore, we 
studied potential implications of zeb2 expression in PD cell lines. We demonstrated 
that mesenchymal-like PD cell lines display high nuclear expression when compared 
to WD cell lines. Using an epithelial-like cell line A431 with Tet regulatable zeb2 
expression, we looked at the expression patterns of p15Ink4b and p21Cip1 under TGF-β 
treatment conditions. These studies pointed the role of zeb2 in inhibition of target 
gene activation. Together with that we also down regulated zeb2 expression in two 
selected PD cell lines and reported a slight upregulation in above targets after TGF-β 
stimulation. Taken together, we concluded that zeb2 overexpression in PD cell lines 
may also be partially responsible for acquired resistance against TGF-β cytostatic 
responses. Owing to the genetic and epigenetic heterogeneity of HCC cell lines, it is 
highly likely that several mechanisms may be involved in resistance to TGF-β. 
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   Interestingly enough, prolonged exposure to TGF-β generated Huh7 
subclones with acquired resistance. Complete establishment of these clones occurred 
in approximately 60 days. We are yet unsure how parental Huh7 cells forced to 
undergo senescence-arrest after sustained TGF-β exposure acquire proliferative 
capacity. However we were able to study the mechanisms underlying maintenance of 
resistance in established subclones. We demonstrated that these cells have 
substantially lost their responsiveness to TGF-β treatment due to deregulated Smad 
signaling. Intact TGF-β receptor activity was detectable in resistant and rescued 
subclones with only slight impairment in the amplitude of Smad phosphorylation. 
However, it was evident that the timing of nuclear accumulation and exclusion 
duration was deregulated in both subclones.  
 According to our data, we also concluded that partial epithelial-
mesenchymal like transformation may play a key role in prolonged resistance to 
TGF-β. Recently, EMT has been proposed as a mechanism to escape from failsafe 
programs (Ansieau et al., 2008), including resistance to TGF-β-mediated growth 
arrest (Ohashi et al., 2010). We hypothesize at this point, that EMT may be 
responsible for the onset and maintenance of TGF-β resistance. Nonetheless, these 
studies need further clarification to delineate the complete contribution of partial 
EMT and sustained mesenchymal-like phenotype to persistence of TGF-β 
unresponsiveness. These encouraging results may also provide further insight into 
resistance against TGF-β cytostatic responses in other mesenchymal-like cells 
including poorly-differentiated HCC cell lines. In addition, studying target gene 
expression patterns in the established subclones after TGF-β treatment revealed 
interesting results. We observed unchanged or slightly impaired regulations in 
epithelial and mesenchymal marker gene expressions in both the established 
subclones. Whereas, those target genes responsible for cytostatic response generation 
were entirely deregulated. This suggested that the interpretation of TGF-β signal in 
the established subclones might be somehow altered. The most interesting finding for 
us was the upregulation of Smad3 in TGF-β-treated parental Huh7 but not in the 
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established subclones. This led to a hypothesis that upregulation of Smad3 might be 
essential for the onset of cytostatic responses but not EMT-like transformation. 
 Another issue that needs to be discussed here is the irreversible resistance 
to TGF-β treatment in the rescued subclone. Even if this subclone presented a partial 
responsiveness to TGF-β stimulation in terms of luciferase reporter activation, this 
was not accompanied by a detectable increase in cytostatic response as tested by 
proliferation assays. Therefore we decided to look at epigenetic regulations on the 
maintenance of entire resistance to TGF-β-induced growth suppression. As tested by 
immunofluorescence analyses, we showed clearly detectable differences in 
H3K27me3 and H3K36me1 staining patters. These results suggested a potential 
involvement of epigenetic regulations in TGF-β-mediated senescence arrest in 
parental Huh7 cells together with an implication in persistent resistance in the 
established subclones. Such histone modifications were partially correlated with 
alterations in gene expression patterns of histone modifying enzyme WHSC1 
(MMSetI and MMSetII).  
 Recently, “cancer stem cells” have been demonstrated to have resistance 
against the effects of DNA-damaging agents (Bao et al., 2006; Gupta et al., 2009; 
Sabisz and Skladanowski, 2009) and anti-proliferative cytokines, including TGF-β 
(Ding et al., 2009). In this regard, we looked at the expression pattern of so far 
identified putative “cancer stem cell” markers. Unfortunately, we were not able to 
demonstrated a significant change in transcriptional expression as well as 
immunofluorescence based staining of selected markers. These results therefore 
suggested that TGF-β does not enrich the population of cancer stem cells found in 
parental Huh7. 
 Conclusively, our findings provide in vitro evidence for a strong senescence 
response of well-differentiated HCC cells to TGF-β. This response was dependent on 
increased ROS production, sustained DNA damage response, and induction of 
p21Cip1 and p15Ink4b expression leading to G1 phase arrest. TGF-β induced 
senescence was independent of p53 and p16Ink4a both of which are frequently 
 209
inactivated in HCC. Our findings implicate that TGF-β-induced senescence may 
serve as a tumor-suppressor mechanism in early HCCs, but also promote the decline 
of hepatocyte proliferation in cirrhosis. We also provide evidence partially shedding 
light on resistance mechanisms to TGF-β-induced growth arrest in mesenchymal-like 
HCC cells.   
     
4.1. Future perspectives 
Beside growth suppressive effects, TGF-β is a multi functional cytokine that 
can also modulate cell motility and invasion, epithelial-mesenchymal transition, and 
immune system regulation that can promote tumor progression (Battaglia et al., 
2009; Huang et al., 2008; Yang et al., 2009). In addition, it is yet unclear whether 
TGF-β activity is increased or decreased during hepatocellular carcinogenesis. In the 
event that TGF-β activity is increased in HCC tumors, their growth and progression 
would require the bypass of TGF-β-induced senescence barrier. Interestingly, about 
50% of HCCs tested so far displayed SA-β-gal activity, as an indication that the 
senescence bypass is not fully accomplished in these tumors. It will be informative to 
know whether the senescence observed in such tumors is related to an increased 
TGF-β production (Abou-Shady et al., 1999; Dong et al., 2008). Nevertheless, the 
apparent paucity of senescent cells in other HCC tumors strongly suggests that HCC 
cells are able to develop a resistance to TGF-β-induced senescence by mechanisms 
that remain to be uncovered. Further exploration of TGF-β-induced senescence 
mechanisms in HCC may prove to be highly beneficial for a better understanding of 
liver malignancy. ROS accumulation after 3 days of TGF-β treatment is mainly 
responsible for senescence induction in this setting. ROS mediated DNA-damage 
mechanisms require further investigation to determine the intensity of damage 
provoked by TGF-β during the onset of senescence induction. It would also be 
noteworthy to determine the involvement of DNA-damage response in senescence-
induction by further studies. Along ROS accumulation during senescence, here we 
presented data implicating Nox4 upregulation in intriguing interplay of the 
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mechanisms during the onset of cellular senescence. Silencing of Nox4 established a 
solid data suggesting Nox4 as one of the key factors responsible for senescence 
induction. It would be interesting to see the effects of Nox4 overexpression in a 
regulatable system not only in vitro but also in vivo mouse tumor models.  
Liver cirrhosis is a premalignant condition and more than 80% of HCCs take 
roots in a cirrhosis background. As shown here, well-differentiated HCC cells 
develop a strong in vitro senescence response to TGF-β even after a minute time of 
exposure. Together with that, we demonstrated the involvement of autocrine TGF-β 
signaling in spontaneous senescence observed in Huh7 cells. In confirmation of this 
hypothesis, we observed that well-differentiated HCC cell lines are not only 
responsive to TGF-β, but they also produce this senescence-inducing cytokine. The 
inhibition of senescence in Huh7 cell line by anti-TGF-β antibody treatment provides 
further evidence for an autocrine or paracrine senescence-inducing role for TGF-β in 
well-differentiated HCC cells. We observed a net increase in cell proliferation by 
antibody-mediated blocking of TGF-β activity in Huh7 cells. These observations 
raise the possibility that the inhibition of TGF-β-induced senescence in cirrhotic liver 
may help to promote the proliferation of not only normal hepatocytes, but also 
premalignant or malignant HCC cells. It is therefore very interesting to address how 
regulatable ectopic TGF-β overexpression would affect senescence onset in Huh7 
cells in vitro and in vivo by playing with the released levels of TGF-β, instead of just 
adding a fixed amount of TGF-β to the growth medium. This way we can more 
precisely mimic the in vivo conditions.  
TGF-β cytokine has been implicated in modulation of tumor 
microenvironment through autocrine and/or paracrine signaling (Massague, 2008; 
Padua and Massague, 2009). Oncogene-induced senescence secretome has also been 
involved in multiple in vivo functions (Coppe et al., 2010). Senescent cells not only 
stop proliferation but also have adverse effects on the homeostasis tissue 
microenvironment. In vivo senescence response that we displayed here is probably a 
reminiscent of oncogene-induced senescence that has been established as a strong 
barrier against tumor development from preneoplastic lesions in other cancers such 
 211
as melanomas (Ozturk et al., 2009). Cytokines such as IL-6 and IL-8 play essential 
role for oncogene-induced senescence but may also provoke tumor progression. 
Thus, TGF-β may contribute to the establishment of a senescence barrier against 
HCC development in cirrhotic liver, by a paracrine or even an autocrine mechanism, 
however the details of such implications are yet to be determined.  
As so far identified, there are many candidate mechanisms which probably 
contribute to TGF-β resistance in PD cell lines. Among those, it is important that one 
has to completely shot down the expression of zeb2 and study the cytostatic effects 
of TGF-β in stable clones. 
As we demonstrated here, TGF-β not only induces senescence in such a short 
notice but also provokes the establishment of resistant clones in prolonged culturing 
conditions. It is obviously not clear whether short-term effects are reversible under 
persistent TGF-β exposure conditions by as yet unknown mechanisms. It is 
noteworthy trying to perform thorough analyses on acquired resistance to TGF-β. 
Therefore, it becomes essential to perform long term studies with TGF-β in vivo 
tumors. Here we identified deregulated Smad expression as well as impaired signal 
transduction in the established subclones. One interesting outcome was the 
upregulation Smad3 expression upon TGF-β exposure in parental Huh7 but not in 
other clones. Here, we are not sure whether such an observation is a cause or a 
consequence in the onset of TGF-β-induced senescence. Therefore, we believe 
silencing each individual Smad partner in parental Huh7 would provide informative 
insights into the mechanisms of cellular senescence in terms of modulation of 
signaling molecules during cell cycle arrest triggered by this cytokine. It is also 
noteworthy saying that, these studies would help defining the downstream signaling 
cascades by which cells decide to undergo senescence or EMT during the 
interpretation of TGF-β signal transduction.  
Finally, we provide preliminary evidence for partial involvement of 
epigenetic regulations during senescence induction and in participation of acquired 
resistance to TGF-β in rescued subclones. Hence it is necessary to draw a broad 
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picture of gene regulations by starting with RNA and protein array studies to narrow 
the list of candidate genes by which we can explain the implications of TGF-β 
signaling pathway in hepatocellular senescence and the mechanisms accountable for 
irreversible resistance.   
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Transforming Growth Factor-Beta Induces Senescence
in Hepatocellular Carcinoma Cells and Inhibits
Tumor Growth
Serif Senturk,1 Mine Mumcuoglu,1 Ozge Gursoy-Yuzugullu,1,2 Burcu Cingoz,1
Kamil Can Akcali,1 and Mehmet Ozturk1,2
Senescence induction could be used as an effective treatment for hepatocellular carcinoma
(HCC). However, major senescence inducers (p53 and p16Ink4a) are frequently inactivated in
these cancers. We tested whether transforming growth factor-b (TGF-b) could serve as a poten-
tial senescence inducer in HCC. First, we screened for HCC cell lines with intact TGF-b signal-
ing that leads to small mothers against decapentaplegic (Smad)-targeted gene activation. Five
cell lines met this condition, and all of them displayed a strong senescence response to TGF-b1
(1-5 ng/mL) treatment. Upon treatment, c-myc was down-regulated, p21Cip1 and p15Ink4b
were up-regulated, and cells were arrested at G1. The expression of p16
Ink4a was not induced,
and the senescence response was independent of p53 status. A short exposure of less than 1 mi-
nute was sufﬁcient for a robust senescence response. Forced expression of p21Cip1 and p15Ink4b
recapitulated TGF-b1 effects. Senescence response was associated with reduced nicotinamide
adenine dinucleotide phosphate oxidase 4 (Nox4) induction and intracellular reactive oxygen
species (ROS) accumulation. The treatment of cells with the ROS scavenger N-acetyl-L-cyste-
ine, or silencing of the NOX4 gene, rescued p21Cip1 and p15Ink4b accumulation as well as the
growth arrest in response to TGF-b. Human HCC tumors raised in immunodeﬁcient mice
also displayed TGF-b1–induced senescence. More importantly, peritumoral injection of TGF-
b1 (2 ng) at 4-day intervals reduced tumor growth by more than 75%. In contrast, the dele-
tion of TGF-b receptor 2 abolished in vitro senescence response and greatly accelerated in vivo
tumor growth. Conclusion: TGF-b induces p53-independent and p16Ink4a-independent, but
Nox4-dependent, p21Cip1-dependent, p15Ink4b-dependent, and ROS-dependent senescence
arrest in well-differentiated HCC cells. Moreover, TGF-b–induced senescence in vivo is associ-
ated with a strong antitumor response against HCC. (HEPATOLOGY 2010;00:000-000)
C
ellular senescence is a permanent withdrawal
from the cell cycle in response to diverse stress
conditions such as dysfunctional telomeres,
DNA damage, strong mitotic signals, and disrupted
chromatin. Senescence is considered to be a major
cause of aging, but also a strong anticancer mecha-
nism.1 The relevance of senescence in chronic liver dis-
eases is poorly known, but it may play a central role.
Hepatocyte telomeres undergo shortening during
chronic liver disease progression,2 and this is accompa-
nied by a progressive decline of hepatocyte prolifera-
tion.3 Senescence-associated b-galactosidase (SA-b-
Gal)-positive cells have been detected in 3%-7% of
normal liver, 50% of chronic hepatitis, 70%-100% of
cirrhosis, and up to 60% of hepatocellular carcinoma
(HCC) tissues.2,4-7 Highly abundant senescence
observed in cirrhosis has been conﬁned to hepatocytes2
and stellate cells.8 Because telomere-deﬁcient mice
Abbreviations: BrdU, bromodeoxyuridine; cDNA, complementary DNA;
NAC, N-acetyl-L-cysteine; Nox4, NADPH oxidase-4; ROS, reactive oxygen
species; SA-b-Gal, senescence-associated-b-galactosidase; siRNA, small interfering
RNA; TERT, telomerase reverse transcriptase; TGF-b, transforming growth
factor-b; TGF-bR1,TGF-b receptor 1.
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1
develop cirrhosis,9 and cirrhotic hepatocytes display
shortened telomeres, telomere dysfunction was pro-
posed to cause senescence in cirrhosis.2 It is assumed
that HCC tumor cells bypass hepatocellular senescence
to become immortalized. Frequent inactivation of
TP53 (encoding the tumor protein p53) and
CDKN2A (cyclin-dependent kinase inhibitor 2A,
encoding p16Ink4a protein) genes in these tumors sup-
ports this hypothesis.10 Nevertheless, the detection of
senescent cells in some HCC tumors suggests that
transformed and presumably immortal hepatocytes
have maintained the capacity to undergo senescence
arrest under appropriate conditions.
With this regard, immortal HCC cell lines can sponta-
neously generate progeny that undergo replicative senes-
cence11; murine HCC tumors generated by the expres-
sion of a mutant Ras gene in p53-deﬁcient hepatoblasts
can be cleared by a massive senescence response upon
reactivation of p53 expression12; c-myc oncogene inactiva-
tion in murine HCCs results in senescence-mediated tu-
mor regression.13 One of our goals is to identify novel
mechanisms of senescence induction in HCC cells. Here,
we identify the transforming growth factor-beta (TGF-b)
as a major cytokine that is able to trigger a massive senes-
cence response in well-differentiated HCC cell lines.
Reduced nicotinamide adenine dinucleotide phosphate
oxidase-4 (Nox4) and reactive oxygen species (ROS) were
key intermediates of TGF-b–induced growth arrest that
was mediated by p21Cip1 and p15Ink4b.
Materials and Methods
Detailed materials and methods are described in the
Supporting Information Materials and Methods. Cell
lines were tested under standard culture conditions in
the presence of 10% fetal bovine serum. Total RNA
was isolated using a NucleoSpin RNA II Kit
(Macherey-Nagel, Duren, Germany), and ﬁrst-strand
complementary DNA (cDNA) was synthesized using
RevertAid First Strand cDNA synthesis kit (MBI Fer-
mentas, Leon-Rot, Germany). Genomic DNA was
extracted as described,11 and polymerase chain reaction
(PCR) assays were done using appropriate primers.
Quantitative PCR was performed using SYBR Green I
(Invitrogen, Carlsbad, CA). Glyceraldehyde 3-phos-
phate dehydrogenase and b-actin were used as internal
controls. The SA-b-Gal assay was performed as
described.11 Commercial and homemade antibodies
were used. Western blot assays were performed as
described,11 using a-tubulin or calnexin as internal
controls. For immunoperoxidase and immunoﬂuores-
cence assays, cells were ﬁxed with 4% formaldehyde,
permeabilized with phosphate-buffered saline supple-
mented with 0.5% saponin and 0.3% TritonX-100
(Sigma, St. Louis, MO), and subjected to indirect im-
munoﬂuorescence and immunoperoxidase assays. To
test permanent cell cycle arrest, cells were labeled with
bromodeoxyuridine (BrdU) for 24 hours in freshly
added culture media, and the anti-BrdU immunoﬂuo-
rescence assay was performed as described.11 Human
p15Ink4b and p21Cip1 were cloned into pcDNA3.1C/
Neo and pcDNA3.1(þ)/hygromycin (Invitrogen),
respectively. Cells were transfected with Lipofectamine
2000 (Invitrogen) and selected with either Geneticin
G418 (Gibco) or hygromycin-B (Roche, Indianapolis,
IN) for 8 days. The NOX4 gene was silenced using
previously described Nox4-speciﬁc small interfering
RNAs (siRNAs).14 A negative control siRNA was used
in parallel experiments. The siRNAs were transfected
with Lipofectamine RNAiMAX (Invitrogen). The
pSBE4-luc reporter was cotransfected with pRL-TK
(plasmid Renilla luciferase, with thymidine kinase pro-
moter; Promega, Madison, WI), using Lipofectamine
2000. The luciferase assay was performed using a
Dual-Glo luciferase kit (Promega). For cell cycle stud-
ies, ﬁxed cells were labeled with propidium iodide and
analyzed using FACSCalibur Flow Cytometer (BD
Biosciences, San Jose, CA). Intracellular ROS were
detected with 20,70-dichloroﬂuorescein diacetate
(DCFH-DA; Sigma), using MitoTracker Red (Invitro-
gen) as a counterstain. Apoptosis was tested by Nega-
tive in Apoptosis (NAPO)15 and active caspase-3 anti-
body (Asp-175; Cell Signaling Technology, Danvers,
MA) immunoassays. Subcutaneous human HCC
tumors were obtained in CD1 nude mice using 5 
106 live cells per injection. All animals received care
according to the Guide for the Care and Use of Labo-
ratory Animals. Results were expressed as mean 6 stand-
ard deviation from at least three independent experi-
ments. Data between groups were analyzed by one-tailed
t test. A P value <0.05 was considered statistically sig-
niﬁcant. TGF-b1 expression in liver disease was analyzed
using a publicly available global gene expression data,16
which were normalized using JustRMA tool from the
Bioconductor group.17 A two-sample t test with random
variance model was used with a 0.05 nominal signiﬁ-
cance level of each univariate test.
Results
Differential Expression of TGF-b1 in Normal
Liver, Cirrhosis, and HCC. We ﬁrst analyzed TGF-
b1 expression in normal liver, cirrhosis, and HCC,
using the publicly available clinical data sets.16 TGF-
b1 expression displayed a bell-shaped distribution with
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a sharp increase in cirrhosis (cirrhosis versus normal
liver, P < 0.001), followed by a progressive decrease
in early HCC (early HCC versus cirrhosis, P < 0.02)
and advanced HCCs (Supporting Information Fig. 1).
This expression pattern closely correlated with reported
frequencies of SA-b-Gal activities in normal liver, cir-
rhosis, and HCC.2,4-7
TGF-b Is an Autocrine Cytokine Inducing a
Senescence-Like Response in Well-Differentiated HCC
Cell Lines. We hypothesized that TGF-b signaling can
induce hepatocellular senescence response, because it is
a potent inducer of G1 arrest.
18 To test this hypothesis,
we ﬁrst formed a panel of ‘‘well-differentiated’’ HCC
cell lines that display E-cadherin expression, epithelial-
like morphology, and hepatocyte-like gene expres-
sion.19 Well-differentiated cell lines also share the same
TGF-b early response gene expression patterns with
normal hepatocytes.20 All selected cell lines expressed
all critical components of TGF-b signaling including
TGF-b1, TGF-b receptor 1 (TGFBR1), TGFBR2,
small mothers against decapentaplegic homolog 2
(SMAD2), SMAD3, and SMAD4 (Supporting Informa-
tion Fig. 2A). Hep3B-TR clone displaying homozygous
deletion of TGFBR221 was used as a negative control
(Supporting Information Fig. 2). All cell lines, except
Hep3B-TR displayed intact TGF-b signaling activity
(Fig. 1A), as tested by pSBE4-Luc reporter activity.22
Treatment of cells with TGF-b1 (5 ng/mL) yielded
9-fold to 19-fold induction of pSBE4-Luc reporter activ-
ity in responsive cell lines. The expression of endogenous
plasminogen activator inhibitor-1 (PAI-1), a well-known
TGF-b target gene,23 was also induced (Supporting
Information Fig. 3). TGF-b1–treated cell lines were kept
in culture with medium changes (without TGF-b1)
every 3 days, examined morphologically, and subjected
to SA-b-Gal assay. All cell lines tested, except Hep3B-
TR, displayed growth inhibition associated with ﬂattened
cell morphology and >50% positive SA-b-Gal activity,
as early as 3 days after TGF-b1 treatment (Fig. 1B).
Expression of TGF-b1 in all tested cell lines sug-
gested that it could act as an autocrine cytokine.
Therefore, we exposed Huh7 cells to either anti-TGF-
b1 antibody (5 lg/mL) or TGF-b1 (5 ng/mL) and
tested for total and SA-b-Gal–positive cells in isolated
colonies 10 days later. Cells treated with anti-TGF-b1
antibody displayed two-fold increased colony size (P <
0.04) and 50% decreased SA-b-Gal activity (P < 0.02;
Supporting Information Fig. 4). In contrast, ectopic
TGF-b1 treatment caused a seven-fold decrease in col-
ony size (P < 0.005) and ﬁve-fold increase in SA-b-
Gal activity (P < 0.0001). Thus, Huh7 cells produced
TGF-b1 acting as a weak autocrine senescence-induc-
ing signal that was inhibited by anti-TGF-b1 antibody,
and ampliﬁed by ectopic TGF-b1.
A Brief Exposure to TGF-b for a Robust
Senescence Response. To test the shortest time of ex-
posure to TGF-b1 for a full senescence response, three
cell lines were treated with TGF-b1 for durations
between <1 minute (20 seconds) and 72 hours, and
subjected to SA-b-Gal staining. To our surprise, <1
minute exposure was sufﬁcient for a robust senescence
response (Fig. 2). Thus, the senescence-initiating effect
of TGF-b1 was immediate, even though the senes-
cence phenotype (>50% SA-b-Gal–positive and ﬂat-
tened cells) was manifested 3 days later.
Lack of Evidence for TGF-b–Induced Apoptosi-
s. Earlier studies indicated that TGF-b induces apo-
ptosis in hepatocytes and some HCC cell lines under
serum-free conditions.24-27 Under our experimental
conditions using 10% fetal bovine serum, all ﬁve cell
lines tested failed to enter apoptosis following TGF-b
Fig. 1. Well-differentiated HCC cell lines are competent for TGF-b
signaling activity and they respond to TGF-b by potent senescence-like
growth arrest. (A) Cells were cotransfected with pSBE4-Luc and control
pRL-TK plasmids, and treated with or without TGF-b1 (5 ng/mL) for
24 hours. The luciferase activity was measured and expressed as fold-
activity of pSBE4-Luc/pRL-TK (mean 6 standard deviation; n ¼ 3).
(B) Cells were plated at low density and treated with 1 or 5 ng/mL
TGF-b1, and tested for SA-b-Gal activity (blue) at days 3 and 7.
Counterstain: Fast Red. TGFBR2-deleted Hep3B-TR cells were used as
negative controls in (A) and (B).
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treatment, as examined by NAPO antibody15 and acti-
vated caspase-3–speciﬁc antibody tests (Supporting In-
formation Figs. 5 and 6).
TGF-b–Induced Senescence Is Associated with
Sustained Induction of p21Cip1 and p15Ink4b. Cellu-
lar senescence is usually associated with cell cycle arrest
induced by p53, p21Cip1, p16Ink4a, and/or p15Ink4b.1,28
TGF-b1 caused c-myc repression and p15Ink4b and
p21Cip1 induction (Fig. 3; Supporting Information Fig.
7A). Decreased pRb phosphorylation, together with
decreased p107 and increased p130 protein levels, was
also observed. These changes in retinoblastoma family
proteins correlate with exit from the cell cycle.29 The
TGF-b response was independent of p53. All HCC cell
lines tested here, except HepG2, display p53 muta-
tions.30 The levels of total p53 did not change following
TGF-b exposure, despite p21Cip1 accumulation (Fig.
3; Supporting Information Fig. 7B). Moreover, we
observed no phosphorylation of wild-type p53 in
HepG2 cells, following TGF-b exposure (Supporting In-
formation Fig. 7B). TGF-b also did not affect p16Ink4a
levels (Fig. 3). Indeed, the CDKN2A gene is frequently
silenced in HCC.31 Accordingly, p16Ink4a protein levels
were extremely low in all tested cell lines, except in
pRb-deﬁcient Hep3B and Hep3B-TR cells (Supporting
Information Fig. 7C). On the other hand, our
Fig. 2. Induction of a strong se-
nescence-like response by TGF-b
after a very short exposure. Cells
were treated with TGF-b1 (5 ng/
mL) for the indicated times, and
SA-b-Gal activity (blue) was tested
at 72 hours. Control: no TGF-b1
treatment. Counterstain: Fast Red.
Fig. 3. TGF-b treatment of HCC cell lines
causes the induction of p15Ink4b and p21Cip1
that is associated with c-myc down-regulation,
pRb underphosphorylation, p107 decrease
and p130 increase. The levels of p53 and
p16Ink4a did not change. Untreated and TGF-
b1–treated cells were tested for indicated pro-
teins by western blotting on day 3. ppRb:
phospho-Ser807/Ser811-pRb, upRb: under-
phosphorylated pRb. The a-tubulin served as
an internal control. p16Ink4a blots were over-
exposed to visualize weak expression.
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observation of senescence arrest in Hep3B cells suggests
that pRb expression is also dispensable for TGF-b–
induced senescence in HCC cells. Taken together, these
ﬁndings suggested that TGF-b was able to induce senes-
cence in HCC cells independent of p53, p16Ink4a, or
pRb status.
TGF-b Induces a Permanent G1 Arrest that Can
Be Reproduced Either by p21Cip1 or p15Ink4b. Cellu-
lar senescence is deﬁned as an irreversible arrest of mitotic
cells at the G1 phase, but some cancer cells enter senescence
at the G2 or S phases.
1 Initially, we used Huh7 cells for cell
cycle studies. These cells accumulated at G1 phase (from
59% to 81%) with a concomitant depletion of S phase
cells (from 18% to 8%), after TGF-b1 exposure (Fig. 4A).
Similar results were obtained with PLC/PRF/5 cells (Fig.
5) and other cell lines (data not shown). These observa-
tions suggested that p21Cip1 and/or p15Ink4b are involved
in TGF-b–mediated G1 arrest and senescence response.
Therefore, we tested respective contributions of p21Cip1
and p15Ink4b in these responses, by transient transfection
assays using Huh7 cells. The p21Cip1-transfected and
p15Ink4b-transfected cells demonstrated highly increased
p21Cip1 protein (Supporting Information Fig. 8A) and
moderately increased p15Ink4b expression (Supporting In-
formation Fig. 8B), respectively. The p21Cip1-overexpress-
ing cells accumulated at G1 (from 61% to 78%), together
with a depletion of S phase cells (from 26% to 13%; Fig.
4B). In association with these changes, SA-b-Gal activity
was increased (Supporting Information Fig. 9A) and BrdU
Fig. 4. G1 arrest induced by TGF-b treatment can be recapitulated
by ectopic expression of p21Cip1 and p15Ink4b. (A) Control and TGF-
b1–treated Huh7 cells were subjected to cell cycle analysis after 3
days of culture. (B, C) Huh7 cells were transiently transfected with (B)
p21Cip1 and (C) p15Ink4b expression vectors, and subjected to cell
cycle analysis after 8 days of culture. Control: cells transfected with
empty plasmid vectors (B,C). [Color ﬁgure can be viewed in the online
issue, which is available at www.interscience.wiley.com.]
Fig. 5. Implication of Nox4 induction and ROS accumulation in TGF-
b–induced growth arrest. (A) TGF-b1 treatement induces the expression
of Nox4, p15Ink4b, and p21Cip1 together with ppRb down-regulation; ROS
scavenger NAC inhibits p15Ink4b and p21Cip1 induction, and ppRb down-
regulation, but not Nox4 accumulation. Cell lysates were collected at day
3, following treatment with TGF-b1 and/or NAC, and tested by western
blotting. (B-D) ROS accumulation observed in TGF-b1–treated cells is
inhibited by NAC cotreatment (B), and this results in (C) inhibition of G1
arrest, and (D) restoration of BrdU incorporation into cellular DNA. (A)
PLC/PRF/5 cells were treated for 3 days with either 10 mM NAC or 5
ng/mL TGF-b1 alone, or in combination, and tested for Nox4, p15Ink4b,
p21Cip1, and ppRb by western blotting. (B) Huh7 and PLC/PRF/5 (PLC)
cells were treated with either 10 mM NAC or 5 ng/mL TGF-b1 alone, or
in combination, and tested for ROS accumulation using a green ﬂuores-
cent ROS indicator, and a red ﬂuorescent mitochondrial marker as coun-
terstain. The effects of 10 mM NAC cotreatment on growth inhibition by
TGF-b1 (0, 1, or 5 ng/mL) were tested by (C) cell cycle analysis, and
(D) BrdU incorporation assay. Blue, red, and green columns in (C) repre-
sent cells at G1, S, and G2/M, respectively.
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incorporation into cellular DNA was inhibited (P <
0.001; Supporting Information Fig. 9B). The p15Ink4b
overexpression caused a moderate response (G1 cells rising
to 66% from 59%; S phase cells decreasing from 22%
from 15%; Fig. 4C). However, p15Ink4b overexpression
was also associated with increased SA-b-Gal activity (Sup-
porting Information Fig. 9C) and decreased BrdU incor-
poration (P < 0.001; Supporting Information Fig. 9D).
TGF-b–Induced Senescence Depends on Nox4
Induction and Intracellular Accumulation of
ROS. TGF-b induces Nox4 expression and ROS accu-
mulation in hepatocytes.32-34 Because ROS have been
implicated in Ras-induced senescence,35 we tested whether
TGF-b–induced senescence was associated with Nox4
induction and ROS accumulation. TGF-b1 induced Nox4
protein expression (Fig. 5A; Supporting Information Fig.
10A), as well as ROS accumulation (Fig. 5B). First, we
used N-acetyl-L-cysteine (NAC) as a physiological ROS
scavenger36 to test the role of ROS in TGF-b–induced se-
nescence. The cotreatment of 5 ng/mL TGF-b1–treated
cells with 10 mM NAC completely suppressed the accu-
mulation of ROS (Fig. 5B) and TGF-b1 effects on
p15Ink4b, p21Cip1, and pRb, but not Nox4 expression (Fig.
5A). More importantly, NAC cotreatment rescued cells
from TGF-b1–induced senescence response (Supporting
Information Fig. 10B) and growth arrest (Fig. 5C,D; Sup-
porting Information Fig. 11). Next, we silenced NOX4
gene in Huh7 cells using a previously described NOX4-
speciﬁc siRNA.14 NOX4-speciﬁc siRNA inhibited the
accumulation of Nox4 transcripts (75%; Fig. 6A) and
protein (Fig. 6B) under TGF-b1 treatment. This resulted
in a strong inhibition of p21Cip1 accumulation and a mod-
erate inhibition of p15Ink4b accumulation in association
with restoration of pRb phosphorylation (Fig. 6B). More
importantly, Nox4 inhibition was sufﬁcient to restore cell
proliferation under TGF-b treatment (Fig. 6C).
TGF-b–Induced Senescence and Antitumor Activity
In Vivo. We tested in vivo relevance of TGF-b–
induced senescence in human HCC tumors raised in
Fig. 6. Rescue of TGF-b–induced p21Cip1 and p15Ink4b accumulation and growth arrest by NOX4 gene silencing. (A) TGF-b–induced accumula-
tion of Nox4 transcripts was strongly inhibited by Nox4 siRNA, but not by control siRNA. Transcript analysis was performed by quantitative reverse
transcription PCR. (B) NOX4 gene silencing rescued TGF-b–induced Nox4, p21Cip1, and p15Ink4b protein accumulation, and the inhibition of pRb
phosphorylation, as tested by western blotting. Compared to others, the inhibition of p15Ink4b accumulation was modest. (C) NOX4 gene silenc-
ing also rescued TGF-b–induced inhibition of DNA synthesis, as tested by BrdU incorporation. Cells were labeled with BrdU for 24 hours prior to
day 3, and percent BrdU-positive cells were counted manually.
Fig. 7. TGF-b induces senescence and inhibits the growth of Huh7
tumors in nude mice. (A,B) TGF-b1–induced SA-b-Gal activity in Huh7
tumors. Huh7 tumors were obtained in nude mice and treated with TGF-b1
(0.5 ng) or a vehicle only. (A) Animals were sacriﬁced 7 days later to col-
lect tumor tissues. (B) Cryostat sections from freshly frozen tumors were
subjected to SA-b-Gal staining (blue). Counterstain: Fast Red. (C) Huh7
tumors were treated with 2 ng TGF-b or vehicle only at 4-day intervals and
tumor sizes were measured. TGF-b–treated tumors were growth arrested,
resulting in >75% inhibition of tumor growth. *P < 0.05; **P < 0.01.
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immunodeﬁcient mice. TGF-b1 (50 lL of a 10 ng/
mL solution)-injected Huh7 tumors were removed 1
week later (Fig. 7A) and subjected to SA-b-Gal stain-
ing. TGF-b1 induced local but expanded SA-b-Gal ac-
tivity in three of four tumors tested; three tumors
treated with vehicle only were negative (Fig. 7B).
To test antitumor effects of TGF-b, early Huh7
tumors were treated with peritumoral injection of 2
ng TGF-b at 4 days of intervals. Vehicle-treated tumors
displayed exponential growth to reach 4 cm3 volume on
average within 24 days. In contrast, TGF-b–treated
tumors were growth arrested throughout the experiment
and remained <1 cm3 on average at the same time pe-
riod. Tumor inhibition was signiﬁcant for at least 24
days (P < 0.01 to P < 0.05). The TGF-b treatment was
stopped at day 24 and animals were observed for an
additional period of 4 weeks. All vehicle-treated and
four TGF-b–treated animals died, whereas complete
remission was observed in two TGF-b–treated animals
(data not shown). We also compared TGFBR2-deleted
Hep3B-TR cells21 with parental Hep3B cells. Hep3B-
TR cells formed palpable tumors 2 weeks after subcuta-
neous injection, and host animals died within 4-6
weeks. In contrast, Hep3B cells formed tumors with a
latency of 6-7 weeks (Supporting Information Fig. 12).
Discussion
Our ﬁndings provide strong evidence for senescence
as a major response of HCC cells to TGF-b. Senes-
cence-associated changes included ﬂattened morphol-
ogy, p21Cip1 and p15Ink4b accumulation, and positive
SA-b-Gal activity. This response has not been noticed
previously, probably because of its late occurrence, at
least 3 days after TGF-b treatment. The primary ﬁnd-
ings of our mechanistic studies on TGF-b–induced se-
nescence in HCC cells are outlined in Fig. 8. TGF-b-
induced senescence response was associated with
p21Cip1-mediated and p15Ink4b-mediated G1 arrest, in-
dependent of p53 or p16Ink4a. This correlates with the
earlier observations showing that TGF-b uses p21Cip1
and p15Ink4b, but not p16Ink4a nor p53 to induce G1
arrest in other cell types.18 Although TGF-b–induced
senescence had been described many years ago,37 its
mechanisms are poorly understood. Here, we show
that the overexpression of p21Cip1, and p15Ink4b to a
lesser degree, recapitulates TGF-b–induced senescence
response. Thus, p21Cip1 and p15Ink4b are able to
induce G1 arrest and senescence response in HCC
cells, as it occurs in other cell types.10 Our most inter-
esting ﬁnding was the implication of both Nox4 and
ROS in the induction of p21Cip1 and p15Ink4b, and
G1 arrest by TGF-b. Either NOX4 gene silencing or
ROS scavenging was sufﬁcient to interrupt the TGF-b
signaling toward growth arrest mediated by p21Cip1
and p15Ink4b induction. Thus, the accumulation of
both Nox4 protein and ROS is a critical step for
p21Cip1 and p15Ink4b accumulation in TGF-b–exposed
HCC cells (Fig. 8). Inhibition of p21Cip1-mediated
ROS accumulation has been previously shown to res-
cue senescence,38 and a feedback between p21Cip1 and
ROS production was necessary for stable growth
arrest.39
Our ﬁndings also provided preliminary evidence for
antitumor activity of TGF-b against HCC. This effect
was associated with in vivo induction of SA-b-Gal ac-
tivity in tumor cells. Thus,TGF-b–induced senescence
in human HCC cells, similar to p53-induced senes-
cence in mouse HCC cells,12 may be a potent tumor
suppressor mechanism. The accelerated tumorigenesis
of TGFBR2-deleted Hep3B-TR cells supports this hy-
pothesis. Previous studies indicated that the disruption
of TGF-b signaling in mice through dominant-nega-
tive Tgfr2 (transforming growth factor receptor 2)
accelerates chemically induced hepatocarcinogenesis.40
A similar disruption in b-spectrin embryonic liver
fodrin knockout mice also leads to hepatocellular can-
cer.41,42 However, our ﬁndings are limited to well-dif-
ferentiated HCC cells that represent early forms of
HCC.43 Poorly differentiated HCC cell lines appear to
Fig. 8. A hypothetical model summarizing major components of
TGF-b–induced senescence in HCC cells.
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be resistant to TGF-b-induced senescence (S. Senturk
and M. Ozturk, unpublished data). Nevertheless,
TGF-b treatment might be an attractive therapeutic
option for early HCCs.
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Summary The serine/threonine kinase Akt, a downstream
effector of phosphatidylinositol 3-kinase (PI3K), is in-
volved in cell survival and anti-apoptotic signaling. Akt
has been shown to be constitutively expressed in a variety
of human tumors including hepatocellular carcinoma
(HCC). In this report we analyzed the status of Akt
pathway in three HCC cell lines, and tested cytotoxic
effects of Akt pathway inhibitors LY294002, Wortmannin
and Inhibitor VIII. In Mahlavu human hepatoma cells Akt
was constitutively activated, as demonstrated by its Ser473
phosphorylation, downstream hyperphosphorylation of
BAD on Ser136, and by a specific cell-free kinase assay.
In contrast, Huh7 and HepG2 did not show hyperactivation
when tested by the same criteria. Akt enzyme hyper-
activation in Mahlavu was associated with a loss of PTEN
protein expression. Akt signaling was inhibited by the
upstream kinase inhibitors, LY294002, Wortmannin, as
well as by the specific Akt Inhibitor VIII in all three
hepatoma cell lines. Cytotoxicity assays with Akt inhibitors
in the same cell lines indicated that they were all sensitive,
but with different IC50 values as assayed by RT-CES. We
also demonstrated that the cytotoxic effect was through
apoptotic cell death. Our findings provide evidence for its
constitutive activation in one HCC cell line, and that HCC
cell lines, independent of their Akt activation status respond
to Akt inhibitors by apoptotic cell death. Thus, Akt
inhibition may be considered as an attractive therapeutic
intervention in liver cancer.
Keywords Akt . PI3K . PTEN . HCC . LY294002 .
Inhibitor VIII .Wortmannin . RTCES
Introduction
Hepatocellular carcinoma (HCC) is one of the most common
cancers worldwide occurs in patients with chronic viral
hepatitis and cirrhosis at a high rate (3–5% annually) and is
a major cause of morbidity and mortality in patients with
advanced liver disease [1]. In healthy individuals, liver is a
quiescent organ and adult hepatocytes are nondividing cells
under normal physiological conditions. However, chronic
liver injury due to viral diseases, exposure to chemicals and
other environmental or host factors results in extensive cell
death and consequently hepatocyte proliferation [2]. Chronic
cell death in liver leads to a state where continuous
hepatocyte regeneration is observed as a result of the
inflammatory response. Continuous cycles of liver cell death
and proliferation induce many cell signaling pathways
including cell survival pathways such as Akt [3, 4].
Knowledge on the signaling pathways and the alterations
involved in HCC is extending, however their role in
molecular targeted therapy still remains to be described.
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The most promising molecular targets in the generation of
new chemotherapy agents are the protein kinases, including
those in the PI3K/Akt pathway. The Akt pathway is involved
in many cancers, as well as HCC development, through its
activation by EGF or IGF signaling or the constitutive
activation of Akt proteins or the inactivation of PTEN tumor
suppressor [5–8]. The serine/threonine kinase Akt is a well-
characterized downstream target of PI3K and resides within
the cytoplasm in an inactive state, but binding of PtdIns
(3,4,5)P3 to its pleckstrin homology (PH) domain recruits
Akt to the plasma membrane and enables its activation by
phosphorylation on the C-terminal hydrophobic tail [9].
Once activated, signaling through Akt can be propagated to a
diverse array of substrates. Activated Akt is known to inhibit
apoptosis through its ability to phosphorylate several targets,
including BAD, FoxO transcription factors, Raf-1 and
caspase-9, which are critical for cell survival [9]. Moreover,
the tumor suppressor protein PTEN prevents Akt activation
by acting as a lipid phosphatase on the PI3K product PtdIns
(3,4,5)P3. Akt pathway hyper-activation has been reported
due to the loss of tumor suppressor protein PTEN function
through mutations, deletions, or epigenetic silencing [10, 11].
The PTEN gene is the second most frequently modified
tumor suppressor gene, and is related to many cancers
including brain, bladder, breast, prostate, endometrial and
liver cancer [10–12].
In primary liver carcinoma, one of the major pathogenic
mechanisms resides in the activated intracellular signal
transduction caused by oncogenes and the tumor suppressor
gene dysfunction that stimulates cell-cycle progression and
enhance cell survival [13]. Despite this much information, the
behavior and relevance of the Akt pathway in HCC and its
therapeutic potential remain to be further elucidated. Since
liver cancer usually develops on the background of chronic
liver disease, conventional anticancer therapies are not
effective. Moreover, the chemotherapeutics currently in use
are non-selective cytotoxic drugs that can lead to systemic
side effects in HCC patients with compromised liver function.
Recently, Sorafenib, a multikinase inhibitor acting through
VEGFR and PDGFR of the Raf kinase pathway, was
approved for hepatocellular carcinoma treatment [4]. The
Sorafenib Hepatocellular Carcinoma Assessment Random-
ized Protocol (SHARP) three-year clinical trial included 602
advanced-stage HCC patients (ClinicalTrials.gov number,
NCT00105443) [4]. The average survival rate for the group
taking Sorafenib was 10.7 months, and that for the group
taking the placebo was 7.9 months. For the Sorafenib group a
one-year survival rate of 44% was observed, whereas it was
33% for the placebo group. FDA- and EU- approved
chemotherapeutic Sorafenib thus prolongs median survival
and the time to progression by nearly three months in patients
with advanced hepatocellular carcinoma. Therefore FDA and
EU approved chemotherapeutic Sorafenib prolongs median
survival and the time to progression by nearly 3 months in
patients with advanced hepatocellular carcinoma. Therefore,
there is a need for new liver cancer specific drugs based on
the molecular mechanisms involved in liver carcinogenesis.
In this study, we investigated the Akt activation status in
HCC cell lines the differential effects of three Akt pathway
inhibitors and the extent of the inhibition of Akt signaling
as a major molecular mechanism in determining inhibitor-
induced apoptosis in these cells. The Akt pathway can be
blocked by cell line specific doses of pathway inhibitors.
Therefore, our findings suggested that PI3K/Akt could
represent an attractive target mitigating in liver cancer.
Materials and methods
Materials
DMEM (cat.12-614F), FCS (cat.DE 14-801F), antibiotics
(cat.DE 17-602E), glutamine and non essential amino acids
(cat.BE 13-114E) were from Lonza (Milan). Calnexin, β-
actin antibody, and Sulforhodamine B (SRB) (cat.86183-
5 g) were from Sigma (St. Louis, MO). Lumi-Light
detection kit (cat.12 015 196001) was from Roche M.B.
(Germany). Akt Inhibitor VIII (cat.124018), Wortmannin
(cat. BML-ST415-0005) and LY294002 (cat.440202) were
from Calbiochem (La Jolla, CA). The DMSO concentration
for drug solubilization was always less than 1% in the cell
culture medium.
The Akt Antibody (cat.610861) was from BD Transduc-
tion Laboratories (Franklin Lakes, NJ) and anti-p-473Ser
Akt (cat.587F11), anti-BAD (cat.185D10), anti-p-BAD
(cat.#9292), recGSK3α/β fusion protein (cat.#9237 L),
anti-p-GSK3α/β (cat.#9331 L), anti-PTEN and anti-PARP
(cat.46D11) antibodies were from Cell Signaling (Danvers,
MA). The immunoprecipitation matrix (cat.sc-45042) was
from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell culture
Hepatoma cells (Huh7, HepG2, Mahlavu) were cultured at
37°C, 5% CO2 in standard medium (2 mML-Glutamine,
0.1 mM NEA, 1xPS in DMEM) with 10% FCS.
Western blotting analysis
Proteins, from cells grown to 60–70% confluence, were
separated on 10% SDS-PAGE, transferred onto nitrocellu-
lose membranes and visualized as described previously [14].
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Akt kinase activity assay
Total homogenates from cells were resuspended in 50 mM
Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 150 mM
NaCl, 1% Triton X-100, 0.1% SDS plus phosphatase and
proteases inhibitors. IP was performed according to the
manufacturer’s instruction. Akt IP was resuspended in
20 mM HEPES pH 7.4, 10 mM MgCl2 and 10 mM MnCl2.
The reaction was started by incubating 10 μl IP, 100 μM
ATP and 1 μg recGSK3α/β for 40 min at RT, and then
stopped by 1 M Tris-HCl pH 6.8, 8% SDS, 40% glycerol,
20% β-ME. GSK3α/β phosphorylation was detected by
western blotting.
NCI-60 Sulforhodamine B (SRB) cytotoxicity assay
The cytotoxicities of LY294002, Akt Inhibitor VIII and
Wortmannin were tested as previously described [15].
Hepatoma cells (5000) were inoculated into 96 well
plates,100 μl/well. Next day, inhibitors with the indicated
concentrations were applied in a total of 200 μl of
medium. After 72 h of treatment, cells were fixed by cold
10% (w/v) TCA and then the wells were washed and
dried. One hundred μl of 0.4% SRB dye was applied to
each well and incubated at RT for 10 min then removed
and wells were dried. SRB dye was solubilized in 200 μl
10 mM Tris-Base and the absorbance was measured at
515 nm.
Real-time cell growth surveillance by cell electronic
sensing
Hepatoma cells (2000cell/well in 150 μl) were inoculat-
ed into 96 E-Plates (Roche) containing 50 μl medium/
well. Proliferation was monitored in real-time cell
electronic sensing RT-CES (xCELLigence-Roche Ap-
plied Science), and the cell index (CI) was measured
every 30 min for 24 h [16]. Next day, 100 μl medium
was discarded and 50 μl fresh medium was added to each
well. Inhibitors with indicated concentrations were ap-
plied to150 μl of medium. CI values were taken every
10 min for 4 h to visualize the fast drug response and then
every 30 min to visualize the long-term drug response.
Impedance measurements are displayed as Cell Index (CI)
values and the effect of the inhibitors on cell growth is
calculated as CIDRUG/CIDMSO. When the cells adhered to
electrodes on the bottom of the wells, CI values increased
in parallel to the cell growth due to the insulating
properties of the cell membrane. As the number of cells
covering the electrodes increases the electrical impedance
(Z) increased (Z0=0 --->Z=Zcell).
Fluorescence microscopy
Cells were seeded at 3×104 cells/cm2 on coverslips,
allowed to grow for 24 h, as indicated in the figure
legends, then washed twice with PBS and fixed with 4%
paraformaldehyde. Subsequently, cells were washed once
more with PBS and stained with 0.5 mg/ml DAPI.
Preparations were dehydrated with increasing concentra-
tions of ethanol and embedded in glycerol containing the
antifading agent to be analyzed with Zeiss Axiophot
epifluorescence microscope coupled with a Photometric
Cool Snap CCD camera for image acquisition. The
percentage of apoptotic cells was determined by counting
fragmented nuclei in a minimum of 4 fields containing at
least 150 cells. These experiments were performed in
triplicate. As a positive control for apoptosis, cells were
treated with 100 ng/ml Doxorubicine.
RT-PCR
Total RNA was isolated with NucleoSpin RNA II Kit (MN,
Germany). cDNAs synthesized from 4 μg RNA with
RevertAid kit (MBI Fermentas, Lithuania) were amplified
by PCR with the primers (PTEN: intron-3-F_5´-AAAGATT
CAGGCAATGTTTGTT-3´, intron-4-R_5´-TCTCACTCGA
TAATCTGGATGAC-3´, exon-4-F_5´-GACATTATGA
C A C C G C C A A A - 3 ´ , e x o n - 5 - R _ 5 ´ - T T C G
TCCCTTTCCAGCTTTA-3´, exon-7-F_5´-CGACGGGAA
GACAAGTTCAT- 3 ´ , e x o n - 8 - R _ 5 ´ AGGTTT
CCTCTGGTCCTGGT-3´, and GAPDH: F-5´-GGCTGA
GAACGGGAAGCTTGTCAT-3´ and R-5´CAGCCTTCTC
CATGGTGGTGAAGA-3´).
Results
Akt hyperphosphorylation in Mahlavu HCC cells
Hyperactivation of Akt was previously reported in HCC
[17]. Therefore, we sought first to analyze the Akt levels
and its serine-473 phosphorylation in hepatoma cells. Akt
total amount seems comparable albeit a slight higher
expression could be observed in Mahlavu cells when
compared to Huh7 and HepG2 cells (Fig. 1a). In addition,
significant Akt phosphorylation was detectable in Mah-
lavu cells, whereas only a slight Akt phosphorylation was
detectable in HepG2 and Huh7 cells under native
conditions.
Therefore, our initial observation suggested that the poorly
differentiated Mahlavu cell line might have hyperactivated
Akt signaling in comparison to the well-differentiated HCC
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cell lines; Huh7 and HepG2 [18]. To further assess whether
Akt hyperphosphorylation in Mahlavu cells is related to the
hyperactivation of its kinase enzymatic activity, we per-
formed a kinase assay on the fusion protein GSK3
containing Akt target-phosphorylation residues. The results
of this assay (Fig. 1b) showed the presence of a very low
intrinsic activity in Huh7 cells, an intermediate activity in
HepG2 cells but a very high kinase activity in Mahlavu cells.
As a control for equal loading, samples of immunoprecipi-
tated total Akt for the kinase assay were used. These data
correlate very well with those obtained by western blot data
on p-Akt (Fig. 1a).
We sought to further verify Akt pathway activation on a
native target of Akt. To this end, we analyzed the
phosphorylation status of BAD, a well-known protein
downstream of Akt, whose phosphorylation prevents cells
from undergoing apoptosis and confers them a proliferative
advantage. The p-BAD antibody used in our study was
specific to the Ser136 target of Akt kinase. In this way we
excluded the possibility of BAD being phosphorylated by
other kinases such as Erk-p90RSK kinase, which targets
Ser122 [19]. pSer136-BAD was absent in Huh7 cells, and
barely detectable in HepG2 cells, whereas a high level of
pSer136-BAD was detected in Mahlavu cells (Fig. 1c).
Interestingly, total BAD protein levels were not equal in the
cell lines analyzed although each lane contained 20 μg of total
cell lysate, in particular Mahlavu showed lower BAD protein
levels than HepG2 (Fig. 1c). However, we observed an
intense phosphorylation by endogenous BAD in this cell
line, which might explain the faint pSer136-BAD band in
HepG2.
Determination of IC50 values for the HCC cells with SRB
cytotoxicity assay
After the analysis of the hyperphosphorylation state of the
Akt protein in well differentiated Huh7, HepG2 cells and
poorly differentiated Mahlavu cells under native conditions,
we decided to see the effect of PI3K inhibitors (LY294002,
Wortmannin) and the specific Akt inhibitor (Inhibitor VIII)
on this signaling pathway. Akt Inhibitor VIII selectively
prevents Akt1 and Akt2 activity through pleckstrin homol-
ogy (PH) domain [20, 21].
Initially we assessed their cytotoxicity by NCI-60
conventional Sulforhodamine B assay that was performed
in quadruplicate and for 5 different concentrations follow-
ing the NCI’s drug screening protocol. The inhibitory effect
of each drug of treatment was plotted (Fig. 2). IC50 values
were calculated from these graphs for 24, 48, and 72 h
(Fig. 2). IC50 values of LY294002 were 3.65 μM,
25.03 μM and 7.19 μM for 24 h and 3.75 μM, 5.82 μM
and 8.71 μM for 72 h in Huh7, HepG2 and Mahlavu cell
lines, respectively. For Wortmannin IC50 values in Huh7,
HepG2 and Mahlavu cell lines were 26.07 μM, 29.23 μM
and 20.19 μM for 24 h and 17.78 μM, 11.27 μM and
36.88 μM for 72 h, respectively. For 24 h, the IC50 values
of Inhibitor VIII were 4.42 μM and 17.16 μM for Huh7
and HepG2, while there was not a significant inhibition
observed in Mahlavu with NCI-60 assay. For 72 h, the IC50
values of Inhibitor VIII were 5.27 μM, 4.48 μM and
9.04 μM for Huh7, HepG2 and Mahlavu cells, respectively.
Real-time, dynamic monitoring of cell growth in HCC cells
treated with the inhibitors
In order to further analyze if the growth inhibition of HCC
cells is permanent or temporary, we used a novel cell
surveillance system to monitor real-time, dynamic changes
in cell growth based on the electrical impedance measure-
ment technique. The RT-CES system allowed us to monitor
the effects of LY294002, Wortmannin, and Inhibitor VIII
on the hepatoma cells by a label-free and a real-time native
approach. The proliferation and cytotoxicity of the inhib-
itors were followed by real-time through electronic cell
sensors, integrated in the bottom of the 96 E-Plates in
triplicates with 5 different concentrations (40 μM, 20 μM,
10 μM, 5 μM, 2.5 μM) (Fig. 3). When normalized to
a MVHepG2Huh7
Akt tot
p-Akt tot
β-actin
b Huh7 HepG2 MV
p-GSK3
Akt 
pSer136-Bad
Huh7 HepG2 MV
Bad tot
c
Fig. 1 Akt activity analysis in HCC cell lines. aWestern blot analysis
of untreated Huh7, HepG2, and Mahlavu cell lines, detected with anti
Akt antibody or anti-p-Akt antibody. b Kinase assay on the fusion
protein of GSK3α/β added to the reaction mixture as an exogenous
substrate. As a control for equal loading, samples of immunoprecipi-
tated Akt for the kinase assay were used. c Western blot analysis of
untreated HCC cell lines was performed with anti-total BAD antibody
or anti-p-BAD antibody. 20 μg of proteins were loaded for each lane.
Data given here are representative of three independent experiments.
SDS are less than 10%. The Mahlavu cell line displays high a Akt
phosphorylation level and the highest enzymatic activity tested on
both exogenous (GSK3α/β) and endogenous (BAD) substrate
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DMSO treated cell proliferation curves the cell growth plots
demonstrated the concentration- and time-dependent cyto-
toxic effect of the inhibitors. In addition to provide also a
visual demonstration of the effects of these drugs on these
cells we treated cells with inhibitors and show their
morphological changes by light microscope images at 24
and 48 hours in parallel with the RT-CES experiments with
IC50 of 24 hours concentrations (Fig. 3b).
High dose treatment of LY294002 (40 μM) suppressed
cell growth permanently after 8 h and continuing up to 84 h
in Huh7 and Mahlavu cell lines. Lower doses (5 μM,
2.5 μM) of LY294002 had a minor effect on cell growth for
up to 48 h but then the cells resumed growth, especially in
the case of the Mahlavu cell line. With Inhibitor VIII
treatment, cells responded similarly as to LY294002
exposure although Inhibitor VIII appeared more effective
at short exposure times. Wortmannin treatment was effec-
tive in inhibiting cell growth only for about 24 h and then
the cells gradually resumed normal growth. This real-time
dynamic continuous analysis of cell growth and toxicity
was essential to determine the optimal time points for
performing biochemical endpoint assays. The continuous,
dynamic analysis of cell growth of LY294002, Wortmannin
and Akt Inhibitor VIII treated Huh7 and Mahlavu cells
supported the time- and concentration-dependent effects of
the three inhibitors on HCC cells as shown in Fig. 2.
We also analyzed Akt enzyme activity in the presence of
inhibitors. The IC50 values of 72 h for LY294002,
Wortmannin and Akt Inhibitor VIII were used to assess
the effects of drug treatments on Akt kinase activity in
HCC cell lines by a specific kinase assay using the fusion
protein fusion protein of GSK3α/β as substrate similarly to
that of Fig. 1b. Our results demonstrated the inhibitory
effect of the three drugs on the kinase activity of the Akt
protein, when compared to the kinase assay under native
conditions. In all cases no Akt phosphorylation activity was
Fig. 2 Inhibitory effects of LY294002, Wortmannin and Akt Inhibitor
VIII on HCC cell growth. % inhibition of cell growth after a 24, b 48,
c 72 and d 96 hours of treatment with the inhibitors. Sulforhodamine
B (SRB) colorimetric assay was performed in quadruplets with 5
different concentrations (50 μM, 15 μM, 10 μM, 5 μM, 1 μM)
represented with error bars (Supplementary Figs. 1–3). The growth
inhibitory effect for shorter exposure is relevant also for low
concentrations. At longer exposure times growth inhibition requires
higher drug concentrations. IC50 values were calculated based on the
logarithmic regression line fitted on the % inhibition vs. log
(concentration) graph, Huh7 ( ), HepG2 ( ), Mahlavu ( )
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detected on the fusion protein of GSK3α/β (data not
shown). These data indicate a very low Akt activity in each
cell line, evidence of a significant inhibition of the pathway
by these inhibitory molecules in HCC cells.
Cytotoxic effect of drugs on HCC cells through apoptosis
It is a well-documented fact that the Akt pathway has an
important anti-apoptotic role in different cells [22, 23].
Morphological changes specific to apoptosis can be
observed quite early after apoptotic stimuli [24, 25]. In
order to see the morphological changes in Huh7, HepG2
and Mahlavu cells after treatment with each drug, cells
were treated with inhibitors for 24 and 48 h. Each drug was
used at its IC50 value obtained after 24 h of treatment.
Apoptotic cells usually exhibit extensive DNA cleavage
during the early stages of this controlled cell death
mechanism. Cleavage may produce double-stranded, low
molecular weight DNA fragments as well as single-
stranded high molecular weight DNA fragments that
manifests themselves as condensed aberrant nuclei, as
shown by DAPI (Fig. 4) and the Hoechst 33258 stain (data
not shown). This observation demonstrated that those cells
displayed the type of cell death that is specific to apoptosis.
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Fig. 3 Cell growth of LY294002, Wortmannin and Akt Inhibitor VIII
treated Huh7 and Mahlavu cells. a Cell growth is assessed with the
xCELLigence system that measures electrical impedance across
micro-electrodes integrated on the bottom of tissue culture E-96
plates. Impedance measurements are displayed as Cell Index (CI)
values, providing real-time quantitative information on cell growth.
The effect of the inhibitors on cell growth is calculated as CIDRUG/
CIDMSO. The cell growth assay was performed in triplicates with 5
different concentrations 40 μM, 20 μM, 10 μM, 5 μM, and 2.5 μM.
Huh7-LY294002 ( ), Huh7-Akt Inhibitor VIII ( ), Huh7-
Wortmannin ( ), Mahlavu-LY294002 ( ), Mahlavu-Akt In-
hibitor VIII ( ), Mahlavu-Wortmannin ( ). b Analysis of
apoptosis associated morphological changes with light microscopy.
Huh7 and Mahlavu cells were treated with the indicated inhibitors at 24
and 48 hours. Huh7 cells : LY294002 (4 μM), Wortmannin (26 μM),
Akt Inhibitor VIII (4.5 μM) ; Mahlavu cells : LY294002 (7 μM),
Wortmannin (20 μM), Akt Inhibitor VIII (10 μM). 20X pictures were
taken with OLYMPUS CKX41 microscope with DP72 camera
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The pro-apoptotic effect of the drugs was assessed by
counting aberrant nuclei in DAPI stained cells. The
morphological features of apoptosis, i.e. condensation of
chromatin and fragmentation of the nucleus, were exam-
ined. Control cells showed rounded and homogeneous
nuclei, whereas drug treated-cells showed condensed and
fragmented nuclei (Fig. 5a). The percentage of apoptosis
ranged from 32% to 25% in Huh7, from 32% to 27% in
HepG2 and from 35% to 28% in Mahlavu, (Fig. 4b).
In order to further clarify the type of cell death
mechanism and the morphological changes that we observe
in Figs. 3b, 4a, in the presence of the inhibitors as
apoptosis, we performed Poly ADP-ribosyl polymerase
(PARP) cleavage analysis by western blot. Huh7, HepG2
and Mahlavu cells were treated with each drug at the
24hours-IC50. PARP is typically cleaved from 113 kDa to
89 and 24 kDa fragments by caspase-3 during apoptosis.
Although cleaved PARP is also detected during necrosis,
the cleaved product’s molecular size is different (50 kDa).
As shown in Fig. 5, the cleaved band (89 kDa) is due to
apoptosis, not necrosis [26]. Our observations clearly
demonstrated that Akt pathway inhibitors had an
apoptosis-dependent cytotoxic effect on HCC cell lines.
Comparative analysis of PTEN in HCC cells
With the aim of identifying differential responses of HCC
cells to Akt pathway inhibitors, we further investigated
PTEN, another pathway related molecule. PTEN protein
expression in HCC cell lines exhibited differential expres-
HepG2
Huh7
b
MV
untreated DMSO Doxo LY294002 Wort Inh VIIIa
Fig. 4 DAPI staining showing the aberrant nuclear DNA due to the
apoptotic cells with condensed nuclei (white arrows) in the presence
of inhibitors with IC50 concentrations. a The pro-apoptotic effect of
Akt pathway inhibitors on the morphology of the nuclear chromatin in
HCC cells. Cells were treated for 24 h with the IC50 values (Huh7 :
LY294002 (4 μM), Wortmannin (26 μM), Akt Inhibitor VIII
(4.5 μM); HepG2 : LY294002 (25 μM), Wortmannin (29 μM), Akt
Inhibitor VIII (18 μM); Mahlavu : LY294002 (7 μM), Wortmannin
(20 μM), Akt Inhibitor VIII (10 μM)), then fixed and stained with
DAPI. No changes were induced by DMSO. All samples treated with
the positive control, Doxorubicine (100 ng/ml) showed evident
apoptotic nuclei. Well markable, even if less present, are apoptotic nuclei
after apoptosis induction with each drug. The results were from one
experiment representative of three experiments. Bar=10 μm b Apoptotic
cells were quantified by counting a minimum of 4 fields containing at
least 150 cells. The results are presented as the mean of three
independent experiments. Doxorubicine, an inhibitor of enzyme top-
oisomerase II progression by intercalation of DNA, induced a marked
percentage of apoptosis. The three inhibitors used in this study within
each cell line, gave similar results. SD was less then 10%
Invest New Drugs
sion patterns, ranging from marked expression in the Huh7
and HepG2 cell lines, to the absence of PTEN expression in
Mahlavu cell line. The absence of PTEN protein expression
was in correlation with the hyperphosphorylation of Akt,
higher kinase activity on exogenous GSK3α/β fusion
protein and on endogenous BAD protein in Mahlavu cell
line. In correlation with the absence of PTEN protein
expression, the Mahlavu cell line had mRNA expression
with a partial deletion in the PTEN gene in exon 4 (Fig. 6),
which may explain the lack of protein that results in the
hyperactivation of the Akt protein in this cell line.
Discussion
In this study, we have shown hyperactivation of the Akt
protein in hepatoma cell lines and apoptosis induction in
time- and dose- dependent manners after treatment with
three specific inhibitors of the PI3K/Akt pathway. The
PI3K/Akt signaling pathway plays a significant role in
carcinogenesis and drug resistance in different types of
cancer including HCC, making Akt a potential target for
cancer treatment [28, 29].
Tumors with activated PI3K/Akt signaling have been
shown to become more aggressive, and Akt pathway
activation has been identified as a significant risk factor
for early disease recurrence and poor prognosis in HCC
patients [30, 31]. Activated Akt correlates also with local
metastasis of tumor cells from the primary liver cancer into
the circulatory system and the survival of the circulating
cells without cell-substratum interaction [32], showing the
significance of this hyperactivated pathway not only in liver
tumor aggressiveness but also in tumor diffusion and
survival in different environments. Therefore we initially
examined total Akt protein and native p-Akt levels in HCC
cell lines. Mahlavu cells were previously reported to be
poorly differentiated when compared to the well-
differentiated “hepatocyte-like” Huh7 and HepG2 cells
[18]. Although the cell lines included in this study showed
similar total Akt protein expression (Fig. 1a), only Mahlavu
cells displayed hyperphosphorylated Akt protein (Fig. 1a),
which was determined by anti-p473Ser-Akt antibodies,
because Ser473 Akt phosphorylation is a requirement for
full Akt enzyme activity [33]. In Mahlavu cells, in parallel to
the hyperphosphorylation of Akt, we also observed a lack of
PTEN protein expression (Fig. 6) and increased phosphor-
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Fig. 5 Investigation of apoptotic cell death in the presence of Akt
pathway inhibitors. Apoptosis activation was detected by means of
PARP cleavage. The antibodies used recognize both the intact form
(113 KDa) and the cleaved one (89 KDa). In each lane 20 μg proteins
were loaded. . Almost no cleavage is observable in control and
DMSO-treated samples. An evident PARP cleavage is induced by the
three inhibitors used. Each cell line induced similar PARP cleavage.
Data were representative of three independent experiments
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Fig. 6 Differential expression
of the PTEN gene in human
HCC cell lines. a Whole-cell
lysates (40 μg) were analyzed
by Western blotting using anti-
PTEN antibody. Mahlavu cell
line has no PTEN expression. b
PCR analysis of PTEN gene in
HCC cell lines. Figure describes
the loss of PTEN gene fragment.
The gene fragment that is
lacking is located within exon
4 and 5
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ylation of the downstream protein Bad on Ser136 and of the
exogenous GSK3 substrate (Fig. 1b and c).
The activation of PI3K/Akt signaling frequently related
to PTEN mutation has also been observed in nearly 50% of
HCC [34], suggesting the importance of this pathway, since
tumors with hyperactive Akt due to PTEN loss depend on
hyperactivated Akt signaling for growth and survival [10].
Indeed, our results support the observations that a PTEN
deficient cell line Mahlavu has hyperactivated Akt protein.
Moreover Mahlavu has the higher IC50 values for
Wortmannin than well differentiated Huh7 and HepG2 cell
lines.
The great majority of protein kinase inhibitors that have
been developed, bind at or near the ATP binding site [35].
These compounds were recommended for use in a
concentration range of 0,1 to 100 μM to assess the roles
of particular protein kinases. Depending on concentration,
kinase inhibitors may act as multi-kinase inhibitors.
Therefore in our study we analyzed the PI3K/Akt signaling
inhibitors with concentrations between 40 μM–2.5 μM
(Figs. 2 and 3) in order to identify their specific IC50
values on hepatoma cell lines. We think that with the
concentration we used LY294002 and Wortmannin exhibit
their cytotoxic activity through binding to the proximity of
the active sites of their target kinases. Structural analysis of
the p110γ isoform of PI3K in the presence of LY294002
demonstrated that this inhibitor binds to the active site. Cell
death induced by LY294002 is through GSK3β activity,
which is also demonstrated in the presence of lithium, a
known inhibitor of GSK3β [36, 37]. Consistent with the
structural similarity between the PI3K and mTOR kinase
domains, LY294002 and Wortmannin act on both of these
kinases with similar IC50 values [38]. Both PI3K and
mTORC2 are the upstream proteins of the Akt pathway.
Therefore, we focused also on the downstream analysis of
Akt protein activation/inhibition regardless of the direct
targets of LY294002 and Wortmannin in HCC cells. To
stress the importance of Akt pathway signaling inhibition as
a potential therapeutic target in liver cancer, we analyzed
the effects of the selective Akt inhibitor, Akt Inhibitor VIII
on HCC cells [20, 21].
We applied two different cytotoxicity assays, conven-
tional NCI-60 method and novel RT-CES system. Both
assays resulted in similar IC50 values for 24, 48, and 72 h
for the specific PI3K/Akt signaling inhibitors LY294002,
Wortmannin, and Akt inhibitor VIII, although it is possible
to calculate IC50 for each time point with RT-CES. As
expected, we were able to demonstrate that all three
inhibitors had cytotoxic activity. At 24 h all three cells
had comparable IC50s but with longer treatment times
Mahlavu cells displayed higher IC50s when compared to
Huh7 and HepG2 cells. RT-CES analysis demonstrated that
normal cell growth has a cell index (CI) of around 1.2
(Fig. 3a). 20 μM inhibitor treatment did not influence the
cell proliferation during the initial 10–16 h. The cytotoxic
effect of the inhibitors became established toward the end
of the 24 h (Fig. 3a, 40–10 μM) as it can be observed by
the CI of 0.5. Between 36 h and to 60 h RT-CES data
demonstrated whether they inhibit cell proliferation irre-
versibly or whether cells can survive afterwards. In the case
of LY294002 and Akt inhibitor VIII, CI approached to 0.2
at the 60th hour meaning almost no cells attached to the
bottom of the cell culture plates to form colonies. We
confirmed this data in parallel experiments by direct light
microscopy visualization of the cells at 24 and 48 h
(Fig. 3b). Cells treated with Wortmannin displayed a
similar growth curve with CI during first 24 h to that of
LY294002 and Akt inhibitor VIII did. However starting
from 36 h both Huh7 and Mahlavu cells continued to
proliferate and expanded to cover the bottom of the E-
plate parallel to the DMSO treated control cells even with
very high (40 μM) concentrations. We confirmed again by
microscopy that the cells presented a healthy morphology
(Fig. 3b).
Continuous very low Cell Index data (0.2–0.3) with
LY294002 and Akt inhibitor VIII treatments on the
hepatoma cells were the indications of apoptotic cell death.
In addition direct light microscopy visualization of the cell
morphology showed that all the inhibitors induced apoptosis
on hepatoma cells. From the above evidence the nature of
the cell death exhibited in the presence of the PI3K/Akt
signaling inhibitors LY294002, Wortmannin, and Akt inhib-
itor VIII was characterized as apoptosis (Figs. 4 and 5).
The three drugs, generated a PARP cleavage process on
the HCC cell lines after being administered (Fig. 5). As
shown above, the drugs appear to have similar apoptotic
effects in all the cell lines tested. In addition, since PI3K-Class
IIIs control autophagic proteolysis, we examined the possi-
bility that the cytotoxic effect of these inhibitors might be
through autophagy [27]. After 48 h of incubation with the
three inhibitors we performed western blot analysis of
autophagy related proteins BECN1 and p62 but did not
observe any alterations that could be attributed to autophagy
(data not shown).
This study suggests that targeting the PI3K/Akt signaling
pathway provides a promising strategy for designing
molecular targeted therapy in the case of solid tumors,
especially HCC. Our data also suggest that PI3K/Akt
activation status serve as a biomarker for identifying
candidate patients for treatment with inhibitors of PI3K
and/or of its downstream targets. However, it should be
noted that drug transporters or IAPs (Inhibitors of Apopto-
sis Proteins) could contribute to the therapeutic resistance.
Likewise, transcription factors, such as NF-κB, can up-
regulate transporters like MRP2 to induce multidrug
resistance in HCC [39]. Furthermore, we have previously
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shown that during liver tumorigenesis HCC cells develop a
“survivor phenotype” independent of the cause of onco-
genic transformation under oxidative stress conditions [40].
It may also be important to raise questions about the
stability of the drugs for longer treatments. We performed
experiments, by monitoring cell growth real time, that
demonstrated that when drug concentration increases,
growth inhibition lasts longer. This observation could be
due to a lower a decay rate of active drug molecule
concentration. Our results obtained by the three PI3K/Akt
pathway inhibitors used clearly demonstrated that the Akt
pathway can still be a target when Akt and BAD are
hyperphosphorylated and the PTEN protein is impaired, as
we show in the Mahlavu cell line. In treatment, chemo-
therapeutic agents are usually given in a protocol with
repeating dosages to target resistant cell populations.
Tumors with hyperactive Akt due to PTEN loss depend
on Akt signaling for growth and survival [10]. Activated
Akt pathway confers resistance to cancer therapy, making
Akt a promising target for cancer treatment [34]. Increasing
knowledge in the molecular mechanisms underlying hep-
atocarcinogenesis and the advent of molecular targeted
therapies provide a promising treatment approach for HCC
patients. Novel therapeutic targets, molecular oncogenic
mechanisms and signaling cascades responsible for tumor
growth should be investigated together with potential
chemotherapeutic agents to improve clinical efficacy.
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Abstract
Background: Breast cancer is a remarkably heterogeneous disease. Luminal, basal-like, ‘‘normal-like’’, and ERBB2+ subgroups
were identified and were shown to have different prognoses. The mechanisms underlying this heterogeneity are poorly
understood. In our study, we explored the role of cellular differentiation and senescence as a potential cause of heterogeneity.
Methodology/Principal Findings: A panel of breast cancer cell lines, isogenic clones, and breast tumors were used. Based on
their ability to generate senescent progeny under low-density clonogenic conditions, we classified breast cancer cell lines as
senescent cell progenitor (SCP) and immortal cell progenitor (ICP) subtypes. All SCP cell lines expressed estrogen receptor (ER).
Loss of ER expression combined with the accumulation of p21Cip1 correlated with senescence in these cell lines. p21Cip1
knockdown, estrogen-mediated ER activation or ectopic ER overexpression protected cells against senescence. In contrast,
tamoxifen triggered a robust senescence response. As ER expression has been linked to luminal differentiation, we compared
the differentiation status of SCP and ICP cell lines using stem/progenitor, luminal, and myoepithelial markers. The SCP cells
produced CD24+ or ER+ luminal-like and ASMA+ myoepithelial-like progeny, in addition to CD44+ stem/progenitor-like cells.
In contrast, ICP cell lines acted as differentiation-defective stem/progenitor cells. Some ICP cell lines generated only CD44+/
CD24-/ER-/ASMA- progenitor/stem-like cells, and others also produced CD24+/ER- luminal-like, but not ASMA+myoepithelial-
like cells. Furthermore, gene expression profiles clustered SCP cell lines with luminal A and ‘‘normal-like’’ tumors, and ICP cell
lines with luminal B and basal-like tumors. The ICP cells displayed higher tumorigenicity in immunodeficient mice.
Conclusions/Significance: Luminal A and ‘‘normal-like’’ breast cancer cell lines were able to generate luminal-like and
myoepithelial-like progeny undergoing senescence arrest. In contrast, luminal B/basal-like cell lines acted as stem/
progenitor cells with defective differentiation capacities. Our findings suggest that the malignancy of breast tumors is
directly correlated with stem/progenitor phenotypes and poor differentiation potential.
Citation: Mumcuoglu M, Bagislar S, Yuzugullu H, Alotaibi H, Senturk S, et al. (2010) The Ability to Generate Senescent Progeny as a Mechanism Underlying Breast
Cancer Cell Heterogeneity. PLoS ONE 5(6): e11288. doi:10.1371/journal.pone.0011288
Editor: Syed A. Aziz, Health Canada, Canada
Received March 16, 2010; Accepted June 4, 2010; Published June 24, 2010
Copyright:  2010 Mumcuoglu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by TUBITAK (The Scientific and Technological Research Council of Turkey), DPT (State Planning Office of Turkey) and TUBA
(Turkish Academy of Sciences). Additional funding was from Institut National de Cancer and INSERM of France. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ozturkm@ujf-grenoble.fr
Introduction
Human breast tumors are heterogeneous, both in their
pathology and in their molecular profiles. Gene expression
analyses classify breast tumors into distinct subtypes, such as
luminal A, luminal B, ERBB2-positive (ERBB2+) and basal-like
[1,2,3]. The prognosis and therapeutic response of each subtype is
different. Luminal A cancers are mostly estrogen receptor-a-
positive (ER+) and sensitive to anti-estrogen therapy, with the best
metastasis-free and overall survival rates. Luminal B tumors have
an incomplete anti-estrogen response and lower survival rates.
Basal-like and ERBB2+ tumors are ER- and display the worst
survival rates [2,3]. The patterns of genetic changes such as
chromosomal aberrations and gene mutations observed in breast
tumors indicate that breast tumorigenesis does not follow a
stepwise linear progression from well-differentiated to poorly
differentiated tumors with cumulative genetic aberrations [4]. This
suggests that different breast tumor subtypes do not represent
different stages of tumor progression, but rather represent the cells
from which they initiate [4]. The mammary gland is composed of
differentiated luminal and myoepithelial cells that are generated
from multi-lineage, luminal-restricted, and myoepithelial-restrict-
ed progenitors originating from a hypothetical breast epithelial
stem cell. Thus, different types of breast cancers might originate
from such stem or progenitor cells at a given stage of commitment
and differentiation, as observed in hematological malignancies
[4,5]. Without compromising the author’s hypothesis, it is also
possible that the molecular heterogeneity of breast cancer is due to
subtle differences in the ability of tumor-initiating cells to generate
differentiated progeny.
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Epithelial cells isolated from mammary gland cells undergo two
successive senescence states in cell culture, termed ‘‘stasis’’ and
‘‘agonescence’’ [6,7]. In contrast to normal mammary epithelial
cells, established breast cancer cells are immortal by definition.
They may owe this phenotype of immortalization to genetic and
epigenetic inactivation of senescence checkpoints and reactivation
of telomerase reverse transcriptase expression [7]. Either in
relation to these changes or independently, breast cancer cells
may also present a stem/progenitor phenotype that is less
subjected or resistant to senescence barriers. However, the
abundance of non-tumorigenic and differentiated cells both in
breast tumors and cell lines strongly suggests that replicative
immortality cannot be assigned to all cells within a tumor or a
cancer cell line, and that spontaneous senescence after a limited
number of population doublings (PD) is likely to occur. If this
hypothesis is correct, then the rate of generation of senescent
progeny may reflect the potential of a cancer stem/progenitor cell
to produce terminally differentiated progeny. We tested this
hypothesis using a panel of luminal and basal-like breast cancer
cell lines (Table S1). Although a single cell line is not representative
of breast tumor heterogeneity, a panel of cell lines might
reproduce the heterogeneity that is observed in primary breast
tumors, albeit with some limitations [5,8]. Therefore, we hoped
that in vitro studies with a panel of cell lines might help to better
understand breast tumor heterogeneity.
Our senescence tests allowed us to classify breast cancer cell
lines as senescent cell progenitor (SCP) and immortal cell
progenitor (ICP) subtypes. We also show that senescent progeny
are observed exclusively in ER-positive cells, as a result of ER
inactivation, partly mediated with p21Cip1 protein. The ability to
produce senescent progeny was associated with the ability to
produce luminal-like and myoepithelial-like progeny from stem/
progenitor-like cells. In contrast, most of the cell lines lacking
senescent progeny were also unable to generate differentiated
progeny. Finally, we show that SCP-subtype cells cluster with
luminal A and ‘‘normal-like’’ breast tumor types and are less
tumorigenic, whereas ICP-subtype cell lines cluster with luminal B
and basal-like tumor types and are more tumorigenic.
Materials and Methods
Ethics Statement
We used archival tumor samples remaining from a previous
study by BB and IGY described in Gur-Dedeoglu et al. [9], for
which the use of the tissue material was approved by the Research
Ethics Committee of Ankara Numune Research and Teaching
Hospital (decision date: 04/07/2007). The tumor samples in this
study were used anonymously. All animals received care according
to the Guide for the Care and Use of Laboratory Animals. All
animal experiments have been pre-approved by the Bilkent
University Animal Ethics Committee (Decision No: 2006/1;
Decision date: 10/5/2006).
Clinical samples and cell lines
Freshly frozen tumor specimens were collected at Ankara
Numune Hospital. Breast cancer cell lines used in this study were
obtained from ATCC (http://www.atcc.org) and listed in Table
S1. Cell line authenticity was verified by short tandem repeat
profiling, as recommended by ATCC (Dataset S1). Isogenic clones
from the T47D (n= 20) cell line were obtained from single cell-
derived colonies. Briefly, cells were plated in 96-well plates to
obtain single colonies in fewer than 70% of the wells. Isolated
colonies were then transferred to progressively larger wells, and to
T25 flasks. Clones were subcultivated weekly at 1:4 dilution ratios,
and maintained in culture for 25–30 passages to reach .60 PD
before testing.
Primary antibodies
The following antibodies were used: anti-CD44 (559046; BD
Pharmingen), anti-CD24 (sc53660; Santa Cruz,), anti-ASMA
(ab7817; Abcam), anti-CK19 (sc6278; Santa Cruz,), anti-p21Cip1
(OP64; Calbiochem), anti-p16Ink4a (NA29, Calbiochem), anti-ERa
(sc8002; Santa Cruz).
Low-density clonogenic assays
Cells were seeded as low-density on coverslips in six-well plates
(500–2000 cells, according to plating efficiency) and allowed to
grow in DMEM supplemented with 10% fetal calf serum (FCS),
with medium change every three days, until they formed colonies
of a few hundred cells. Depending on the cell line, this took one to
two weeks. For bromodeoxyuridine (BrdU) incorporation assays,
cells were labeled for 24 h prior to immunocytochemistry, as
described previously [10].
Immunocytochemistry
For simple immunoperoxidase assays, cells were fixed with cold
methanol for five minutes, then blocked with 10% FCS in
phosphate-buffered saline (PBS) for 1 hour. This was followed by
incubation with a primary antibody for 1 h. Cells were then washed
with PBS three times and subjected to immunostaining using the
Dako-Envision-dual-link system and the liquid diaminobenzidine
(DAB) substrate chromogen system (Dako, CA, USA), according to
the manufacturer’s instructions. Hematoxylin was used as a
counter-stain when the visualization of cells was necessary. For
SABG-immunoperoxidase co-staining studies, unfixed cells were
first subjected to SABG assay, and then fixed prior to immuno-
staining assays. Hematoxylin counter-staining was omitted for co-
staining experiments, unless cells were negative for SABG staining.
Immunoblot analyses
Cell pellets were incubated in an NP-40 lysis buffer containing
50 mM Tris–HCl, pH 8.0, 250 mM NaCl, 0.1% Nonidet P-40,
and a protease inhibitor cocktail (Roche) for 30 minutes in a cold
room. Cell lysates were then cleared by centrifugation, and a
Bradford assay was performed to quantify their protein concen-
tration. 30 mg of protein was denatured and resolved by SDS-
PAGE using 10% or 12% gels. The proteins were then transferred
to the PVDF or nitrocellulose membranes. Membranes were
treated for 1 h with a blocking solution of TRIS-buffered saline
containing 0.1% Tween-20 and 5% non-fat milk powder (TBS-T)
and probed with a primary antibody for 1 h. Next, membranes
were washed three times with TBS-T and incubated with an HRP-
conjugated secondary antibody for 1 h. Immunocomplexes were
then detected by an ECL-plus (Amersham) kit on the membrane.
a-tubulin was used as an internal control.
SABG assay and BrdU/SABG co-staining
SABG activity was detected as described [11], except that cells
were counterstained with eosin or nuclear fast red following SABG
staining. For BrdU/SABG co-staining, cells were first labeled with
BrdU (10 mg/ml) for 24 h in a freshly added culture medium as
described [10]. Next, cells were subjected to a SABG assay, fixed
in 70% methanol, and subjected to BrdU immunostaining.
Estrogen and tamoxifen treatment
Cells were seeded under low-density clonogenic conditions onto
coverslips in six-well plates, and cultivated in a standard culture
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medium for seven to eight days. Then, cells were fed with phenol
red-free DMEM (Gibco) supplemented with 5% charcoal-stripped
FCS for 48 h, followed by two successive 48 h treatments with
1029 M estrogen (E2; 17b-estradiol; Sigma), 1026 to 1029 M 4-
hydroxytamoxifen (4OHT; Sigma) or an ethanol vehicle, under
the same conditions. Colonies were then subjected to a SABG
assay. Each experimental condition was conducted in triplicate
and experiments were repeated three times.
Generation of estrogen receptor-overexpressing clones
T47D-iso23 cells were transfected with the expression vector
pCMV- ERa [12] or an empty vector, using FuGENE-6 (Roche).
ER overexpressing and control clones were selected with 500 mg/
ml G418 for three weeks. Isolated single cell-derived colonies were
picked and expanded in the presence of G418.
Lentiviral infection and generation of p21Cip1 knockdown
clones
We used mission shRNA plasmid pLKO.1,-puro-p21
(NM_000389.2-640s1c1, Sigma) for p21cip1 knockdown experi-
ments. The Control vector shRNA-pGIPz-SCR-puro and a helper
packaging mix (Invitrogen) were also used. HEK293T was co-
transfected with the appropriate vector and packaging mix, using
the CalPhos Mammalian Transfection Kit (Clontech) and
following the manufacturer’s instructions. After 48 h of culture,
virus-containing culture media were collected, filtered, and used to
infect T47D-iso23 cells. After 4 h of infection, stable cells were
selected with 1 mg/ml puromycin for seven days.
Nude mice tumorigenicity and in vivo senescence assays
T47D and MDA-MB-231 cells (56106) were injected subcuta-
neously into CD-1 nude mice (Charles River). Females (n = 5 for
each cell line) and males (n = 4 for each cell line) were used.
Tumor sizes were measured up to 47 days post-injection. In
addition, four tumors from each cell line were analyzed for the
presence of senescent cells by SABG staining, as described
previously [10].
Cluster analysis
The two-channel microarray data containing 8102 cDNA
genes/clones generated by Sorlie et al. [2] were downloaded from
the Stanford Microarray Database (SMD) (http://genome-www.
stanford.edu/MicroArray/). In the downloading process, the ‘‘log
(base 2) of R/G Normalized Ratio (median)’’ parameter was used
for data filtering. We have median-centered expression values for
each array. We selected arrays and genes with greater than 75%
good data (representing the amount of data passing the spot
criteria). Sixty-eight tissue samples were obtained according to this
criterion and annotated with the subtypes described by the
authors, found in the ‘‘Supplementary Information’’ of the data set
in SMD. The expression values of ‘‘500 gene signature,’’ defined
by the authors, were extracted from the data. Gene expression
profiles of 31 breast cancer cell lines performed by Charafe-
Jauffret et al. [13], using the whole-genome cDNA microarray
Affymetrix HGU-133 plus 2, was obtained from the ‘‘Supplemen-
tary Table’’ of the article. The authors filtered genes with low and
poorly measured expression, and with low expression variation,
retaining 15, 293 genes. After log transformation of the data, we
median normalized the data arrays in R language, using the
Bioconductor biostatistical package (www.r-project.org/ and
www.bioconductor.org/). The ‘‘500 gene signature’’ tumor data
[2] and the normalized breast-cancer cell line data [13] were
combined with respect to probe IDs using a set of customized perl
routines (source codes are available upon request). A set of 175
genes was common. ‘‘Median center’’ normalization of genes was
done for the merged data set for the total samples. We performed
unsupervised hierarchical clustering with the 99 samples (the 31
breast cell line [13] and 68 breast tumor [2] samples) by the pair-
wise complete-linkage hierarchical clustering parameter, using the
Gene-Pattern program. The Pearson correlation method was used
for distance measurements. Clustering was visualized by java
treeview, again using Gene-Pattern (http://www.broad.mit.edu/
cancer/software/genepattern/).
Statistical analyses
Significant differences were evaluated using unpaired Student’s
t test for compared samples sizes of 10 or higher. Otherwise, one-
tailed Fisher’s exact test was used with 262 tables; P,0.05 was
considered statistically significant. On the graphical representation
of the data, y-axis error bars indicate the standard deviation for
each point on the graph.
Results
Classification of breast cancer cell lines as senescent-cell
progenitor and immortal-cell progenitor subtypes
Clonogenic assays have been successfully used to test the
generation and self-renewal abilities of phenotypically distinct
progeny of mammary stem/progenitor cells [14]. We previously
applied this technique to test the ability of cancer cells to produce
progeny with replication-dependent senescence arrest [10]. Cells
were plated under low-density clonogenic conditions and cultivat-
ed for one to two weeks until individual cells performed eight to
ten PDs and generated isolated colonies composed of several
hundred cells. This method permits tracing progeny generated by
a few hundred cells under the same experimental conditions. We
explored a panel of 12 breast cancer cell lines, composed of
luminal (n = 7) and basal (n = 5) subtypes (Table S1). Cell lines
formed two groups, according to the presence of senescent cells in
isolated colonies. One group of cell lines generated colonies with
high rates of senescence, while others did not produce appreciable
amounts of senescent cells. Representative pictures of colonies
subjected to the SABG assay are shown in Fig. 1A. The percent of
SABG+ progeny was calculated by manual counting of at least 10
different colonies for each cell line. Colonies derived from five cell
lines generated SABG+ cells at high rates (means: 5-40%)
Senescence rates were negligible (means ,5%) in the progeny of
the remaining seven cell lines. The first group, the senescent cell
progenitor subtype, included T47D, BT-474, ZR-75-1, MCF-7,
and CAMA-1 cell lines. The second group, the immortal cell
progenitor subtype, included MDA-MB-453, BT-20, SK-BR-3,
MDA-MB-468, HCC1937, MDA-MB-231 and MDA-MB-157
(Fig. 1B).
In order to verify whether the occurrence of senescent cells in the
SCP group was intrinsic to each cell line or due to the presence of a
side population, we generated clones from the T47D (n=20) cell
line, and subjected them to the SABG assay at different intervals. All
clones acted similarly to the parental T47D cell line with similar rates
of SABG+ progeny. No clone gained the ICP phenotype. More
importantly, none of the clones tested over a long period of time
(.60 PDs) entered full senescence (data not shown), unlike normal
mammary epithelial cells that undergo two stages of senescence
arrest over a period of ,20 PDs [7]. The SABG assay can provide
false-positive responses, especially when cells remain under conflu-
ence for a long period [15]. Although all our tests used low-density
clonogenic conditions, we wanted to confirm the senescence arrest
by a long-term (24 h) BrdU labeling assay under mitogenic
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conditions, as senescent cells in permanent cell cycle arrest cannot
incorporate BrdU under these conditions [16]. Co-staining of cells
for SABG and BrdU from CAMA-1, T47D, and T47D-iso23
colonies provided clear indication that the great majority of SABG+
senescent cells were BrdU-, whereas non-senescent BrdU+ cells were
usually SABG- (Fig. 1C). These findings indicated that SABG+
senescent cells were at the terminal differentiation stage with an
irreversible loss of DNA synthesis ability. Our observations also
indicated that SABG and BrdU tests could be used alternatively to
identify senescent (SABG+/BrdU-) and immortal (SABG-/BrdU+)
cells under our experimental conditions.
Senescent cell progenitor phenotype association with
p21Cip1 expression
p16Ink4a and p21Cip1 (in a p53-dependent manner or indepen-
dently) have been shown to be mediators of senescence arrest in
different cells, including mammary epithelial cells [6,15,17,18,19].
We therefore analyzed the expression of p16Ink4a and p21Cip1 in
the cell line panel. Heterogeneously positive nuclear p21Cip1
immunoreactivity was observed in four of the five SCP cell lines,
but not in any of the seven ICP cell lines (Fig. 2A). The association
of p21Cip1 expression with the SCP subtype was statistically
significant (P=0.01). We also compared the expression of p16Ink4a.
Three of five SCP cell lines displayed heterogeneously positive
immunostaining, whereas three of seven ICP cell lines displayed
homogenously positive staining (Fig. S1). The difference of
p16Ink4a expression between the two groups was not significant
(P=1). These observations indicated that the SCP phenotype was
associated with p21Cip expression in breast cancer cell lines.
To test whether p21Cip1 was directly involved in the senescence
observed in SCP cells, we first performed p21Cip1/SABG staining
in T47D-iso23 cells (hereafter termed T47D). p21Cip1, but not
p16Ink4a staining, was associated with SABG staining (Fig. S2).
Next, we generated two derivative cell lines following infection of
T47D with lentiviral vectors encoding p21Cip1 shRNA (T47D-
p21sh) or a scrambled control (T47D-scr). Following the
Figure 1. Classification of breast cancer cell lines as senescent cell progenitor and immortal cell progenitor subtypes. (A) Examples of
SABG staining for senescence of breast cancer cell line colonies obtained after plating at low-density clonogenic conditions. Breast cancer cell lines
(Table S1) were plated to obtain a few hundred colonies with 1–2 weeks of cell culturing and were subjected to SABG assay, followed by
counterstaining with nuclear fast red. T47D, ZR-75-1, MCF-7, CAMA-1 and BT-474 generated heterogeneous colonies composed of with SABG+ and
SABG- cells (shown here), but also fully negative and/or fully positive colonies. All other cell lines produced only SABG- colonies (,5% SABG+ cells).
Scale bar: 50 mm. (B) Classification of breast cancer cell lines as senescent cell progenitor (SCP) and immortal cell progenitor (ICP) subtypes by
quantification of the ability to generate senescent progeny. Cell lines with a mean of SABG+ cells higher than 5% were termed SCP, and the other cell
lines as ICP. Colonies that were generated and stained as described in (A) were counted manually to calculate % SABG+ cells. At least 10 colonies
were counted for each cell line. Error bars represent mean 6 SD. (C) SABG+ senescent cells displayed terminal growth arrest. CAMA-1, T47D and
T47D-iso23 colonies were generated as described in (A), labeled with BrdU for 24 h in the presence of freshly added culture medium, and subjected
to SABG/BrdU double-staining. SABG+ cells are BrdU-, and vice versa. T47D-iso23 is a clone derived from T47D. Note that parental T47D and T47D-
iso23 clones displayed similar staining features.
doi:10.1371/journal.pone.0011288.g001
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demonstration of p21Cip1 knockdown in T47D-p21sh cells by
western blot assay (Fig. 2B), both cell lines were plated under low-
density plating conditions, colonies were grown for 10 days, and
subjected to SABG and BrdU staining. It was not possible to
quantify SABG+ cells in T47D-p21sh cells because they formed
tight clusters in culture (data not shown). We therefore used BrdU
staining as an alternative method for senescent cell quantification
(Fig. 2C). Randomly selected colonies were counted for the
number of BrdU+ and BrdU- cells (Fig. 2D). The T47D-scr cell
line generated BrdU+ progeny at a rate of 48620% per colony
(n = 18). Under the same conditions, T47D-p21sh cells displayed
BrdU+ progeny at a rate of 65612% per colony (n= 18), with a
significant (P= 0.0043) increase in the number of cells escaping
terminal arrest (Fig. 2E). These results indicated that p21Cip1 was
responsible, at least partly, for inducing the senescence observed in
the progeny of T47D cells.
The control of senescent cell progeny generation by an
estrogen receptor
As stated above, p21Cip1 is a downstream target of p53 for
senescence, but T47D cells do not express wild-type p53 (Table S1).
Estrogen inhibits p21Cip1 expression [20] by c-Myc-mediated
repression [21], MYC gene being a direct target of ER complex
[22]. We therefore tested whether ER could be involved in the
senescence observed in T47D cells. The data shown in Fig. 3A
indicates that T47D cells displayed nuclear ER immunoreactivity in
their great majority, but some progeny was ER-. More interestingly,
these ER- cells tended to be SABG+, suggesting that senescence
occurred in T47D cells as a result of ER loss. Next, we tested
whether experimentally modifying ER activity in T47D cells had
any effect on senescence response. After plating at low-density
clonogenic conditions, cells were grown in a regular cell culture
medium that contained weakly estrogenic phenol red [23] for seven
days in order to obtain visible colonies. The culture medium was
then changed with phenol-free DMEM complemented with
charcoal-treated FCS, grown for two more days, and then cultivated
for four more days in the presence of E2 (1029 M), OHT (1029 M
to 1026 M), or an ethanol vehicle as control. Colonies were
subjected to SABG staining (Fig. 3B). Total and SABG+ cells were
counted from 20 randomly selected colonies for each treatment
(Fig. 3C). Colonies grown in a phenol-free charcoal-treated control
medium complemented with an ethanol vehicle only displayed
31613% SABG+ cells. Complementing this medium with 1029 M
Figure 2. Growth arrest observed in senescent cell progenitors was inhibited by p21Cip1 silencing. (A) Four of five senescent SCP cell
lines (top four from left) generated colonies with heterogeneous expression of p21Cip1; in contrast none of seven ICP cell lines generated p21Cip1 cells.
Colonies were immunostained for p21Cip1, with hematoxylin used as counterstain. Scale bar: 50 mm. (B–E) p21Cip1 silencing inhibited the production
of the terminally arrested progeny of SCP cells. (B) shRNA-mediated inhibition of p21Cip1 expression. T47D cells were infected with lentiviral vectors
encoding p21Cip1 shRNA or scrambled shRNA to generate T47D-p21sh and T47D-scr stable cell lines, and tested for p21Cip1 knockdown by western
blotting. (C–E) The ability to generate growth-arrested cells was inhibited by p21Cip1 knockdown. Colonies were generated from respective cell lines,
labeled with BrdU for 24 h, immunostained for BrdU, and slightly counterstained with hematoxylin to visualize BrdU+ and negative cells. Scale bar:
50 mm. (C). Individual colonies were manually counted for quantification of % BrdU cells. Each bar represents one colony (D). The silencing of p21Cip1
caused a significant increase (P = 0.0043) in % ratios of BrdU+ cells (E). Mean % BrdU+ cells (6 SD) values were calculated from data presented in (D).
Error bars represent mean 6 SD. Tub.; a-tubulin.
doi:10.1371/journal.pone.0011288.g002
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E2 generated colonies with 17618% SABG+ cells. Senescence
inhibition by E2 was nearly 50% and statistically significant when
compared to the ethanol-complemented control cells (P= 0.0093).
In contrast to E2, OHT provoked a dose-dependent increase in the
proportion of SABG+ cells. At the maximum dose used (1026 M
OHT), 90613% of colony-forming cells displayed a SABG+ signal
(Fig. 3D), indicating that tamoxifen-mediated inactivation of ER
can induce almost a complete senescence response in these cells
(P,0.0001). The increase in senescence rate was also significant
with 1027 M OHT (P= 0.0002).
Our findings strongly suggested that the senescence observed in
the SCP T47D cell line was due to a loss of expression and/or
function of ER in a subpopulation of the progeny of these cells.
For confirmation, we constructed ER-overexpressing stable clones
from T47D cells. The thhree clones with the highest ER
expression were selected. In addition, three clones with endoge-
nous expressions of ER were selected from stable clones obtained
with an empty vector (Fig. 4A). Progeny obtained from these six
clones were tested by BrdU assay (Fig. S3). Randomly selected
colonies (n = 10) from each clone were evaluated for total and
BrdU+ number of cells (Fig. 4B). Consistently higher levels of
BrdU+ cells were observed with clones ectopically expressing the
ER protein (Fig. 4C). Overexpression of ER resulted in a
significant increase in the BrdU+ progeny (P= 0.034). The
protective effect of ER overexpression was not as important as
the senescence-promoting effects of ER inhibition. This was not
unexpected, since the parental cells used for the ER overexpres-
sion studies were already expressing high levels of endogenous ER
(Fig. 4A), displaying a baseline anti-senescence activity due to the
serum estrogen and phenol red found in the cell culture medium.
The close relationship between ER and senescence in the ER+
T47D cell line, and the highly effective treatment of ER+ breast
tumors with tamoxifen, which induced senescence in our
experimental model, suggested that senescence induction might
be a relevant mechanism involved in anti-estrogen treatments. As
fresh tumor tissues cannot be obtained from tamoxifen-treated
patients for obvious ethical reasons, we analyzed untreated ER+
breast tumor samples for evidence of spontaneously occurring in
vivo senescence. We screened a panel of 12 snap-frozen ER+
breast tumor tissues from 11 patients for senescence by an SABG
Figure 3. Generation of senescent cell progeny was controlled by the estrogen receptor-a. (A) SCP cells (T47D) expressed nuclear ER.
Colonies were co-stained for senescence by SABG and for ER expression by immunoperoxidase. The MDA-MB-231 cell line was used as a negative
control. (B–D) The production of senescent progeny in SCP cells was inhibited by estrogen (E2), but enhanced by tamoxifen (4OHT) treatment. After
plating in low-density clonogenic conditions, T47D cells were grown in standard cell culture medium for seven days, followed by phenol-free DMEM
complemented with charcoal-treated fetal calf serum for two days, and then cultivated for four days in the presence of E2, OHT, or an ethanol vehicle
(control). Colonies were subjected to SABG staining (B). Total and SABG+ and SABG- cells were counted from 20 randomly selected colonies (C), and
mean % SABG+ cells (6 SD) values were calculated (D). Error bars represent mean6 SD. The inhibition of senescence by E2 and its activation by OHT
was statistically significant when compared to ethanol-complemented control cells (P values 0.0093, 0.0002 and,0.0001 for 1029 M E2, 1027 M OHT
and 1026 M OHT, respectively).
doi:10.1371/journal.pone.0011288.g003
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assay. The mean age of the patients was 58612 yrs, with a mixed
menopause status (Table S2). Two tumors (17%) displayed
SABG+ cells that were scattered within the tumor area (Fig. S4).
Thus, ER+ breast tumors also produced senescent progeny in vivo,
but at a lower rate.
Senescent cell progenitor and immortal cell progenitor
subtypes’ abilities to differentiate into luminal and
myoepithelial cell types
The cellular specificity of ER expression in the mammary
epithelial cell hierarchy is poorly understood. Previous data
suggests that normal ER+ cells may represent either relatively
differentiated luminal cells with limited progenitor capacity or
primitive progenitors with stem cell properties in the luminal cell
compartment [4,24,25]. Based on the close association between
senescence (which can be considered a manifestation of terminal
differentiation) and loss of ER positivity, we hypothesized that
ER+ SCP cells may differ from ER- ICP cells by their
differentiation potential. We surveyed a few hundred single-cell-
derived colonies from each of the 12 cell lines for production of
stem/progenitor-like, luminal-like, and myoepithelial-like cells.
We used CD44 as a positive stem/progenitor cell marker [26,27],
CD24, ER, and CK19 as luminal lineage markers [27,28,29], and
ASMA as a myoepithelial lineage marker [29].
Representative examples of marker studies by immunoperox-
idase staining in SCP and ICP cell lines are shown in Fig. 5. All
five SCP cell lines displayed a heterogeneous pattern of positivity
for CD44; some colonies were fully positive, some fully negative,
and others were composed of both positive and negative cells.
CD44/CD24 double immunofluorescence studies with the T47D
cell line indicated that SCP cells produce also CD44+/CD24-
stem/progenitor cells, as expected (data not shown). In sharp
contrast, five of the seven ICP cell lines generated only fully
positive CD44 colonies, indicating they do not produce CD44-
cells. One cell line was totally CD44-. Only one cell line displayed
Figure 4. Overexpression of estrogen receptor-a inhibited the production of terminally arrested progeny. (A) ER-overexpressing (ER-5,
ER-7, ER-26) and control (C-8, C-10, C-11) clones were established from T47D cells and tested for ER expression by western blotting using decreasing
amounts of total proteins. Calnexin was used as loading control. (B–C). Colonies were generated, labeled with BrdU for 24 h and immunostained for
BrdU (shown in Fig. S3). Individual colonies were manually counted for quantification of % BrdU cells (B), and mean % BrdU+ cells values were
calculated (C). Error bars represent mean6 SD. ER overexpression caused a significant increase in % ratio of BrdU+ cells (*three ER clones versus three
controls; P = 0.034).
doi:10.1371/journal.pone.0011288.g004
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a pattern similar to that of SCP cell lines. A comparison of the two
subtypes indicated that the ability to generate both CD44+ and
CD44- progeny was significantly associated with the SCP
phenotype (P= 0.0046). All five SCP cell lines displayed
heterogeneous, but mostly positive ER immunostaining, whereas
all seven ICP cell lines never generated ER+ cells. The expression
of ER was also significantly associated with the SCP subtype
(P= 0.0012), as well as the ability to produce ASMA+ progeny
(P= 0.0046). The ICP cell lines did not generate ASMA+ cells,
while four out of five SCP cell lines generated rare ASMA+ cells
under low-density clonogenic conditions. Interestingly, the abun-
dance of ASMA+ cells was much higher in the two SCP cell lines
that were tested at high cell density (Fig. S5). This suggests that
either the production of ASMA+ cells is enhanced at high cell
density, or these myoepithelial-like cells display limited survival
under long-term culture conditions. We did not find a strong
association between the expression of CD24 and CK19 markers
and cell subtype. All five SCP cell lines and three ICP cell lines
Figure 5. Senescent cell progenitor and immortal cell progenitor subtypes greatly differed in their ability to differentiate into
luminal and myoepithelial lineage cells. Senescent cell progenitor and immortal cell progenitor subtype cell lines were studied by
immunoperoxidase staining using CD44 and markers for luminal epithelial (CD24, CK19, ER) and myoepithelial (ASMA) lineages. Insets: magnified
views of positive cells. Both subtypes have CD44+ cells. Senescent cell progenitor cell lines produced both progenitor-like (CD44+; CD242), as well as
ER+ luminal-like and ASMA+ myoepithelial-like cells (except ZR-75-1 for myoepithelial-like cells). Immortal cell progenitor cell lines were defective for
generation of ER+ luminal-like or ASMA+ myoepithelial-like cells. Moreover, five of seven cell lines could not generate CD44- cells. The expression of
CD24 and CK19 markers did not differ significantly between the two subgroups, except that some immortal cell progenitor subtype cell lines did not
express CD24 or CK19.
doi:10.1371/journal.pone.0011288.g005
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generated heterogeneously staining colonies for CD24 expression.
Similarly, all five SCP cell lines, as well as three ICP cell lines,
expressed CK19, but homogenously.
Typical features of senescent progenitor and immortal
progenitor breast cancer cell lines
As summarized in Fig. 6, SCP and ICP subtype cell lines
displayed several subtype-specific features. All SCP cell lines
produced differentiated and senescent cells, in addition to putative
CD44+/CD242 stem/progenitor cells. Indeed, all of them
produced ER+ and CD24+ luminal-like cells and most of them
(n = 4/5) also produced ASMA+ myoepithelial-like cells. In
contrast, five of the seven ICP cell lines never produced CD44-
cells, suggesting they cannot generate differentiated progeny under
the experimental conditions tested. In confirmation of this
hypothesis, four ICP cell lines only produced CD44+/CD242/
ER-/CK19-/ASMA- stem/progenitor-like, but never differentiat-
ed cells. Furthermore, all seven ICP cell lines were unable to
produce ASMA+ myoepithelial-like, ER+ luminal-like or SABG+
senescent cells. CD24 and CD19 luminal lineage markers were
expressed in three cell lines, one of which was fully positive for the
CD44 stem/progenitor marker.
SCP and ICP subtype cell lines correlate with distinct
breast tumor subtypes
Distinct cell-type features associated with SCP and ICP subtypes
suggest that they may be phenocopies of molecularly defined
breast tumor subtypes [1,2,3,30]. As the prognosis and therapeutic
response of each subtype is different [2,3], we questioned whether
we could assign SCP and ICP cell lines to known molecular
subtypes of breast tumors. Using cell line and primary tumor gene
expression datasets, we conducted a hierarchical clustering
analysis. The ‘‘intrinsic gene set’’ data generated by Sorlie et al.
[2] to classify breast tumors into five molecular subtypes was used
to filter cell line data generated by Charafe-Jauffret et al. [13]. A
set of 175 genes was common between the two data sets. Sixty-
eight tumors and 31 cell lines were subjected to pair-wise
complete-linkage hierarchical clustering and distance measure-
ments. This tumor–cell line combined analysis produced two
major clusters. One cluster was composed of basal and luminal B
subtype tumors and five of six ICP cell lines. The other cluster
included luminal A, ERBB2+, and ‘‘normal-like’’ subtype tumors
and all five SCP subtype cells. Four cell lines clustered with the
luminal A tumor subclass. Finally. one cell line clustered with the
‘‘normal-like’’ subclass (Fig. 7A). A full list of clustered tumors and
cell lines is provided in Fig. S6.
Luminal A tumors clustering with our SCP subtype cell lines
displayed the longest tumor-free, distant metastasis-free, and
overall survival rates. In contrast, basal and luminal B tumors
clustering with our ICP subtype cell lines had the worst prognosis,
with shorter tumor-free, distant metastasis-free, and overall
survival times [2]. Our cluster analysis suggested that the ability
to generate differentiated and senescent progeny characterized
breast cancers with poor tumorigenicity, and that resistance to
differentiation and senescence was indicative of more aggressive
tumorigenicity. We compared in vivo intrinsic tumorigenic
behaviors of the SCP cell line T47D and the ICP cell line
MDA-MB-231 in female (n = 5 for each cell line) and male (n = 4
for each cell line) CD1 nude mice Fig. 7B). MDA-MB-231 cells
displayed higher tumorigenicity than T47D cells. In total, we
observed progressively growing tumors in five of nine animals
injected with MDA-MB-231. In contrast, T47D formed smaller
and regressing tumors in nine of nine animals (P,0.03).
Interestingly, the difference in tumorigenicity between these two
cell lines was more pronounced in male animals (P,0.05 after 20
days post-injection). To test whether the difference in tumorige-
nicity between MDA-MB-231 and T47D cells was correlated with
spontaneous in vivo senescence, we analyzed four tumors from
each cell line. Two T47D tumors displayed positive SABG
staining, whereas no positive staining was observed with all four
MDA-MB-231 tumors (Fig. S7).
Discussion
In recent years, phenotypic heterogeneity of breast cancers has
been correlated with genetic and molecular heterogeneity [1,3].
Breast cancer subtypes may represent cancers originating from
different progenitor cells. Molecular and phenotypic heterogeneity
and associated clinical manifestations of breast tumor subtypes
have been related to the type of hypothetical tumor progenitor
cells originating from a hypothetical mammary epithelial stem cell
or from downstream progenitor cells [4,5]. This hypothesis has
not been fully validated, mainly because a hierarchical map of
cells involved in mammary epitheliogenesis has not yet been
established.
To better understand phenotypic differences between breast
cancer subtypes, we applied senescence as a surrogate marker for
the potential to generate terminally differentiated progeny. We
completed these studies with markers for breast stem/progenitor
and differentiated luminal and myoepithelial lineage cells. The use
of low-density clonogenic conditions allowed us to follow the fate
Figure 6. Typical features of senescent progenitor and
immortal progenitor breast cancer cell lines.
doi:10.1371/journal.pone.0011288.g006
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of a large number of progeny for each cell line studied. From these
approaches, we draw several important conclusions. First, breast
cancer cell lines form two distinct groups: SCP and ICP subtypes.
The SCP cell lines produce non-senescent and senescent progeny,
whereas the ICP cell lines produce only non-senescent progeny.
Second, SCP and ICP cell lines are exclusively ER+ and ER- cell
lines, respectively. Senescence occurs as a result of ER loss
associated with p21Cip1 induction in SCP cells. Inversely,
experimental activation of ER by E2 protects from senescence,
whereas its inactivation by tamoxifen aggravates it. Thus,
senescence in ER-dependent cells appears to result from the loss
of survival signals generated by transcriptional activity of ER. A
similar type of senescence has been reported for lymphoma,
osteosarcoma, and hepatocellular carcinoma tumors upon c-MYC
inactivation [31]. Third, SCP cells generate ER+, CD24+, or
CK19+ luminal-like, as well as ASMA+ myoepithelial-like
progeny. These findings strongly suggest that most, if not all,
SCP cells have the capacity to give rise to two major types of
differentiated cells that are found in normal mammary epithelium.
In sharp contrast, ICP cells never produce ER+ luminal-like or
Figure 7. Senescence cell progenitor and immortal cell progenitor subtype cell lines correlate with distinct breast tumor subtypes.
(A) Unsupervised hierarchical clustering of breast tumor and cell line gene expression data were obtained from Sorlie et al [2] and Charafe-Jauffret et
al [25]. Dendrogram displaying the relative organization of tumor and cell line data demonstrated that ICP cell lines cluster with basal and luminal A
tumors in the same branch, except for MDA-MB-453. In contrast, SCP cell lines clustered with luminal A (BT-474, CAMA-1, MCF-7, T47D) and ‘‘normal-
like’’ tumors (ZR-75-1). No data was available for MDA-MB-468. A dendrogram with sample IDs was provided in Fig. S6. The ‘‘intrinsic gene set’’ data
generated by Sorlie et al. [2] was used to filter cell line data generated by Charafe-Jauffret et al. [13]. A set of 175 genes was common between the
two data sets. Sixty-eight tumors and 31 cell lines were subjected to pair-wise complete-linkage hierarchical clustering and distance measurements.
(B) Immortal cell progenitor MDA-MB-231 was more tumorigenic than the SCP type T47D cell line. Female (n = 5 per cell line) and male (n = 4 per cell
line) CD1nudemice received 56106 cells by subcutaneous injection and observed up to 47 days for tumor formation. Chart displays mean tumor sizes
(6 S.D.) generated by MDA-MB-231 and T47D cell lines, respectively in female (top) and mala (bottom) mice. T47D cells formed smaller tumors that
regressed and completely resolved within 30 days. Tumors formed by MDA-MB-231 were larger in size and did not show total resolution. Note that
this cell line was more tumorigenic in male mice.
doi:10.1371/journal.pone.0011288.g007
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ASMA+ myoepithelial-like cells. Indeed, some ICP cells generate
only CD44+ stem/progenitor-like cells and never CD442,
CD24+, CK19+, ER+, or ASMA+ cells. These findings indicate
that ICP cells have limited differentiation ability, at least under in
vitro conditions. The differentiation ability of ICP cells appears to
be lost completely or partially, so that they do not differentiate
fully while they self-renew as stem/progenitor-like cells. Fourth,
SCP cell lines form the same molecular cluster with luminal A and
‘‘normal-like’’ breast tumors. This suggests that SCP cell lines are
phenocopies of these relatively benign and/or anti-estrogen-
responsive tumors. The poor tumorigenicity of SCP cells in nude
mice correlates with better tumor-free and metastasis-free survival
of patients with luminal A type tumors. In contrast, ICP cell lines
cluster with luminal B and basal-like breast tumor subtypes, and
they are more tumorigenic, as expected for luminal B and basal-
like tumor cells. It is presently unknown whether breast tumor
subtypes that cluster with SCP or ICP cell lines are also composed
of either differentiating or mostly self-renewing stem/progenitor
cells. Recent studies reported that breast tumors may contain only
CD44+, or only CD24+ cells, as well as mixed cell populations,
and that CD44+ tumor cells express many stem-cell markers
[27,32]. In addition, an association between basal-like breast
cancer and the presence of CD44+/CD242 cells has been
established [32].
The mechanisms of the differentiation block observed in ICP
cell lines are not known. One might argue that cell lines that
produce only CD44+, but never differentiation marker-positive
cells, cannot be defined as stem/progenitor cells. However, such
cell lines are not completely inert to differentiation stimuli, and
may undergo differentiation under special conditions. For
example, MDA-MB-231 and MDA-MB-468 cells (identified as
ICP cell lines here) can be induced to differentiate into ER+ cells
by Wnt5a treatment, and MDA-MB-231 cells then become
sensitive to tamoxifen [33].
Most of the findings reported here are derived from in vitro
studies performed with established cancer cell lines. Presently, it is
unknown to what extent these findings are also relevant for breast
tumors. We provide here some promising data that supports in
vivo relevance of our conclusions. First, our cluster analyses
associated SCP cell types with luminal A and ‘‘normal-like’’ breast
tumors, whereas ICP cell types shared similar gene expression
profiles with luminal B and basal-like breast tumors. Second, ICP-
type MDA-MB-231 cells were more tumorigenic than SCP-type
T47D cells. T47D cells formed smaller tumors in some animals,
and all tumors displayed regression between 10 and 15 days post-
injection. Accordingly, we observed positive SABG staining in two
out of four T47D tumors, but not in MDA-MB-231 tumors.
Obviously, ICP-like and SCP-like tumors in affected women may
or may not display similar tumorigenic potentials, depending on
the women’s hormonal status and treatment conditions. However,
as most SCP-like luminal A or ER+ tumors are successfully treated
with tamoxifen [34], their less aggressive behavior could be related
to their highly effective senescence response to tamoxifen
treatment, as shown here with T47D cells under in vitro
conditions (Fig. 3). It will be interesting to examine whether the
success of anti-estrogenic treatments is indeed associated with
senescence induction in breast tumors. If this is the case,
senescence-inducing treatments could be considered for breast
cancer.
In conclusion, our analyses reveal that the in vitro ability to
generate senescent progeny permits discrimination between cells
that share molecular and tumorigenic similarities with luminal A
subtype breast tumors from cells related to basal/luminal B
subtype tumors. We also provide in vitro evidence for classifying
breast cancers into two major groups based on the ability to
generate differentiated progeny. Less-tumorigenic SCP cell lines
generate both luminal- and myoepithelial-like cells. In contrast,
more-tumorigenic ICP cell lines are defective in their ability to
generate differentiated progeny. Our findings may have prognostic
relevance and serve as a basis for therapeutically inducing
differentiation and senescence in breast cancer.
Supporting Information
Dataset S1 STR analysis data that shows the authenticity of
breast cancer cell lines used in this study.
Found at: doi:10.1371/journal.pone.0011288.s001 (1.50 MB
XLS)
Table S1 Gene clusters, genetic mutations and epigenetic
changes of breast cancer cell lines used in this study.
Found at: doi:10.1371/journal.pone.0011288.s002 (0.05 MB
DOC)
Table S2 Estrogen receptor (ER) status, main pathological
features of senescence staining (SABG) of breast tumors used in
this study.
Found at: doi:10.1371/journal.pone.0011288.s003 (0.05 MB
DOC)
Figure S1 p16Ink4a expression in colonies obtained from breast
cancer cell lines. There was no correlation between p16Ink4a
expression and progenitor subtype.
Found at: doi:10.1371/journal.pone.0011288.s004 (3.39 MB TIF)
Figure S2 Co-staining experiments indicate that SABG staining
is associated with p21Cip1, but with p16Ink4a expression in SCP
cells. Colonies were generated from T47D and MB-MDA-231
cells and subjected to SABG staining, followed by p21Cip1 or
p16Ink4a immunoperoxidase (brown) staining. MDA-MB-231
cells were used as negative control.
Found at: doi:10.1371/journal.pone.0011288.s005 (2.74 MB TIF)
Figure S3 Effect of estrogen receptor-overexpression on the
production of BrdU-negative terminally arrested cell progeny. ER-
overexpressing (ER-5, ER-7, ER-26) and control (C-8, C-10, C-
11) stable clones were established from T47D cells. Following
transfection with ER expression and control vectors, colonies were
generated from respective cell lines, labeled with BrdU for 24 h,
immunostained for BrdU (brown), and slightly counterstained with
hematoxylin to visualize BrdU+ and BrdU- cells.
Found at: doi:10.1371/journal.pone.0011288.s006 (6.57 MB TIF)
Figure S4 Detection of SABG+ senescent cells in estrogen
receptor-positive breast tumors. Snap-frozen tumors were used to
obtain 6 m thick sections and used directly to detect SABG+ cells.
H&E: hematoxylin-eosin staining.
Found at: doi:10.1371/journal.pone.0011288.s007 (9.45 MB TIF)
Figure S5 ASMA+ myoepithelial-like cells are produced fre-
quently in senescent cell progenitor T47D and MCF-7 cell lines
under confluent conditions. ASMA was tested by immunoperox-
idase.
Found at: doi:10.1371/journal.pone.0011288.s008 (4.08 MB TIF)
Figure S6 Unsupervised hierarchical clustering of breast tumor
and cell line gene expression data that is described in Fig. 7A.
Dendrogram shown here includes tumor and cell line sample IDs.
Found at: doi:10.1371/journal.pone.0011288.s009 (1.05 MB TIF)
Figure S7 Tumors derived from T47D but not from MDA-MB-
231 display SABG (+) senescent cells. Two of four T47D tumors
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displayed SABG+ cells. All four MDA-MB-231 tumors lacked
SABG+ cells.
Found at: doi:10.1371/journal.pone.0011288.s010 (7.97 MB TIF)
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E-mail address: ozturkm@ujf-grenoble.fr (M. OztCellular senescence is a process leading to terminal growth arrest with characteristic mor-
phological features. This process is mediated by telomere-dependent, oncogene-induced
and ROS-induced pathways, but persistent DNA damage is the most common cause. Senes-
cence arrest is mediated by p16INK4a- and p21Cip1-dependent pathways both leading to ret-
inoblastoma protein (pRb) activation. p53 plays a relay role between DNA damage sensing
and p21Cip1 activation. pRb arrests the cell cycle by recruiting proliferation genes to facul-
tative heterochromatin for permanent silencing. Replicative senescence that occurs in
hepatocytes in culture and in liver cirrhosis is associated with lack of telomerase activity
and results in telomere shortening. Hepatocellular carcinoma (HCC) cells display inactivat-
ing mutations of p53 and epigenetic silencing of p16INK4a. Moreover, they re-express telo-
merase reverse transcriptase required for telomere maintenance. Thus, senescence bypass
and cellular immortality is likely to contribute signiﬁcantly to HCC development. Onco-
gene-induced senescence in premalignant lesions and reversible immortality of cancer
cells including HCC offer new potentials for tumor prevention and treatment.
 2008 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Senescence is an evolutionary term meaning ‘‘the pro-
cess of becoming old”; the phase from full maturity to
death characterized by accumulation of metabolic prod-
ucts and decreased probability of reproduction or survival
[1]. The term ‘‘cellular senescence” was initially used by
Hayﬂick and colleagues to deﬁne cells that ceased to divide
in culture [2]. Today, cellular senescence is recognized as a
response of proliferating somatic cells to stress and dam-
age from exogenous and endogenous sources. It is charac-
terized by permanent cell cycle arrest. Senescent cells also
display altered morphology and an altered pattern of gene
expression, and can be recognized by the presence ofand Ltd. All rights reserved.
herche INSERM-Uni-
iot, Grenoble 38000,
6 54 94 54.
urk).senescence markers such as senescence-associated
b-galactosidase (SABG), p16INK4A, senescence-associated
DNA-damage foci and senescence-associated heterochro-
matin foci (for a review see Ref. [3]). This cellular response
has both beneﬁcial (anti-cancer) and probably deleterious
(such as tissue aging) effects on the organism. Most of
our knowledge of cellular senescence is derived from
in vitro studies performed with ﬁbroblasts, and some epi-
thelial cells such as mammary epithelial cells. Animal
models are increasingly being used to study cellular senes-
cence in vivo. Telomerase-deﬁcient mouse models lacking
RNA subunit (TERC/) have been very useful in demon-
strating the critical role of telomeres in organ aging and tu-
mor susceptibility [4]. Other mouse models including
tumor suppressor gene-deﬁcient and oncogene-expressing
mice were also used extensively.
Compared to other tissues and cancer models, the role
of senescence in liver cells and its implications in hepato-
cellular carcinogenesis have been less explored. One of
104 M. Ozturk et al. / Cancer Letters 286 (2009) 103–113the main obstacles is the lack of adequate in vitro systems.
As hepatocytes can not divide in cell culture, the study of
their replicative senescence mechanisms is not easy. Nev-
ertheless, these cells are able to quit their quiescent state
in vivo and proliferate massively in response to partial
hepatectomy or liver injury [5]. This capacity can be ex-
plored to study in vivo senescence of hepatocytes using ro-
dent models. Studies with clinical samples indicate that
hepatocyte senescence occurs in vivo in patients with
chronic hepatitis, cirrhosis and HCC [6–8]. In contrast to
the paucity of studies directly addressing cellular senes-
cence, the critical role of telomere shortening (as a feature
associated with replicative senescence) in cirrhosis and
HCC development is well established [9]. Telomeres in nor-
mal liver show a consistent but slow shortening during
aging. In contrast, hepatocyte DNA telomere shortening is
accelerated in patients with chronic liver disease with
shortest telomeres described in cirrhotic liver and HCC.
Telomerase-deﬁcient mice have also been used elegantly
to demonstrate the critical roles of telomerase and telo-
meres in liver regeneration and experimentally induced
cirrhosis [10,11]. A major accomplishment in recent years
was the demonstration of critical role played by senes-
cence for the clearance of ras-induced murine liver carci-
nomas following p53 restoration [12].
Despite a relatively important progress, the mecha-
nisms of hepatocellular senescence and the role of cellular
immortality in HCC remain ill-known issues. As one of the
rare tissues with ample clinical data on senescence-related
aberrations, liver may serve as an excellent model to fur-
ther explore the relevance of cellular senescence in human
biology. Moreover, a better understanding of senescence
and immortality in hepatic tissues may help to develop
new preventive and therapeutic approaches for severe li-
ver diseases such as cirrhosis and HCC. Here we will review
recent progress on senescence and immortality mecha-
nisms with a speciﬁc emphasis on hepatocellular
carcinogenesis.2. Senescence pathways
Cellular senescence has long been considered as a
mechanism that limits the number of cell divisions (or
population doublings) in response to progressive telomere
shortening. Most human somatic cells are telomerase-deﬁ-
cient because of the repression of telomerase reverse
transcriptase (TERT) expression. Therefore, proliferating
somatic cells undergo progressive telomere DNA erosion
as a function of their number of cell divisions. This form
of senescence is now called as replicative or telomere-
dependent senescence (Fig. 1).
Human chromosome telomere ends are composed of
TTAGGG repeats (5–20 kb) in a DNA-protein complex
formed by six telomere-speciﬁc proteins, called ‘‘shelterin”
[13]. Telomeric DNA has a structure called ‘‘t-loop” which
is formed as a result of invasion of the single stranded G-
rich sequence into the double-stranded telomeric tract.
Since the 1930s, it has been known that telomeres, with
telomere-binding proteins, prevent genomic instability
and the loss of essential genetic information by ‘‘capping”chromosome ends. They are also indispensable for proper
recombination and chromosomal segregation during cell
division. Telomeres become shorter with every cell divi-
sion in somatic cells, because of replication complex’s
inability to copy the ends of linear DNA, which also makes
them a ‘‘cell cycle counter” for the cell [14]. Telomeres are
added to the end of chromosomes with a complex contain-
ing the RNA template TERC and the reverse transcriptase
TERT [15]. Most somatic cells lack telomerase activity be-
cause the expression of TERT is repressed, in contrast to
TERC expression. The lack of sufﬁcient TERT expression in
somatic cells is the main cause of telomere shortening dur-
ing cell replication. This telomerase activity also helps to
maintain telomere integrity by telomere capping [15].
The loss of telomeres has long been considered to be the
critical signal for senescence induction. It is now well
known that telomere-dependent senescence is induced
by a change in the protected status of shortened telomeres,
whereby the loss of telomere DNA contributes to this
change [16]. The loss of telomere protection or any other
cause of telomere dysfunction results in inappropriate
chromosomal end-to-end fusions through non-homolo-
gous end joining or homologous recombination DNA repair
pathways [17]. These DNA repair pathways are used prin-
cipally to repair double-strand DNA breaks (DSBs). Thus, it
is highly likely that the open-ended telomere DNA is
sensed as a DSB by the cell machinery when telomere
structure becomes dysfunctional. Accordingly, dysfunc-
tional telomeres elicit a potent DSB type DNA damage re-
sponse by recruiting phosphorylated H2AX, 53BP1, NBS1
and MDC1 [18].
Telomere-dependent senescence is not the only form of
senescence. At least two other forms of telomere-indepen-
dent senescence are presently known: (1) oncogene-in-
duced senescence; and (2) reactive oxygen species (ROS)-
induced senescence (Fig. 1).
Oncogene-induced senescence had initially been identi-
ﬁed as a response to expression of Ras oncogene in normal
cells ([19], for a recent review see [20]). The expression of
oncogenic Ras in primary human or rodent cells results in
permanent G1 arrest. The arrest was accompanied by accu-
mulation of p53 and p16INK4a, and was phenotypically
indistinguishable from cellular senescence. This landmark
observation suggested that the onset of cellular senescence
does not simply reﬂect the accumulation of cell divisions,
but can be prematurely activated in response to an onco-
genic stimulus [19]. In 10 years following this important
discovery, telomere-independent forms of senescence have
become a new focus of extensive research leading to the
recognition of senescence as a common form of stress re-
sponse. Moreover, oncogene-induced senescence is now
recognized as a novel mechanism contributing to the ces-
sation of growth of premalignant or benign neoplasms to
prevent malignant cancer development [21]. In addition
to Ras, other oncogenes including Raf, Mos, Mek, Myc
and Cyclin E also induce senescence [20]. Conversely, the
loss of PTEN tumor suppressor gene also leads to senes-
cence [22]. Similar to telomere-dependent senescence,
oncogene-induced senescence is also primarily a DNA
damage response (Fig. 1). Experimental inactivation of
DNA damage response abrogates Ras-induced senescence
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and oncogene-induced senescence are established follow-
ing DNA hyper-replication immediately after oncogene
expression. Senescent cells arrest with partly replicated
DNA, where DNA replication origins have ﬁred multiple
times, prematurely terminated DNA replication forks and
DNA double-strand breaks are present [23,24].
ROS-induced senescence, the other telomere-indepen-
dent senescence pathway is gaining importance (for a re-
cent review see Ref. [25]). Mitochondria are the major
intracellular sources of ROS which are mainly generated
at the respiratory chain. Therefore, ROS have been sus-
pected for many years as cellular metabolites involved in
organismal aging [26]. ROS are also generated in the cyto-
plasm by the NOX family of enzymes [27]. Experimental
induction of ROS accumulation in cells (for example by
mild H2O2 treatment or glutathione depletion) induces
senescence-like growth arrest in different cell types,
whereas anti-oxidant treatment can inhibit senescence
[25]. More importantly, ROS have been identiﬁed as critical
mediators of both telomere-dependent and oncogene-in-
duced senescence. Telomere-dependent senescence arrestis accelerated in cells grown under high O2 conditions. In-
versely, cells grown under low O2 conditions display in-
creased lifespan ([28], see Ref. [25]). ROS also play a
critical role in Ras-induced senescence [29,30].
Currently, mechanisms of ROS-induced senescence are
not fully understood. It is generally accepted that oxidative
stress and ROS eventually cause DNA damage, whereby
DNA damage response may contribute to senescence
induction. The relationship between mitochondrial dys-
function, ROS, DNA damage and telomere-dependent
senescence has recently been demonstrated [31]. However,
ROS may also induce modiﬁcations in the cellular signaling
pathways resulting in senescence arrest. For example, ROS
induce senescence in hematopoietic stem cells by activat-
ing p38 MAPK [32].
Whether induced by telomere dysfunction, DNA repli-
cation stress following oncogene activation, or ROS accu-
mulation, DNA damage is one of the common steps in
the generation of senescence arrest via p53 activation
(Fig. 1). Upstream checkpoint kinases, such as ATM or
ATR are activated in response to DNA damage in the form
of double-stand breaks. These kinases phosphorylate
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phosphorylate p53. Phosphorylation of p53 results in its
activation by the displacement of the MDM2 protein. Crit-
ical involvement of this p53 activating pathway has been
reported for both telomere-dependent [33], and onco-
gene-induced senescence [34].
Other mechanisms of senescence that are apparently
not driven by DNA damage should also be discussed here.
Of particular interest is the INK4 locus encoding two inhib-
itors of cyclin-dependent kinases (p16INK4a, p15INK4b), and
ARF, a p53 regulatory protein (for a review see Ref. [35]).
p16INK4a and p15INK4b connect some senescent initiating
signals to the retinoblastoma (Rb) pathway, independent
of p53 activation. These proteins are easily activated in cell
culture and induce senescence arrest. Cells that escape
senescence often display inactivation of p16INK4a, and
sometimes p15INKb and ARF either by homozygous deletion
or by shutting-down gene expression. A prominent role for
p16INK4a in senescence and tumor suppression in humans
has emerged, despite some confusion due to the fact that
a relatively small DNA segment encodes the 3 proteins of
the INK4 locus. p16INK4a is activated during telomere-
dependent and oncogene-induced senescence [19,36].
Moreover, its expression is induced in aging tissues [37].
The mechanisms of regulation of p16INK4a expression are
not well known. Although individual components of INK4
locus can respond independently to positively – (for exam-
ple to Ras) or negatively – (for example c-Myc) acting sig-
nals, the entire INK4 locus might be coordinately regulated
by epigenetic mechanisms (reviewed in Ref. [35]).
A very recent addition to the list of senescence mecha-
nisms is to be qualiﬁed as ‘‘senescence induced by secreted
proteins”. It was reported many years ago that TGF-b is a
mediator of oncogene-induced senescence [38]. This
mechanism of induction is of particular interest, because
it suggests that not only intrinsic cellular factors, but also
extracellular or secreted proteins can induce senescence.
Recent discovery of several other secreted proteins, includ-
ing IGFBP7 and IL6 as autocrine/paracrine mediators of
oncogene-induced senescence arrest, provide strong sup-
port for an extracellularly induced form of senescence
[39–41]. This new form of senescence regulation is remi-
niscent of the so called active apoptosis induction by death
ligands. Thus, an active form of cellular senescence in-
duced by ‘‘aging ligands” could be a major physiological
regulator of tissue/organism aging.
3. Cyclin-dependent inhibitors as commonmediators of
senescence arrest
We have already stated that senescence and apoptosis
share interesting similarities. Another similarity between
these cellular processes is the convergence of different
pathways in a common place to induce the same cell fate,
independent of the initial signal. Similarly to caspase acti-
vation, prior to apoptosis induction by different stimuli,
most if not all senescence pathways result in the activation
of cyclin-dependent kinase inhibitors (CDKIs) in order to
induce permanent cell cycle arrest. Senescent cells accu-
mulate at G1 phase of the cell cycle due to an inability toenter into S phase in order to initiate DNA synthesis. The
transition of proliferating cells from G1 to S phase requires
the release of E2F factors from their inhibitory partner ret-
inoblastoma protein (pRb) following phosphorylation by
cyclin-dependent kinases (CDKs), in particular by CDK4/
CDK6 and CDK2 at this stage of the cycle [35]. The senes-
cence arrest is mediated by inhibition of pRb phosphoryla-
tion by CDK4 and CDK2. The activities of these enzymes are
controlled by different mechanisms, but the major proteins
involved in the control of senescence arrest are CDKIs. Al-
most all known CDKIs have been reported to be implicated
in senescence arrest, but three of them are best character-
ized: p16INK4a and p15INK4b which inhibit CDK4/CDK6, and
p21Cip1 which inhibits CDK2 (Fig. 2).
p21Cip1 is one of the main targets of p53 for the induc-
tion of cell cycle arrest following DNA damage [42]. Path-
ways that generate DNA damage response and p53
activation use p21Cip1 as a major mediator of cellular
senescence to control pRb protein [43]. Exceptionally,
p21Cip1 can be activated by p53-independent pathways to
induce senescence [44].
The Rb protein plays two important and complemen-
tary roles that are necessary to initiate and to permanently
maintain the cell cycle arrest in senescent cells. pRb pro-
teins ﬁrstly contribute to the exit from the cell cycle by
arresting cells at G1 phase, as expected [45]. In senescent
cells, this exit is complemented with a dramatic remodel-
ing of chromatin through the formation of domains of fac-
ultative heterochromatin called SAHF [46–48]. SAHF
contain modiﬁcations and associated proteins characteris-
tic of transcriptionally silent heterochromatin. Prolifera-
tion-promoting genes, such as E2F target genes are
recruited into SAHF in a pRb protein-dependent manner.
This recruitment is believed to contribute to irreversible
silencing of these proliferation-promoting genes [49].
4. Senescence of hepatocytes and chronic liver disease
Hepatocytes in the adult liver are quiescent cells, they
are renewed slowly, approximately once a year, as esti-
mated by telomere loss which is 50–120 bp per year in
healthy individuals [50,51]. However, the liver has an ex-
tremely powerful regenerative capacity, as demonstrated
experimentally in rodents, and as observed in patients
with chronic liver diseases [5]. This regenerative capacity
is due mostly to the ability of mature hepatocytes to prolif-
erate in response to a diminution of total liver mass either
experimentally, or following exposure to viral and non vir-
al hepatotoxic agents. In addition, the adult liver seems to
harbor hepatocyte-progenitor cells (<0.10% of total hepato-
cyte mass) that are able to restore liver hepatocyte popula-
tions [52]. However, hepatocytes, like any other somatic
cells, do not have unlimited replicative capacity, due to
the lack of telomerase activity that is needed to avoid telo-
mere shortening during successive cell divisions. This is
best exempliﬁed by decreased hepatocyte proliferation in
liver cirrhosis stage of chronic liver diseases [53], providing
in vivo evidence for the exhaustion of hepatocyte prolifer-
ation capacity. Senescence mechanisms in hepatocytes and
in liver tissue are not well known. However, a limited
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numerous descriptive in vivo studies in liver tissue provide
sufﬁcient evidence that hepatocytes can undergo senes-
cence type changes.
In vitro senescence in hepatocytes: as stated earlier,
limited proliferative capacity of somatic cells is controlled
by replicative senescence. The experimental study of repli-
cative senescence is done traditionally by serial culture of
primary cells. Initially observed in ﬁbroblasts, this phe-
nomenon has also been well understood in some epithelial
cells, mammary epithelial cells in particular [54]. On the
other hand, our knowledge of hepatocyte replicative senes-
cence is highly limited. In contrast to in vivo conditions,
mature hepatocytes are extremely resistant to cell prolifer-
ation in cell culture. Usually, more than 99.9% of adult liver
hepatocytes do not divide and can only be maintained in
culture for a few weeks at most. A small progenitor-type
cell population (so called small hepatocytes) has been
shown to proliferate in vitro, but they usually stop growing
at passages 5–7, with an ill-deﬁned senescence-like pheno-
type [55].
Fetal hepatocytes display better proliferation capacity
in culture. A few studies have shown that these fetal cells
enter replicative senescence, as shown by senescence-
associated b-galactosidase assay (SABG) at population dou-
bling (PD) 30–35 [55]. This is accompanied by progressive
shortening of telomeres down to 6 kbp, as these cells like
adult hepatocytes lack telomerase activity. However, it was
possible to immortalize these fetal hepatocytes by stableexpression of TERT [55]. Such immortalized cells have been
expanded beyond known senescence barriers (>300 PD).
In vivo senescence in liver tissue: in contrast to in vitro
studies, in vivo senescence of human hepatocytes is better
known. Indeed, the liver is one of the rare tissues where
in vivo evidence for senescence has been convincingly
and independently demonstrated by different investigators
[6–9]. Replicative senescence (as tested by SABG assay)
displayed a gradual increase from 10% in normal liver, to
84% in cirrhosis ([6,7]. It was also detected in 60% HCCs
[6]. It has also been demonstrated that telomere shorten-
ing in cirrhosis is restricted to hepatocytes and this hepa-
tocyte-speciﬁc shortening was correlated with SABG
staining [7].
Potential mechanisms of senescence in hepatocytes and
the liver: as presented in detail in the previous section,
multiple pathways of senescence have been described in
different experimental systems. Key molecules that are al-
ready involved in senescence arrest have also been sum-
marized. The published data on different senescence
pathways in the liver is fragmented and control mecha-
nisms involved in hepatocyte senescence are not com-
pletely understood. Therefore, existing data on
hepatocellular senescence together with potential mecha-
nisms that may be involved in this process will be
presented.
For reasons previously described, almost nothing is
known about molecular mechanisms involved in replica-
tive senescence and immortalization of hepatocytes in cul-
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immortalization in vitro. Thus, ectopically expressed TERT
may induce hepatocyte immortalization. However, as the
published data using TERT immortalization is scarce, it is
highly likely that the immortalization of hepatocytes is
not an easy task even with a well-established protocol that
works with other epithelial cell types such as mammary
epithelial cells. The mechanisms of in vitro senescence
induction in hepatocytes are also mostly unknown. Rapid
induction of a senescence arrest in cultured hepatocytes
suggests that these cells display robust telomere-indepen-
dent senescence-inducing systems that are functional
in vitro. However, they remain to be discovered. It is highly
likely that, similar to other somatic cells, p53 and RB path-
ways in general, and some CDKIs in particular are also in-
volved in hepatocyte senescence, but the evidence is
lacking for the time being.
Telomere shortening during aging is slow (55–120 base
pairs per year) and stabilizes at mid age in healthy liver, so
that the loss of telomeric DNA does not reach a level to in-
duce telomere dysfunction and DNA damage response
[50,51]. Other forms of telomere-independent senescence
such as ROS-induced senescence may also be rare under
normal physiological conditions. On the other hand, telo-
mere loss is accelerated in chronic liver disease to reach
lowest levels in the cirrhotic liver [7,51]. Therefore, one
plausible mechanism involved in cirrhosis is probably telo-
mere-dependent senescence, or replicative senescence.
The relevance of replicative senescence to liver tissue aging
has been demonstrated experimentally using telomerase-
deﬁcient mice. Late generation telomerase-deﬁcient mice
display critically shortened telomeres and an impaired li-
ver growth response to partial hepatectomy. A subpopula-
tion of telomere-shortened hepatic cells displayed
impaired proliferative capacity that is associated with
SABG activity [11,56]. On the other hand, it has been re-
ported that mouse liver cells are highly resistant to exten-
sive telomere dysfunction. Conditional deletion of the
telomeric protein TRF2 in hepatocytes resulted in telomer-
ic accumulation of phospho-H2AX and frequent telomere
fusions, indicating loss of telomere protection. However,
there was no induction of p53 and liver function appeared
unaffected. The loss of TRF2 did not compromise liver
regeneration after partial hepatectomy. Liver regeneration
occurred without cell division involving endoreduplication
and cell growth, thereby circumventing the chromosome
segregation problems associated with telomere fusions.
Thus, it appears that hepatocytes display intrinsic resis-
tance to telomere dysfunction, although they are appar-
ently vulnerable to severe telomere loss [57].
Hepatocyte senescence that is observed in severe
chronic liver diseases such as cirrhosis may also be induced
by telomere-independent pathways. Chronic liver injury
observed under such conditions is accompanied with
inﬂammation, cell death, and oxidative stress [58–60].
Some of the etiological factors such as HCV and alcohol in-
duce mitochondrial dysfunction may result in ROS accu-
mulation [61,62]. Thus, ROS-induced senescence may also
occur during cirrhosis, although this has not yet been re-
ported. The status of DNA damage in chronic liver disease
is less well-known. 8-Hydroxydeoxyguanosine, an indica-tor of DNA lesions produced by ROS, was reported to be in-
creased in chronic liver disease [63]. On the other hand, the
upregulation of DNA repair enzymes in cirrhosis has also
been reported [64]. Increased DNA repair activity in cirrho-
sis which may reﬂect increased DNA damages as a conse-
quence of chronic liver injury, but also inhibition of DNA
damage responses such as senescence were observed. Ta-
ken together, these observations suggest that the primary
cause of senescence in cirrhotic patients is telomere dys-
function and that ROS may also play additional roles.
Among senescence-related proteins, p16INK4a and
p21Cip1 expression was found to be high in cirrhosis, as
compared to normal liver and tumor tissues [65], suggest-
ing that these major senescence-inducing proteins accu-
mulate in the cirrhotic liver. Promoter methylation of
these CDKIs was also studied. Chronic liver disease sam-
ples displayed lower levels of methylation as compared
to HCCs [66]. Thus, the progression of chronic liver disease
towards cirrhosis is accompanied with a progressive acti-
vation of different CDKIs, as expected.5. Senescence pathway aberrations and telomerase
reactivation in hepatocellular carcinoma
As stated earlier, p53 and retinoblastoma (Rb) pathways
play a critical role in senescence arrest as observed in dif-
ferent in vitro and in vivo models. Indirect evidence sug-
gests that these pathways may also be important in
hepatocellular senescence. The accumulation of p21 and
p16 in cirrhotic liver tissues has been reported indepen-
dently by different reports. On the other hand, HCC rarely
develops in liver tissues absent of chronic liver disease.
More than 80% of these cancers are observed in patients
with cirrhosis [9]. As the appearance of proliferating malig-
nant cells from this senescence stage requires the bypass of
senescence, the status of both p53 and RB pathways in HCC
is of great importance in terms of molecular aspects of
hepatocellular carcinogenesis.
HCC is one of the major tumors displaying frequent p53
mutations [67,68]. The overall p53 mutation frequency in
HCC is around 30%. Both the frequency and the spectrum
of p53 mutations show great variations between tumors
from different geographical areas of the World. A hotspot
mutation (codon 249 AGG? AGT) has been linked to
exposure to aﬂatoxins which are known to be potent
DNA damaging agents (for a review see Ref. [67]).
Although, it is unknown whether aﬂatoxins are able to
generate a DNA damage-dependent senescence response
in hepatocytes, their association with DNA damage and
p53 mutation provides indirect evidence for such an abil-
ity. Other p53 mutations described in HCCs from low aﬂa-
toxin areas may similarly be correlated with other DNA
damaging agents, such as ROS which are known to accu-
mulate in the livers of patients with chronic liver diseases,
including cirrhosis.
Another player of senescence arrest, the p16 gene is
rarely mutated in HCC, but its epigenetic silencing by pro-
moter methylation is highly frequent in this cancer. More
than 50% of HCCs display de novo methylation of the pro-
moter of CDKN2A gene, encoding p16 protein, resulting in
M. Ozturk et al. / Cancer Letters 286 (2009) 103–113 109loss of gene expression [67]. Major components of p53 and
Rb pathways in the same set of HCCs with different etiolo-
gies have been analyzed [69]. Retinoblastoma pathway
alterations (p16 INK4a, p15INK4b or RB1 genes) were present
in 83% of HCCs, whereas p53 pathway alterations (p53 or
ARF genes) were detected in only 31% of tumors. Altera-
tions in both Rb and p53 pathways were present in 30%
of HCCs. Thus, it appears that either the Rb and/or the
p53 pathway are affected in the great majority of HCCs,
and that both pathways are affected in at least one third
of these tumors. Unfortunately, p53 and p16INK4a aberra-
tions observed in HCC have not yet been studied in relation
to senescence aberrations. However, these observations
provide supporting evidence on the critical role of senes-
cence-controlling pathways in the development of HCC.
The lack of telomerase activity in normal and cirrhotic
liver correlates with progressive loss of telomere
sequences ending up with a senescence arrest. The
emergence of malignant hepatocytes from this senes-
cence-dominated cirrhotic milieu would require not only
the bypass of senescence, but also a way of survival despite
critically shortened telomeres. Additionally, the prolifera-
tive expansion of neoplastic cells in order to form
sustained tumor masses would require telomeres at a min-
imal length required to maintain intact chromosomal
structures.
Many studies showed that telomerase activity is a hall-
mark of all human cancers, including 80–90% of HCCs
[70–72]. It is currently unclear how the TERT expression
is repressed and released in normal hepatocytes and HCC
cells, respectively. The integration of HBV DNA sequences
into TERT gene provides evidence for a virus-induced
deregulation of TERT expression, but this appears to rarely
occur, as only four cases have been reported thus far [73–
75]. Hbx and PreS2 proteins may upregulate TERT expres-
sion [76,77]. The molecular mechanisms involved in TERT
suppression in somatic cells and its reactivation in cancer
cells are ill-known. The TERT promoter displays binding
sites for a dozen of transcriptional regulators: estrogen
receptor, Sp1, Myc and ER81 acting positively, and vitamin
D receptor, MZF-2, WT1, Mad, E2F1 and SMAD interacting
protein-1 (SIP1, also called ZEB-2 or ZFHX1B) acting nega-
tively [78]. Despite high telomerase activity, telomeres in
HCC were repeatedly found to be highly shortened
[65,79,80]. However, 30 telomere overhangs were found
to be increased in nearly 40% HCCs [80]. Moreover, the
expression of several telomeric proteins is increased in
HCC [80,81].
Another ill-known aspect of TERT activity in HCC cells is
the cellular origin of these malignant cells. It is presently
unclear whether HCC arises from mature hepatocytes
which lack telomerase activity, or stem/progenitor cell-like
cells that may already express TERT at sufﬁcient levels to
maintain telomere integrity. In the non-tumor area sur-
rounding the cancer tissue, telomerase activity could not
be detected, or was detected at very low levels.
The importance of telomerase activity in HCC
development has been studied experimentally using telo-
merase-deﬁcient mouse model. These mice show in-
creased susceptibility to adenoma development (tumor
initiation), but they are quite resistant to fully malignanttumor development [82]. Likewise, telomerase deletion
limits the progression of p53-mutant HCCs with short telo-
meres [83]. These observations suggest that the aberra-
tions affecting telomerase activity and senescence
controlling genes such as p53 may cooperate during hepa-
tocellular carcinogenesis.
In summary, HCC is characterized by mutational inacti-
vation of p53, a major player in DNA damage-induced
senescence. In addition, p15INK4b, p16INK4a, p21Cip1 CDKIs
are often inactivated in this cancer mostly by epigenetic
mechanisms involving promoter methylation. These
changes may play a critical role in the bypass of senescence
that is observed in most cirrhosis cases, allowing some ini-
tiated cells to escape senescence control and proliferate. In
the absence of telomerase activity such cells would proba-
bly not survive due to telomere loss. However, since more
than 80% of HCCs display telomerase activity, it is highly
likely that the telomerase reactivation, together with the
inactivation of major CDKIs, plays a critical role in HCC
development by conferring premalignant or malignant
cells the ability to proliferate indeﬁnitely (Fig. 3). However,
cellular immortality is not sufﬁcient for full malignancy
[84]. Thus, senescence-related aberrations that are ob-
served in HCC cells, may confer a partial survival advan-
tage that would need to be complemented by other
genetic or epigenetic alterations.6. Senescence as an anti-tumor mechanism in
hepatocellular carcinoma
Senescence in normal somatic cells and tissues is ex-
pected. How about cancer cells and tumors? Initial studies
using different cancer cell lines provided ample evidence
for the induction of senescence by different genetic as well
as chemical or biological treatments [85]. Thus, it appeared
that cancer cells, immortalized by deﬁnition, do have a
hidden senescence program that can be revealed by differ-
ent senescence-inducing stimuli. These studies provided
preliminary evidence for considering senescence induction
as an anti-cancer therapy. The in vivo relevance of these
observations and expectations became evident only very
recently. Senescence was observed in tumors or pre-neo-
plastic lesions. SABG activity as well as several other senes-
cence markers were detected in lung adenomas, but not in
adenocarcinomas observed in oncogenic Ras ‘‘knock-in”
mice [86]. Ras-driven mouse T-cell lymphomas entered
senescence after drug therapy, when apoptosis was
blocked [87]. The ﬁrst direct evidence of cellular senes-
cence in humans was reported for the melanocytic nevus
[88].
Senescence response of HCC cells was not the subject of
intensive study until very recently. Therefore the potential
role of senescence in these tumors is less well understood.
Treatment of HCC cell lines with 5-aza-2-deoxycytidine in-
duced the expression of p16INK4a, hypophosphorylation of
pRb and G1 arrest associated with positive SABG staining
[89]. Recent ﬁndings indicate that senescence induction
is a powerful mechanism of HCC regression. Xue et al. ex-
pressed H-ras oncogene and suppressed endogenous p53
expression in mouse hepatoblasts which produced massive
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However, these tumors regressed rapidly upon restoration
of p53 expression. Tumor regression was due to differenti-
ation and massive senescence induction, followed by im-
mune-mediated clearance of senescent cells. These
observations may indicate that oncogene-induced senes-
cence is also involved in HCC. On the other hand, HCCs in-
duced by tet-regulated c-Myc activation in mouse liver
cells differentiate into mature hepatocytes and biliary cells
or undergo senescence [90]. Thus, senescence induction
may also be relevant to oncogene inactivation in HCC. In
this regard, c-Myc down-regulation and senescence induc-
tion in several HCC cell lines as a response to TGF-b was
observed (S. Senturk, M. Ozturk, unpublished data).
So far, all the reported examples of senescence induc-
tion in HCC cells are in the form of a telomere-independent
permanent cell cycle arrest. Until recently, it was unknown
whether replicative senescence could also be induced in
immortal cancer cells. Ozturk et al. reported recently that
immortal HCC cells can revert spontaneously to a replica-
tive senescence phenotype [91]. Immortal HCC cells gener-
ated progeny that behaved, in vitro, similar to normal
somatic cells. Such senescence-programmed progeny
lacked telomerase activity due to TERT repression (proba-
bly mediated by SIP1 gene), and displayed progressive
telomere shortening in cell culture, resulting in senescence
arrest. It will be interesting to test whether such spontane-
ous reversal of replicative immortality is involved in wellknown tumor dormancy and/or spontaneous tumor
regression.
7. Concluding remarks
Cellular senescence has gained great interest in recent
years following the demonstration that it also occurs
in vivo. It is also highly interesting that senescence can
be mediated by a large number of pathways and mole-
cules, as is the case for apoptosis. Recent ﬁndings that
implicate secreted molecules in senescence induction
strongly suggest that cellular senescence is not just a cellu-
lar event, but also a physiologically relevant process for the
whole organism. In terms of tumor biology, oncogene-in-
duced senescence that may serve as anti-tumor mecha-
nism in pre-neoplastic lesions underlines its clinical
relevance. On the other hand, induced or spontaneous
senescence that is observed in cancer cells is promising
to explore new approaches for tumor prevention and treat-
ment. The role of senescence bypass and cellular immortal-
ity in hepatocellular carcinogenesis is not well deﬁned.
But, many ﬁndings (inactivation of senescence-mediator
genes such as p53, p16INK4a and p15INK4b, as well as reacti-
vation of TERT) indicate that senescence mechanisms and
their aberrations are critically involved in HCC. We may
expect that this ﬁeld will attract more attention in coming
years for a better deﬁnition of senescence implications in
hepatocellular carcinogenesis.
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Abstract
Background: -catenin mutations that constitutively activate the canonical Wnt signaling have been observed in a
subset of hepatocellular carcinomas (HCCs). These mutations are associated with chromosomal stability, low histological
grade, low tumor invasion and better patient survival. We hypothesized that canonical Wnt signaling is selectively
activated in well-differentiated, but repressed in poorly differentiated HCCs. To this aim, we characterized differentiation
status of HCC cell lines and compared their expression status of Wnt pathway genes, and explored their activity of
canonical Wnt signaling.
Results: We classified human HCC cell lines into "well-differentiated" and "poorly differentiated" subtypes, based on the
expression of hepatocyte lineage, epithelial and mesenchymal markers. Poorly differentiated cell lines lost epithelial and
hepatocyte lineage markers, and overexpressed mesenchymal markers. Also, they were highly motile and invasive. We
compared the expression of 45 Wnt pathway genes between two subtypes. TCF1 and TCF4 factors, and LRP5 and LRP6
co-receptors were ubiquitously expressed. Likewise, six Frizzled receptors, and canonical Wnt3 ligand were expressed
in both subtypes. In contrast, canonical ligand Wnt8b and noncanonical ligands Wnt4, Wnt5a, Wnt5b and Wnt7b were
expressed selectively in well- and poorly differentiated cell lines, respectively. Canonical Wnt signaling activity, as tested
by a TCF reporter assay was detected in 80% of well-differentiated, contrary to 14% of poorly differentiated cell lines.
TCF activity generated by ectopic mutant -catenin was weak in poorly differentiated SNU449 cell line, suggesting a
repressive mechanism. We tested Wnt5a as a candidate antagonist. It strongly inhibited canonical Wnt signaling that is
activated by mutant -catenin in HCC cell lines.
Conclusion: Differential expression of Wnt ligands in HCC cells is associated with selective activation of canonical Wnt
signaling in well-differentiated, and its repression in poorly differentiated cell lines. One potential mechanism of
repression involved Wnt5a, acting as an antagonist of canonical Wnt signaling. Our observations support the hypothesis
that Wnt pathway is selectively activated or repressed depending on differentiation status of HCC cells. We propose
that canonical and noncanonical Wnt pathways have complementary roles in HCC, where the canonical signaling
contributes to tumor initiation, and noncanonical signaling to tumor progression.
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Hepatocellular carcinoma (HCC) is an epithelial cancer
that originates from hepatocytes or their progenitors. It is
the fifth most frequent neoplasm worldwide (>500,000
deaths/year), and its incidence is steadily increasing in the
West [1]. Hepatocellular carcinoma is graded into four
stages as well-differentiated, moderately differentiated,
poorly differentiated and undifferentiated tumors, respec-
tively. HCC arises as a very well differentiated cancer and
proliferates with a stepwise process of dedifferentiation.
Indeed, well-differentiated histology is exclusively seen in
early stage and is rare in advanced HCC. Well-differenti-
ated and moderately differentiated HCC cells are morpho-
logically similar to hepatocytes, and are distinguished
only by their smaller size and architectural organization as
irregular trabecular or pseudoglandular patterns. In con-
trast, poorly differentiated and undifferentiated HCC cells
are characterized with scanty cytoplasms and pleomor-
phism [2]. Like in other epithelial tumors, in HCC the
progenitors evolve during tumor progression and become
more and more autonomous. In this process, the tumor
cells change their morphology and behavior; they loose
cuboidal shape and polarity, and become more independ-
ent from neighboring tissues. Finally, they acquire the
capacity to invade the underlying tissue and form distant
metastases. These morphological changes are usually
associated with progressive loss of biochemical and mor-
phological features of hepatocytes, hence the process is
qualified as "dedifferentiation" [3]. Portal venous inva-
sion is significantly associated with poorly differentiated
and undifferentiated HCCs and the tumor invasiveness is
the most crucial factor in determining the long-term out-
come for the patient [4].
Molecular changes involved in HCC dedifferentiation and
invasiveness are known only partially. Epithelial markers
such as hepatocyte nuclear factors and E-cadherin were
reported to be down-regulated in HCC [3,5] and their loss
is closely related to tumor invasion and metastasis [5]. In
contrast, mesenchymal cell markers such as snail [6], twist
[7] and vimentin [8] display positive correlation with
HCC invasiveness and/or metastasis. These changes have
been considered to represent the epithelial-mesenchymal
transition (EMT) in HCC, based on in vitro studies [9-15].
Hepatocyte nuclear factor-4 (Hnf-4) is essential for
morphological and functional differentiation of hepato-
cytes [16,17], and its expression is downregulated during
HCC progression in mice [18]. HCC dedifferentiation
process is associated with a progressive accumulation of
genomic changes including chromosomal gains and
losses, as well as p53 mutations [19]. A rare exception to
this picture is the status of the CTNNB1 gene that encodes
-catenin, a key component of the Wnt/-catenin (canon-
ical Wnt) signaling pathway.
Independent studies showed that -catenin mutations are
associated with a subset of low grade (well-differentiated)
HCCs with a favorable prognosis and chromosome stabil-
ity [20-25]. Among 366 unifocal HCCs studied by Hsu et
al. [20], -catenin mutations were associated with grade I
histogoly. Another study with similarly high number of
tumors (n = 372) also indicated that mutant nuclear -cat-
enin correlated positively with non-invasive tumor and
inversely with portal vein tumor thrombi [23]. In addi-
tion, -catenin mutations were associated with signifi-
cantly better 5-year patient survival in these large cohorts.
Direct study of canonical Wnt signaling activity in primary
tumors is not possible. However, this can be studied indi-
rectly by using target genes [22]. Using glutamine syn-
thetase (encoded by canonical Wnt signaling target GLUL
gene) as a sensitive and specific marker, Audard et al. [22]
showed that 36% HCCs displayed canonical Wnt activa-
tion. These tumors exhibited significant features associ-
ated with well-differentiated morphology. The association
of -catenin mutation and nuclear translocation with
well-differentiated tumor grade was also reported during
hepatocellular carcinogenesis, using several transgenic
mouse models [26]. Activation of -catenin was most fre-
quent in liver tumors from c-myc and c-myc/TGF-1
transgenic mice. However, it was very rare in faster grow-
ing and histologically more aggressive HCCs developed in
c-myc/TGF- mice. Taken together, these studies suggest
that nuclear translocation of -catenin and activation of
canonical Wnt signaling are early events in liver carcino-
genesis, mostly affecting well-differentiated HCCs.
Mutations of -catenin gene initially identified in colorec-
tal cancers, cause constitutive activation of canonical Wnt
signaling, as a result of aberrant -catenin protein accu-
mulation. Inactivating mutations of APC gene in colorec-
tal cancer and AXIN1 in HCC also activate canonical Wnt
signaling by the same mechanism. Therefore, tumors dis-
playing -catenin, APC or AXIN1 mutation are considered
to display active or constitutive canonical Wnt signaling
[27] Activation of canonical Wnt signaling appears to be a
common event for colorectal cancer, as opposed to HCC
with mutations limited to a subset of these cancers. Inter-
estingly, transgenic mice expressing oncogenic -catenin
in hepatocytes develop only hepatomegaly [28,29], in
contrast to intestinal polyposis and microadenoma when
expressed in intestinal cells [30].
Taken together, published data indicate that Wnt pathway
and -catenin mutations may play a complex role in HCC.
Close association of -catenin mutation with low tumor
grade suggests that canonical Wnt signaling has a dual role
in HCC cells, depending on their differentiation state. As
an initial attempt to characterize differentiation-depend-
ent functions of Wnt pathway and canonical Wnt signal-
ing in HCC, we used a panel of HCC-derived cell lines. WePage 2 of 20
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analyses to classify HCC cell lines into two distinct sub-
types. The first subtype that we named here as "well-differ-
entiated" was formed by epithelial cell lines with limited
motility and invasiveness. Mesenchymal-like cell lines
that have lost their epithelial-, hepatocyte-like features
clustered into a second subtype named as "poorly differ-
entiated". Next, we compared these two subtypes for the
expression of 45 Wnt pathway genes, as well as for the
activity of canonical Wnt signaling. Our findings provided
evidence for the constitutive activation of canonical Wnt
signaling in well-differentiated, but not in poorly differen-
tiated cell lines. We also report the upregulation canonical
Wnt3 ligand in the majority of HCC cell lines. Canonical
Wnt8b was selectively expressed in well-differentiated cell
lines. In contrast, noncanonical Wnt4, Wnt5a, Wnt5b and
Wnt7b ligands were expressed selectively in poorly differ-
entiated HCC cell lines. In addition, ectopic expression of
noncanonical Wnt5a inhibited canonical Wnt signaling
in two different cell lines. Our findings support the differ-
ential involvement of canonical and noncanonical Wnt
signaling in HCC, depending on tumor cell differentia-
tion state.
Results
Classification of hepatocellular carcinoma cell lines into 
"well-differentiated" and "poorly differentiated" subtypes
Fuchs et al. [12] have recently classified HCC cell lines
into "epithelial" and "mesenchymal" types based on E-
cadherin and vimentin expression. We performed a simi-
lar analysis using our cell line panel. Initially, we analyzed
15 cell lines (Figure 1). The expression of -fetoprotein
(AFP) was limited to six cell lines (Huh7, Hep40, HepG2,
Hep3B, Hep3B-TR, PLC/PRF/5); the other cell lines being
either not expressing (SNU182, SNU387, SNU398,
SNU423, SNU449, SK-Hep1, Mahlavu, FOCUS) or
weakly expressing (SNU475). All AFP-positive (AFP+) cell
lines also expressed E-cadherin, whereas only 3/9 (33%)
of AFP- cell lines expressed this epithelial marker. Mesen-
chymal cell markers including vimentin, slug, snail, twist-
1 and twist-2 were also positive in most AFP- cell lines.
These markers also displayed weakly positive expression
in some AFP+ cell lines. For confirmation, we performed
immunocytochemical analysis of vimentin protein
expression in five AFP+ and five AFP- cell lines (Figure 2).
We observed strong and homogenous immunostaining
with all five AFP- cell lines. In contrast AFP+ cell lines were
either negative or displayed heterogeneously positive
immunoreactivity. These findings suggested that all AFP+
HCC cell lines were epithelial-like based on E-cadherin
expression, but they also expressed some mesenchymal
cell markers at variable degrees. In contrast, AFP- cell lines
were usually negative for E-cadherin, and most of them
were strongly positive for mesenchymal cell markers. The
expression patterns of these mesenchymal markers
showed marked heterogeneity. For example, SNU182 was
positive for all five markers tested, whereas FOCUS was
positive only for vimentin expression.
Expression analysis of a-fetoprotein (AFP), E-cadherin and five mesenchymal cell markers in HCC cell linesFigure 1
Expression analysis of a-fetoprotein (AFP), E-cadherin and five mesenchymal cell markers in HCC cell lines. 
Total RNAs were extracted from cell lines and used to detect gene expression by RT-PCR assay. GAPDH was used as a con-
trol for expression analyses shown here and in figures 4 to 7.Page 3 of 20
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ther analysis. HNF-4 and its downstream target HNF-1
are best known hepatocyte-associated epithelial cell mark-
ers [3]. These two genes that are involved in liver develop-
ment and hepatocyte specification have previously been
identified as specific markers for HCC cells with well-dif-
ferentiated function and morphology [31]. The expression
of these HNFs displayed perfect correlation with the
expression of AFP (Figure 3a): four AFP+ cell lines (Huh7,
Hep3B, HepG2, Hep40) were also highly positive for both
HNF-4 and HNF-1. In contrast, seven AFP- cell lines
(SNU398, SNU475, SNU449, SNU387, FOCUS, Mahl-
avu, SNU182) did not express these factors. SNU449,
another AFP- cell line displayed only weak HNF-4
expression. Epithelial cells including hepatocytes show
low motility, in contrast to mesenchymal cells that display
high motility and invasive behavior. To test whether epi-
thelial and mesenchymal gene expression patterns of
HCC cells correlated with their in vitro motility, we used
wound-healing assay. After 24 hours of wounding, AFP-
HCC cells (Mahlavu, SNU449, SNU475, SNU182) moved
through the wound, whereas AFP+ HCC cells (Huh7,
Hep3B, Hep G2, Hep40) cells did not (Figure 3b; Hep40
and SNU182 data not shown). A quantitative analysis of
this data confirmed that poorly differentiated cell lines
display higher motility (Figure 3c).
Based on expression analysis, together with in vitro motil-
ity and previously published invasiveness data, we classi-
fied our panel of HCC cell lines into two subtypes (Table
1). We qualified HepG2, Huh7, Hep3B and Hep40 as
"well-differentiated" HCC cell lines, because they express
AFP, E-cadherin, HNF-4 and HNF-1, and they display
low motility and/or low invasiveness. Most of these fea-
tures are confined to "well-differentiated" HCC tumors
([2,18,32,33]. We qualified the remaining seven cell lines
(SNU398, SNU475, SNU449, SNU387, FOCUS, Mahl-
avu, SNU182) as "poorly-differentiated" HCC cell lines,
based on the lack of expression of both hepatocyte lineage
and epithelial cell markers analyzed here. In addition,
these poorly differentiated cell lines shared many features
with mesenchymal cells including the expression of mes-
enchymal markers (vimentin, slug, snail, twist-1, and
twist-2), high motility and invasiveness. These expression
Immunocytochemical analysis of mesenchymal marker vimentin protein in AFP+ and AFP- HCC cell linesFigure 2
Immunocytochemical analysis of mesenchymal marker vimentin protein in AFP+ and AFP- HCC cell lines. 
Cells grown on coverslips were subjected to immunoperoxidase assay using anti-vimentin antibody (brown), and counter-
stained with hematoxylin (blue).Page 4 of 20
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entiation and confined to poorly differentiated HCCs [6-
8,14,34].
Expression TCF/LEF family of transcription factors
Following the identification of well-differentiated and
poorly differentiated HCC cell lines, we analyzed the
expression of 45 Wnt pathway genes by RT-PCR assay. We
first investigated the expression profile of TCF/LEF factors.
The TCF-1 and TCF-4 were highly expressed in all HCC
cell lines, while TCF-3 expression was limited to a subset
of cell lines (Figure 4). LEF-1 transcript expression was
weak, except for SNU398 cells. These findings indicated
that at least two different nuclear factors mediating canon-
ical Wnt signaling were expressed in any of HCC cell lines
tested.
Expression of Frizzled receptors and LRP co-receptors
Next we analyzed the expression of 10 Frizzled receptors
and their two co-receptors. Two canonical (Fzd1, Fzd5)
and three noncanonical (Fzd3, Fzd4, Fzd6) Frizzled recep-
tors were expressed in all cell lines tested. Also, Fzd2, Fzd7
and Fzd8 were expressed in most cell lines independent of
their differentiation status (Figure 5-top). Lrp-5 and Lrp-6
co-receptors also were consistently expressed in all cell
lines (Figure 5-bottom). These findings indicated that
HCC cell lines were equipped with the expression of sev-
eral canonical and noncanonial Wnt signaling receptors,
Expression of hepatocyte lineage markers HNF-4 and HNF-1 in HCC cell line correlate with low motilityFigure 3
Expression of hepatocyte lineage markers HNF-4 and HNF-1 in HCC cell line correlate with low motility. 
(a)Selective expression of HNF-4 and HNF-1 in AFP+ HCC cell lines. Total RNAs were extracted from cells and used for 
RT-PCR analysis of HNF-4 and HNF-1 expression. GAPDH RT-PCR was used as a loading control. (b. c) Differential motil-
ity of AFP+ and AFP- HCC cell lines. Cells were cultured in six-well culture plates, and a single linear wound was made with a 
pipette tip in confluent monolayer cells. The distances between wound edges were measured at fixed points in each dish 
according to standardized template. After 24 hours migration, cell migration into the wound was visualized using phase con-
trast microscopy at ×20 magnification (b). The number of cells migrating beyond the wound edge was counted (c). Assays in 
six replicates, error bars; SD. SNU475 cells are larger cells giving rise to visual overestimation of migrating cell number in the 
picture shown in b.Page 5 of 20
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canonical and noncanonical Wnt signals.
Differential expression of canonical and noncanonical 
Wnt ligands
In humans, there are 19 known genes encoding canonical
and noncanonical Wnt ligands [35]. We studied the
expression profile of the complete list of human Wnt lig-
ands (Figures 6 and 7). From the group of eight known
canonical Wnt ligands, only Wnt3 was strongly and uni-
formly expressed in all cell lines tested. Wnt10b was also
strongly expressed, but not in all cell lines (Figure 6). We
observed selective expression of canonical Wnt8b in well
differentiated cell lins. In contrast, among seven nonca-
nonical Wnt ligands, Wnt4, Wnt5a, Wnt5b and Wnt7b
were expressed in almost all poorly differentiated cell
lines tested. This contrasted with their poor expression in
well differentiated cell lines (Figure 7-top). Signaling spe-
cificity of four other Wnt ligands have not yet been clearly
established [35]. Among these ligands, Wnt9a expression
was detectable in nearly all cell lines tested. In contrast,
Wnt9b and Wnt2b expressions were associated to well dif-
ferentiated and poorly differentiated cell lines, respec-
tively (Figure 7-bottom).
Our comprehensive analysis of Wnt signaling molecules
in HCC cell lines revealed several features. First, with the
exception of Wnt ligands, most of the major components
of Wnt signaling pathway were expressed redundantly in
HCC cell lines, independent of their differentiation status.
In contrast, Wnt ligand expression displayed two types of
selectivity. First, out of eight known canonical only Wnt3
and Wnt10b displayed strong expression in most cell
lines, independent of differentiation status. Second, out of
seven noncanonical Wnt ligands, four were expressed in
HCC cell lines with a high selectivity for poorly differenti-
ated ones. Well-diffferentiated cell lines displayed selec-
tive expression of Wnt8b. These findings may have several
Table 1: Well-differentiated and poorly differentiated HCC cell lines according to hepatocyte lineage, epithelial and mesenchymal 
markers, and in vitro motility and invasiveness assays
Cell Lines Fetal 
Hepatocyte 
Marker
Epithelial & Hepatocyte 
Markers
Mesenchymal markers Motility Invasivene
ss
AFP HNF4a HNF1a E-cadherin vimentin slug Snail Twist-1 Twist-2
Well-
differentiated
HepG2 High High High Low (-) Low Low Low High Low Low [14]
Huh7 High High High High Low (±) Low Low (-) Low Low [14]
Hep3B High High High High Low High Low (-) (-) Low Low ([74]
Hep40 High High High Low High (-) High High Low Low n.t.
Poorly 
differentiated
SNU398 (-) (-) (-) Low High Low High High High Low n.t.
SNU475 (±) (-) (-) (-) High High High High Low High n.t.
SNU449 (-) Low (-) (±) High Low Low High High High n.t.
SNU387 (-) (-) (-) (-) Low High High (-) (±) n.t. n.t.
FOCUS (-) (-) (-) Low High Low (-) (-) Low n.t. n.t.
Mahlavu (-) (-) (-) (±) High Low (-) High Low High High [74]
SNU182 (-) (-) (±) High high High High High High High n.t.
(-); not detected; ±; traces; n.t.; not tested.Page 6 of 20
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equipped with an autocrine/paracrine canonical Wnt sig-
naling system, as reported previously for breast and ovar-
ian cancer cell lines [36]. In contrast, because of selective
expression of noncanonical Wnt ligands, only poorly dif-
ferentiated cell lines could serve from an autrocrine non-
canonical Wnt signaling system. In addition, poorly
differentiated HCC cells could also provide noncanonical
Wnt signals to other cells by a paracrine mechanism.
Finally, noncanonical Wnt ligands such as Wnt5a might
inhibit canonical Wnt signaling in HCC cells, as previ-
ously reported in other cell types [37-39].
Autocrine canonical Wnt signaling in well differentiated 
hepatocellular carcinoma cell lines
Canonical Wnt signaling activates TCF/LEF-dependent
transcription, which can be monitored by reporters con-
taining TCF/LEF-responsive elements [27,40]. We sur-
veyed canonical Wnt signaling in HCC cell lines using
TCF/LEF reporter pGL3-OT plasmid, as described previ-
ously [41]. First, we compared TCF/LEF (TCF) activity in
three cell lines with known mutations in canonical Wnt
signaling pathway (Figure 8a). Well-differentiated HepG2
cell line displays -catenin mutation. Poorly-differenti-
ated SNU398 and SNU475 cell lines display -catenin and
AXIN1 mutations, respectively [42,43]. Normalized TCF
activity was the highest in HepG2 cells. Compared to
HepG2, SNU398 cells displayed 50% less activity. More
interestingly, despite a homozygous deletion leading to a
loss of Axin1 expression (data not shown; [42,43], there
was no detectable TCF activity in SNU475 cells. This con-
trasted sharply with another well-differentiated AXIN1
mutant HCC cell line, namely PLC/PRF/5 (Alexander)
that displayed high TCF activity [42] (additional data not
shown).
Next, we compared TCF activity of eight other cell lines
that displayed wild-type -catenin and AXIN1 status [41-
43]. Hep40 cells that harbor a missense AXIN1 mutation/
polymorphism (R454H) was included in this group, since
functional significance of this mutation is unknown [41].
We detected weak, but significant (3-4 fold) TCF activity
in well-differentiated Huh7 and Hep3B cell lines. On the
other hand, all five poorly differentiated cell lines, as well
as well-differentiated Hep40 cells displayed no detectable
activity under our experimental conditions (Figure 8b).
Taken together, we collected TCF activity data from 12
HCC cell lines. Independent of -catenin or AXIN1 status,
TCF activity was detected in four out of five (80%) well-
differentiated cell lines, whereas only one out of seven
(14%) poorly differentiated cell lines had constitutive
TCF activity [P < 0.046 (one-tailed), 0.071(two-tailed);
Fisher Exact Probability Test]. This data supports the
hypothesis that well-differentiated HCC cells display an
autocrine/paracrine canonical Wnt signaling, probably
because they co-express Wnt3 and several canonical Friz-
zled receptors. However, the great majority of poorly dif-
ferentiated cell lines failed to generate canonical Wnt
signaling activity, although they similarly co-expressed
Wnt3 and canonical Frizzled receptors.
Comparative analysis of TCF/LEF transcription factors in hepatocellular carcinoma cell linesFigure 4
Comparative analysis of TCF/LEF transcription factors in hepatocellular carcinoma cell lines. Total RNAs were 
extracted from cell lines and used to detect gene expression by RT-PCR assay of four members of TCF/LEF family. See Figure 
1 for GAPDH loading control.Page 7 of 20
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differentiated hepatocellular carcinoma cells
The lack of canonical Wnt activity in poorly differentiated
cells could be due to either lack of sufficient Wnt ligand
activity. Alternatively, canonical Wnt signaling could be
repressed in these cell lines. A number of proteins down-
stream to -catenin such as Axin2, HTLE family, hAES,
Chibby, CTBP and ICAT are known to display inhibitory
activity on canonical Wnt signaling [44]. We compared
the expression of genes encoding these inhibitory pro-
teins, but found no correlation with TCF activity or differ-
entiation state (Figure 9).
Next, we compared TCF activity in Huh7, SNU449 and
SNU182 cell lines following transient expression of a
mutant (S33Y)--catenin (Figure 10). Transfection with
S33Y--catenin resulted in an increase in total -catenin
protein in Huh7 and SNU449. This increase was less evi-
dent in SNU182 cells (Figure 10a). Well-differentiated
Huh7 cells responded to S33Y--catenin expression by a
strong activation of TCF/LEF reporter (130 folds). Under
the same experimental conditions, the response of
SNU449 cells was minimal (5 folds). More importantly,
SNU182 cells were totally unresponsive (Figure 10b).
These important differences between well-differentiated
Huh7 and two different poorly differentiated cell lines
(SNU449 and SNU182) are apparently not due to differ-
ences in transient transfection efficiencies, since the meas-
ured activities have been corrected for such differences
(see material and methods section).
In order to confirm the data on weakened response in
poorly differentiated cell lines, we generated a clone from
SNU449 cells (SNU449-cl8) with Tet repressor controlled
expression of N-terminally truncated -catenin (aa 98-
781). N-terminally truncated -catenin forms are fre-
quently detected in cancer cells including HCC cells. They
lack Ser/Thr phosphorylation sites (aa Ser23, Ser29,
Ser33, Ser37, Thr41, Ser45) that are critically involved in
its ubiquitin-mediated degradation, and they accumulate
in the cell nucleus leading to oncogenic activation canon-
ical Wnt signaling [27]. As shown in figure 11a, SNU449-
cl8 cells expressed only wild-type -catenin in the pres-
ence of tetracycline (Tet-on conditions), while expressing
both wild-type and truncated -catenin at comparable lev-
els in Tet-off conditions. The induced expression of trun-
cated -catenin resulted in only a weak activation (3-4
fold) of TCF reporter activity, similar to data obtained by
Comparative analysis of Frizzled receptors and LRP co-receptors in hepatocellular carcinoma cell linesFigure 5
Comparative analysis of Frizzled receptors and LRP co-receptors in hepatocellular carcinoma cell lines. Frizzled 
receptors involved in canonical and noncanonical Wnt signaling were tested for expression by RT-PCR assay (Top). The 
expression of LRP co-receptors was analyzed similarly (bottom). Total RNAs were extracted from cell lines and used to detect 
gene expression by RT-PCR assay. See Figure 1 for GAPDH loading control.Page 8 of 20
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level of activation was similar to that seen in well-differen-
tiated HCC cells in the absence of -catenin or Axin-1
mutation (Fig. 8b), and strongly suggests that canonical
Wnt signaling is actively repressed in this poorly differen-
tiated HCC cell line. For comparison, well-differentiated
HepG2 cells expressing wild-type and a similar N-termi-
nally truncated -catenin (25-140 aa) activated TCF
reporter gene by more than 60-fold (Figure 8a). In other
words, although both Tet-off SNU449-cl8 and HepG2
cells displayed a heterozygous truncating -catenin muta-
tion, TCF activation was 15-fold less in poorly differenti-
ated SNU449 background. To test whether this repression
was related to cellular localization of -catenin, we per-
formed immunofluorescence detection using confocal
microscopy (Figure 11c). Wild-type -catenin was local-
ized at the cell membrane with weak nuclear localization.
The induction of truncated -catenin in Tet-off SNU449-
cl8 cells did not change this distribution significantly. We
observed only weak cytoplasmic accumulation, with
slight increases in both membrane and nuclear localiza-
tion. In sharp contrast with these observations, in colorec-
tal cancer cells (APC-mutated), used as a positive control
[45], we detected strong nuclear accumulation of -cat-
enin by the same technique.
WNT5A inhibits canonical Wnt signaling in HCC cells
Presently, the mechanism of repression of canonical Wnt
signaling in poorly differentiated HCC cells is unknown,
but it is associated with a lack of nuclear accumulation of
-catenin. Among noncanonical Wnt ligands, Wnt5a is
best known for its antagonistic effect on canonical Wnt
signaling [46]. Therefore, we tested the effect of ectopic
Wnt5a expression on mutant--catenin-induced TCF
activity in Huh7 cell line. In the absence of Wnt5a, TCF
activity was induced more than 160-fold by mutant -cat-
enin in this cell line. Co-expression of Wnt5a resulted in
three-fold repression of TCF activity (Figure 12a). To con-
firm our observations, we also tested the effects of Wnt5a
on TCF activity induced by endogenous mutant -catenin
using HepG2 cell line. The expression of Wnt5a in this cell
line caused a significant inhibition of TCF activation
mediated by endogenous -catenin (P < 0.05; Figure 12b).
We concluded that Wnt5a that is selectively expressed in
poorly differentiated HCC cell lines, and probably simi-
larly acting noncanonical Wnt ligands are involved, at
least partly, in the repression of canonical Wnt signaling
in these cells.
Discussion
Since the initial description of -catenin mutations in
HCCs in 1998 [33], Wnt signaling became a center of
interest for these tumors. A large set of Wnt ligands and a
large array of receptors are implicated in different cell
processes by initiating canonical, but also noncanonical
Wnt signals [35]. The antagonism between canonical and
noncanonical Wnt pathways has also been reported
[37,38,46]. Thus, both -catenin and Wnt signaling are
Comparative analysis of canonical Wnt ligands in hepatocellular carcinoma cell linesFigure 6
Comparative analysis of canonical Wnt ligands in hepatocellular carcinoma cell lines. Canonical Wnt ligands were 
tested for expression by RT-PCR assay. Total RNAs were extracted from cell lines and used to detect gene expression by RT-
PCR assay. See Figure 1 for GAPDH loading control.Page 9 of 20
(page number not for citation purposes)
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some are mediated by canonical Wnt pathway. This com-
plexity is also observed during liver development and as
well as in adult liver homeostatic events. Canonical Wnt
signaling contributes to liver growth and regeneration,
but also to liver "zonation" by controlling some liver-spe-
cific metabolic programs. ([47]). In addition, it contrib-
utes to the activation of liver stem or progenitor cells, as
well as HCC-initiating cells [48-51].
Mutational activation of canonical Wnt signaling is not a
frequent event in HCC, in contrast to hepatoblastoma dis-
playing very high rates [52]. Mutations of -catenin were
restricted to a group of HCCs associated with low p53
mutation rate, negative HBV status and chromosomal sta-
bility, as stated earlier. These mutations were also associ-
ated with lower histological grade and better patient
survival. Unexpectedly, -catenin mutations are rare in
more advanced and poorly differentiated HCCs [20,23].
Therefore, although considered to play an active role in
HCC malignancy, the activation of canonical Wnt signal-
ing may not be necessary for, or even repressed in
advanced HCCs. Thus, -catenin mutation and constitu-
tive activation of canonical Wnt signaling may be differen-
tiation-dependent events with mechanistic implications
in HCC initiation and progression. We attempted to
address this issue by using HCC-derived cell lines.
We first classified 11 HCC cell lines into "well-differenti-
ated" and "poorly differentiated" subtypes using hepato-
cyte lineage, epithelial and mesenchymal cell markers,
and in vitro migration assays. Well-differentiated HCC
cell lines shared many features with hepatocytes such as
expression of HNF-1, HNF-4, and E-cadherin, and epi-
thelial morphology. Poorly differentiated cell lines were
usually deficient in the expression of hepatocyte lineage
and epithelial markers, but they expressed different mes-
enchymal markers strongly. These two types of HCC cell
lines were also distinguished from each other by their in
vitro behaviors. Poorly differentiated cell lines were usu-
ally more motile and more invasive than well-differenti-
ated cell lines (Table 1). A global expression profiling
study classified HCC cell lines in Group I and Group II
[51]. Our well-differentiated and poorly differentiated cell
line subtypes showed perfect correlation with Group I and
Group II, respectively. Well-differentiated Group I was
characterized by the activation of oncofetal promoters
leading to increased expression of AFP and IGF-II,
whereas poorly differentiated Group II was characterized
by overexpression of genes involved in metastasis and
Comparative analysis of noncanonical (top) and unclassified (bottom) Wnt ligands in hepatocellular carcinoma cell linesFigure 7
Comparative analysis of noncanonical (top) and unclassified (bottom) Wnt ligands in hepatocellular carcinoma 
cell lines. Noncanonical and unclassified Wnt ligands were tested for expression by RT-PCR assay. Total RNAs were 
extracted from cell lines and used to detect gene expression by RT-PCR assay. See Figure 1 for GAPDH loading control.Page 10 of 20
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ated subtypes were also in perfect correlation with respec-
tively epithelial and mesenchymal HCC cell line types
that have been identified very recently [12]. Mesenchymal
cancer cells are considered as the products of EMT that is
believed to be a key mechanism for the acquisition of
invasive and metastatic capabilities by tumor cells [53].
Higher motility of poorly differentiated HCC cell lines
reported here is in line with this concept. Thus, our two
classes of cell lines share many similarities with well-dif-
ferentiated and poorly differentiated HCC tumors. We
used this model to compare the status of Wnt pathway
according to HCC differentiation status.
A comprehensive analysis of Wnt signaling components
in liver or hepatocytes is lacking. However, the expression
of Wnt ligands and Frizzled receptors in mouse hepato-
cytes has been published [54]. Mouse hepatocytes
expressed canonical receptors Fzd7 and Fzd9, as well as
noncanonical Fzd2, Fzd3, Fzd4 and Fzd6. We observed
highly similar pattern of expression in HCC cell lines with
the exception of Fzd9 that showed weak expression. In
addition, we detected increased expression of canonical
Fzd1 and Fzd5 in most HCC cell lines. The expression fre-
quency of these receptors was not associated with HCC
cell differentiation status. Mouse hepatocytes expressed
canonical Wnt1 and Wnt2, and noncanonical Wnt4,
Wnt5a, Wnt5b and Wnt11. All or most HCC cell lines
Frequent constitutive activation of canonical Wnt signaling in well-differentiated, but not in poorly differentiated hepatocellular carcinoma cell linesigur  8
Frequent constitutive activation of canonical Wnt signaling in well-differentiated, but not in poorly differenti-
ated hepatocellular carcinoma cell lines. (a) Comparative analysis of the canonical Wnt signaling in hepatoma cell lines 
with known mutations of -catenin or Axin-1 genes. TCF reporter assay shows that well-differentiated HepG2 cells display 
high signaling activity. In contrast, canonical Wnt signaling is attenuated in poorly differentiated SNU398, and undetectable in 
poorly differentiated SNU475 cell line. Assays in triplicate, error bars; SD. (b) Comparative analysis of the canonical Wnt sign-
aling in HCC cell lines with wild-type -catenin and Axin-1 genes. Huh7 and Hep3B cell lines (both well-differentiated) display 
weak but significantly increased TCF reporter activity. Other cell lines (all poorly differentiated, except Hep40) display no 
detectable TCF reporter activity. TCF activity denotes the ratio of signals detected with pGL3-OT (OT) and pGL3-OF (OF) 
plasmids, respectively. Assays in triplicate, error bars; S. D. Cells were transfected with the reporter gene pGL3-OT (OT) har-
boring LEF-1/TCF binding sites for -catenin and the corresponding pGL3-OF (OF) without these sites.Page 11 of 20
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they displayed increased expression of canonical Wnt3
and Wnt10b ligands. Another canonical ligand, Wnt8b
was expressed selectively in well-differentiated cell lines.
In contrast, noncanonical Wnt4, Wnt5a and Wnt5b lig-
ands were expressed in the majority of poorly differenti-
ated cell lines, but not in most of well-differentiated cell
lines. In addition, most HCC cell lines (poorly differenti-
ated cell lines in particular) also displayed increased
expression of noncanonical Wnt7b. Among Wnt ligands
and Frizzled receptors that we found to be expressed or
upregulated in HCC cell lines, Wnt3, Wnt4, Wnt5a, Fzd3,
Fzd6 and Fzd7 have been previously reported to be over-
expressed also in primary HCC tumors [55-57]. Overex-
pression of Wnt10b was also reported in HCC cels [58].
Increased levels of Wnt5a transcripts were detected in
chronic hepatitis, cirrhosis and HCC [59]. A C-terminally
mutated HBV X protein was shown to upregulate Wnt5a
expression in HCC cells [60]. Thus, Wnt5a upregulation
observed in clinical samples might be related to HBV at
least in HBV-related liver diseases. Based on our observa-
tions that associate noncanonical Wnt ligand expression
to poorly differentiated HCC cell lines, it will be interest-
ing to test the predictive value of noncanonical Wnt
expression for HCC prognosis.
Another important finding of this study is the differential
activity of canonical Wnt signaling in different HCC sub-
types. Well-differentiated cell lines displayed active
canonical Wnt signaling at variable degrees. In addition to
strong signaling activity associated to -catenin and Axin1
mutations in two well differentiated cell lines, we also
observed autocrine canonical Wnt signaling in two other
well differentiated cell lines, as reported for some other
cancer cell lines [36]. The functional significance of auto-
crine canonical Wnt signaling in these cell lines is not
known.
However, small molecule antagonists of Tcf4/beta-catenin
complex were shown to inhibit TCF reporter activity and
down-regulate the endogenous Tcf4/-catenin target
genes c-Myc, cyclin D1, and survivin in Huh7 cells [61].
This observation strongly suggests that the autocrine
canonical Wnt signaling is functional in well-differenti-
ated HCC cell lines. Canonical Wnt signaling has been
linked to both stem cell and cancer cell self-renewal in
other cancer types. It was proposed that some adult can-
cers derive from stem/progenitor cells and that canonical
Wnt signaling in stem and progenitor cells can be sub-
verted in cancer cells to allow malignant proliferation
[62]. Indeed, well-differentiated-HCC cell lines identified
Expression analysis of genes inhibiting canonical Wnt signaling downstream to -catenin in HCC cellsFigure 9
Expression analysis of genes inhibiting canonical Wnt signaling downstream to -catenin in HCC cells. Total 
RNAs were extracted from cell lines and used to detect gene expression by RT-PCR assay. GAPDH RT-PCR was used as a 
loading control.Page 12 of 20
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reported to harbor HCC stem cells [63]
Our third noteworthy observation was the lack of detecta-
ble canonical Wnt signaling activity in six out of seven
poorly differentiated cell lines. Even a poorly differenti-
ated cell line with a deleterious Axin1 mutation
(SNU475) lacked detectable signaling activity. Thus, most
probably, the canonical Wnt signaling was not only inac-
tive, but also repressed in poorly differentiated HCC cell
lines. In confirmation of this expectation, transient or Tet-
regulated expression of mutant -catenin failed to gener-
ate significant canonical Wnt signaling activity in two dif-
ferent poorly differentiated cell lines. Furthermore, we
linked this weak activity to poor nuclear accumulation of
-catenin protein in SNU449.cl8 cell line. Thus, unlike
well-differentiated cell lines, poorly differentiated HCC
cells displayed strong resistance to canonical Wnt signal
activation.
The mechanisms of resistance to canonical Wnt signal
activation in poorly differentiated HCC cells are presently
unknown. We provide here one potential mechanism.
Wnt5a has been previously implicated in canonical Wnt
signaling as an antagonist and regulator of -catenin lev-
els in other cell types [48,49]. Using both ectopic and
endogenous mutant -catenin expression systems in two
different cell lines, we demonstrated that co-transfections
with Wnt5a-expressing plasmid can significantly inhibit
canonical Wnt signaling in HCC cells. The mechanism of
Wnt5a antagonism on canonical Wnt signaling in HCC
cells is not known. In breast cancer cells, the loss of Wnt5a
Ectopic expression of mutant -catenin induces high canonical Wnt activity in well-differentiated, but not in poorly differenti-ated hepatoc llular carcinoma cellsFigur 10
Ectopic expression of mutant -catenin induces high canonical Wnt activity in well-differentiated, but not in 
poorly differentiated hepatocellular carcinoma cells. (a) Well-differentiated Huh7, and poorly differentiated SNU449 
and SNU182 cell lines have been co-transfected with either pCI-neo-mutant -catenin (S33Y) plasmid (S33Y--catenin +) or 
empty pCI-neo plasmid (S33Y--catenin -), and cellular -catenin levels at post-transfection 48 h were tested by immunoblot-
ting. Calnexin was used as a loading control. (b) Cell lines were treated as described, then pCI-neo-mutant -catenin (S33Y)-
transfected cells were subjected to TCF reporter assay. TCF activity denotes the ratio of signals detected with pGL3-OT (OT) 
and pGL3-OF (OF) plasmids, respectively. Assays in triplicate, error bars; SD. Co-transfections included pGL-OT or pGL-OF, 
in addition to pCI-neo plasmids in both (a) and (b).Page 13 of 20
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and expression of Wnt/beta-catenin target genes [64].
However, both ectopically and endogenously expressed
mutant -catenins used in our experiments were N-termi-
nally truncated devoid of their Ser/Thr phosphorylation
motifs. Thus, Wnt5a appears to inhibit canonical Wnt sig-
naling in HCC cells, downstream to -catenin, independ-
ent of its glycogen synthase 3-- and bTrCO-dependent
degradation. Wnt5a has been shown to inhibit canonical
Wnt signaling either by bTrCP-independent proteasomal
degradation [65], or, by downregulating -catenin-
induced reporter gene expression without influencing -
catenin levels [37] in kidney epithelial cells. Wnt5a may
use similar mechanisms in Huh7 and HepG2 cells. Fur-
ther studies with downregulation of noncanonical Wnt
ligands in poorly differentiated HCC cell lines may help
to better define the implications of such ligands in liver
cancer biology.
The role of Wnt5a in cancer is complex. It may play
tumor-promoting or tumor-suppressing functions
depending on cellular context. Wnt5a has been described
as a tumor promoter in melanoma, gastric, pancreas, pros-
tate cancer, but as a tumor suppressor in HCC, neuroblas-
toma, leukemia, colon, and thyroid cancers [46]. The
inability of Wnt5a to transform cells or signal through the
canonical -catenin pathway pointed that it cannot pro-
mote tumorigenesis by upregulation of canonical Wnt sig-
naling, unlike canonical Wnt ligands [66]. Our results
suggest that Wnt5a, upregulated in poorly differentiated
highly motile mesenchymal-like HCC cells may play a
role in tumor progression by inducing EMT. Upregulation
of Wnt5a expression during EMT has been reported [67].
Furthermore, the Wnt5A/Protein kinase C pathway was
shown to mediate motility in melanoma cells via of an
EMT [68]. Similarly, CUTL1-upregulated Wnt5a signifi-
cantly enhanced migration, proliferation and invasiveness
Minimal TCF reporter activity and lack of nuclear accumulation of mutant -catenin in poorly differentiated SNU449Figure 11
Minimal TCF reporter activity and lack of nuclear accumulation of mutant -catenin in poorly differentiated 
SNU449.cl8 cells. SNU449 cells were stably transfected with Tet-responsive N--catenin expression vector to obtain 
SNU448.cl8 cells. (a) Induced expression of N-terminally truncated N--catenin protein in the Tet-Off conditions, as tested 
by western blot assay. Total cell lysates were extracted from cells and subjected to western blot assay using anti--catenin anti-
body. (b) TCF activity is only weakly induced in Tet-off conditions, as tested by duplicate experiments. (c) SNU449.cl8 cells at 
Tet-On state express wild-type endogenous -catenin protein principally located at cell membrane. Under Tet-Off conditions 
the staining pattern remains almost identical despite N--catenin expression. Note lack of nuclear accumulation. SW480 cells 
used as positive control display strong nuclear -catenin staining. Cells were grown on coverslips, subjected to indirect immun-
ofluorescence assay using anti--catenin antibody (red), counterstained with DAPI (blue) and examined by confocal micros-
copy.Page 14 of 20
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nied by a marked modulation of marker genes associated
with EMT. Wnt5a may promote EMT in HCC cells by a
similar mechanism.
The expression status of Wnt5a in HCC is not well known.
To our knowledge, only one report addressed this issue
[59]. Compared to normal tissue, Wnt5a mRNA expres-
sion was strongly induced in HCC, as well as in chronic
hepatitis and cirrhosis. However, immunostaining of
Wnt5a protein showed a bell-shaped pattern: low to
undetectable levels were present in normal tissue and in
tumor samples, whereas strong immunostaining was seen
in chronic hepatitis, cirrhosis and dysplastic liver cells.
The reasons of the discrepancy between transcript and
protein expression in HCC tissues are not known pres-
ently. However, it appears that peritumoral liver tissues
express high levels of Wnt5a protein that could trigger
noncanonical Wnt signaling in adjacent tumor cells. It
will be important to further investigate the role of Wnt5a
in HCC tumor progression.
Taken together, our studies demonstrate that canonical
Wnt activity is active in well-differentiated, but repressed
in poorly differentiated HCC cell lines. This correlates
with in vivo tumor studies indicating that -catenin muta-
tions are prevelant in well-differentiated, but not in
poorly differentiated tumors. In addition, we showed that
poorly differentiated cell lines express noncanonical Wnt
ligands such as Wnt5a acting as an antagonist of canonical
Wnt signaling. Thus, it appears that HCC cells may acti-
vate or repress their canonical Wnt signaling, using auto-
crine/paracrine systems based on selective use of
canonical and noncanonical Wnt ligands.
We hypothesize that the active canonical Wnt signaling
observed in well-differentiated HCC cells contributes to
tumor initiation, but not necessarily to tumor progres-
sion. Instead, noncanonical Wnt signaling may be used by
poorly differentiated HCC tumors to promote cell motil-
ity and invasion. Selective use of canonical and nonca-
nonical Wnt signaling at different stages may be a key
mechanism involved in hepatocellular carcinogenesis.
Recent studies showed that canonical Wnt signaling con-
tributes to the self-renewal and expansion of HCC-initiat-
ing cells with stem/progenitor cell features [50,70].
However, the lack of HCC development in -catenin
transgenic mice strongly suggests that canonical Wnt sign-
aling activation has limited tumorigenic potential in liver
tissue. Indeed, recent studies showed that canonical Wnt
signaling plays a major role in the specification of mature
hepatocytes for perivenous-specific gene expression
([71,72]. Such a hepatocyte differentiation function of
canonical Wnt signaling may not be compatible with cel-
lular dedifferentiation that goes along with HCC develop-
ment. Therefore, alternative pathways such as Wnt5a-
Wnt5a inhibits canonical Wnt signaling activity in Huh7 and HepG2 cellsFigure 12
Wnt5a inhibits canonical Wnt signaling activity in Huh7 and HepG2 cells. (a) Huh7 cells were co-transfected with 
either pCI-neo-mutant -catenin (S33Y) plasmid (S33Y--catenin +) along with pShuttle-IRES-WNT5a or empty pShuttle-IRES 
vector. 48 hours post transfection; cells were subjected to TCF reporter assay. TCF activity denotes the ratio of signals 
detected with pGL3-OT (OT) and pGL3-OF (OF) plasmids, respectively. Assays in triplicate, error bars; SD. Co-transfections 
included pGL-OT or pGL-OF, in addition to pCI-neo-S33Y--catenin and pIRES plasmids. (b) HepG2 experiments were per-
formed under similar conditions, except that pCI-neo-mutant -catenin (S33Y) plasmid was omitted.Page 15 of 20
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for sustained growth and progression of HCC tumors.
Melanoma may serve as a demonstrated model to our
hypothesis. Similar to HCC, canonical Wnt signaling acti-
vation is an early event and nuclear -catenin accumula-
tion is associated with better patient survival in
melanoma. Nuclear -catenin is lost in more aggressive
melanomas that express Wnt5a that promotes EMT, cell
motility and metastasis[46]. Chien et al. [73] have
recently demonstrated that canonical Wnt signaling
induces growth inhibition and differentiation in
melanoma cells, whereas Wnt5a can antagonize some of
these effects. These findings clearly establish a dual func-
tion of Wnt signaling in melanoma. In light of these
recent developments, our findings call for further investi-
gations on respective roles of canonical and noncanonical
Wnt signaling in HCC.
Conclusion
Our observations support the hypothesis that Wnt path-
way is selectively activated or repressed depending on dif-
ferentiation status of HCC cells. We propose that
canonical and noncanonical Wnt pathways have comple-
mentary roles in HCC, where the canonical signaling con-
tributes to tumor initiation, and noncanonical signaling
to tumor progression.
Methods
Cell lines
Hepatocellular carcinoma cell lines Huh7, Hep40,
Hep3B, Hep3B-TR, FOCUS, Mahlavu, SNU182, SNU 387,
SNU 398, SNU423, SNU 449, SNU 475, PLC/PRF/5, SK-
Hep-1, hepatoblastoma cell line HepG2 and colorectal
cancer cell line SW480 were cultivated as described previ-
ously [41].
Reverse transcription-polymerase chain reaction (RT-
PCR) analysis
Total RNAs were extracted from cultured cells using
NucleoSpin RNA II Kit (MN Macherey-Nagel, Duren, Ger-
many) according to the manufacturer's protocol. The
cDNAs were prepared from total RNA (2 g) using Rever-
tAid First Strand cDNA Synthesis Kit (MBI-Fermentas, Vil-
nius, Lithuania). A negative control without reverse
transcriptase (1 l ddH2O instead) was also prepared for
each sample. All PCR reactions were carried out using 1 l
cDNA from the reverse transcription mix, for 35 cycles
except GAPDH, which was amplified for 24 cycles. Nega-
tive controls without reverse transcriptase were included
for each set of primers (primer sequence information is
available upon request). PCR products were analyzed on
a 2% (w/v) agarose gel.
Wound-healing assay
Cells were cultured in six-well culture plates in RPMI 1640
or DMEM with 10% FBS. A single linear wound was made
with a p200 pipette tip in confluent monolayer cells. The
distances between wound edges were measured at fixed
points in each dish according to standardized template.
Debris were removed by washing the cells twice with PBS
and then cells were incubated in RPMI 1640 or DMEM
with 2% FBS. After 24 hours migration, cells were fixed
with methanol and stained with 0.2% crystal violet. Cell
migration into the wound was visualized using phase con-
trast microscopy (x20 magnification). The number of cells
migrating beyond the wound edge was quantified micro-
scopically in the randomly selected fields for each tripli-
cate well.
Immunocytochemistry
Cells were grown on coverslips, fixed in 4% formalde-
hyde, permeated with 0.5% saponin/0.1% Triton X-100,
and stained with mouse monoclonal anti-human vimen-
tin antibody (Dako) using Envision kit (Dako), developed
with diaminobenzidine, and counterstained with hema-
toxylin.
Confocal microscopy
Cells were grown on slides in 6 well plates and were fixed
in 3.5% paraformaldehyde (PFA) for 15 minutes, and per-
mealized using 0,25% Triton-X-100 for 10 min. Non spe-
cific protein binding was blocked by 30 minutes of
incubation with 5% bovine serum albumin (BSA) in
phosphate-buffered saline (PBS) at room temperature.
Cells were then incubated 2 hours with monoclonal anti-
-catenin antibody M5.2 (1:200 dilution) in 1% BSA in
PBS at room temperature in a moist chamber. Immun-
ofluorescence staining was obtained by incubating for 1
hour with Alexa Fluor® 594 F(ab')2 fragment of rabbit
anti-mouse IgG (H+L) (Invitrogen) (dilution 1:750).
Cells were counterstained with DAPI (dilution 1:750),
slides were mounted using ProLong® Gold antifade rea-
gent (Invitrogen) and examined under Zeiss LSM 510
Meta laser scanning confocal microscope (MPI Freibourg,
Germany) using 488 nm and 543 nm laser excitation
lines, and photographed.
Plasmids
The pShuttle-IRES-Wnt5a expression plasmid was con-
structed by subcloning of an EcoRI-cut Wnt5a cDNA frag-
ment from plasmid pGEMTz-Wnt5a vector (a gift from R.
Kemler) into BglII site of the pShuttle-IRES-hrGFP-1 vec-
tor (Stratagene, USA). pCI-Neo-mutant -catenin (S33Y)
expression plasmid, and pGL3-OT and pGL3-OF reporter
plasmids were kindly provided by B. Vogelstein. Other
plasmids were pCI-Neo (Promega) and pEGFP-N2 (Clon-
tech, Palo Alto, CA). The pAUCT-N--catenin plasmid
expressing N-terminally truncated -catenin (aa 98-781)Page 16 of 20
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pAUCT-CCW vector (gift from Ali Fattaey, USA). A cDNA
fragment of XhoI-NotI digestion from pCI-Neo-mutant -
catenin (S33Y) plasmid was inserted into XhoI-NotI site
of pAUCT-CCW vector.
Transfections
Endogenous TCF/LEF-dependent transcriptional activity
was tested by using pGL3-OT and pGL3-OF reporter plas-
mids, as described previously [41], except that cells were
transfected using Lipofectamin 2000 reagent (Invitrogen),
following instructions provide by the supplier. Mutant -
catenin-induced TCF/LEF-dependent transcriptional
activity was tested after co-transfection of cells with pCI-
Neo-mutant -catenin (S33Y) expression plasmid (1.75
g/well) together with the reporter plasmids. pCI-Neo
(1.75 g/well) was used as negative control. The effect of
Wnt5a expression on TCF/LEF-dependent transcriptional
activity was tested using Huh7 and HepG2 cell lines.
Huh7 cell line was co-transfected with pCI-Neo-mutant -
catenin (S33Y) expression plasmid (1 g/well) together
with either pShuttle-IRES-Wnt5a (0.75 g/well) or the
empty vector pShuttle-IRES-hrGFP-1 (0.75 g/well) and
pGL3-OT/pGL3-OF reporter plasmids (0.75 g/well for
each). At 48 h following transfection, luciferase assay was
performed by using Luciferase Reporter Gene Assay, con-
stant light signal kit (Roche Diagnostics GmbH., Man-
nheim, Germany). Luciferase activity was read with The
Reporter® Microplate Luminometer (Turner BioSystems
Inc., Sunnyvale, CA) and data was normalized according
to transfection efficiency obtained with each transfection,
as described previously [41]. HepG2 cell line was co-trans-
fected with either pShuttle-IRES-Wnt5a (0.5 g/well) or
the empty vector pShuttle-IRES-hrGFP-1 (0.5 g/well)
and pGL3-OT/pGL3-OF reporter plasmids (0.5 g/well
for each), with an internal control (0.05 g/well pRL-TK
Renilla luciferase vector) in a 12-well plate, using Lipo-
fectamine 2000 Transfection Reagent. Forty-eight hours
post-transfection, the cells were washed with PBS, and
lysed in passive lysis buffer (Dual Luciferase kit;
Promega). The cell lysates were transferred into an Opti-
Plate 96-well plate (Perkin-Elmer) and assayed in a 1420-
Multilabel counter luminometer, VICTOR3 (Perkin-
Elmer) using the Dual-Luciferase kit (Promega). Relative
TOP-FLASH luciferase units were measured and normal-
ized against Renilla luciferase activity and further normal-
ized luciferase activity against FOP-FLASH activity. All
transfection experiments were performed in triplicate and
data were expressed as mean of triplicate values (±S. D.)
and p values were calculated. TCF/LEF activity was
reported as the ratio of normalized luciferase activities
obtained with pGL-OT and pGL-OF plasmids, respectively
(mean ± S. D.).
Generation of mutant -catenin expressing SNU449-cl8 
cell line
SNU449 cell line clone ectopically expressing N-termi-
nally truncated (aa 98-781) -catenin, under the control
of Tet repressor was generated by stable transfection with
pAUCT-N--catenin plasmid. Briefly, SNU449 cells were
plated onto 6-well plate and transfected with 2 g of plas-
mid DNA using Lipofectamin 2000 reagent (Invitrogen).
24 hours post transfection, cells were transferred to 90
mm dishes and subjected to G418 (0.6 g/ml) selection in
the presence of tetracycline (1 g/ml) until resistant cell
colonies became visible. Several clones were tested by
Western blot for the expression of N-terminally truncated
(aa 98-781) -catenin after withdrawing tetracycline from
the culture medium to induce the expression of the trans-
gene. Only one clone (SNU449-cl8) displayed Tet-
dependent expression of mutant -catenin, and it was
used for further studies.
Western blotting
Detergent-soluble cell lysates were prepared at 48 h post-
transfection and used for western blot analysis, as
described previously [41]. Antibodies to -catenin (Santa
Cruz Biotechnology, Inc., CA) and calnexin (Sigma) were
obtained commercially. ECL kit (Amersham Life Science,
Inc., Piscataway, NJ) was used for detection of antigen-
antibody complexes. Equal protein loading was verified
by Western blot assay with calnexin antibody.
Statistical analysis
The statistical significance of the active TCF reporter activ-
ity between well-differentiated and poorly differentiated
HCC cell lines was tested by Fisher Exact Probability Test
using an on-line tool http://faculty.vassar.edu/lowry/Vas
sarStats.html.
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Tumor cells have the capacity to proliferate indefinitely that is
qualified as replicative immortality. This ability contrasts with the
intrinsic control of the number of cell divisions in human somatic
tissues by a mechanism called replicative senescence. Replicative
immortality is acquired by inactivation of p53 and p16INK4a genes
and reactivation of hTERT gene expression. It is unknown whether
the cancer cell replicative immortality is reversible. Here, we show
the spontaneous induction of replicative senescence in p53-and
p16INK4a-deficient hepatocellular carcinoma cells. This phenome-
non is characterized with hTERT repression, telomere shortening,
senescence arrest, and tumor suppression. SIP1 gene (ZFHX1B) is
partly responsible for replicative senescence, because short hairpin
RNA-mediated SIP1 inactivation released hTERT repression and
rescued clonal hepatocellular carcinoma cells from senescence
arrest.
immortality  liver cancer  SIP1  telomerase  p53
Tumor cells are clonal (1), and tumorigenesis usually requiresthree to six independent mutations in the progeny of pre-
cancerous cells (2). For this to occur, preneoplastic somatic cells
would need to breach the replicative senescence barriers. Rep-
licative senescence is a telomere-dependent process that sets a
limit to the successive rounds of cell division in human somatic
cells (3). Progressive telomere shortening is observed in almost
all dividing normal cells. This phenomenon is linked to the lack
of efficient hTERT expression that is observed in most human
somatic cells (3). Replicative senescence (permanent growth
arrest also called M1 stage) is believed to be initiated by a DNA
damage-type signal generated by critically shortened telomeres,
or by the loss of telomere integrity, leading to the activation of
cell cycle checkpoint pathways involving p53, p16INK4a, andor
retinoblastoma (pRb) proteins (4, 5). In the absence of func-
tional p53 and p16INK4apRb pathway responses, telomeres
continue to shorten resulting in crisis (also called M2 stage).
Cells that bypass the M2 stage by reactivating hTERT expression
gain the ability for indefinite cell proliferation, also called
immortality (3, 4, 6). There is accumulating evidence that cancer
cells undergo a similar process during carcinogenesis to acquire
immortality. Telomerase activity associated with hTERT reex-
pression is observed in 80% of human tumors (7), and senes-
cence controlling p53 and p16INK4A genes are commonly inacti-
vated in the majority of human cancers (8). Moreover,
experimental transformation of normal human cells to tumor
cells requires hTERT-mediated immortalization, as well as
inactivation of p53 and pRb genes (9).
Aberrant expression of hTERT, together with the loss of p53
and p16INK4apRb control mechanisms, suggests that the repli-
cative immortality is a permanent and irreversible characteristic
of cancer cells. Although some cancer cells may react to extrinsic
factors by a senescence-like stress response, this response is
immediate, telomere-independent, and cannot be qualified as
replicative senescence (10). Experimental inactivation of telom-
erase activity in cancer cells mostly results in cell death (11),
whereas ectopic expression of p53, p16INK4a, or pRb provokes an
immediate senescence-like growth arrest or cell death (10).
Thus, to date there is no experimental evidence for spontaneous
reprogramming of replicative senescence in immortalized cancer
cells. Using hepatocellular carcinoma (HCC)-derived Huh7 cells
as a model system, here we show that cancer cells with replicative
immortality are able to spontaneously generate progeny with
replicative senescence. Thus, we provide preliminary evidence
for the reversibility of cancer cell immortality. The replicative
senescence of cancer cells shares many features with normal cell
replicative senescence such as repression of hTERT expression,
telomere shortening, and permanent growth arrest with mor-
phological hallmarks of senescence. However, the p53 gene is
mutated, whereas p16INK4a promoter is hypermethylated in these
cells. Thus, we show that fully malignant and tumorigenic HCC
cells that display aberrant hTERT expression and lack functional
p53 and p16INK4a genes are able to revert from replicative
immortality to replicative senescence by an intrinsic mechanism.
Furthermore, we demonstrate that the SIP1 gene, encoding a
zinc-finger homeodomain transcription factor protein involved
in TGF- signaling (12, 13) and hTERT regulation (14), serves
as a molecular switch between replicative immortality and
replicative senescence fates in HCC cells.
Results
When analyzing clones from established cancer cell lines, we
observed that some clones change morphology and cease pro-
liferation at late passages with features reminiscent of cellular
senescence (data not shown). We reasoned that this could be an
indication for generation of progeny programmed for replicative
senescence. We surveyed a panel of HCC and breast carcinoma
cell lines and hTERT-immortalized human mammary epithelial
cells (hTERT-HME). Plated at low clonogenic density, cells
were maintained in culture until they performed 6–10 popula-
tion doublings (PD), and tested for senescence-associated -
galactosidase (SABG) activity (15). Different cancer cell lines
generated progeny with greatly contrasting SABG staining
patterns. The first group, represented here by HCC-derived
Huh7 and breast cancer-derived T-47D and BT-474 cell lines,
generated heterogeneously staining colonies. Cells of some
colonies were mostly positive for SABG, but others displayed
significantly diminished or complete lack of staining (Fig. 1A).
The second group, represented by HCC-derived Hep3B and
Mahlavu, and hTERT-HME generated only SABG-negative
colonies (Fig. 1B). Manual counting of randomly selected col-
onies demonstrated that mean SABG-labeling indexes for Huh7,
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T-47D and BT-474 progenies were 45  23%, 40  29%, and
33  7%, respectively (Fig. 1C, lanes 1–3). In contrast, Hep3B,
Mahlavu, and hTERT-HME progenies displayed 3  3%
mean SABG-labeling indexes (Fig. 1C, lanes 4–6). Clones from
representative cell lines were expanded and subjected to the
same analysis. SABG-staining patterns of all clones tested were
closely similar to the patterns of their respective parental cell
lines. For example, mean SABG staining indexes of Huh7-
derived clones were 14  15%, 47  27%, and 17  11% (Fig.
1C, lanes 7–9), whereas Hep3B-derived clones generated 2 
3% SABG-positive progenies (Fig. 1C, lanes 10–12). We spec-
ulated that the first group of cell lines comprised progenies in
different stages of replicative senescence process at the time of
analysis, whereas the second group of cell lines were composed
mostly of immortal cells. The results obtained with the first
group were unexpected. These cell lines have been established
20 years ago (16–18) and expanded in culture over many years,
with PD well beyond the known senescence barriers for normal
human cells (3), but they were still capable of generating
presumably senescent progeny.
The study of a potentially active replicative senescence pro-
gram in the progeny of immortal cancer cell lines requires the
long-term follow up of single cell-derived clones. To this end, we
chose to focus our investigations on Huh7 cell line. We expanded
different Huh7-derived clones in long-term culture and exam-
ined their potential to undergo replicative senescence. Some
clones performed 100 PD in culture with stable proliferation
rates and heterogeneous SABG staining, whereas others sus-
tained a limited number of PD, then entered a growth arrest
phase with full SABG staining patterns. For example, C3 clone
performed only 80 PD, whereas C1 clone replicated 150 PD.
Permanently arrested C3 cells (PD 80) displayed enlarged size,
f lattened shape, and fully positive SABG staining, whereas early
passage C3 (PD 57) and C1 (PD 179) cells displayed normal
morphology with heterogeneous SABG staining (Fig. 2AUpper).
Normal human cells at replicative senescence (M1) are refrac-
tory to mitotic stimulation and display 5% BrdUrd index (19).
Growth-arrested C3 cells displayed very low BrdUrd staining
(2  2%), in contrast to early passage C3 and late passage C1
cells, which exhibited 89  6%, and 96  3% BrdUrd indexes,
respectively (Fig. 2A Lower). Senescent C3 cells remained
growth arrested, but alive when maintained in culture for at least
3 months, with no emergence of immortal clones (data not
shown).
Biological mechanisms of replicative senescence observed
here are of particular interest, because senescence-regulatory
p53 is inactivated (20–22) and p16INK4a promoter is hypermethy-
lated (23) in Huh7 cells. Accordingly, there was no change in p53
levels, whereas the low level p16INK4a expression did not in-
crease, but decreased in senescent C3 (PD 80) cells, when
compared to presenescent C3 (PD 57) or immortal C1 (PD 179)
cells. Retinoblastoma protein (pRb) displayed partial hypophos-
Fig. 1. Established human cancer cell lines generate senescence-associated
-galactosidase (SABG)-expressing progeny. (A) Representative pictures of
HCC (Huh7) and breast cancer (T-47D and BT-474) cell lines that generate both
SABG-positive (Upper) and SABG-negative (Lower) colonies. (B) Representa-
tive pictures of HCC (Hep3B and Mahlavu) and telomerase-immortalized
mammary epithelial (hTERT-HME) cell lines that generate only SABG-negative
colonies. Cells were plated at clonogenic density to generate colonies with
6–10 population doublings, and stained for SABG activity (blue), followed by
eosin counterstaining (red). (C) Quantification of SABG-positive cells in colo-
nies. Randomly selected colonies (n 10) obtained from parental (lanes 1–6)
cell lines and expanded clones (lanes 7–12) were counted to calculate the
average % SABG positive cells per colony (% SABG index). Lanes 1–6 designate
Huh7, T-47D, BT-474, Hep3B, Mahlavu, and hTERT-HME, respectively. Lanes
7–9 are Huh7-derived C1, C3, and C11 clones, and lanes 10–12 are Hep3B-
derived 3B-C6, 3B-C11, and 3B-C13 clones. Error bars indicate SD.
Fig. 2. p53-and p16INK4a-deficient Huh7 cells generate progeny that un-
dergo in vitro and in vivo replicative senescence resulting in loss of tumori-
genicity. (A) Huh7-derived clones C3 and C1 were tested for replicative senes-
cence arrest by SABG and BrdUrd staining at different passages. Presenescent
C3 and immortal C1 cells display low SABG staining (Upper) and high BrdUrd
incorporation (Lower), whereas senescent C3 cells are fully positive for SABG
(Upper) and fail to incorporate BrdUrd into DNA after mitogenic stimuli
(Lower). (B) p53 and p16INK4a protein levels show no increase in senescent C3
cells, compared to presenescent C3 and immortal C1 cells, but senescent C3
cells display partial hypophosphorylation of pRb. Calnexin was used as a
loading control. Proteins were tested by Western blotting. PS, presenescent
(PD 57); S, senescent (PD 80); I, immortal (PD 179). (C) C1 cells (black line) were
fully tumorigenic, but C3 cells (red line) were not in nude mice. (D) C1 tumors
displayed low SABG staining (Upper Right), whereas implanted C3 cells re-
maining at the injection site are fully positive for SABG in situ (Upper Left), as
well as after short-term in vitro selection (Lower). Animals were injected with
presenescent C3 (PD 59) and immortal C1 (PD 119) cells, and tumors and
nontumorigenic cell samples were collected at day 35 and analyzed.
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phorylation in senescent C3 cells, apparently in a p53- and
p16INK4a-independent manner (Fig. 2B). Cyclin E and A levels
were also decreased, but p21cip1 levels were elevated in both
presenescent and senescent C3 cells (Fig. 5A, which is published
as supporting information on the PNAS web site). Cyclin D1,
CDK4, and CDK2 protein levels (Fig. 5A) and p14ARF transcript
levels (Fig. 5B) did not change.
Cancer cell senescence that we characterized here shared
many features with normal cell replicative senescence (3), except
that it was not accompanied with wild-type p53 or p16INK4a
induction. However, in vivo relevance of the replicative senes-
cence observed in cell culture is debated (6). Therefore, we
compared in vivo replicative potentials of C3 (PD 59) and C1
(PD 119) cells in CD-1 nude mice. C3 cells did not form visible
tumors, whereas C1 cells were fully tumorigenic in the same set
of animals (Fig. 2C), like parental Huh7 cells (data not shown;
ref. 24). C1 tumors collected at day 35 displayed scattered but
low-rate SABG-positive staining, but remnant C3 cell masses
collected from their injection sites were fully SABG-positive
(Fig. 2D Upper). For confirmation, these remnants were re-
moved from two different animals, passaged twice in cell culture
for selection, and examined. Nearly all cells displayed senescence
features including enlarged size, f lattened shape, and highly
positive SABG staining (Fig. 2D Lower). We concluded that loss
of C3 tumorigenicity was due to replicative senescence in vivo.
Replicative senescence, also called telomere-dependent se-
nescence is associated with progressive telomere shortening due
to inefficient telomerase activity (3). When compared to paren-
tal Huh7 cells, presenescent C3 cells at PD 57 had telomeres that
have already been shortened to 7 kbp from 12 kbp. These
cells eroded their telomeres to5 kbp at the onset of senescence.
In contrast, immortal C1 clone (PD 179) telomeres did not
shorten (Fig. 3A). These observations showed a perfect corre-
lation with telomerase activity and hTERT expression. Immortal
C1 cells displayed robust telomerase activity, whereas both
presenescent and senescent C3 cells had no detectable telom-
erase activity (Fig. 3B). Accordingly, the expression of hTERT
gene was high in C1, but barely detectable in C3 cells (Fig. 3C).
Thus, senescence observed with C3 cells was characterized with
the loss of hTERT expression and telomerase activity, associated
with telomere shortening.
Mechanisms of hTERT expression are presently unclear, but
several genes including SIP1, hSIR2, c-myc, Mad1, Menin, Rak,
and Brit1 have been implicated (14, 25). Therefore, we analyzed
their expression in C1 and C3 clones. All tested genes, except
SIP1, were expressed at similar levels in both C1 and C3 clones,
independent of hTERT expression (Fig. 6, which is published as
supporting information on the PNAS web site). SIP1 transcripts
were undetectable in C1 cells, but elevated in C3 cells, moder-
ately in presenescent, but strongly in senescent stages (Fig. 3C).
We verified these findings with another Huh7-derived clone
(G12) that displayed replicative senescence resulting in perma-
nent cell proliferation arrest. Like C3, presenescent G12 cells
that displayed low SABG staining with high BrdUrd index (98
1%), became fully positive for SABG, and nearly negative for
BrdUrd (3  2%) at the onset of senescence (Fig. 7, which is
published as supporting information on the PNAS web site).
Presenescent G12 cells displayed only a weak hTERT repression
associated with a slight increase in SIP1 expression, whereas
SIP1 was strongly elevated in hTERT-negative senescent cells
(Fig. 3D). Thus, there was a close correlation between SIP1
expression and hTERT repression in all Huh7 clones tested. The
analysis of SIP1 and hTERT expression in primary HCCs and
their corresponding nontumor liver tissues confirmed this rela-
tionship. SIP1 transcript levels were high, but hTERT expression
was low in nontumor liver tissues, whereas respective HCC
tumors displayed diminished SIP1 expression associated with
up-regulated hTERT expression (Fig. 3E).
The SIP1 gene (Zinc finger homeobox 1B; ZFHX1B) en-
codes a transcriptional repressor protein that interacts with
SMAD proteins of the TGF- signaling pathway and CtBP
corepressor (12, 13). This gene has recently been implicated in
TGF--dependent regulation of hTERT expression in breast
cancer cells (14). Our observations implicated SIP1 gene as a
candidate regulator of replicative senescence in HCC cells. To
investigate whether SIP1 expression constitutes a protective
barrier against hTERT expression and senescence bypass, we
constructed SIP1 short hairpin RNA (shRNA)-expressing
plasmids, based on a reported effective SIP1 siRNA sequence
(14). SIP1 shRNA was expressed by using either G-418-
resistance plasmid pSuper.retro.neoGFP or puromycin-
resistance plasmid pSUPER.puro (see shRNA in Methods).
Presenescent C3 cells at PD 75 were used for transfections, 3–4
weeks before expected senescence arrest stage.
pSuper.retro.neoGFP-based SIP1 shRNA suppressed the
accumulation in SIP1 when expressed transiently (Fig. 4A, day
5). This resulted in a weak increase in hTERT expression.
Transfected cells were maintained in culture in the presence of
500 gml G-418 and observed for 30 days. At this period, C3
cells transfected with a control plasmid reached senescence-
arrested stage with further up-regulation of SIP1 expression
(Fig. 4A, day 30) and resistance to BrdUrd incorporation after
mitogenic stimuli (BrdUrd index  3  1%; Fig. 4B Upper
Left). In sharp contrast, SIP1 shRNA-transfected cells lost
Fig. 3. C3 clonal cells undergo telomere-dependent replicative senescence
associated with SIP1 expression and hTERT repression. SIP1 expression is lost,
whereas hTERT is induced in primary HCC tumors. (A) Genomic DNAs from
parental Huh7 and immortal C1 cells display long telomeres, whereas C3
telomeres are progressively shortened in presenescent and senescent stages,
respectively. Equal amounts of genomic DNAs were blotted with a telomere
repeat probe. C. Low, short telomere control DNA. (B) Presenescent and
senescent C3 cells have lost telomerase activity, as measured by TRAP assay.
Telomerase activity was shown as % value of test samples ( SD) compared to
‘‘high positive’’ control sample. (C) hTERT expression as tested by RT-PCR was
high in immortal C1, but decreased to weakly detectable levels in C3 cells.
Inversely, SIP1 expression tested by RT-PCR was undetectable in C1 cells, but
showed a progressive increase in presenescent and senescent C3 cells. (D)
Inverse relationship between SIP1 and hTERT expression was confirmed with
another senescence-programmed Huh7 clone named G12 (for SABG and
BrdUrd assays, see Fig. 7). hTERT expression in G12 showed a slight decrease in
presenescent stage, followed by a loss at the onset of senescence. Inversely,
the expression of SIP1 gene was weakly positive in presenescent G12, but
highly positive in senescent G12 cells. C1 was used as control. PS, presenescent;
S, senescent; I, immortal. (E) Negative correlation between hTERT and SIP1
expression in primary tumors (T) and nontumor liver tissues (NT).
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SIP1 expression and up-regulated hTERT transcripts (Fig. 4A,
day 30). Furthermore, SIP1-inactivated cells escaped senes-
cence, as evidenced with 70 9% BrdUrd index (Fig. 4B Upper
Right). Morphologically, SIP1 shRNA-transfected cells formed
proliferating clusters, whereas cells transfected with control
plasmid displayed hallmarks of senescence such as scattering,
enlargement, and multiple nuclei (Fig. 4B Lower). Twelve
independent clones were selected from SIP1 shRNA-
transfected C3 cells. All but one of these clones have per-
formed so far 15 PD beyond the expected senescence barrier
(data not shown). As an additional confirmatory assay, C3 cells
were transfected with the puromycin-selectable pSUPER.puro-
based SIP1 shRNA vector and subjected to puromycin selec-
tion. SIP1 shRNA-transfected cells survived and formed large
number of colonies after 30 days of puromycin selection. In
contrast, no surviving colony was obtained from cells trans-
fected with the control plasmid, as expected (Fig. 4C).
Discussion
Our observations provide experimental evidence for the gen-
eration of senescence-arrested clones from immortal HCC and
breast cancer cell lines. Detailed analysis of clones from
HCC-derived Huh7 cell line further indicates that what we
observe is a replicative senescence, but not a stress-induced
premature senescence-like arrest. Clonal C3 cells displayed
telomerase repression, progressive telomere shortening, and
permanent growth arrest after 80 PD with senescence-
associated morphological changes and positive SABG stain-
ing. Similar changes have also been observed with G12,
another independently derived clone. Thus, we demonstrate
that immortal cancer cells have the intrinsic ability to repro-
gram the replicative senescence. As expected, this shift in cell
fate results in a complete loss of tumorigenicity. The replica-
tive senescence arrest that we identified with clonal C3 cells
was not accompanied with the induction of the p53, p16INK4a,
p14ARF, or p21Cip1 gene. The nonparticipation of p53 and
p16INK4a to the senescence arrest described here was expected,
in the light of published observations showing that Huh7 cells
express a mutant p53 protein (20–22) and they are deficient in
p16INK4a expression (23). Although the levels of p21Cip1 protein
displayed a slight increase in C3 cells, this was not related to
senescence arrest, as early passage proliferating C3 cells also
displayed this slight increase (Fig. 5). The early loss of hTERT
expression in this clone could contribute to early p21Cip1
up-regulation, because hTERT is known to down-regulate
p21Cip1 promoter activity (26). p53, p16INK4a, p14ARF, and
p21Cip1 form a group of replicative senescence-related cell
cycle checkpoint genes. The lack of induction of these genes in
senescence-arrested C3 cells clearly indicates that there are
additional genes involved in senescence arrest in these tumor-
derived cells.
The loss of hTERT expression in senescence programmed
clones prompted us to analyze the expression of genes that have
been implicated in hTERT regulation. Among seven candidate
genes studied, only one, the SIP1 gene, displayed a differential
expression between immortal and senescence-programmed
clones. This gene has been identified as a mediator of TGF--
regulated repression of hTERT expression in a breast cancer cell
line, although it was not effective in an osteosarcoma cell line
(14). In our studies, SIP1 was not expressed in immortal hTERT-
expressing C1 clone, but expressed in senescence-programmed
hTERT-repressed C3 and G12 clones (Fig. 3 B and C). Further-
more, experimental depletion of SIP1 transcripts resulted in
hTERT up-regulation in C3 clonal cells (Fig. 4A). This effect has
been confirmed by using SKHep1, another HCC cell line (data
not shown). Thus, we demonstrate that the SIP1 gene acts as an
hTERT repressor in HCC cells. More importantly, we also
showed the bypass of senescence arrest after functional inacti-
vation of SIP expression by shRNA in senescence-programmed
C3 clonal cells. In contrast to C3 cells transfected with a control
plasmid, SIP1 shRNA-treated cells displayed continued prolif-
eration beyond PD 80 as evidenced by 70% BrdUrd incorpo-
ration index, and formation of large number of colonies. Se-
lected shRNA-transfected clones from these experiments have
already performed15 PD beyond the senescence barrier. Thus,
our findings indicate that the functional inactivation of SIP1 in
senescence-programmed cancer cells is sufficient to bypass
senescent arrest.
SIP1 is a zinc finger and homeodomain containing tran-
scription factor that exerts a repressive activity by binding to
CACCT sequences in regulatory elements of target genes (12,
27). The SIP1 gene is expressed at high levels in almost all
human somatic tissues tested, including liver (28). Therefore,
we also performed comparative analysis of hTERT and SIP1
expression in nontumor liver and primary HCC tissues. SIP1
Fig. 4. ShRNA-mediated down-regulation of endogeneous SIP1 transcripts
releases hTERT repression and rescues C3 cells from senescence arrest. (A) At
day 5 after transfection, SIP1 shRNA-transfected cells (Sh-SIP1) show decreased
expression of SIP1 and weak up-regulation of hTERT expression. At day 30, the
expression of SIP1 is lost completely, and hTERT expression is stronger. (B) Cells
transfected with empty vector (Control) are senescence-arrested as evidenced
by resistance to BrdUrd incorporation (Upper Left) and morphological
changes (Lower Left), but cells transfected with SIP1 shRNA vector (Sh-SIP1)
escaped senescence arrest as indicated by high BrdUrd index (Upper Right)
and proliferating cell clusters (Lower Right). (C) Colony-forming assay shows
that C3 cells formed large number of colonies following puromycin selection
after transfection with a puromycin-resistant SIP1-shRNA-expressing plasmid
(Right), whereas cells transfected with empty vector did not survive (Left).
SIP1 shRNA was expressed by using either G-418-resistance plasmid
pSuper.retro.neoGFP (A and B) or puromycin-resistance plasmid pSUPER.
puro (C). Presenescent C3 cells at PD 75 were transfected with either SIP1
shRNA-expressing or empty plasmid vectors, maintained in culture in the
presence of appropriate selection media and tested at days 5 (A) and 30 (A–C).
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was strongly positive in nontumor liver samples, but its ex-
pression was significantly decreased in corresponding HCC
samples. Inversely, hTERT expression was negative or low in
nontumor liver samples, but highly positive in HCC tumors
(Fig. 3E). We also detected complete loss of SIP1 expression
in 5 of 14 (36%) of HCC cell lines (data not shown). Taken
together with in vitro studies, these observations strongly
suggest that SIP1 acts as a tumor suppressor gene in HCC.
Although SIP1, as a repressor of E-cadherin promoter, has
been suggested to be a promoter of invasion in malignant
epithelial tumors (29), a tumor suppressive activity by the
repression of hTERT and inhibition of senescence arrest is not
precluded.
Hepatocellular carcinoma is one of the most common
cancers worldwide. Liver cirrhosis is the major etiology of this
tumor with limited therapeutic options (30, 31). Telomere
shortening and senescence play a major role in liver cirrhosis,
from which the neoplastic HCC cells emerge with high rates of
telomerase reactivation (32). Furthermore, p53 and p16INK4a
are the most frequently inactivated genes in these tumors. This
fact enhances the importance of our findings for potential
therapeutic applications of replicative senescence program-
ming in HCC.
Methods
Tissues, Cells, and Clones. Snap-frozen HCC and nontumor liver
tissues were used. HCC and breast cancer cell lines T-47D
(ATCC) and BT-474 (ATCC) were cultivated as described (33).
hTERT-HME cells (Clontech) were cultivated in DMEM
Ham’s F-12 (Biochrom) containing insulin (3.5 gml), EGF
(0.1 ngml), hydrocortison (0.5 gml), and 10% FBS (Bio-
chrom). Huh7- and Hep3B-derived isogenic clones were ob-
tained by either G-418 selection after transfection with neomy-
cin-resistance pcDNA3.1 (Invitrogen) or pEGFP-N2 (Clontech)
plasmids, or by low-density cloning. Huh7-derived isogenic
clones C1 and C3 were obtained with pCDNA3.1, and G12 with
pEGFP-N2. Huh7-derived C11, and Hep3B-derived 3B-C6,
3B-C11 and 3B-C13 were obtained by low-density cloning. Cells
transfected with calcium phosphateDNA-precipitation method
were cultivated in the presence of geneticin G-418 sulfate (500
gml; GIBCO), and isolated single cell-derived colonies were
picked up by using cloning cylinders and expanded in the
presence of 200 gml geneticin G-418 sulfate. For low-density
cloning, cells were plated at 30 cells per cm2 and single-cell
derived colonies were expanded. Initial cell stocks were pre-
pared when total number of cells became 1–3  107, and the
number of accumulated population doubling (PD) at this stage
was estimated to be 24, assuming that the progeny of the initial
colony-forming cells performed at least 24 successive cell divi-
sions until that step. Subsequent passages were performed every
4–7 days, and the number of additional PD was determined by
using a described protocol (34).
Low-Density Clonogenic Assay. Cells (30–50 per cm2) were plated
in six-well plates and grown 1–3 weeks to obtain isolated colonies
formed with 100–1,000 cells. The medium was changed every 4
days, and colonies were subjected to SABG staining (see below).
In Vivo Studies. Cells were injected s.c. into CD-1 nude mice
(Charles River Breeding Laboratory). Tumors and nontumori-
genic cells at the injection sites were collected at day 35 and
analyzed directly or after in vitro culture by SABG assay (see
below). These experiments have been approved by the Bilkent
University Animal Ethics Committee.
SABG Assay. SABG activity was detected by using a described
protocol (15). After DAPI or eosin counterstaining, SABG-
positive and negative cells were identified and counted.
BrdUrd Incorporation Assay. Subconfluent cells were labeled with
BrdUrd for 24 h in freshly added culture medium and tested as
described (33), using anti-BrdUrd antibody (Dako) followed by
tetramethylrhodamine B isothiocyanate-labeled secondary an-
tibody (Sigma). DAPI (Sigma) was used for counterstaining.
Immunoblotting. Antibodies against cyclin D1, CDK4, CDK2,
p21Cip1, pRb (all from Santa Cruz Biotechnology), cyclin E
(Transduction), cyclin A (Abcam), p16INK4a (Abcam), p53 (clone
6B10; ref. 35), and calnexin (Sigma) were used for immunoblot-
ting as described (33).
RT-PCR.RT-PCR expression analysis was performed as described
(33), using primers listed in Table 1, which is published as
supporting information on the PNAS web site.
TRAP and Telomere Length Assays. Telomerase activity and telo-
mere length assays were performed by using TeloTAGGG
Telomerase PCR ELISAPLUS and TeloTAGGG Telomere
Length Assay (Roche Diagnostics), following kit instructions.
shRNA. SIP1-directed shRNA was designed according to a pre-
viously described effective siRNA sequence (14) using the
pSUPER RNAi system instructions (Oligoengine) and cloned
into pSuper.retro.neoGFP and pSUPER.puro (Oligoengine),
respectively. SIP1 shRNA-encoding sequence was inserted
by using 5-GATCCCCCTGCCATCTGATCCGCTCTT-
TCAAGAGAAGAGCGGATCAGATGGCAGTTTTTA-3
(sense) and 5-AGCTTAAAAACTGCCATCTGATCCGC-
TCTTCTCTTGAAAG AGCGGATCAG ATGGCAGGGG-3
(antisense) oligonucleotides.
The integrity of the inserted shRNA-coding sequence has been
confirmed by nucleic acid sequencing of recombinant plasmids.
Clone C3 cells were transfected with calcium phosphate precipita-
tion method, using either pSuper.retro.neoGFP-based or pSU-
PER.puro-based SIP1 shRNA expression plasmid, and cells were
maintained in the presence of 500 gml geneticin G-418 sulfate
and 2 gml puromycin (Sigma), respectively. Empty vectors were
used as control. Media changed every 3 days, and cells were tested
at days 5 and 30.
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